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Abstract 
 
Bacterial thioredoxin (Trx) was first identified in Escherichia coli in 1964. Today, 50 years 
later, its prototypical Trx-fold comprises a large superfamily counting hundreds of proteins 
involved in diverse biological processes. Its structural hallmarks are a highly conserved 
βαβ / ββα motif, two redox active cysteines (CXXC motif) and the cisPro loop located in 
structural proximity to the active site. 
 
Mutagenesis experiments performed in the early 1990s revealed a novel class of secreted 
Trx-fold proteins in Gram-negative bacteria, which were classified as Disulfide bond 
formation (Dsb) proteins. In particular DsbA, the primary enzyme in the bacterial periplasm 
which catalyzes disulfide bond formation, has received major attention over the last two 
decades. More recently DsbA’s central role in folding secreted virulence factors has been 
documented, leading to efforts to develop anti-virulence drugs by inhibiting its activity. 
Previous data has demonstrated that bacterial cells are highly attenuated and fail to 
establish infection in the absence of DsbA. However, compared to traditional antimicrobial 
approaches, inhibition of DsbA has no influence on cellular viability. Instead of killing 
bacteria it disarms them. As a consequence, bacteria might be subject to less selective 
pressure to develop drug resistance in the presence of drugs that target DsbA. 
 
Antibiotic resistant strains are on the rise. In particular the development of super-resistant 
Gram-negative pathogens has escalated during recent years. Members of the 
Enterobacteriaceae family such as Klebsiella pneumonia and Proteus mirabilis, present an 
increasing threat in clinical environments. The first two results chapters of this thesis 
(chapters II & III) focus on the structural and functional investigation of E. coli DsbA 
homologues from K. pneumoniae and P. mirabilis with an emphasis on identifying highly 
conserved structural areas, which could be amenable for the development of a DsbA 
subclass specific inhibitor. In parallel, screening of synthetic peptides produced scaffolds 
with optimized affinities for this particular subclass of DsbA enzymes. Thus co-
crystallization of these peptides and P. mirabilis DsbA was conducted, resulting in the first 
structure of a non-covalent complex between a DsbA protein and a peptide. Results are 
described in detail in chapter III.  
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An alternative way to block DsbA’s activity might be achieved through inhibition of its 
upstream regulator DsbB, a transmembrane protein that shuttles electrons between the 
membrane electron transport system and DsbA. High-resolution structural information on 
DsbB is limited. Moreover there are no structures of EcDsbB homologs, which could 
provide valuable insights into the conservation of its co-factor (ubiquinone) binding site. 
Therefore work was initiated on DsbB from P. mirabilis to establish a robust purification 
protocol using GFP-fusions with the aim of producing sufficient quantities for protein 
crystallization and inhibitor screenings. Chapter IV describes the application of GFP to 
generate milligram amounts of PmDsbB from 1 L bacterial cultures.  
 
Bioinformatic analysis revealed a novel Trx-fold protein (DsbP, P = plasmid encoded) that 
was predominantly found on mobile genetic elements. Strikingly its sequence was 
absolutely conserved throughout different plasmids isolated from important pathogens. Its 
discovery and characteristics are described in Chapter V. DsbP is associated with the 
dissemination of multidrug resistance-genes. Hence DsbP might constitute a potential 
target to modulate or inhibit the spread of resistance-genes amongst bacteria. 
 
The final results chapter (chapter VI) investigates the structure and function of a novel Trx-
fold homologue (ScsC) identified in the genome of Proteus mirabilis. It contains a unique 
and previously uncharacterized N-terminus. Its structural elucidation resulted in the 
discovery of the first secreted trimeric Trx-fold protein, with a highly distinctive architecture.  
 
In summary this thesis provides insights into the value of DsbA/B proteins as novel anti-
virulence targets and identifies and characterizes two important and new bacterial Trx-fold 
proteins from P. mirabilis. 
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1 Introduction 
 
The discovery of penicillin in 1929 by Alexander Fleming heralded the dawn of the “golden 
age” of antibiotic drug discovery (Fernebro, 2011). Today it is clear that excessive use of 
antibiotics imposes a selective pressure on bacteria that can foster growth of resistant 
strains (Levin et al., 2000, MacLean et al., 2010) (Figure 1-1). The timeline shown in 
Figure 1-1 exhibits a considerable gap between 1970 and 2000 indicating that release of 
novel antibacterial classes have been scarce during the last few decades (Freire-Moran et 
al., 2011, Cooper & Shlaes, 2011). 
 
Figure 1-1 The upper part of the timeline shows the year of antibiotic release. Reported 
cases of resistance to each antibiotic are depicted below; modified from (Clatworthy et al., 2007).  
 
Multidrug-resistant (MDR) Gram-negative bacteria are on the rise. In particular pan-drug 
(“pan” in Greek for “all” or “whole”) resistant strains from the family of Enterobacteriacea, 
such as Escherichia coli (Ec, E. coli), Klebsiella pneumoniae (Kp, K. pneumoniae), Proteus 
mirabilis (Pm, P. mirabilis) and Salmonella (St) are a major concern (Boucher et al., 2009, 
Ho et al., 2010, Souli et al., 2008, ECDC/EMEA, 2009, Keynan & Rubinstein, 2007, 
Brusselaers et al., 2011, Rice, 2008). Novel strategies to tackle these superbugs are 
urgently needed. In all of these pathogens, enzymes have been identified that share a 
central thioredoxin fold (Trx-fold), such as Disulfide bond forming protein A (DsbA), which 
assist in the folding of secreted virulence factors. Importantly, in its absence pathogenic 
strains become highly attenuated and fail to establish an infection, though cell survival is 
not affected. Therefore DsbA proteins comprise highly attractive targets for the 
development of a novel class of antivirulence drugs.  
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1.1 Thioredoxin proteins 
 
Thioredoxins (Trxs) represent a ubiquitous class of diverse proteins that can be found in 
unicellular organisms, such as bacteria, through to multicellular organisms and mammals. 
Trx from Escherichia coli was first discovered half a century ago. In 1964, Laurent et al. 
identified bacterial Trx as an electron donor, serving as a cofactor for ribonucleotide 
reductase during the first step of DNA synthesis (Laurent et al., 1964). During the following 
decades, it became clear that beyond its function as a hydrogen donor, Trx plays a role in 
a plethora of cellular processes. Today, Trx proteins are known to be involved in many 
functions including: the regulation of redox processes (Holmgren, 1981, 1985); protein 
folding (Shouldice et al., 2011, Ito & Inaba, 2008, Depuydt et al., 2011); protection from 
oxidative stress (Zhang et al., 1997, Chae et al., 1999); regulation of apoptosis (Lu & 
Holmgren, 2012), growth of cancer cells (Powis et al., 2000); modulation of inflammatory 
responses (Bertini et al., 1999, Nakamura et al., 1997, Nakamura et al., 2005); lifecycles of 
several viruses (Russel & Model, 1986, Feng et al., 1999); photorespiration; lipid 
metabolism; membrane transport (Balmer et al., 2004); and many others (Lillig & 
Holmgren, 2007, Arner & Holmgren, 2000, Collet & Messens, 2010). The majority of these 
roles of Trx are organism-specific, while some (e.g. reducing intracellular protein 
disulfides) are shared amongst species (Stewart et al., 1998). 
 
1.1.1 The thioredoxin/glutaredoxin pathways are important for maintaining a reducing 
cytosolic environment 
 
Prototypical Trx is part of two disulfide-bond reducing systems, which together maintain a 
highly reducing environment in the cytosol. Both pathways are critical for the activity of 
several metabolic enzymes that contain disulfide bonds as part of their catalytic reaction 
cycle. These enzymes are inactive in their oxidized disulfide-bonded form and hence 
require free thiol groups to function correctly. The two systems that reduce these disulfides 
are the thioredoxin pathway (trxA/C/B) and the glutathione/glutaredoxin pathway 
(grxA/B/C, gor) (Figure 1-2A).  
 
In E. coli Trx and glutaredoxin (Grx) form an overlapping system as demonstrated through 
analysis of single mutants of either of these genes which are still viable (Gleason & 
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Holmgren, 1988). However, double mutants of key components in both pathways (trxB 
with gshA or gor) are not viable (Prinz et al., 1997). Trx directly interacts in its reduced 
active form (Trxred) with substrate proteins, such as methionine sulfoxide reductase (MsrA), 
phosphoadenylyl-sulfate (PAPS) reductase or ribonucleotide reductase (RNR). Trx 
catalyzes a SN2 bimolecular nucleophilic substitution reaction (Figure 1-2A). Generally, 
electrons from reduced thiol groups of the active site CXXC cysteines in Trxred are utilized 
to reduce disulfide bonds in substrate proteins, which results in a net transfer of a single 
disulfide bond from the substrate protein onto Trx. Firstly, the more N-terminal cysteine 
(CGPC) attacks (via an SN2 mechanism) the cysteine from a disulfide bonded substrate 
protein, which leads to formation of a covalently linked mixed disulfide and a free thiol 
group. The attack is favourable since approximately 50% of CGPC is present in its thiolate 
anion form. The pKa of the thiolate anion form is ~ 7, which is two pH units lower than the 
pKa of a free cysteine (pKa ~ 9) (Dyson et al., 1991, Dillet et al., 1998). A hydrogen bond 
network between the thiolate anion and its neighbouring residues stabilizes its negative 
charge (Foloppe et al., 2001). The linkage is resolved by nucleophilic attack of the C-
terminal cysteine of the CGPC motif (Figure 1-2A). It was suggested that the driving force 
for this last step is a transiently reduced pKa value in CGPC caused by stabilization of its 
thiolate form by hydrogen bonds with backbone atoms from the active site (Roos et al., 
2009). However, the exact mechanism remains controversial. In any case, Trx gets 
oxidized (Trxox) despite the highly reducing environment of the periplasm.  
 
The reaction is thermodynamically favourable since the oxidized state of Trx is more stable 
than its reduced form (ΔΔGox/red = 16.9 kJ/mol) (Mossner et al., 1998). Also its redox 
potential of -270 mV ensures that Trx is the predominant dithiol reductant in the cytosol 
(Krause et al., 1991, Lin & Kim, 1989). Trxox requires reoxidation to complete the reaction 
cycle. Trx reductase (trxB) is an NADPH-dependent flavo-enzyme which reduces Trxox. 
Previous studies have shown that an trxB mutant accumulates Trxox (Debarbieux & 
Beckwith, 1998).  
 
The second pathway consists of different isoforms of glutaredoxin (grxA-C), the small 
tripeptide glutathione (GSH) and glutathione oxidoreducatase (gor). The major difference 
with the Trx pathway is the replacement of Trx reductase enzyme by GSH. Both pathways 
acquire electrons from coenzyme NADPH (Figure 1-2B).  
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Figure 1-2. Cytoplasmic thioredoxin and glutathione/glutaredoxin disulfide bond reducing 
system in E. coli. A. Schematic representation of the thioredoxin pathway. The reaction cycle 
starts with an SN2 nucleophilic attack of the N-terminal cysteine (CGPC) in Trx (trxA/C) targeting 
the disulfide of a substrate protein. In the second step a mixed disulfide is formed, which is 
resolved through an intramolecular nucleophilic attack by the C-terminal cysteine (CGPC) of Trx. 
Trx reductase (trxB) reduces Trxox using NADPH as a cofactor, and completes the reaction cycle. 
Reduced states of proteins are colored in blue, oxidized states are in green, the active site motif is 
in red and the transition state is in light yellow. B. Oxidoreductase activities of the 
glutathione/glutaredoxin system. Similar to the Trx pathway, electrons are derived from NADPH 
(generated in the pentose phosphate cycle), which are used by glutathione reductase (gor) to 
reduce glutathione (GSSG) to GSH. Finally redox equivalents of GSH can be utilised by 
glutaredoxin (grxA/B/C) to reduce substrate proteins. Both pathways overlap and share several 
common substrates. The same color code is applied as in A (Collet & Messens, 2010).  
 
1.1.2 Thioredoxin contains an archetypal Trx-fold 
 
The first crystal structure of a Trx superfamily member was that of E. coli Trx solved in 
1975 (Holmgren et al., 1975) (Figure 1-3A). The tertiary structure of cytosolic EcTrx (12 
kDa) revealed a five-stranded central β-sheet sandwiched by four α-helices. EcTrx 
contains an N-terminal β1α1β2α2β3 motif, which is linked to the C-terminal β4β5α4 motif by  
connecting helix α3. The N-terminal end of helix α2 accommodates its prototypical active 
site motif “CGPC”, containing two redox active cysteines separated by two amino acids. In 
addition, two residues located in the loop connecting α2-helix and β3-strand are critical for 
Trx function, stability and folding (Ren et al., 2009, Charbonnier et al., 1999, Georgescu et 
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al., 1998, Kelley & Richards, 1987). This loop typically features an Iso/Val/Thr residue 
followed by a cisPro. The cisPro loop is distant in sequence, however, lies in close 
proximity to the CGPC active site motif in the tertiary structure.  
 
Figure 1-3: Structure of Trx-fold superfamily members: thioredoxin (Trx) and glutaredoxin 
(Grx). A. On the left, structural elements of Trx are illustrated in a 2D topology diagram. The N-
terminal βαβ-motif is colored in cherry; the C-terminal ββα-motif is shown in cyan. Trx-specific 
secondary structure elements are shown in gray and a yellow asterisk indicates the location of the 
CXXC active site. On the right, the crystal structure of EcTrx (PDB: 2TRX) is represented as a 
cartoon using an identical color code. Secondary structure elements are annotated as well as the 
active site region (CGPC, yellow spheres, orange residues) and the cisPro motif (IP, orange 
residues). B. Similar representation to A showing glutaredoxin (PDB: 1EGO). Compared to Trx, β1 
and α1 are absent in Grx.  
 
The N-terminal motif forms a parallel β-sheet arrangement, while β4β5 at the C-terminus is 
oriented in an antiparallel fashion. Both helix α1 and α2 are located on one side of the 
central β-sheet, whereas helix α3 and α4 are located on the opposite side. The connecting 
helix α3 is located approximately perpendicular to α2 (Figure 1-3A).  
 
The archetypal Trx-fold comprises the N-terminal βαβ-motif, the C-terminal ββα-motif and, 
in most cases, a CXXC active site. The minimal scaffold of a functional protein that 
contains all elements of the Trx-fold can be found in glutaredoxin (Grx), which uses 
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glutathione (GSH/GSSG) as a cofactor and functions as an electron carrier in the 
glutathione-dependent synthesis of deoxyribonucleotides (Fernandes & Holmgren, 2004) 
(Figure 1-3B). Grx lacks the N-terminal β1α1 region of Trx and contains only the β1α1β2-
/β3β4α3-motif of the Trx-fold linked together by the short connecting helix α2.  
 
The Trx-fold is found in many other functionally related proteins, such as disulfide bond 
formation and disulfide isomerization proteins (introduced in the following sections). 
However, many Trx proteins have been identified with completely different functions. For 
example, the Ca2+ binding protein calsequestrin, which is important in muscle contraction-
relaxation (Beard et al., 2004) or glutathione peroxidase, which reduces peroxide species 
in oxidative stress (Deponte, 2013). The Trx superfamily currently encompasses more 
than 200 protein structures (~80% X-ray, ~20% NMR), deposited in the protein data bank 
(PDB, RCSB.org) database. Thus, evolution has used this fold in proteins with distinct and 
diverse functions.  
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1.1.3 Bacterial Dsb Proteins contain a Trx-fold 
 
In 1991, Bardwell and coworkers reported a gene that was essential in vivo for the 
formation of protein disulfide bonds (Bardwell et al., 1991). This gene encoded DsbA, a 
secreted protein exclusively located to the periplasmic space in E. coli. The discovery of 
DsbA then led to the identification of several related Dsb type proteins that all contain a 
Trx-fold including a CXXC and cisPro motif (Figure 1-4).  
 
EcDsbA primarily introduces disulfide bonds between consecutive cysteine residues 
(Berkmen et al., 2005). However, non-native cysteine-cysteine linkages can occur through 
DsbA action in secreted proteins with more than two cysteines. Correcting these errors is 
the task of DsbC disulfide bond isomerase which can shuffle disulfide bonds in misfolded 
substrate proteins (Missiakas et al., 1994) (Hiniker & Bardwell, 2003). Similar to EcDsbA it 
contains all hallmark features of a Trx-fold protein (Figure 1-4). DsbC is maintained in its 
reduced active state by transmembrane protein DsbD which contains a soluble periplasmic 
N-/C-terminal domain (αDsbD / γDsbD) connected via a central transmembrane region 
(8TM known as βDsbD) (Missiakas et al., 1995). Interestingly the crystal structure of 
γDsbD revealed another Trx-fold containing domain (Stirnimann, Rozhkova, et al., 2006).  
 
In addition, several structural homologs of DsbC have been identified. For example, CcmG 
(and its structural homologues, DsbE/DsbF/TlpA) constitute an inner-membrane anchored 
protein that plays an important role in the synthesis of cytochrome c, which requires the 
reduction of two cysteine residues before heme attachment (Ouyang et al., 2006). 
Moreover, DsbG (Andersen et al., 1997) a homolog of DsbC, is another Dsb isomerase 
with a more narrow substrate specificity, primarily involved in protection of free cysteine 
thiols from oxidative damage (Bessette et al., 1999, Depuydt et al., 2009) (Figure 1-4).  
 
Figure 1-4 provides a selection of known Trx superfamily members of secreted periplasmic 
proteins. These enzymes share very little sequence similarity, however each member 
contains a highly conserved Trx-fold, including the redox active CXXC motif and cisPro 
region (Figure 1-4). Variations occur mostly in the insertion domain and at the N-terminus. 
The latter seems to have evolved as a modular site that can enable multimerization and 
therefore generate new enzymatic function. The individual families of proteins themselves 
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contain many members. For example DsbA proteins are divided into several subclasses 
(McMahon et al., 2014) (1.2.2).  
 
Figure 1-4: TRX-fold superfamily members in the bacterial periplasm. A. Cartoon 
representation of Trx (E. coli, PDB: 2TRX), γDsbD (E. coli, PDB: 2FWH), the soluble domain of 
CcmG/DsbE (E. coli, PDB: 2B1K), DsbA (E. coli, PDB: 1FVK), DsbC (E. coli, PDB: 1EEJ), and 
DsbG (E. coli, PDB: 1V57). In all structures the N-terminal βαβ-motif is colored in cherry and the C-
terminal ββα-motif is highlighted in cyan. The linker region connecting both motifs is colored in 
green, while all residues upstream of strand β2 are in gray. The two sulfurs from the active site 
cysteines (CXXC) are shown as yellow spheres. The secondary structure elements that 
correspond to the Trx-fold are annotated as well as the active site CXXC and cisPro (position 
indicated by orange circle) sequence. To ease the identification of the two Trx-motifs, both folds 
were separated (PDB: 2TRX). The Trx-fold is highly conserved in all structures. Residues of the 
insertion domain vary significantly. The N-terminal extension, which can enable homodimerization 
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(DsbC/DsbG), is not conserved amongst the proteins. B. Schematic representation of the 
secondary structure elements of the proteins described in A. The color code is identical to A. The 
βαβ/ββα-motif, the linker helix, CXXC motif and cisPro region are highlighted. The insertion domain 
is mostly characterized by the presence of 1-4 α-helical segments, while the N-terminal extension 
can vary significantly.  
 
1.2 Oxidative Protein Folding in Bacteria 
 
EcDsbA donates its disulfide bond to unfolded substrate proteins which results in reduction 
of it active site cysteines. For a continuous catalytic cycle EcDsbA needs to be reoxidized. 
Because reduced (inactive) EcDsbA is thermodynamically more stable than its oxidized 
form, it requires the presence of an oxidant to overcome the kinetic barrier of C30-X-X-C33 
oxidation. DsbB, a (20 kDa) transmembrane protein located in the inner membrane, uses 
the oxidizing power from the electron transport chain (ETC) to reoxidize DsbA in bacterial 
cells (Missiakas et al., 1993, Bardwell et al., 1993). Usually EcDsbA is strictly found in its 
oxidized state in vivo, however in a dsbB mutant in E. coli, it accumulated in its reduced 
form (Kishigami, Akiyama, et al., 1995). As expected cells defective in dsbB reveal 
pleiotropic effects similar to dsbA mutants (Dailey & Berg, 1993, Missiakas et al., 1993, 
Bardwell et al., 1993).  
 
Two pathways co-exist that convey electrons from the disulfide bond formation machinery 
to the electron transport chain (Bader et al., 1999, Bader et al., 1998, Kobayashi et al., 
1997, Kobayashi & Ito, 1999) (Figure 1-5). Under aerobic conditions electrons are 
transferred from DsbB onto ubiquinone, while in the absence of oxygen (anaerobic 
conditions) electrons are passed onto menaquinone (MQ). Ubiquinone is further oxidized 
by terminal cytochrome bd or bo oxidases as shown by the accumulation of reduced DsbB 
in a double knock mutant strain (Bader et al., 1999). Terminal oxidases then utilize 
electrons in the conversion of molecular O2 to H2O to complete the electron cycle. MQ can 
transfer its electrons to anaerobic electron acceptors such as fumarate or nitrate (Figure 
1-5).  
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Figure 1-5: Oxidative folding pathway in E. coli. 1. EcDsbA donates its disulfide to an unfolded 
substrate protein; as a result the substrate cysteines become oxidized and the protein acquires its 
native conformation. 2. The active site cysteines C30/33 of EcDsbA are reduced during this process. 
3. EcDsbA reoxidation requires interaction with EcDsbB, in particular C104, which forms a mixed 
disulfide with EcDsbA C30. The N-terminal region (PSPFATC104DFM) of the P2 loop of EcDsbB 
directly interacts with EcDsbA as depicted on the top left panel (PDB: 2ZUP). 4. In the presence of 
oxygen, EcDsbB transfers electrons to its cofactor ubiquinone (Q); under anaerobic conditions to 
menaquinone (MQ). 5. In the final step, reduced ubiquinone (QH2 = Ubiquinol) is oxidized by 
cytochrome bo/bd oxidase of the ETC; * mechanism is shown for cytochrome bd oxidase. 
Cytochrome oxidase mechanism (step 5) adapted from Figure 2 (Borisov et al., 2011).  
 
1.2.1 Structure and Function of EcDsbA 
 
EcDsbA is a monomeric 21 kDa enzyme which contains a Trx-fold (β2α1β3/β4β5α7-motif) 
(Martin et al., 1993) (Figure 1-6A). The two segments are connected via a linker helix (α6) 
and the α-helical insertion domain, which in EcDsbA contains a sequence of four α-helices 
(α2-5). The active site C30P31H32C33 is located at the N-terminus of helix α1, embedded in 
the Trx-fold. In close proximity to the active site is the highly conserved cisPro (ValPro) 
loop region (between β4 and α6). Overall, EcDsbA contains a central mixed β-sheet 
arrangement, which is capped by the α-helical domain (Figure 1-6A). A hydrophobic 
groove is formed that runs underneath the active site and is restricted by linker helix α6 on 
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the left. On the rear side of EcDsbA, an additional groove is present, formed at the 
interface between the α-helical domain and the Trx-domain (Figure 1-6B).  
 
Figure 1-6: Overview of EcDsbA. A. Cartoon representation of EcDsbA structure (PDB: 1FVK). 
Coloring similar to Figure 1-4 showing the β2α1β3- / β4β5α7-motif in cherry and cyan, the linker helix 
and the helical insertion domain in green. The N-terminal extension is colored in gray and the 
active site thiol groups are highlighted as yellow spheres. Secondary structure elements are 
annotated and a close-up view of the oxidized active site in EcDsbA is shown on the right. B. 
Surface representation of the front and rear side of EcDsbA. Electrostatic surface potential was 
calculated with APBS (Baker et al., 2001). Positive (blue), negative (red), and hydrophobic (white) 
surfaces are contoured between −7.5 (red) and +7.5 (blue) kT/e. The hydrophobic groove (white 
surface) and the hydrophobic patch located above the active site are indicated. The narrow groove 
on the reverse surface, which is sandwiched between the α-helical and Trx-domain, is also shown. 
C. Disulfide exchange reaction catalyzed by DsbA proteins. A free thiol from a substrate attacks 
Cys30 of DsbA to form a mixed disulfide. Linkage is resolved by an intramolecular SN2 reaction of a 
second cysteine with the mixed disulfide.  
 
Several factors stabilize the reduced form of the DsbA enzymes and thus 
thermodynamically drive the disulfide bond exchange reaction. The disulfide bond in 
EcDsbA is highly reactive and was shown in kinetic measurements to oxidize glutathione 
~1000x faster than generic protein disulfides (Zapun et al., 1993, Wunderlich & 
Glockshuber, 1993a). This reactivity is due to the low pKa of one of the active site 
cysteines. Thiol groups are reactive in their deprotonated thiolate anion state. Of the active 
site cysteines in EcDsbA, only the first is surface exposed (C30-X-X-C33) and exhibits an 
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extremely low pKa of ~ 3.5 (Nelson & Creighton, 1994), while the pKa of a free thiol group 
is ~ 9 (Houk et al., 1987). Hence C30 should be half ionized at pH 3.5, and almost fully 
deprotonated (thiolate anion state) at physiological pH ~ 7. The structure of EcDsbA gives 
several clues to explain this low pKa value of C30. First, the partial positive dipole moment 
derived from helix α1 stabilizes the negative charge of the C30 thiolate anion. In addition 
His32 can form hydrogen bond interactions with C30 in its reduced form and several other 
electrostatic interactions exist which are unique to its reduced state (Guddat et al., 1998). 
Because of this reactivity, the half-life of the mixed disulfides between EcDsbA and its 
substrate proteins are extremely short-lived. Indeed, reduced EcDsbA is ~ 10 ºC (3.6 ± 1.4 
kcal/mol) more stable than its oxidized form (Zapun et al., 1993). Similarly, the reduced 
form of DsbA from Vibrio cholerae is more rigid and hence more stable compared to its 
oxidized form (Horne et al., 2007).  
 
In comparison to DsbA, the vast majority of proteins become stabilized through the 
formation of a disulfide. The difference in stability leads to another important property of 
this class of enzymes: their intrinsic redox potential. The strength to oxidize substrates is 
usually measured as an equilibrium constant (Keq) using glutathione (DsbA-2xSH + GSSG 
 DsbA-S-S + 2GSH). Strong oxidants show small Keq values, maintaining the majority of 
glutathione in its oxidized (GSSG) state. EcDsbA has a Keq of ~ 10-4 (-122 mV) and 
therefore is a very strong oxidant (Huber-Wunderlich & Glockshuber, 1998, Zapun et al., 
1993).  
 
Interestingly, the redox properties of DsbA and other Trx-fold members can be altered 
dramatically by introduction of changes to the dipeptide sequence within the active site 
CXXC motif. For example, exchange of CPHC to CPPC generates EcDsbA with a redox 
potential of -220 mV, almost as reducing as cytoplasmic thioredoxin (-270 mV) (Bessette 
et al., 2001). The dipeptide region can also render EcDsbA’s activity towards a disulfide 
bond isomerase and affect its interaction with substrate proteins (Quan et al., 2007). In 
addition to the CXXC motif, the second conserved site in EcDsbA and other Trx-
superfamily enzymes is the cisPro region. Amino acid exchanges in cisPro151 can lead to 
destabilization of EcDsbA and reduced activity by 50% (Charbonnier et al., 1999). In 
particular, the residue preceding the cisPro has been demonstrated to influence redox 
properties and substrate interactions (Lafaye et al., 2009, Ren et al., 2009). For example a 
P151 to T151 EcDsbA mutant enabled trapping of mixed disulfide complexes, indicating the 
importance of cisPro151 in substrate release (Kadokura et al., 2004).  
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Less is known about the function of the α-helical domain but some evidence suggests that 
it protects DsbA from nonspecific reduction by DsbD (Haebel et al., 2002) and contributes 
to a hydrophobic patch thought to play a role in substrate recognition (Paxman et al., 
2009).  
 
1.2.2 Classification of DsbA proteins 
 
The past two decades have seen the structural and functional characterization of many 
DsbA homologues, primarily from important human pathogens (Shouldice et al., 2011). 
These crystal structures permitted the categorization of DsbA enzymes into four different 
classes (McMahon et al., 2014). Structural and functional homologs of EcDsbA fall into the 
DsbA-Ia class, which contain homologs from Klebsiella pneumoniae (discussed in chapter 
II), Salmonella Typhimurium (Heras et al., 2010), Proteus mirabilis (discussed in chapter 
III) and several other important pathogens. Members of the DsbA-Ib class are most similar 
to Burkholderia pseudomallei DsbA (BpsDsbA) (Ireland et al., 2014), such as DsbA from 
Pseudomonas aeruginosa (PaDsbA) (Shouldice, Heras, et al., 2010) and Neisseria 
meningitidis (NmDsbA) (Vivian et al., 2009, Lafaye et al., 2009), which differ in length and 
amino acid variability in several loop regions. These subtle differences have important 
structural consequences, for example a shallower, less defined hydrophobic pocket 
(Ireland et al., 2014, McMahon et al., 2014). DsbA-II differs significantly in its location of 
the β1 sheet, which pairs with β5 (3-2-4-5-1 topology) rather than β3 (1-3-2-4-5 topology) in 
class I enzymes (Premkumar et al., 2013, Heras et al., 2008, Crow et al., 2009). 
Interestingly, the structural rearrangement of β1 is also present in the class of disulfide 
bond isomerases (Figure 1-4 & Figure 1-10), which provides in their case a structural 
anchor for the linker helix that points away from the catalytic core domain and facilitates 
homo dimer formation (discussed in chapters V & VI). In general, DsbA-IIa proteins are 
derived from Gram-positive bacteria, align poorly with class I enzymes and exhibit a 
negative surface potential at the catalytic site. In comparison, DsbA from Gram-negative 
organisms such as Wolbachia pipientis (WpDsbA) (DsbA-IIb) displays a positive surface 
potential at equivalent sites (Kurz et al., 2009) (Figure 1-7).  
 
The diversity of DsbA proteins is further illustrated by the fact that several organisms (e.g. 
Salmonella Typhimurium, N. meningitidis) contain multiple paralogues of DsbA (DsbL, 
SrgA etc.), reflecting diverse roles in pathogenicity (Heras et al., 2010, Totsika et al., 2009, 
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Lafaye et al., 2009). The classification of DsbA enzymes is the first step towards the 
development of DsbA subclass specific antivirulence drugs. DsbA’s involvement in 
pathogenicity and its potential as drug target are discussed in section 1.4 and chapters II & 
III. 
 
Figure 1-7: Comparison of four structural classes of DsbA proteins. A. Structural differences 
in loop region L1-3 between DsbA-Ia and DsbA-Ib (e.g. L1 is oriented towards the CXXC motif in 
class Ia, whereas L1 from class Ib points away from the active site). B. Altered topology of the β1-
sheet, discriminating DsbA-I from DsbA-II. C. DsbA-IIa contains a negative surface potential 
surrounding the active site (yellow, S) (DsbA from Mycobacterium tuberculosis). Equivalent sites in 
DsbA-IIb consist mainly of positively charged residues (DsbA from Wolbachia pipientis). Positive 
(blue), negative (red), and hydrophobic (white) surfaces are contoured between −7.5 (red) and 
+7.5 (blue) kT/e. Figure modified from (McMahon et al., 2014).  
 
1.2.3 EcDsbA-EcDsbB interaction 
 
EcDsbB forms a transient interaction with EcDsbA. Thus engineering of a stable complex 
between EcDsbA and EcDsbB for structure determination required the engineering of two 
cysteine mutants. Subsequently, the crystal structure of the covalently linked DsbA 
(C30A33) and DsbB (C104S130) complex was solved (Inaba, Murakami, et al., 2006). It 
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revealed binding of the N-terminal portion of the P2 loop (PSPFATC104DFM) to three 
distinct sites: (1) the hydrophobic pocket of EcDsbA situated between helix α1 and α8, 
comprising F36, L40, I42, F36, F174 and Y178, (2) a shallow surface area in close proximity to 
the active (CPHC) site and (3) residues of the cisPro loop (within the loop connecting β4-
α6) (Figure 1-7). Bioinformatic analysis identified 26 residues (13 each from EcDsbA and 
EcDsbB) that contribute to the interface between EcDsbA and EcDsbB (Shouldice et al., 
2011). However, beside the covalent linkage between EcDsbA C30 and EcDsbB C104, no 
specific interactions were identified. Binding appears to occur mainly through hydrophobic 
interactions. A single hydrogen bond is located between backbone atoms of EcDsbA R148 
and EcDsbB F106. Additional studies, using nuclear magnetic resonance (NMR) to 
determine the solution structure of EcDsbB, suggested binding of ASGDC131A (C-terminal 
region of P2) to residues of the loop region connecting DsbA β3-α2 (Zhou et al., 2008). In 
particular binding to EcDsbA M64 might be important, which was proposed previously to 
play a role in spatial separation of C104/130 (Inaba, Murakami, et al., 2006).  
 
It is believed that redox reactions follow a thermodynamic gradient of redox potentials, 
where electrons flow from a less oxidizing (large Keq) to a more oxidizing environment 
(small Keq). However, it was surprising when Inaba and colleagues published the redox 
potential values of both cysteine pairs in EcDsbB (-210 mV for C41/44 and -220 mV for 
C104/130). These findings indicated a thermodynamically unfavorable uphill reaction with 
EcDsbA, which has a much lower redox potential of -122 mV (Zapun et al., 1993). Two 
models then emerged across the literature that sought to explain this discrepancy (Figure 
1-8A). In the first scenario oxidation of C30-X-X-C33 in EcDsbA is achieved by a series of 
highly concerted thiol-disulfide exchange reactions with EcDsbB. Precisely, EcDsbA C30 
(thiolate state) attacks EcDsbB104 (disulfide bonded with EcDsbB C130) leading to the 
formation of a mixed (inter-protein) disulfide between EcDsbA and EcDsbB (C30/104) 
(Kadokura & Beckwith, 2002, Guilhot et al., 1995, Kishigami, Kanaya, et al., 1995). 
Subsequently, electron transfer between P2 and P1 is mediated by the attack of C130 on 
C41, forming an inter-loop disulfide (Inaba et al., 2004, Kadokura & Beckwith, 2002, 
Regeimbal & Bardwell, 2002). This covalent linkage functions as a lock that prevents the 
unwanted back reaction that would result in reduced EcDsbA. It is also believed that the 
formation of the inter-loop disulfide is crucial due to the low redox potential of EcDsbB 
cysteines, which would favor the reverse reaction. Next, EcDsbA C33 attacks the C30/104 
mixed disulfide, liberating oxidized EcDsbA and reduced C104. The latter reacts with C130 
(breaking the inter-loop disulfide) to regenerate the C104/130 disulfide, leaving both C41/44
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behind in their reduced state. In the final step C41 and C44 are directly reoxidized by 
quinones through the formation of a charge-transfer complex (CTC) (Inaba, Takahashi, et 
al., 2006) (Figure 1-8B). In this model a covalent transient adduct between C44 and 
ubiquinone was proposed, which is resolved through the attack of the transient adduct by 
C41, resulting in reduced ubiquinone and oxidized C41/44. The existence of the charge 
transfer complex was confirmed by the presence of a purple colored complex upon 
interaction of EcDsbB with reduced EcDsbA (Inaba et al., 2004, Tapley et al., 2007). 
Additionally R48 was suggested to stabilize the CTC. The concerted model is supported by 
kinetic measurements and NMR data (Jensen et al., 2009, Zhou et al., 2008). 
 
Figure 1-8: Concerted model of EcDsbB catalyzed EcDsbA oxidation. A. 1. The thiolate anion 
form of EcDsbA C30 attacks EcDsbB C104/130 forming the EcDsbA/B complex. 2. EcDsbB C130 
attacks the second disulfide of EcDsbB C41/44 resulting in an inter-loop disulfide linkage. This step 
prevents back reaction of step 1/2. 3. Mixed disulfide between EcDsbA and EcDsbB is resolved. 4. 
Attack of C104 of the inter-loop disulfide linkage restores oxidized C104/130. In the final steps (5,6), a 
charge transfer complex is formed between EcDsbB C44/41, leading to reduction of Q; modified from 
(Zhou et al., 2008) B. Mechanistic details of the charge transfer between DsbB and Q. Electron 
transfer starts with the formation of a covalent adduct between C44 and Q. In a second step, C41 
forms a disulfide with C44 and liberates reduced QH2. Modified from (Kadokura & Beckwith, 2010). 
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In the second model, electrons are transferred from EcDsbA to quinones through a 
sequential set of two thiol-disulfide exchange reactions (Inaba et al., 2005). Here the 
formation of the mixed disulfide between C30/104 induces a conformational change, which 
separates EcDsbB from the mixed disulfide, preventing the back reaction (Inaba, 
Murakami, et al., 2006). In the next step C33 of DsbA attacks the mixed disulfide, which 
releases oxidized DsbA and reduced C104 prior to formation of the inter-loop disulfide 
between C130 and C41. The residual pathway is similar to the concerted model, where C104 
resolves the inter-loop disulfide linkage and forms its native disulfide with C130, while C41/44 
transfer their electrons via the charge transfer complex (described above) onto quinones.  
 
In summary both models describe the electron flow from EcDsbA to EcDsbB C104/130 / 
EcDsbB C41/44 and finally to quinones, which transport them to downstream electron 
acceptors (Regeimbal & Bardwell, 2002, Kobayashi & Ito, 1999). Currently available 
structures of EcDsbB agree with both mechanisms (Zhou et al., 2008, Malojcic et al., 
2008, Inaba, Murakami, et al., 2006, Inaba et al., 2009). 
 
1.3 Disulfide Bond Isomerization in E. coli  
 
The presence of more than two cysteine residues in a secreted protein can result in the 
formation of different disulfide bond linkages. For example, in proteins with four cysteines 
(formation of two disulfide bonds) there are 6 possible combinations (1-2, 1-3, 1-4, 2-3, 2-
4, 3-4) how the free thiol groups can be connected. Furthermore, in a protein such as 
ribonuclease A (RNaseA), the presence of 4 disulfide bonds (8 cysteine residues) permits 
the formation of 105 possible disulfide arrangements.  
 
EcDsbA artificially reduces this complexity since it is prone to catalyze the introduction of 
consecutive disulfide bonds in unfolded polypeptides as they sequentially emerge from the 
secretion system (Kadokura & Beckwith, 2009). One prominent example is the assembly 
of pertussis-toxin, which depends on the formation of eleven consecutive disulfides. In the 
latter, protein folding is solely dependent on the presence of EcDsbA (Stenson & Weiss, 
2002). However, the sequential processivity of EcDsbA can introduce non-native 
disulfides. Thus, many secreted proteins containing non-consecutive disulfides require a 
proofreading system that can shuffle incorrect disulfide bonds. In bacteria, the primary 
enzyme to perform this task is the isomerase/reductase EcDsbC. In general it appears that 
proteins with consecutive disulfides e.g. pertussis toxin, human growth hormone and anti-
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CD18 only require the presence of dsbA, while protein levels of RNase A, phytase, 
melanoma growth stimulating activity and insulin-like growth factor-1 containing non-
consecutive disulfides are dsbC dependent (Joly & Swartz, 1997, Hiniker & Bardwell, 
2004, Berkmen et al., 2005).  
 
1.3.1 The isomerization pathway in Gram-negative bacteria 
 
The majority of EcDsbC is found in its active reduced state in vivo (Joly & Swartz, 1997). 
EcDsbD, an inner-membrane protein with three distinct domains maintains EcDsbC in its 
reduced state (Bessette et al., 1999, Missiakas et al., 1995). EcDsbD contains N-terminal 
(n/αDsbD) and C-terminal (c/γDsbD) periplasmic domains and a central 8TM core 
(t/βDsbD) region (59 kDa). All three domains can be expressed separately, and when 
combined maintain their function in vivo (Katzen & Beckwith, 2000, Porat et al., 2004). 
Both the N- and C-terminus have been structurally characterized, however the precise 
topology of the transmembrane region remains elusive. The N-terminus revealed an 
immunoglobulin-like fold containing a C103X104-8C109 motif, while the C-terminal domain 
comprises a classical Trx-fold, including a C461-V-A-C464 and cisPro (LP) motif (Goulding et 
al., 2002, Stirnimann, Rozhkova, et al., 2006). Similar to n/cDsbD, tDsbD contains two 
invariant cysteines, the first in the middle of TM1 (C163) and the second located in the 
middle of TM4 (C285). Both play a key role in the directional electron transport from the 
cytoplasm to the periplasm. Electron transport is achieved beginning from NADPH in the 
cytosol, to Trx-reductase, Trx-1, tDsbD, cDsbD, nDsbD and DsbC or other nDsbD 
substrate proteins.  
 
In contrast to the oxidative folding pathway the electron flow of the isomerization pathway 
is a thermodynamically favorable process. The standard redox potential of the active site 
cysteines of all components have been determined (-270mV = TrxA, -246mV = tDsbD, -
241mV = cDsbD, -229 mV = cDsbD, -130 mV DsbC and -126 mV DsbG), revealing an 
electrochemical gradient supporting unidirectional flow of electrons (Collet et al., 2002, 
Rozhkova & Glockshuber, 2008, Kadokura & Beckwith, 2010). The mechanism of electron 
transfer was proposed. A mixed disulfide has been observed between tDsbD C163 and Trx-
1 as well as C285 and cDsbD (Cho & Beckwith, 2006, Cho et al., 2007). These findings are 
consistent with the notion that the cytoplasmic and periplasmic sides of tDsbD are 
accessible as evidently shown by alkylation of cysteine C163 and C285 (Katzen & Beckwith, 
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2003). The mechanism of how electrons are transferred from C163 to C285 is unknown. The 
crystal structure between nDsbD and cDsbD provided valuable insights into how electrons 
can bridge across the TM region (tDsbD) (Rozhkova et al., 2004). In addition structural 
comparison with the complex of nDsbD-DsbC also showed that the N-terminal domain has 
to undergo significant movements to accommodate nDsbD into the central cleft of the V-
shaped homodimer of EcDsbC (Haebel et al., 2002, Stirnimann, Grutter, et al., 2006). The 
orientation of nDsbD in complex with EcDsbC enables an engagement with both catalytic 
sites of EcDsbC. Interestingly, the primary binding site (CXXC region) between nDsbD and 
EcDsbC is similar to the interface between nDsbD and cDsbD. However, EcDsbC forms a 
second unique binding interface with nDsbB between the active site region (EcDsbC) of 
the second protomer and β-strand β1/12 of nDsbD. The latter provided an explanation as 
to why only dimeric, full-length EcDsbC can bind to nDsbD (Goldstone et al., 2001). In 
2005 a third complex between nDsbD and CcmG (= DsbE/F), an enzyme involved in 
cytochrome c maturation was reported (Stirnimann et al., 2005). CcmG is unique 
compared to most other periplasmic Trx-fold proteins, since it contains a single 
transmembrane anchor at its N-terminus. Taken together, these studies suggest a highly 
flexible and adaptable N-terminal domain in DsbD, which can bind to different substrate 
proteins. In contrast cDsbD constitutes a very rigid structure as demonstrated through 
NMR studies (Mavridou et al., 2007).  
 
Figure 1-9: DsbD, a shuttle for electrons from the cytoplasm to periplasm. DsbD consists of 
the periplasmic α/nDsbD – γ/cDsbD domain and the transmembrane segment β/tDsbD. Electrons 
flow from cytoplasmic electron carriers (e.g. NADPH) to Trx-reductase (PDB: 1TDE) and Trx (PDB: 
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2TRX), which interacts with βDsbD. Electrons are transferred to γDsbD (PDB: 2FWH) and αDsbD 
(PDB: 1L6P). The latter binds to several substrate proteins, such as DsbC/G (PDB: 1EEJ, 1V57) 
and the membrane anchored CcmG/DsbE (PDE: 2B1K), which is involved in cytochrome c 
maturation. All three enzymes are kept in their reduced (active) state by α/nDsbD. DsbC 
constitutes the primary disulfide bond isomerase in bacteria, which can bind unfolded substrate 
proteins and shuffle non-native disulfide bonds. Modified from (Heras et al., 2007, Stirnimann, 
Grutter, et al., 2006); (αDsbD-γDsbD complex, PDB: 1VRS; αDsbD-DsbC complex PDB: 1JZD; 
αDsbD-CcmG complex PDB:1Z5Y).  
 
1.3.2 The oxidation and isomerization pathway are separated in the periplasm 
 
As described in the previous sections, the oxidative folding pathway and the isomerization 
pathway coexist in the periplasmic space. Both pathways utilize proteins of the Trx-fold 
superfamily. Since EcDsbA is primarily found in its oxidized state and EcDsbC in its 
reduced state, a tight barrier between both is required to prevent futile redox cycles. 
Theoretically one could imagine the oxidation of EcDsbC by EcDsbB or reduction of 
EcDsbA by EcDsbD. However, it is clear now that several mechanisms have developed to 
ensure the integrity and kinetic separation of both systems. The catalysis constant for both 
the oxidation of EcDsbA by EcDsbB (Kcat = 2.7 x 106 M-1s-1) and the reduction of EcDsbC 
by EcDsbD (Kcat = 3.9 x 106 M-1s-1) are extremely rapid (Rozhkova et al., 2004, Grauschopf 
et al., 2003). However, the oxidation of EcDsbC by EcDsbB or the reduction of EcDsbA by 
EcDsbD is very much slower (103 to 107 – fold) (Segatori et al., 2006, Depuydt et al., 2011, 
Nakamoto & Bardwell, 2004, Bader et al., 2000). One explanation for the different kinetics 
came from random mutagenesis studies in EcDsbC from E. coli. Here a point mutant 
(G49R) located in the dimerization domain resulted in a monomeric version of the enzyme, 
which was impaired in its isomerase function (now present in its oxidized state in vivo) and 
behaving as a DsbA-like protein amenable to EcDsbB oxidation (Bader et al., 2001). In 
addition, the active site orientation and the length of the α-helical linker in EcDsbC was 
found to restrict its accessibility (Segatori et al., 2006). Moreover, no reduction of EcDsbA 
by nDsbD was observed in vitro (Collet et al., 2002).  
 
Generally, data indicate that Trx-fold proteins can be manipulated to work either as a 
reductase or an oxidase dependent on their environment and available interaction 
partners. However, to prevent futile redox cycles it seems that evolution has created key 
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non-Trx-fold proteins (e.g. DsbB/nDsbD) within both pathways, which are absolutely 
required to maintain a tight kinetic barrier and prevent futile redox cycles.  
 
1.3.3 Structure and Function of DsbC: the prototypical disulfide bond isomerase from E. 
coli 
 
DsbC forms a V-shaped homodimer (46 kDa) and is located in the lumen of the periplasm 
of Gram-negative bacteria. Each monomer can be divided into an N-terminal dimerization 
domain (1-61), an α-helical linker region (62-77) and the catalytic domain composed of a 
Trx-fold (78-122, 167-216) and an α-helical insertion domain (123-166) (Figure 1-10A). 
The dimer interface is formed by a mixed β-sheet of six β-strands, flanked by helix α1 at 
the N-terminal site. Orientation of the linker helix α2 leads to separation of the catalytic 
domains as well as minimal contact between the dimerization/catalytic domains. The Trx-
fold provides the active site C98-G99-Y100-C101 motif including the characteristic cisPro 
(G181-T182-P183) site Figure 1-10A.  
 
 
Figure 1-10: DsbC isomerase structural overview. A. Cartoon representation of DsbC protomer 
A (PDB: 1EEJ). Secondary structure elements are shown in black. A close-up of the active site 
CGYC / cisPro region is depicted in the upper left corner. B. Surface representation of the V-
shaped DsbC homo-dimer. Electrostatic surface potential was calculated with APBS (Baker et al., 
2001). Positive (blue), negative (red), and hydrophobic (white) surfaces are contoured between 
−7.5 (red) and +7.5 (blue) kT/e. The hydrophobic cleft (white surface) is indicated with a dashed 
back circle; a green asterisk highlights the location of the active site.  
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Two models have been proposed for how EcDsbC-dependent disulfide isomerization can 
occur: the classical isomerase model and the reductase model. In both pathways, the most 
N-terminal cysteine (C98) of the active site motif engages with a disulfide from a substrate 
protein, forming a covalent mixed disulfide. At this stage the ‘classical isomerase model’ 
suggests a nucleophilic attack from the appropriate thiol in the substrate protein, resulting 
in the formation of a native disulfide that causes reduction of EcDsbC. In this sense, 
EcDsbC acts as a true isomerase, without the consumption of electrons. In the ‘reductase 
model’, the binary complex is resolved by the nucleophilic attack of the most C-terminal 
active site cysteine (C101), generating oxidized EcDsbC and two reduced thiol groups in 
the substrate protein. This process renders EcDsbC inactive, hence energy and electrons 
are required to reoxidize EcDsbC. In the reductase model, the resulting unfolded 
polypeptide chain becomes amenable for an additional cycle of disulfide bond formation by 
EcDsbA. Data from the literature supports both models, suggesting their coexistence 
(Rietsch et al., 1997, Shouldice, Cho, et al., 2010, Walker & Gilbert, 1997, Schwaller et al., 
2003). 
 
The surface lining the cleft of EcDsbC predominantly accommodates hydrophobic 
residues, providing an unspecific interaction site for misfolded/unfolded proteins (Figure 
1-10B). Both protomers exhibit substantial flexibility, as shown by the comparison of the 
reduced and oxidized crystal structure of DsbC in H. influenza and the EcDsbC complex 
with αDsbD (McCarthy et al., 2000a, Banaszak et al., 2004, Zhang et al., 2004, Haebel et 
al., 2002). Domain motion likely facilitates binding of differently sized substrate proteins. It 
is also believed that flexibility is crucial in EcDsbC’s role to function as a chaperone. It was 
proposed that EcDsbC shields incompletely folded proteins, while it undergoes and 
explores different conformations and disulfide bond combinations. Its chaperone activity 
does not require the pair of active site cysteines (Liu & Wang, 2001). Interestingly, 
EcDsbC interacts up to 1x107 times faster with peptides than with small redox compounds 
such as glutathione (Darby et al., 1998). Fast kinetics are presumably driven by non-
covalent interactions. Dimerization of EcDsbC is essential for its isomerase and chaperone 
function, since fusion of its N-terminal domain with EcDsbA generates EcDsbA with 
isomerase/chaperone activity (Segatori et al., 2004, Zhao et al., 2003). In addition dsbC 
mutants showed an increased sensitivity towards copper ions. Metal ions can catalyze 
random disulfide bond formation. EcDsbC is thought to protect cells against the 
detrimental effects by reshuffling mixed non-native disulfides in affected cells (Hiniker et 
al., 2005). Even though EcDsbC interacts with many proteins in vitro, only a few in vivo 
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substrates have been identified whose protein levels are reduced in the absence of 
EcDsbC (e.g. MepA, End1, YebF and Ivy) (Vertommen et al., 2008). 
 
1.3.4 EcDsbG a structural homolog of DsbC 
 
DsbG a homolog of EcDsbC was identified in the periplasm of E. coli (Andersen et al., 
1997). Although it only shares 26% sequence identity with EcDsbC, its structure also 
constitutes a V-shaped homodimer with several features similar to EcDsbC (Heras et al., 
2004). One major structural difference between EcDsbG and EcDsbC is the length of its 
linker helix, which is ~ 2.5x longer, resulting in a significantly larger cleft formed between 
both catalytic domains. In addition, several acidic residues line the cleft, providing a 
negatively charged surface (Figure 1-11). On this basis, EcDsbG was proposed to interact 
with larger partially folded substrates with a complementary surface charge distribution, as 
opposed to DsbC, which binds to unfolded hydrophobic polypeptide chains (Heras et al., 
2004).  
 
Figure 1-11: Structural comparison of DsbG with DsbC. A. Cartoon representation of DsbG 
protomer A (PDB: 1V57). Secondary structural elements are annotated in black. Close-up of the 
active site CPYC / cisPro region is depicted on the side. B/C. Dimensions of the V-shaped DsbC/G 
homodimer. Geometry of DsbG provides a much larger cleft than DsbC (DsbC, PDB: 1EEJ; DsbG 
PDB: 1V57). 
 
For many years the function of EcDsbG was ambiguous since attempts to identify in vivo 
substrates were unsuccessful. However recent studies have highlighted the importance of 
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DsbG in the control of the global sulfenic acid content of periplasmic proteins (Depuydt et 
al., 2009). In particular three substrates were identified, all of which belong to the class of 
L,D transpeptidases, containing only a single cysteine. These findings indicated a key role 
of EcDsbG to counteract oxidative stress. Sulfenic modification of single cysteines can 
occur during exposure to reactive oxygen species (ROS). Cysteines can be stably 
modified through additional rounds of oxidation into sulfinic and sulfonic acid species. 
EcDsbC to some extent is able to protect cysteines from sulfenic modification, but less 
efficiently than EcDsbG. The larger size of the cleft in EcDsbG was hypothesized to allow 
binding of the transpeptidase enzymes. In addition EcDsbG was shown to function as a 
molecular chaperone. Stoichiometric amounts were sufficient to impede aggregation of 
citrate synthase and luciferase, two classical chaperone substrates. Moreover EcDsbG’s 
ability to act as a chaperone was found to be autonomous of its redox state (Shao et al., 
2000). EcDsbG shows isomerase activity, albeit weaker compared with EcDsbC. For 
example EcDsbG is not able to catalyze insulin reduction or refolding of scrambled 
RNaseA, however it can partially rescue phenotypes in a dsbC mutant strain when 
overexpressed in vivo (Bessette et al., 1999). Interestingly, mutants of EcDsbG exist which 
can complement the copper sensitivity of dsbC null strains, demonstrating a DsbC like 
activity purely based on a single amino acid alteration (Hiniker et al., 2007). Lastly, both 
EcDsbC and EcDsbG play an important role in biotechnological applications, since they 
can facilitate folding of eukaryotic proteins in heterologous expression systems and 
promote correct folding of proteins targeted to the periplasm (Kurokawa et al., 2000, 
Zhang et al., 2002, Terpe, 2006).  
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1.4 Targeting virulence: a new antimicrobial approach 
 
Bacterial virulence is commonly described as the level of impairment to the host that 
results from an infection. The ability to cause damage to host cells correlates with the 
presence of virulence determinants, i.e. factors that play an essential role in the 
establishment and maintenance of an infection. Inhibiting virulence, rather than killing 
bacteria, has been suggested as an alternative approach to the traditional route of 
antibiotics, which commonly target cell viability (Heras et al., 2014, Clatworthy et al., 
2007). Antivirulence drugs might induce less selective pressure on bacteria to develop 
resistance, which could significantly increase the time span of effective treatment. This 
strategy offers additional advantages, such as (1) development of antimicrobials with a 
novel mode of action, (2) increased number of pharmacological antimicrobial drug targets 
and (3) the preservation of the beneficial human gut flora. Additionally, leaving the majority 
of the microbiome intact could reduce secondary infections and colonization with drug-
resistant strains (Blaser, 2011, Blaser & Falkow, 2009). Different virulence pathways and 
individual protein targets are currently being explored for their potential to inhibit or 
suppress bacterial virulence (Clatworthy et al., 2007, Heras et al., 2014, Rasko & 
Sperandio, 2010, Lasica & Jagusztyn-Krynicka, 2007). These include proteins essential for 
(1) cellular attachment; (2) formation of the secretion machinery, (3) toxicity; (4) quorum 
sensing and (5) disulfide-bond formation. These strategies will be outlined in turn.  
 
1.4.1 Targeting attachment of bacterial cells to its host 
 
In the early stages of an infection, bacteria try to establish initial host-pathogen 
interactions, eventually resulting in the formation of a biofilm layer. Colonization is 
facilitated by several types of bacterial surfactant proteins, such as adhesins, 
autotransporters and multiprotein scaffolds (e.g. pili, also known as fimbriae) (Figure 1-12). 
In particular cellular attachment relies on the proper assembly of pili structures in gram-
negative bacteria (Soto & Hultgren, 1999, Kline et al., 2010). In general, cells that lack pili 
cannot adhere to host cells and therefore cannot establish an infection (Wright et al., 
2007). Two different approaches have been employed to interfere with pilus-mediated 
cellular attachment. Pilicides have been developed that target proteins of the usher-
chaperone pathway, thus blocking the pilus assembly process. In the absence of 
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chaperones, pilus subunits cannot fold properly and form aggregates, which leads to DegP 
protease mediated degradation (Waksman & Hultgren, 2009). These bicyclic 2-pyridones 
bind between the two domains of chaperone PapD and result in inhibition of 
haemagglutination and biofilm formation in uropathogenic Escherichia coli (UPEC), caused 
by the absence of type 1 and P pilus formation. The usher-chaperone assembly pathway 
is conserved in many important bacterial pathogen species, such as Escherichia, 
Salmonella, Klebsiella, Yersinia and Pseudomonas, providing pilicides with potential 
broad-spectrum activity. A second strategy is to block bacterial adhesion at the FimH site, 
which is located at the tip of type I pili structures binding to mannose carbohydrate 
moieties. Competitive inhibitors of FimH (Alkyl- and aryl-α-D-mannosides), which mimic 
mammalian glycans, were found to impair bacterial adhesion of UPEC cells and biofilm 
formation. (Bouckaert et al., 2005, Totsika et al., 2013, Touaibia & Roy, 2007, Wellens et 
al., 2008)  
 
1.4.2 Targeting secreted effector proteins and their machinery 
 
Upon establishment of a host cell interaction, bacteria utilize complex machineries such as 
the needle-like type III secretion system (TTSS) to inject toxins and effector proteins 
directly into the host cells, which enables the pathogen to survive and circumvent the host 
cellular immune response (Bleves & Cornelis, 2000) (Figure 1-12). Similar to pili structures 
the TTSS is present in over a dozen of Gram-negative clinically important pathogens 
(Cornelis, 2006). The TTSS is an attractive target since many pathogens fail to cause an 
infection in its absence. Indeed, several TTSS inhibitors have been developed over the 
last ten years, e.g. the class of salicylideneanilides. Screening of compound libraries has 
identified salicylidene acylhydrazide derivatives, which effectively target the TTSS in 
Yersinia, Chlamydia, Pseudomonas, E. coli, Salmonella and Shigella (Kauppi et al., 2003, 
Duncan et al., 2012). In addition, 2-imino-5-arylidene thiazolidinone was shown to block 
type II and type III specific secretion and virulence functions in several Gram-negative 
pathogens (Felise et al., 2008). The latter and additional active compounds point towards 
the potential to develop antimicrobials with a broad spectrum of activity (Duncan et al., 
2012).  
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1.4.3 Neutralization of toxins 
 
A third approach is directed against bacterial toxins, which represent the primary virulence 
factor of several pathogens. Many toxins can manipulate the host cell metabolism, leading 
to misregulation of important signaling pathways, prevent protein synthesis and cause 
damage to the cellular membrane resulting in deleterious effects for the host (Figure 1-12). 
Their extreme impact on host cellular survival has led to the development of several toxin 
specific strategies that either inhibit downstream transcription or expression of the toxin or 
neutralize their actions by direct interaction with an antibody or small molecule. For 
example, virstatin, an inhibitor of virulence regulation in Vibrio cholerae, was shown to 
inhibit transcriptional regulator ToxT, preventing the expression of cholera toxin and 
cholera co-regulated pilus, resulting in protection of infant mice from intestinal colonization 
by V. cholera (Hung et al., 2005).  
 
1.4.4 Targeting quorum sensing pathways 
 
Bacterial infections are a concerted effort of a local pathogenic cell population to invade 
the host. Cell-cell communication or quorum sensing (QS) is an essential bacterial 
mechanism to coordinate gene expression among clusters of pathogens (Figure 1-12). 
Examples from the literature demonstrate that inhibition of QS can be efficacious against 
several pathogens, since QS is a means to regulate gene expression enabling invasion, 
defense and spread (Hirakawa & Tomita, 2013, LaSarre & Federle, 2013). Secreted 
signaling molecules, also termed autoinducers (AI, e.g. acyl-homoserine lactones = AHLs) 
or pheromones, facilitate communication between population densities of Gram-negative 
cells. As the population grows, the concentrations of autoinducers attain a certain 
threshold, which results in activation of sensor receptors (e.g. LuxR, including QscR/LasR 
homologs) and LuxS), which subsequently promote up-regulated gene expression of 
virulence factors, amongst others. Primarily, QS signaling can be disrupted by at least 
three different routes: (1) prevention of cells to synthesize signaling molecules, (2) quench 
/ eliminate AHL molecules e.g. by antibodies and (3) physically block the interaction sites 
by receptor agonists (Hirakawa & Tomita, 2013, LaSarre & Federle, 2013, Heras et al., 
2014). Extensive work has been conducted on the development of receptor agonists, 
which has already produced promising candidates for several bacteria of the 
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Enterobacteriaceae family and others. More importantly, inhibitors promoted bacterial 
clearance in the lung of infected mice, prolonging their survival rates (Hentzer et al., 2002, 
Hentzer et al., 2003, Wu et al., 2004, Christensen et al., 2012). 
 
Figure 1-12: Overview of current antivirulence strategies. 1. Preventing establishment of stable 
contacts between pathogen and host cells (top right). Pilicides have been developed that disrupt 
attachment sites, which lead to avirulent strains. 2. Upon formation of a stable interaction, needle-
like secretion systems, such as the Type III secretion system enable pathogens to inject effector 
proteins into host cells. Perturbing the formation of the secretion system inhibits virulence in 
several strains. 3. Toxins secreted by the bacteria can lead to cell death in the host. Virulence can 
be prevented through inhibition of toxins by small compounds or neutralizing antibodies. 4. 
Communication between pathogenic cell populations is critical (using auto-inducers such as AHL) 
for biofilm formation. QS inhibitors are known to promote bacterial clearance. 5. The oxidative 
folding machinery (DsbA/B) constitutes an essential pathway for the maturation of a variety of 
virulence factors. Inhibition of either DsbA or DsbB affects different virulence traits, responsible for 
adhesion, secretion and toxin production. Modified from (Heras et al., 2014).  
 
1.4.5 Targeting DsbA/B: global inhibition of virulence factor maturation 
 
Disulfide bond linkages are essential for many secreted proteins in bacteria and help to 
preserve their tertiary structure and physical stability. Loss of function in dsbA/B mutants 
leads to pleiotropic effects, including the reduced production of virulence factors (Heras et 
al., 2009, Yu & Kroll, 1999). Several studies have emphasized the importance of the 
DsbA/B machinery in virulence. In a study using a mouse model, a control cohort was 
infected with wild type Burkholderia pseudomallei, a bacteria that causes melioidosis, 
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whereas the study group were infected with B. pseudomallei dsbA mutant cells. Strikingly, 
all mice infected with wild type cells died after 42 days, whereas all mice infected with the 
mutant dsbA strain survived (Ireland et al., 2014). Further evidence was found in UPEC, 
where knockout strains of dsbA or dsbB strongly attenuated its ability to colonize the 
bladder (Totsika et al., 2009). Similarly, a study examining the role of Dsb enzymes in 
Salmonella pathogenesis reported that the presence of dsbA is required for the expression 
of virulence traits, whereas dsbA mutants showed reduced virulence (Miki et al., 2004).  
 
Several research articles have been published that directly link DsbA-mediated disulfide 
bond catalysis with virulence factor maturation. For example, pilus biogenesis was shown 
to depend on the presence of the usher chaperone PapD, which is only functional when 
modified by EcDsbA (Jacob-Dubuisson et al., 1994, Zhang & Donnenberg, 1996). In 
addition the activity of type IV pili in enteropathogenic E. coli (EPEC) and N. meningitidis 
was shown to require DsbA (Tinsley et al., 2004). Interestingly N. meningitidis contains 
three homologous DsbA enzymes (one soluble, two inner-membrane associated), which 
are required to form five disulfide bonds in lipopolysaccharide phosphoethanolamine 
transferase (LptA). Functional LptA decorates lipopolysachharide (LPS) headgroups in the 
bacterial membrane of N. meningitidis leading to resistance of cells to cationic 
antimicrobial peptides (CAMP’s) such as polymyxin (Piek et al., 2014). Also, the triple 
DsbA mutant in N. meningitidis failed to grow at 37 ºC (Tinsley et al., 2004). 
 
In Pseudomonas aeruginosa the expression of the type III secretion system was DsbA 
dependent (Ha et al., 2003). Also several bacteria are highly mobile due to the presence of 
flagella structures. A simple phenotype that has been widely used in complementation 
experiments is the absence of motility in E. coli dsbA mutant cells. This is due to the 
impaired function of FlgI, which usually decorates the P-ring of the bacterial flagellar 
motor. FlgI contains a single intramolecular disulfide bond, which was shown to be 
essential in P-ring assembly (Hizukuri et al., 2006, Dailey & Berg, 1993). 
 
Thus, the DsbA/B machinery can be regarded as a hub for the maturation of many 
different virulence factors, which perform multifaceted roles at various stages of an 
infection (Figure 1-13). Targeting either DsbA or DsbB would affect many virulence 
pathways in parallel compared to individual approaches (see 1.4.1-1.4.4) described above 
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(Figure 1-12). The location of the DsbA/B system in the periplasm also makes it more 
suitable for drug delivery than cytosolic targets (Heras et al., 2014, Heras et al., 2009). 
 
At this point we lack inhibitors that bind to either DsbA or DsbB and show inhibition in vivo. 
TM1 in DsbB is slightly tilted, which generates a cavity to accommodate its cofactor 
ubiquinone (Bader et al., 1999), providing a potential inhibitor binding site, which could 
ultimately block DsbB/A activity. Recently a fragment-based approach using targeted 
immobilized NMR screening resulted in the identification of hits against EcDsbB with an 
IC50 range of 7-200 µM in vitro (Fruh et al., 2010). However, chemical shift measurements 
with the double cysteine mutant EcDsbB[CSSC] and all eight fragments revealed 
ambiguous results regarding their binding sites (Fruh et al., 2010). Therefore validation 
and further optimization of these scaffolds is indispensable to verify their suitability for 
future drug design studies.  
 
Figure 1-13: Role of the DsbA/B oxidative machinery in virulence factor maturation. A. 
Simplified representation of the oxidative folding machinery from E. coli. Many virulence factors 
require the DsbA/B pathway for post-translational modifications and proper folding. B. Current 
strategies to inhibit DsbA/B and its consequence on virulence factor maturation. Small molecule 
inhibitors block the ubiquinone (Q) binding site, leading to accumulation of inactive DsbA in its 
reduced state. In contrast, inhibition of DsbA, by synthetic peptides/peptidomimetics could directly 
block its interaction with substrates or DsbB. In all scenarios virulence factor maturation would be 
disrupted, leading to cells that are unable to establish or maintain an infection. 
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In the case of DsbA, several structures have been solved that revealed binding to small 
fragments present in the crystallization solution such as glycerol in DsbA from P. 
aeruginosa (Shouldice, Heras, et al., 2010) and PEG in W. pipientis DsbA (Kurz et al., 
2009) and Salmonella Typhimurium (Heras et al., 2010). However, the impact of binding of 
these small compounds was not further investigated.  
 
Overall EcDsbA is a challenging target since it lacks a distinct binding site for substrate 
proteins. EcDsbA is an enzyme that mainly interacts with unfolded proteins and therefore 
needs to provide a universal binding surface, which can be targeted by a multitude of 
substrates. Thus given its promiscuity, the EcDsbA binding surface is difficult to 
specifically target with a small molecule inhibitor. However peptide-like scaffolds might 
effectively bind to DsbA and could be modified as a suitable drug. 
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1.5 Significance  
 
The archetypal element of the Trx-fold has been identified in over 100 proteins involved in 
a plethora of cellular pathways of all living organisms. Among these, the class of bacterial 
Dsb proteins is of particular interest since its members are involved in processes such as 
protein folding, stability of virulence factors and the dissemination of antibiotic resistance 
genes.  
 
The DsbA/B oxidative folding pathway constitutes a major hub for the maturation of 
virulence traits. In the absence of DsbA or DsbB, pathogenic strains become attenuated 
and fail to establish an infection. However, compared to classical antibiotics, growth is not 
affected in dsbA/B mutants. Therefore, inhibitors of the DsbA/B system would target 
pathogenicity rather than cellular viability. The consequence might be a reduction in 
selective pressure in bacteria to evolve resistance.  
 
A successful drug development pipeline requires comprehensive structural and functional 
knowledge about the drug target. The first two chapters of this thesis explore the structural 
diversity of DsbA proteins from two clinically relevant Enterobacteriaceae: K. pneumonia 
and P. mirabilis DsbA (see chapters II & III, published in PlosOne and JBC). Members of 
the Enterobacteriaceae family account for the majority of nosocomial infections, 
pneumonia, urinary tract infections (UTI), intra-abdominal infections and bloodstream 
infections. Multidrug resistant genes, such as carbapenems or NDM-1 are frequently 
identified in all of these pathogens.  
 
Structural characterization of class Ia enzymes was initiated to identify highly conserved 
hotspots among these targets, which could serve as binding sites for 
peptide/peptidomimetic scaffolds. The structural investigation was accompanied by the 
structure determination of the complex between synthetic peptides and DsbA to facilitate 
structure based inhibitor design studies (see chapter III).  
 
The same rational approach was used for production and crystallization of the 
transmembrane protein DsbB from P. mirabilis (see chapter IV). PmDsbB represents a 
homolog of DsbB from E. coli, which has been extensively characterized. Similarly to 
DsbA, DsbB qualifies as a novel antivirulence target as its oxidizing nature is required to 
keep DsbA active. DsbB contains a binding cavity for ubiquinone, its essential co-factor, 
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which is currently being explored as a binding site for small compounds. However, 
molecular docking experiments and structure guided drug design efforts are hampered 
due to the lack of high-resolution structures. In addition currently available structures of 
DsbB have a resolution >3.5 Å.  
 
The discovery and structural and functional characterization of a novel Dsb member is 
described in chapter V (published in JBC). DsbP is a highly conserved disulfide-bond 
isomerase found exclusively on mobile genetic elements, which play a crucial role in the 
dissemination of antibiotic resistance genes. Strikingly, the deletion of a structural homolog 
in the SXT/R391 family of ICE abolished conjugative transfer. Hence, functional and 
structural work on DsbP might pave the way for a novel target to regulate the 
dissemination of antibiotic resistance genes.  
 
The last few decades have seen many structures of different Trx-fold proteins enabling us 
to identify their interplay and involvement in different cellular processes. However, many 
predicted Trx-fold proteins are still uncharacterized. A bioinformatic search for DsbA/C/G 
homologs in P. mirabilis revealed a novel uncharacterized protein which was predicted to 
have a typical Trx-fold, CXXC motif and a cisPro region. Interestingly, sequence 
comparison revealed a unique N-terminal α-helical segment not present in DsbA or 
DsbC/G. Chapter VI elucidates the structure and function of this previously 
uncharacterized protein and provides insights into a novel class of secreted Trx-fold 
proteins in bacteria.  
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1.6 Aims  
 
The aims of this thesis were: 
 
1) structurally and functionally characterize two DsbA homologs from pathogenic K. 
pneumoniae and P. mirabilis to complement our limited structural knowledge of 
Enterobacteriaceae DsbA proteins. Both structures were examined for their suitability 
as targets for peptide/peptidomimetic based antivirulence drugs (chapters II, III). 
 
2) explore different approaches to co-crystallize KpDsbA/PmDsbA with synthetic peptides. 
The structural knowledge of these complexes will then serve to optimize and refine the 
design of peptide/peptidomietic scaffolds as inhibitors  (chapter III). 
 
3) recombinantly produce the PmDsbB membrane protein for crystallisation and small 
compound screening (chapter IV). 
 
4) unravel the structure and function of a novel highly conserved plasmid encoded Trx-fold 
protein, DsbP (chapter V). 
 
5) determine the structure and function of a novel secreted Trx-fold protein from Proteus 
mirabilis (chaperVI). 
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2 Comparative Sequence, Structure and Redox Analysis of Klebsiella 
pneumoniae DsbA Show That Anti-Virulence Target DsbA Enzymes 
Fall into Distinct Classes 
 
 
This chapter has been published as a research article in PLoS One. It describes the 
structural and functional characterization of DsbA from K. pneumoniae to complement 
limited structural knowledge of Enterobacteriaceae DsbA proteins. In particular, KpDsbA’s 
structure was examined for its suitability to develop a peptide/peptidomimetic based 
antivirulence drug. 
 
Contributions 
 
Experiments were conceived and designed by myself, Kieran Rimmer, Martin Scanlon and 
Jenny Martin. I conducted the majority of experiments. NMR data were generated by 
Kieran Rimmer and Biswaranjan Mohanty at Monash University. ITC measurements were 
performed by Wilko Duprez under supervision of David Fairlie. Peptide oxidation 
measurements and analysis came from Maria Halili. Stephen Shouldice cloned the original 
vector construct. Begoña Heras assisted me with biochemical assays and Premkumar 
Lakshmanane assisted during structure refinement. I wrote the first draft of the paper. All 
authors contributed to manuscript preparation and provided critical comments during 
editing phase.  
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GLVXOILGH IRUP >@ ,QKLELWLRQ RI WKH LQWHUDFWLRQ EHWZHHQ'VE$
DQGVXEVWUDWHSURWHLQVRUEHWZHHQ'VE$DQG LWVSDUWQHU'VE%
FRXOGFRQVWLWXWHDPHDQVRIEORFNLQJYLUXOHQFHIDFWRUIRUPDWLRQ
DQG WKHUHE\ RI LQKLELWLQJ YLUXOHQFH RI EDFWHULDO SDWKRJHQV
6XSSRUWLQJ WKLV QRWLRQ GHOHWLRQ RI 'VE$ KRPRORJXHV LQ
3/2621(_ZZZSORVRQHRUJ  1RYHPEHU_9ROXPH_,VVXH_H
CHAPTER II                                                                                                                                                KPDSBA 
 
 39  
SDWKRJHQLF RUJDQLVPV UHVXOWV LQ GLPLQLVKHG YLUXOHQFH LQ
LQIHFWLRQ PRGHOV >@ DQG GHOHWLRQ RI GVE$ RU GVE% LQ
XURSDWKRJHQLF(FROL 83(&VHYHUHO\DWWHQXDWHG LWVDELOLW\ WR
FRORQL]HWKHEODGGHU>@
7KH FKDUDFWHULVWLF SURSHUWLHV RI (F'VE$ LQFOXGH DQ DFWLYH
VLWH&3+&PRWLIWKDWIRUPVDGHVWDELOL]LQJGLVXOILGH7PUHGXFHG
(F'VE$.7PR[LGL]HG(F'VE$. >@ WKHPRUH1
WHUPLQDORI WKH WZRF\VWHLQHV LVQXFOHRSKLOLFDQGKLJKO\DFLGLF
S.D XVXDOYDOXH IRUDF\VWHLQH LV >@DQG(F'VE$ LV
KLJKO\R[LGL]LQJUHGR[SRWHQWLDOP9>@7KHSDVW\HDUV
KDV VHHQ WKH FKDUDFWHUL]DWLRQ RI 'VE$ HQ]\PHV IURP PDQ\
RWKHU EDFWHULD LQFOXGLQJ 'VE$V ZLWK YDU\LQJ GHJUHHV RI
VHTXHQFH LGHQWLW\ WR (F'VE$ VXFK DV 1HLVVHULD PHQLQJLWLGLV
'VE$ 1P'VE$  LGHQWLW\ 3VHXGRPRQDV DHUXJLQRVD
'VE$ 3D'VE$  DQG9LEULR FKROHUDH 'VE$ 9F'VE$ RU
7FS*7KHVH'VE$VVKDUHDVLPLODUVWUXFWXUDO IROGZLWK
(F'VE$ WKRXJK WKHLU VXUIDFH SURSHUWLHV YDU\ >@ DQG WKH\
H[KLELWDZLGHUDQJHRIUHGR[SURSHUWLHV7DEOH,PSRUWDQWO\
WKH(F'VE$K\GURSKRELFJURRYHWKDWLQWHUDFWVZLWKLWVHVVHQWLDO
SDUWQHU (F'VE% LV FRQVLGHUDEO\ WUXQFDWHG LQ 1P'VE$
3D'VE$ DQG 9F'VE$ >@ 7KLV PRGLILFDWLRQ DQG RWKHU
VXUIDFH FKDQJHV LQ WKHVH'VE$V LQGLFDWH WKDW WKH\ IDOO LQWR D
VHSDUDWH FODVV GLVWLQFW IURP (F'VE$ DQG WKDW LQKLELWRUV
GHVLJQHG DJDLQVW (F'VE$ PD\ QRW LQKLELW PHPEHUV RI WKLV
FODVV RI 'VE$&RQYHUVHO\ 'VE$V FORVHO\ UHODWHG WR (F'VE$
VKRXOGEHVXVFHSWLEOHWRWKHVDPHPRGHRIFKHPLFDOLQKLELWLRQ
+HUHZHWHVWHGKRZFORVHWKHVHTXHQFHUHODWLRQVKLSPXVWEH
WR SURGXFH VLPLODU UHGR[ SURSHUWLHV DQG ELQGLQJ LQWHUDFWLRQV
:H LQYHVWLJDWHG WZR ZHOOFKDUDFWHULVHG 'VE$V VKDULQJ 
VHTXHQFH LGHQWLW\ IURP ( FROL . VWUDLQ (F'VE$ DQG 6
HQWHULFD 7\SKLPXULXP 'VE$ VWUDLQ 6/ 6H'VE$ E\
DSSO\LQJFRPSDUDWLYHVWUXFWXUDOVHTXHQFHDQGUHGR[DQDO\VHV
WR LGHQWLI\ SURSHUWLHV FRQVHUYHG DFURVV WKHVH WZR HQ]\PHV
7KH UHVXOWV DOORZ XV WR SODFH 'VE$V RI ILYH RWKHU *UDP
QHJDWLYHEDFWHULD(QWHUREDFWHULDFHDHQDPHO\6KLJHOODIOH[QHUL
7DEOH&RPSDULVRQRIVWUXFWXUHVDQGUHGR[SURSHUWLHVRI
'VE$V

6HTLGWR
(F'VE$
506'
c
506'
&Į (¶P9
S.D
³&\V´
7P.
UHGR[
2WKHU'VE$V
D 




 


(F'VE$E      
6H'VE$F      
.S'VE$      
9F'VE$G      
1P'VE$H      
D >@  UHGR[ SRWHQWLDO UDQJH IRU1P'VE$  :S'VE$   S.D UDQJH
1P'VE$ 9F'VE$ 7PR[LGLVHG PLQ1P'VE$ PD[9F'VE$DQG
UHGXFHGPLQ1P'VE$PD[9F'VE$
E>@>@506'RI(F'VE$GHULYHGIURPWKHRYHUOD\RIPROHFXOHV$DQG%IURP
WKHDV\PPHWULFXQLWLQ)9.
F>@DQG>@
G>@
H>@
GRLMRXUQDOSRQHW
  6I'VE$  VHTXHQFH LGHQWLW\ WR (F'VE$
(QWHUREDFWHU FORDFDH 6&) (Q'VE$  &LWUREDFWHU
NRVHUL$7&&%$$&N'VE$&URQREDFWHUVDND]DNLL
63&V'VE$DQG.SQHXPRQLD.S'VE$
LQWR WKH VDPH 'VE$ FOXVWHU DV 6H'VE$ DQG (F'VE$ 7R
DVVHVV ZKHWKHU WKH UHGR[ DQG VWUXFWXUDO SURSHUWLHV DUH
PDLQWDLQHG LQ WKLV'VE$JURXSZH IRFXVHGRQ.S'VE$ZKLFK
VKDUHV WKH ORZHVW VHTXHQFH LGHQWLW\ ZLWK (F'VE$ :H
GHWHUPLQHG WKH KLJK UHVROXWLRQ FU\VWDO VWUXFWXUH RI UHGXFHG
.S'VE$DQG WKH105VROXWLRQ VWUXFWXUHRI R[LGL]HG.S'VE$
DQG ZH PHDVXUHG WKH UHGR[ SURSHUWLHV RI WKLV HQ]\PH $V
H[SHFWHG WKH UHGR[ SURSHUWLHV VXUIDFH FKDUDFWHULVWLFV DQG
ELQGLQJ SURSHUWLHV RI .S'VE$ DUH VLPLODU WR WKRVH RI (F'VE$
VXJJHVWLQJWKDWLQKLELWRUVGHYHORSHGDJDLQVW(F'VE$DUHOLNHO\
WR DOVR EH HIIHFWLYH DJDLQVW RWKHU PHPEHUV RI WKLV 'VE$
VXEFODVV
0DWHULDOVDQG0HWKRGV
3URWHLQSURGXFWLRQ
&RGRQRSWLPL]HG . SQHXPRQLDH GVE$ *HQ%DQN
DFFHVVLRQQXPEHU$&,ODFNLQJWKHVHTXHQFHFRGLQJIRU
WKH SUHGLFWHG VLJQDO VHTXHQFH  DD ZDV FORQHG LQWR D
PRGLILHG S0&6* 0LGZHVW &HQWHU IRU 6WUXFWXUDO *HQRPLFV
YHFWRU FRPSDWLEOH ZLWK OLJDWLRQLQGHSHQGHQW FORQLQJ 7KLV
PRGLILHGYHFWRUHQFRGHGDOHDGHUVHTXHQFHFRQVLVWLQJRIDQ1
WHUPLQDO +LVWDJ IROORZHG E\ D OLQNHU FRQWDLQLQJ WKH WREDFFR
HWFKYLUXVSURWHDVH7(9UHFRJQLWLRQVHTXHQFH.S'VE$ZDV
H[SUHVVHGLQ%/'(S/\VFHOOVXVLQJDXWRLQGXFWLRQPHGLXP
>@ DQG SXULILHGZLWK 7DORQ UHVLQ &ORQWHFK $XVWUDOLD 7KH
+LVWDJ ZDV UHPRYHG E\ 7(9 SURWHDVH OHDYLQJ WKH
HQJLQHHUHG.S'VE$ZLWKWZRDGGLWLRQDODPLQRDFLGV6±DQG
1 DW WKH1WHUPLQXV $ ILQDO VL]HH[FOXVLRQ FKURPDWRJUDSK\
VWHS XVLQJ D 6XSHUGH[ FROXPQ *( +HDOWKFDUH 86$
\LHOGHG KLJKO\ SXULILHG .S'VE$ DV MXGJHG E\ 6'63$*(
2[LGL]HG RU UHGXFHG .S'VE$ ZDV SUHSDUHG XVLQJ D IROG
PRODU H[FHVV RI FRSSHU,,SKHQDQWKUROLQH RU '77
UHVSHFWLYHO\2[LGL]LQJUHGXFLQJ DJHQWZDV WKHQ UHPRYHGDQG
WKH SURWHLQ EXIIHUH[FKDQJHG LQWR  P0 +(3(6 S+  LQ
RQH VWHS XVLQJ *( 6HSKDGH[ GHVDOWLQJ UHVLQ IRU
FU\VWDOOL]DWLRQDQGELRFKHPLFDOH[SHULPHQWV
3UHSDUDWLRQ RI ( FROL 'VE$ &$$ 6 HQWHULFD
7\SKLPXULXP'VE$$$%DQG(FROL'VE&$$$
ODFNLQJWKHSHULSODVPLFOHDGHUVLJQDOZHUHSXULILHGDVGHVFULEHG
IRU .S'VE$ )RU SHSWLGH R[LGDWLRQ H[SHULPHQWV( FROL 'VE%
$$& PHPEUDQH H[WUDFWV ZHUH SUHSDUHG DV GHVFULEHG
SUHYLRXVO\>@DQGUHVXVSHQGHGLQSKRVSKDWHEXIIHUHGVDOLQH
3%6  P0 1D&O  P0 .&O 1D+32  P0 DQG
.+32S+FRQWDLQLQJJO\FHURO
.S'VE$&RPSOHPHQWDWLRQRI(F'VE$
7KHDELOLW\RI.S'VE$WRUHVFXHQRQPRWLOH(FROLGVE$QXOO
-&% DQG GVE$GVE% GRXEOHQXOO -&% VWUDLQV ZDV
DVVHVVHG LQ D FHOOVZDUPLQJ DVVD\ DV GHVFULEHG SUHYLRXVO\
>@ 7KH PDWXUH .S'VE$ FRGLQJ VHTXHQFH ZDV FORQHG LQWR
S%$' XQGHU DQ DUDELQRVH LQGXFLEOH SURPRWRU ZLWK WKH
(F'VE$ SHULSODVPLF VLJQDO VHTXHQFH $ ZLOGW\SH (F'VE$
FORQHG LQWR S%$' YHFWRU ZDV XVHG DV D SRVLWLYH FRQWURO
&RPSDUDWLYH$QDO\VLVRI.OHEVLHOODSQHXPRQLDH'VE$
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1RQPRWLOH( FROL GVE$ GHILFLHQW -&% RU GVE$  GVE%
GRXEOHPXWDQW -&% >@ FHOOV [ WUDQVIRUPHG ZLWK D
.S'VE$ RU (F'VE$ S%$' LQGXFLEOH YHFWRU ZHUH VSRWWHG
RQWRWKHFHQWHURIDVRIW0PLQLPDODJDUSODWHFRQWDLQLQJ
PJP/ RI HDFK DPLQR DFLG H[FHSW /F\VWHLQH 3ODWHV ZHUH
LQFXEDWHG DW  & DQG PRWLOLW\ RI FHOOV PRQLWRUHG XVLQJ D
0ROHFXODU ,PDJHU *HO 'RF V\VWHP IURP %,25$' &$
86$DIWHU  K&RPSOHPHQWDWLRQH[SHULPHQWVZHUH
UHSHDWHGDVELRORJLFDOWULSOLFDWHV
.S'VE$'LVXOILGH5HGXFWDVH$FWLYLW\
8QGHU PLOG UHGXFLQJ FRQGLWLRQV 'VE$ SURWHLQV FDQ UHGXFH
WKH LQWHUPROHFXODU GLVXOILGH ERQGV IRUPHG EHWZHHQ LQVXOLQ
FKDLQV$DQG%>@7KHUDWHRIGLVXOILGHERQGUHGXFWLRQFDQEH
VSHFWURVFRSLFDOO\IROORZHGDW2'QPE\DQLQFUHDVHLQWXUELGLW\
UHVXOWLQJ IURPSURGXFWLRQRI WKH LQVROXEOH LQVXOLQFKDLQ% >@
6DPSOHVZHUHSUHSDUHG LQFPFXYHWWHVFRQWDLQLQJȝ0RI
SURWHLQ .S'VE$ (F'VE$ RU (F'VE&  P0 '77 DQG 
P0('7$ LQP01D+32 1D+32 WLWUDWHG WRS+
&DWDO\VLV ZDV LQLWLDWHG E\ WKH DGGLWLRQ RI  P0 LQVXOLQ
, 6LJPD$OGULFK $XVWUDOLD WR WKH VDPSOH PL[WXUH 7KH
DVVD\ZDVUHSHDWHGWKUHHWLPHVDQGGDWDZHUHSORWWHGVKRZLQJ
VWDQGDUGGHYLDWLRQV
0HDVXUHPHQWRI.S'VE$5HGR[3RWHQWLDO
7KH VWDQGDUG UHGR[ SRWHQWLDO RI .S'VE$ ZDV PHDVXUHG
XVLQJ LWV LQWULQVLF WU\SWRSKDQ IOXRUHVFHQFH DV GHVFULEHG
SUHYLRXVO\IRU(F'VE$>@2[LGL]HG.S'VE$ZDVLQFXEDWHGIRU
KDW&LQGHJDVVHGP01D+321D+32EXIIHU
S+   P0 ('7$ . FRQWDLQLQJ  P0 R[LGL]HG
JOXWDWKLRQH *66* DQG YDU\LQJ FRQFHQWUDWLRQV RI UHGXFHG
JOXWDWKLRQH *6+ ± P0 .S'VE$  / IURP HDFK
UHGR[ FRQGLWLRQZDVGLVSHQVHG LQWR D ZHOO SODWH 733$*
6ZLW]HUODQG  DQG WU\SWRSKDQ IOXRUHVFHQFH ZDV
PHDVXUHGH[FLWDWLRQDWQPHPLVVLRQVHWWRQPXVLQJ
D PLFURSODWH UHDGHU 6\QHUJ\ + DQG *HQ  VRIWZDUH
%LRWHN 86$ 'DWD ZHUH QRUPDOL]HG DQG WKH UHGR[ SRWHQWLDO
ZDV FDOFXODWHG DV GHVFULEHG IRU (F'VE$ >@ ,Q EULHI WKH
HTXLOLEULXPFRQVWDQW.HTZDVFDOFXODWHGXVLQJWKHHTXDWLRQ< 
>*6+@  >*66+@.HT  >*6+@  >*66+@ ZKHUH < LV WKH
IUDFWLRQ RI UHGXFHGSURWHLQ DW HTXLOLEULXP7KH UHGR[ SRWHQWLDO
IRU.S'VE$ZDVFDOFXODWHGIURPWKH1HUQVWHTXDWLRQ(¶.S'VE$ 
(¶*6+*66+57Q)OQ.HTZKHUH(¶*6+*66+ P95LVWKH
LGHDO JDV FRQVWDQW  -.PRO 7 LV WKH DEVROXWH
WHPSHUDWXUHLQ.QLVWKHQXPEHURIHOHFWURQVWUDQVIHUUHGQ 
) LV WKH)DUDGD\FRQVWDQW[&PRODQG.HT LV WKH
HTXLOLEULXP FRQVWDQW GHULYHG IURP WKH ELQGLQJ HTXDWLRQ $OO
PHDVXUHPHQWV ZHUH SHUIRUPHG DV ELRORJLFDO WULSOLFDWHV 7KH
JUDSKVKRZVDSORWRI WKHDYHUDJHYDOXHV LQFOXGLQJHUURUEDUV
UHSUHVHQWLQJWKHVWDQGDUGGHYLDWLRQIRUWKHUHSOLFDWHV
.S'VE$7KLRODWH$QLRQS.D'HWHUPLQDWLRQ
7KHS+GHSHQGHQWDEVRUEDQFHRIWKHFDWDO\WLFWKLRODWHDQLRQ
RI .S'VE$ ZDV IROORZHG DW  QP >@ XVLQJ D &$5< 
899,6 VSHFWURSKRWRPHWHU $JLOHQW 7HFKQRORJLHV 86$ 7KH
S+WLWUDWLRQPHDVXUHPHQWVRIR[LGL]HGRUUHGXFHG.S'VE$
ȝ0 LQ  P/ FRPSRVLWH EXIIHU  P0 7ULV  P0 VRGLXP
FLWUDWH P0.+32 P0.+32 P0.&O DQG
P0('7$ZHUHFRQGXFWHGDW&$EVRUEDQFHȜ DQG
 QP ZDV PHDVXUHG EHWZHHQ S+  DQG  LQ 
LQFUHPHQWV 7KH S.D YDOXH ZDV FDOFXODWHG IURP WKH ILWWHG
FXUYHV RI WKUHH UHSOLFDWHV XVLQJ WKH +HQGHUVRQ+DVVHOEDOFK
HTXDWLRQS+ S.DORJ>$»$@UHG»>$»$@R[LG
([SHULPHQWVZHUH UHSHDWHG DW OHDVW WKUHH WLPHV 3ORWWHG GDWD
UHSUHVHQW DYHUDJH YDOXHV DQG HUURU EDUV UHSUHVHQW WKH
VWDQGDUGGHYLDWLRQVDFURVVWKHUHSOLFDWHV
5HODWLYH6WDELOLW\RI2[LGL]HGDQG5HGXFHG)RUPVRI
'VE$(Q]\PHV
7HPSHUDWXUHLQGXFHG XQIROGLQJ RI QDWLYH 6H'VE$ DQG
.S'VE$ZDVGHWHUPLQHGDVGHVFULEHGSUHYLRXVO\ >@XVLQJD
-DVFR-FLUFXODUGLFKURLVP&'VSHFWURSRODULPHWHU-DVFR
86$ 7KH UHGR[ VWDWH RI WKH SURWHLQ ZDV FRQILUPHG XVLQJ
(OOPDQ¶VUHDJHQW>@7KHODUJHVWGLIIHUHQFHLQPRODUHOOLSWLFLW\
IRUR[LGL]HGRUUHGXFHGHQ]\PHVZDVFDOFXODWHGIURPLQLWLDOIDU
89&'VSHFWUDIURPQPWRQPUHFRUGHGDW&DQG
 & UHVSHFWLYHO\ 7KH XQIROGLQJ RI R[LGL]HG DQG UHGXFHG
SURWHLQ 6H'VE$R[    QP 6H'VE$UHG    QP DQG
.S'VE$R[ QP.S'VE$UHG QPZDVPRQLWRUHGDW
DKHDWUDWHRI.PLQIURP.WR.LQDPPTXDUW]
FXYHWWH$OOPHDVXUHPHQWVZHUHFDUULHGRXWZLWK0SURWHLQ
LQ  P0 1D+32  1D+32  P0 ('7$ DW S+ 
6DPSOHV IRUPHDVXUHPHQWRI UHGXFHGHQ]\PHFRQWDLQHG
P0'775DZGDWDZHUHDQDO\]HGLQ3ULVPDQGILWWHGWRDWZR
VWDWH XQIROGLQJ PRGHO DV GHVFULEHG SUHYLRXVO\ >@ 7KH
VWDQGDUGGHYLDWLRQZDVPHDVXUHGIURPWKUHHUHSOLFDWHV
.S'VE$'LWKLRO2[LGDWLRQ$FWLYLW\
$ SHSWLGH &44*)'*7416&. ZLWK D 
WHWUDD]DF\FORGRGHFDQHWHWUDDFHWLFDFLG'27$JURXS
DPLGHFRXSOHG WR WKH 1WHUPLQXV DQG D PHWK\OFRXPDULQ
DPLGHFRXSOHG WR WKH İDPLQR JURXS RI WKH &WHUPLQDO O\VLQH
ZDV SXUFKDVHG IURP $QD6SHF )UHPRQW &$ /\RSKLOL]HG
SHSWLGH ZDV UHVXVSHQGHG LQ  P0 LPLGD]ROH S+  DW D
FRQFHQWUDWLRQ RI  P0 (XURSLXP WULIOXRURPHWKDQHVXOIRQDWH
6LJPD$OGULFK$XVWUDOLDVROXWLRQP0ZDVDGGHGWRWKH
SHSWLGHDWDPRODUUDWLRRIDQGLQFXEDWHGIRUPLQDWURRP
WHPSHUDWXUHWRDOORZHXURSLXPFKHODWLRQ7KHSHSWLGHVROXWLRQ
ZDV WKHQ LPPHGLDWHO\DOLTXRWHG IODVK IUR]HQ LQ OLTXLGQLWURJHQ
DQGVWRUHGDW&$Q LQFUHDVH LQIOXRUHVFHQFHRFFXUVXSRQ
R[LGDWLRQ RI WKH SHSWLGH F\VWHLQHV WR IRUP D GLVXOILGH 7KXV
IOXRUHVFHQFH FDQ EH XVHG WR PRQLWRU WKH FDSDFLW\ RI 'VE$
HQ]\PHVWRFDWDO\VHGLWKLROR[LGDWLRQ
$VVD\VZHUHFRQGXFWHGXVLQJD6\QHUJ\+PXOWLPRGHSODWH
UHDGHU%LR7HN86$ZLWKWKHH[FLWDWLRQZDYHOHQJWKVHWWR
QP DQG HPLVVLRQ WR  QP $  ȝV GHOD\ EHIRUH UHDGLQJ
DQG  ȝV UHDGLQJ WLPH ZHUH XVHG IRU WLPHUHVROYHG
IOXRUHVFHQFH 7KH DVVD\ ZDV SHUIRUPHG LQ D ZKLWH ZHOO
SODWH3HUNLQ(OPHU2SWL3ODWH3DUW7KHEXIIHU
FRQVLVWHGRIP00(6P01D&ODQGP0('7$DWS+
 7KH UHDFWLRQ FRQVLVWHG RI D  ȝ/ VROXWLRQ LQ HDFKZHOO
FRQWDLQLQJ  Q0 (F'VE$ .S'VE$ RU 6H'VE$  ȝ0
(F'VE% FUXGH PHPEUDQH H[WUDFWV FRQWDLQLQJ XELTXLQRQH
DQGȝ0SHSWLGHVXEVWUDWHDGGHG ODVW WR LQLWLDWH WKHUHDFWLRQ
6DPSOHV FRQWDLQLQJ EXIIHU DQG 'VE$ RU EXIIHU DQG SHSWLGH
ZHUH XVHG DV FRQWUROV 'DWD ZHUH PHDVXUHG IRU WKUHH
&RPSDUDWLYH$QDO\VLVRI.OHEVLHOODSQHXPRQLDH'VE$
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UHSOLFDWHV DQG DUH SUHVHQWHG DV PHDQ YDOXHV ZLWK WKH
VWDQGDUGHUURURIWKHPHDQLQGLFDWHGE\HUURUEDUV
.S'VE$&U\VWDOOL]DWLRQDQG&U\VWDO6WUXFWXUH
'HWHUPLQDWLRQ
$IWHU LQLWLDOVFUHHQLQJXVLQJWKH8452&;IDFLOLWLHVFU\VWDOV
RI UHGXFHG .S'VE$ ZHUH JURZQ DW  & LQ 9';P ZHOO
SODWHV +DPSWRQ 5HVHDUFK XVLQJ WKH KDQJLQJGURS YDSRU
GLIIXVLRQPHWKRG6FUHHQLQJSODWHVZHUHLPDJHGDQGLQFXEDWHG
LQ D 5RFN,PDJHU  )RUPXODWUL[ 0$ 86$ 'URSV
FRQWDLQHGȝ/RIPJP/UHGXFHG.S'VE$DQGȝ/RI
FU\VWDOOL]DWLRQVROXWLRQ0VXFFLQLFDFLGS+ZY
SRO\HWK\OHQH JO\FRO  DQG   YY PHWK\O
SHQWDQHGLRO )RU GLIIUDFWLRQ GDWDPHDVXUHPHQW FU\VWDOVZHUH
IUR]HQ LQ OLTXLG QLWURJHQ ZLWKRXW DGGLWLRQDO FU\RSURWHFWDQW
'LIIUDFWLRQ GDWDZHUHPHDVXUHG DW WKH$XVWUDOLDQ6\QFKURWURQ
PLFURIRFXV 0; EHDPOLQH XVLQJ %OXH,FH VRIWZDUH >@
5HIOHFWLRQV ZHUH SURFHVVHG LQ 0RVIOP >@ DQG ;'6 >@
DQDO\]HGDQGFRQYHUWHGWR07=LQ3RLQWOHVV>@DQGVFDOHGLQ
6&$/$>@3KDVHVZHUHREWDLQHGE\PROHFXODUUHSODFHPHQW
05XVLQJ3+$6(5>@ZLWK(F'VE$DVWHPSODWH3'%FRGH
'6%  7KH LQLWLDO PRGHO ZDV LPSURYHG E\ LWHUDWLYH PRGHO
EXLOGLQJ LQ &227 >@ DQG UHILQHPHQW LQ 3+(1,; >@
+RZHYHUWKHSURJUHVVRIUHILQHPHQWZDVVWDOOHGZLWKDKLJK5
IDFWRU5IUHH RI      'LIIUDFWLRQ GDWD DQDO\VLV LQ
3KHQL[[WULDJH LQGLFDWHG WKDW WKH FU\VWDO ZDV PHURKHGUDOO\
WZLQQHG ZLWK D WZLQQLQJ IUDFWLRQ RI  )XUWKHU UHILQHPHQW
F\FOHV ZHUH SHUIRUPHG XVLQJ WKH WZLQ WDUJHW IXQFWLRQ DV
LPSOHPHQWHG LQ 3+(1,; ZLWK WKH WZLQQLQJ RSHUDWRU KKNO
7ZR IROG QRQFU\VWDOORJUDSKLF V\PPHWU\ 1&6 LV SUHVHQW
ZKLFKGRHVQRWDOLJQZLWKVSDFHJURXSD[HVWKRXJK1&6ZDV
QRW XVHG DW DQ\ VWDJH RI UHILQHPHQW 7KH UHILQHPHQW ILQDOO\
FRQYHUJHGDIWHUVHYHUDO7/6UHILQHPHQWF\FOHV1RDWRPVZHUH
PRGHOHG LQWR DGGLWLRQDOO\ VSKHULFDO GHQVLW\ ORFDWHG EHWZHHQ
FKDLQ'/DQGFKDLQ%7EHFDXVHLWZDVQRWREYLRXV
ZKDWZDVERXQG7KHVWHUHRFKHPLFDOTXDOLW\RIWKHILQDOPRGHO
ZDV DVVHVVHG XVLQJ0RO3URELW\ >@ $ VXPPDU\ RI WKH GDWD
SURFHVVLQJDQGUHILQHPHQWVWDWLVWLFVDUHSURYLGHGLQ7DEOH
0ROHFXODU ILJXUHV ZHUH JHQHUDWHG LQ 3\02/ 7KH 3\02/
0ROHFXODU*UDSKLFV6\VWHP9HUVLRQ6FKU|GLQJHU//&
DQGILJXUHVRI WKHHOHFWURVWDWLFSRWHQWLDOZHUHJHQHUDWHGXVLQJ
$3%6 >@ 7KH VXUIDFH LQFOXGLQJ WKH SURSRUWLRQ RI FDUERQ
DWRPV OLQLQJ WKH K\GURSKRELF JURRYH LQ .S'VE$ ZDV
FDOFXODWHG XVLQJ WKH&DVW3 VHUYHU >@ E\ DYHUDJLQJ RYHU DOO
VL[ PROHFXOHV ZLWKLQ WKH DV\PPHWULF XQLW 506' FDOFXODWLRQV
DQG VWUXFWXUDO DOLJQPHQWV ZHUH FRQGXFWHG XVLQJ 3\02/ DV
ZHOODV)$7&$7>@
1056WUXFWXUH'HWHUPLQDWLRQRI2[LGL]HG.S'VE$
$VDPSOHRIXQLIRUPO\&1 ODEHOHGR[LGL]HG.S'VE$
P0ZDVSUHSDUHGLQP00(6S++2DQG
+2105H[SHULPHQWVZHUHFRQGXFWHGDW.RQHLWKHU
 0+] RU  0+] VSHFWURPHWHUV HTXLSSHG ZLWK
FU\RJHQLFDOO\ FRROHG SUREHV $OO VSHFWUD ZHUH DFTXLUHG ZLWK
VWDQGDUG SXOVH VHTXHQFHV DQG SURFHVVHGXVLQJ72363,1
%UXNHU %LR6SLQ +1 1 &Į &Į &ȕ &ȕ SHDN OLVWV ZHUH
JHQHUDWHG PDQXDOO\ LQ &$5$ XVLQJ ' >1+@+64& '
+1&$'&%&$&21+DQG'+1&$&%VSHFWUDDQGXVHG
DVWKHLQSXWIRUDXWRPDWHGEDFNERQHDVVLJQPHQWVXVLQJ81,2
0$7&+ 7KHVH DVVLJQPHQWV ZHUH UHILQHG PDQXDOO\ DQG
H[WHQGHG XVLQJ ' 1UHVROYHG >++@12(6< +ȕ +Į
DVVLJQPHQWV ZHUH REWDLQHG XVLQJ D ' +%+$&%&$&21+
VSHFWUXP+11&ĮDQG&ȕDVVLJQPHQWV WRJHWKHUZLWK+ȕ+Į
ZHUH SURYLGHG DV LQSXW IRU 81,2$7126$6&$1 IRU
DXWRPDWHG VLGHFKDLQ DVVLJQPHQWV XVLQJ ' 1 &DOL  DQG
&DUR  UHVROYHG >++@12(6<GDWDVHWV >@8SSHU OLPLWV
IRU GLVWDQFH UHVWUDLQWV XVHG LQ VWUXFWXUH FDOFXODWLRQV ZHUH
DXWRPDWLFDOO\ JHQHUDWHG IURP 12(6< GDWDVHWV XVLQJ 81,2
$7126&$1',' DQG WKH VWUXFWXUH RI R[LGL]HG .S'VE$ ZDV
GHWHUPLQHG XVLQJ WKH WRUVLRQ DQJOH G\QDPLFV SURJUDP
&<$1$>@&RQIRUPHUVZLWKORZHVW&<$1$WDUJHWIXQFWLRQ
YDOXHV ZHUH HQHUJ\ PLQLPL]HG XVLQJ 23$/S DQG YDOLGDWHG
XVLQJ VWUXFWXUH YDOLGDWLRQ WRROV KWWSZZZSGERUJ DQG KWWS
ZZZQLKVHUYHUPELXFODHGX 6WUXFWXUHV ZHUH LQVSHFWHG DQG
7DEOH;UD\GDWDPHDVXUHPHQWDQGUHILQHPHQWVWDWLVWLFV
IRU.S'VE$
'DWDFROOHFWLRQ 9DOXH
6SDFHJURXS 3
8QLWFHOOGLPHQVLRQV 
Dc 
Ec 
Fc 
ĮȕȖ 
:DYHOHQJWKc 
5HVROXWLRQc 
1XPEHUPHDVXUHGUHIOHFWLRQV 
1XPEHURIXQLTXHUHIOHFWLRQV 
5PHUJHD 
5SLP 
,!ı,! 
5HGXQGDQF\ 
&RPSOHWHQHVV 
5HILQHPHQWVWDWLVWLFV 
1XPEHURI5HIOHFWLRQV 
5HVROXWLRQc 
5IUHH 
5ZRUN 
1XPEHURIPRQRPHUVLQDX 
1XPEHURISURWHLQDWRPV 
1XPEHURIZDWHUV 
%IDFWRUVc 
:LOVRQ 
3URWHLQDWRPV 
:DWHUV 
506'%RQGOHQJWKc 
506'%RQGDQJOHV 
5DPDFKDQGUDQIDYRUHGRXWOLHU 
0ROSURELW\FODVKVFRUHVFRUHE >WK@>WK@
D7KHYDOXHVLQSDUHQWKHVHVUHIHUWRWKHKLJKHVWUHVROXWLRQVKHOO
E WK 0ROSURELW\ >@ SHUFHQWLOH LV WKH EHVW DPRQJ VWUXFWXUHV RI FRPSDUDEOH
UHVROXWLRQ WK SHUFHQWLOH LV WKH ZRUVW 7KH QXPEHU RI VWUXFWXUHV LQFOXGHG LQ WKH
FRPSDULVRQLVJLYHQLQSDUHQWKHVHVZLWKLQVTXDUHEUDFNHWV
GRLMRXUQDOSRQHW
&RPSDUDWLYH$QDO\VLVRI.OHEVLHOODSQHXPRQLDH'VE$
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DQDO\]HG ZLWK 02/02/ >@ 7DEOH  VXPPDUL]HV WKH 105
VWDWLVWLFV
%LQGLQJ$IILQLW\RI'VE$,QWHUDFWLQJ3HSWLGHV
&U\VWDOVWUXFWXUHVRI WKH(F'VE$(F'VE%FRPSOH[ UHYHDOHG
WKDW WKH 3 ORRS UHJLRQ RI (F'VE% LQWHUDFWV ZLWK (F'VE$
>@7ZRSHSWLGHVGHULYHG IURP WKH3 ORRSVHTXHQFHVRI
(F'VE%DQG.S'VE%(F±363)$7&'DQG.S±363)47&'
ZHUH V\QWKHVL]HG E\ VROLGSKDVH PHWKRGV XVLQJ )PRF
GHSURWHFWLRQRQ ULQNDPLGH0%+$UHVLQ OHDGLQJ WR&WHUPLQDO
DPLGDWLRQ DQG FDSSHG E\ 1WHUPLQDO DFHW\ODWLRQ $PLGDWLRQ
DQG DFHW\ODWLRQ HQVXUH WKDW WKHUH DUH QR FKDUJHV RQ WKH
SHSWLGH WHUPLQL DV WKHVH DUH QRW SUHVHQW LQ WKH QDWLYH 'VE%
7DEOH  3DUDPHWHUV IRU VWUXFWXUH FDOFXODWLRQ DQG
FKDUDFWHUL]DWLRQ RI  ORZHVW HQHUJ\ PLQLPL]HG 105
FRQIRUPHUVRIR[LGLVHG.S'VE$ņ
4XDQWLW\D 9DOXH
12(XSSHUGLVWDQFHOLPLWV 
LQWUDUHVLGXDO 
VKRUWUDQJH 
PHGLXPUDQJH 
ORQJUDQJH 
5HVLGXDOWDUJHWIXQFWLRQYDOXH>c@ 
5HVLGXDO12(YLRODWLRQV 
QXPEHUc 
PD[LPXP>c@ 
5HVLGXDOGLKHGUDODQJOHYLRODWLRQV 
QXPEHU 
PD[LPXP>@ 
$0%(5HQHUJLHV>NFDOPRO@ 
WRWDO 
YDQGHU:DDOV 
HOHFWURVWDWLF 
506'IURPPHDQFRRUGLQDWHVE>c@ 
)RUZHOOGHILQHGUHJLRQV 
EDFNERQH 
KHDY\DWRPV 
)RU75;GRPDLQ 
EDFNERQH 
KHDY\DWRPV 
)RUKHOLFDOGRPDLQ 
EDFNERQH 
KHDY\DWRPV 
5DPDFKDQGUDQSORWVWDWLVWLFVF 
PRVWIDYRXUHGUHJLRQV>@ 
DGGLWLRQDODOORZHGUHJLRQV>@ 
JHQHURXVO\DOORZHGUHJLRQV>@ 
GLVDOORZHGUHJLRQV>@ 
D ([FHSW IRU WKH WRS ILYH HQWULHV WKRVH UHODWLQJ WR 12(V DYHUDJH YDOXHV DQG
VWDQGDUGGHYLDWLRQVIRUWKHHQHUJ\PLQLPL]HGFRQIRUPHUVDUHJLYHQ7KHWRSVL[
HQWULHV UHSUHVHQW WKH RXWSXW JHQHUDWHG LQ WKH ILQDO F\FOH RI WKH 81,2$7126
&$1','&<$1$ FDOFXODWLRQ E 7KH QXPEHUV LQ SDUHQWKHVHV LQGLFDWH WKH
UHVLGXHVIRUZKLFKWKH506'ZDVFDOFXODWHGF$VGHWHUPLQHGE\352&+(&.
GRLMRXUQDOSRQHW
ORRS VHTXHQFH %LQGLQJ DIILQLW\ ZDV PHDVXUHG XVLQJ D
0LFUR&DO$XWRL7& IURP *(+HDOWKFDUH 86$ DW  &
7KHVDPSOHFHOOZDVORDGHGZLWKȝ/RIȝ0.S'VE$RU
(F'VE$ LQP0+(3(6P01D&OS+DQG'062
  7KH SHSWLGH  P0 GLOXWHG LQ WKH VDPH EXIIHU ZDV
WLWUDWHGZLWKDQLQLWLDOLQMHFWLRQRIȝ/LQWR'VE$IROORZHGE\
 FRQVHFXWLYH LQMHFWLRQV  ȝ/ RIIVHW E\  V ZKLOH WKH
VROXWLRQZDVFRQVWDQWO\VWLUUHGUSP'DWDZHUHILWWHGWRD
VLQJOHVLWHELQGLQJPRGHOXVLQJ0LFUR&DO2ULJLQVRIWZDUH
2ULJLQ  65 Y ([SHULPHQWV ZHUH FRQGXFWHG LQ
WULSOLFDWH DQG DIILQLW\ DQG WKHUPRG\QDPLF SDUDPHWHUV DUH
UHSRUWHGDVPHDQVDQGVWDQGDUGGHYLDWLRQV7DEOH
&RPSDUDWLYH6HTXHQFHDQG6WUXFWXUDO$QDO\VHV
7KH VHTXHQFH FRQVHUYDWLRQ RI WHQ YLUXOHQFH IDFWRUV
SUHYLRXVO\ LGHQWLILHG >@ DV VXEVWUDWHV RI'VE$ZHUH DQDO\]HG
KHUH6HTXHQFHVIURPSXEOLVKHGDQGYDOLGDWHG'VE$VXEVWUDWH
YLUXOHQFH IDFWRUV ZHUH WDNHQ IURP WKH RULJLQDO OLWHUDWXUH DQG
XVHGWRVHDUFKWKHSXEOLFO\DYDLODEOH8QL3URWGDWDEDVH>@IRU
SRWHQWLDO KRPRORJXHV LQ( FROL6 HQWHULFD7\SKLPXULXP DQG
.SQHXPRQLDH0RVWRIWKHIDFWRUVZHUHRULJLQDOO\LGHQWLILHG
LQWKRVHWKUHHRUJDQLVPVH[FHSW<VF&DQG&DI0ZKLFKZHUH
LQLWLDOO\ UHSRUWHG LQ <HUVLQLD SHVWLV $ SURWHLQSURWHLQ %/$67
VHDUFK ZDV SHUIRUPHG XVLQJ WKH 8QL3URW EDFWHULDO JHQRPH
GDWDEDVH ZLWK D WKUHVKROG RI 3   8QOHVV VWDWHG
RWKHUZLVH KRPRORJXHV ZHUH LGHQWLILHG LQ SDWKRJHQLF VWUDLQV
LH(FROL83(&2.+DQG(3(&2+ 2+
6 HQWHULFD 7\SKLPXULXP 6/ DQG QRQPRWLOH .
SQHXPRQLHDHKY.30*+178+.6HTXHQFH
LGHQWLW\ EHWZHHQ KRPRORJXHVZDV H[WUDFWHG IURP WKH8QL3URW
SURWHLQ%/$67UHVXOWV$OORWKHUVHTXHQFHDOLJQPHQWVUHSRUWHG
KHUHLQHJIRU7DEOHZHUHFRQGXFWHGXVLQJ&OXVWDO:>@
5HVXOWV
%LQGLQJ5HVLGXHVRI(F'VE$DUHFRQVHUYHGLQ6H'VE$
DQG'VE$VRI)LYH2WKHU(QWHUREDFWHULDFLDH
(F'VE$DQG6H'VE$VKDUHVHTXHQFHLGHQWLW\DQGERWK
KDYH EHHQ FKDUDFWHUL]HG SUHYLRXVO\ >@ 6H'VE$ FDQ
FRPSOHPHQW (F'VE$ >@ LQ D QXOO PXWDQW PRWLOLW\ DVVD\
LQGLFDWLQJ WKDW 6H'VE$ LV DEOH WR LQWHUDFW ZLWK WKH (F'VE$
ELQGLQJSDUWQHU(F'VE%DQGZLWKWKH(F'VE$VXEVWUDWH(FROL
)OJ, >@ %RWK DUH ZHDN GLVXOILGH UHGXFWDQWV LQ WKH VWDQGDUG
7DEOH  $IILQLW\ DQG HQWKDOS\ IRU 'VE%GHULYHG SHSWLGHV
ELQGLQJWR'VE$SURWHLQV
'VE$ 'VE%SHSWLGH 6WRLFKLRPHWU\ .Gȝ0 ǻ+NFDOPRO
(F'VE$ 363)$7&'   
 363)47&'   
.S'VE$ 363)$7&'   
 363)47&'   
 $SSDUHQW GLVVRFLDWLRQ FRQVWDQW .G DQG HQWKDOS\ RI ELQGLQJ ǻ+ DW  &
REWDLQHG IURP WKUHH LQGHSHQGHQW ,7& H[SHULPHQWV 6HH )LJXUH 6 IRU
UHSUHVHQWDWLYH,7&WUDFHV
GRLMRXUQDOSRQHW
&RPSDUDWLYH$QDO\VLVRI.OHEVLHOODSQHXPRQLDH'VE$
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LQVXOLQ UHGXFWLRQ DVVD\ IRU UHGR[ HQ]\PHV >@ %RWK DUH
VLPLODUO\ R[LGL]LQJ HQ]\PHV WKH UHGR[ SRWHQWLDOV RI (F'VE$
DQG 6H'VE$ DUH  DQG  P9 UHVSHFWLYHO\ >@
ZKHUHDVWKHUDQJHIRUDOO'VE$VLVWRP97DEOH,Q
ERWK (F'VE$ DQG 6H'VE$ WKH PHDVXUHG S.D RI WKH
QXFOHRSKLOLFF\VWHLQHLV>@WKRXJKYDOXHVYDU\DFURVVDOO
'VE$V IURP  WR  7DEOH  $OWKRXJK GLVXOILGH ERQGV
JHQHUDOO\ VWDELOL]H IROGHG SURWHLQV WKH GLVXOILGH IRUP RI 'VE$
HQ]\PHVLVGHVWDELOL]LQJ>@7KHPHOWLQJWHPSHUDWXUHVRIWKH
R[LGL]HG DQG UHGXFHG IRUPV RI (F'VE$ DQG 6H'VE$ DUH
DOPRVWLGHQWLFDOUHGXFHG.DQG.R[LGL]HG.DQG
 . UHVSHFWLYHO\ >@ )LJXUH 6 ZKHUHDV WKH UDQJH RI
PHOWLQJ WHPSHUDWXUHV DFURVV DOO 'VE$V YDULHV FRQVLGHUDEO\
7DEOH  ,PSRUWDQWO\ WKH FU\VWDO VWUXFWXUHV RI (F'VE$ DQG
6H'VE$FDQEHVXSHULPSRVHGZLWKDQ506'RIcIRU
&ĮDWRPVZKHUHDVDFURVVDOOVWUXFWXUDOO\FKDUDFWHUL]HG'VE$V
WKH506'ZLWK(F'VE$YDULHVIURPcWRcIRU
&ĮDWRPV7DEOH>@
7ZR FDWDO\WLFDOO\ UHOHYDQW (F'VE$ FRPSOH[ VWUXFWXUHV KDYH
EHHQ GHVFULEHG D FRPSOH[ EHWZHHQ (F'VE$ DQG (F'VE%
>@DQGRQHEHWZHHQ(F'VE$DQGDSHSWLGHVHJPHQWRI
6LJ$ DQ DXWRWUDQVSRUWHU SURWHLQ IURP 6KLJHOOD IOH[QHUL >@
$QDO\VLVRIWKHVHVWUXFWXUHVUHYHDOHGWKDWWKHELQGLQJLQWHUIDFH
FRPSULVHVWKH1WHUPLQDOUHJLRQVRIWKHDFWLYHVLWHKHOL[+DV
ZHOO DV ORRSV / WKH ILUVW RI WZR ORRSV FRQQHFWLQJ WKH
WKLRUHGR[LQDQGKHOLFDOGRPDLQV/ WKHVHFRQGRI WZR ORRSV
FRQQHFWLQJWKHWKLRUHGR[LQDQGKHOLFDOGRPDLQVDOVRUHIHUUHGWR
DVWKHFLV3URORRSDQG/+UHVLGXHVLQWKH ORRSSUHFHGLQJ
DQG DW WKH 1WHUPLQDO UHJLRQ RI KHOL[ + )LJXUH $ $
K\SRWKHVLVLVWKDW'VE$VVKDULQJRYHUDOOKLJKVHTXHQFHLGHQWLW\
ZLWK (F'VE$ DQG ZLWK KLJKO\ FRQVHUYHG ORRS OHQJWKV DQG
UHVLGXHVLQWKHVHUHJLRQVZLOOVKDUHVLPLODUELQGLQJDFWLYLWLHV$V
VKRZQ LQ )LJXUH % 6H'VE$ IDOOV LQWR WKLV FOXVWHU DV GRHV
6KLJHOOD IOH[QHUL 6I'VE$ 3 (QWHUREDFWHU FORDFDH
(Q'VE$(*/&LWUREDFWHUNRVHUL&N'VE$$$/DQG
&URQREDFWHUVDND]DNLL &V'VE$ ,('DQG.SQHXPRQLDH
.S'VE$ )LJXUH % 2I WKHVH WKH 'VE$ ZLWK ORZHVW
VHTXHQFHLGHQWLW\WR(F'VE$LV.S'VE$HQFRGHGE\DQ
LPSRUWDQW KXPDQ SDWKRJHQ UHVSRQVLEOH IRU PDQ\ DQWLELRWLF
UHVLVWDQWQRVRFRPLDOLQIHFWLRQV>@7RGHWHUPLQHZKHWKHU
.S'VE$ IDOOV ZLWKLQ WKH VDPH FODVV DV (F'VE$ ZH
LQYHVWLJDWHGLWVVWUXFWXUHVXUIDFHUHGR[DQGELQGLQJSURSHUWLHV
DQGFRPSDUHGWKHPZLWK(F'VE$
.S'VE$&RPSOHPHQWV(F'VE$LQYLYR
7KH(FROLSURWHLQ)OJ, LVUHTXLUHGIRU(FROLPRWLOLW\DQG LQ
WXUQ)OJ,UHTXLUHVWKH'6%PDFKLQHU\RI(FROLWRIXQFWLRQ)OJ,
IXQFWLRQ LV LPSDLUHG LQ ( FROL GVE$ GHILFLHQW -&% DQG
GVE$GVE% GRXEOHPXWDQW -&% VWUDLQV GXH WR WKH
DEVHQFHRI(F'VE$PHGLDWHGGLWKLROR[LGDVHDFWLYLW\>@$VD
FRQVHTXHQFHWKHVH(FROLVWUDLQVDUHQRQPRWLOH,QWULJXLQJO\
. SQHXPRQLDH LV QRQPRWLOH DQG GRHV QRW HQFRGH D )OJ,
KRPRORJXH:H WHVWHGZKHWKHU.S'VE$ZDVDEOH WR FDWDO\VH
GLVXOILGH ERQG IRUPDWLRQ RI ( FROL )OJ, XVLQJ DQ LQ YLYR
FRPSOHPHQWDWLRQVWUDWHJ\>@:HGHPRQVWUDWHGWKDW.S'VE$±
OLNH 6H'VE$ >@ ± FDQ IXOO\ UHVWRUH WKH PRWLOLW\ RI GVE$
GHILFLHQWVWUDLQVEXWQRWLQWKHGRXEOHGVE$GVE%PXWDQWFHOOV
)LJXUH 6 7KLV H[SHULPHQW VKRZV WKDW .S'VE$ LV DEOH WR
R[LGL]H )OJ, F\VWHLQHV DQG WKLV UHTXLUHV WKH SUHVHQFH RI
(F'VE%
6RPHGLVWDQWO\UHODWHG'VE$VGRQRWFRPSOHPHQW(F'VE$LQ
WKLV DVVD\ LQFOXGLQJ *UDPQHJDWLYH :ROEDFKLD SLSLHQWLV Į
'VE$ >@ DQG *UDPSRVLWLYH 6WDSK\ORFRFFXV DXUHXV 'VE$
>@ +RZHYHU UHVFXH RU SDUWLDO UHVFXH RI PRWLOLW\ KDV EHHQ
REVHUYHGIRUDZLGHUDQJHRI'VE$KRPRORJXHVVRPHVKDULQJ
TXLWHORZVHTXHQFHLGHQWLW\ZLWK(F'VE$VXFKDV9F'VE$
 3D'VE$   DQG 1P'VE$   >@
&RQVHTXHQWO\(F'VE$FRPSOHPHQWDWLRQPD\QRWEHDVXLWDEOH
JXLGHIRUFDWHJRUL]LQJ'VE$HQ]\PHVLQWRGLVWLQFWFODVVHV
.S'VE$KDVUHGR[SURSHUWLHVDOPRVWLGHQWLFDOWRWKRVH
RI(F'VE$DQG6H'VE$
(F'VE$ H[KLELWV ZHDN LQVXOLQ UHGXFWDVH DFWLYLW\ LQ WKH
SUHVHQFH RI GLWKLRWKUHLWRO >@ ZKHUHDV WKH ( FROL GLVXOILGH
LVRPHUDVH(F'VE&LVKLJKO\DFWLYH LQWKLVDVVD\5HGXFWLRQRI
WKHLQWHUPROHFXODUGLVXOILGHERQGVEHWZHHQWKH$DQG%FKDLQV
RILQVXOLQUHVXOWVLQSUHFLSLWDWLRQRIWKH%FKDLQDQGWKLVFDQEH
PRQLWRUHG E\ PHDVXULQJ WKH 2'QP :H IRXQG WKDW SXULILHG
UHFRPELQDQW .S'VE$ KDV WKH VDPH ZHDN LQVXOLQ UHGXFWDVH
DFWLYLW\DV(F'VE$)LJXUH$DQG6H'VE$ >@7KHDFWLYLW\
RI RWKHU FKDUDFWHUL]HG 'VE$ HQ]\PHV YDULHV 1P'VE$ IRU
H[DPSOHKDVDPXFKZHDNHUDFWLYLW\WKDQWKDWRI(F'VE$>@
DQG 'VE$ IURP 0\FREDFWHULXP WXEHUFXORVLV 0WE'VE$ LV
LQDFWLYH LQ WKLV DVVD\ >@ ,Q FRQWUDVW 7FS* 9F'VE$ IURP
9LEULR FKROHUDH FDWDO\VHV LQVXOLQ UHGXFWLRQ PXFK IDVWHU WKDQ
(F'VE$>@
:HQH[WGHWHUPLQHGWKHVWDQGDUGUHGR[SRWHQWLDORI.S'VE$
UHODWLYH WR JOXWDWKLRQH >*6+@*66* (¶    9 7KH
HTXLOLEULXP FRQVWDQW IRU .S'VE$ ZDV HVWLPDWHG IURP WKH
>*6+@*66*WLWUDWLRQH[SHULPHQWWREH0)LJXUH
%ZKLFK FRUUHVSRQGV WR D VWDQGDUG UHGR[SRWHQWLDO RI 
P9 7KLV YDOXH IDOOV YHU\ FORVH WR WKH YDOXHV UHSRUWHG IRU
(F'VE$P9>@DQG6H'VE$P9>@FRQVLGHULQJ
WKH ZLGH UDQJH RI YDOXHV UHSRUWHG DFURVV DOO 'VE$ HQ]\PHV
WRP9>@
7KHS.DYDOXHRI WKHQXFOHRSKLOLFF\VWHLQH LQ WKHDFWLYHVLWH
&;;& PRWLI LV D NH\ GHWHUPLQDQW RI 'VE$ UHDFWLYLW\ WRZDUGV
VXEVWUDWH SURWHLQV :H PHDVXUHG WKH S.D YDOXH IRU WKH
QXFOHRSKLOLF F\VWHLQH RI .S'VE$ XVLQJ S+GHSHQGHQW WKLRODWH
DEVRUEDQFH DW Ȝ    QP )LJXUH & 7KH S.D&\V IRU
.S'VE$ZDVIRXQGWREHQHDUO\LGHQWLFDOWRWKDWRI(F'VE$
DQG6H'VE$FRPSDUHGZLWKWKHREVHUYHGUDQJHIRURWKHU
'VE$V
:HDOVRFRQILUPHG WKDW UHGXFHG.S'VE$ 7PUHG 
. LVPRUH VWDEOH WKDQR[LGL]HG.S'VE$ 7PR[   .
)LJXUH ' 7KH PHOWLQJ WHPSHUDWXUHV IDOO EHWZHHQ YDOXHV
UHSRUWHGSUHYLRXVO\IRU(F'VE$7PUHG.7PR[
  . >@ DQG WKRVH IRU 6H'VE$ 7PUHG    . 7PR[
   . UHSRUWHG KHUH )LJXUH 6 $JDLQ WKH UDQJH
UHSRUWHG IRU DOO 'VE$V LV PXFK ZLGHU 7PUHG   7PR[
.>@
:HWKHQWHVWHGWKHGLWKLROR[LGDVHDFWLYLW\RI.S'VE$XVLQJD
IOXRUHVFHQWO\ ODEHOHG SHSWLGH VXEVWUDWH 7KH DFWLYLW\ ZDV
PRQLWRUHG E\ WKH LQFUHDVH LQ HXURSLXP IOXRUHVFHQFH UHVXOWLQJ
IURP F\FOL]DWLRQ RI WKH VXEVWUDWH SHSWLGH WKURXJK IRUPDWLRQ RI
DQ LQWUDPROHFXODU GLVXOILGH ERQG ,Q WKH SUHVHQFH RI (F'VE%
&RPSDUDWLYH$QDO\VLVRI.OHEVLHOODSQHXPRQLDH'VE$
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ZH IRXQG WKDW WKH UDWH IRU .S'VE$ DQG 6H'VE$ FDWDO\]HG
GLVXOILGHERQGIRUPDWLRQZDVDOPRVWLQGLVWLQJXLVKDEOHIURPWKDW
RI (F'VE$ PHDVXUHG DW WKH VDPH FRQFHQWUDWLRQ RI HQ]\PH
)LJXUH7KLVUHVXOWVXJJHVWV WKDW.S'VE$DQG6H'VE$ LV
DEOH WR LQWHUDFW LQ WKH VDPHZD\DV(F'VE$ZLWK WKHSHSWLGH
VXEVWUDWH DQG ZLWK (F'VE% 7FS* KDV D VLPLODU DFWLYLW\ WR
(F'VE$LQWKLVDVVD\>@ZKHUHDV0WE'VE$LVLQDFWLYHLQWKH
SUHVHQFHRI(F'VE%>@
&U\VWDOVWUXFWXUHRIUHGXFHG.S'VE$
:H GHWHUPLQHG WKH FU\VWDO VWUXFWXUH RI UHGXFHG .S'VE$
3'%0&8DW c UHVROXWLRQE\PROHFXODU UHSODFHPHQW
XVLQJ (F'VE$ DV WKH WHPSODWH $V H[SHFWHG WKH VWUXFWXUH LV
YHU\VLPLODUWRWKDWRI(F'VE$)LJXUH$7KHDV\PPHWULFXQLW
FRQWDLQVVL[.S'VE$PROHFXOHVHDFKDGRSWLQJWKHW\SLFDO'VE$
IROG 6WUXFWXUDO VXSHUSRVLWLRQ RI WKHVH VL[ LQGHSHQGHQW FRSLHV
\LHOGHGDURRWPHDQVTXDUHGHYLDWLRQ506'cIRU
&ĮDWRPVEHWZHHQUHVLGXHV*O\9DO/LNHZLVHVWUXFWXUDO
)LJXUH&RPSDULVRQRI(F'VE$DQG6H'VE$$6WUXFWXUDOVXSHUSRVLWLRQRI(F'VE$PDJHQWD3'%LG)9.DQG6H'VE$
EOXH 3'% ,G /6 1 DQG&WHUPLQL KHOLFHV +   DQG VWUDQGV ȕ DUH LQGLFDWHG ,Q DGGLWLRQ VXUIDFH ORRSV / ± /
SUHGLFWHGWREHLQYROYHGLQELQGLQJ(F'VE%SHULSODVPLFORRS3RUVXEVWUDWHDUHODEHOHGLQUHG$FWLYHVLWHF\VWHLQHVDUHVKRZQDV
RUDQJHVSKHUHVDQGWKHFLV3URPRWLI LQ WKH/ ORRS LV LQGLFDWHGE\D\HOORZVWDU%6HTXHQFHVRI(F'VE$ ORRSVWKDWELQG'VE%
EOXHUHGRU6LJ$VXEVWUDWHEOXH+RPRORJXHVZLWKKLJKO\FRQVHUYHGORRSVHTXHQFHVDUHVKRZQ6IOH[QHUL6I'VE$36
HQWHULFD 7\SKLPXULXP 6H'VE$(:(& NRVHUL &N'VE$ $$/( FORDFDH (Q'VE$ (*/& VDND]DNLL &V'VE$
,('DQG.SQHXPRQLDH.S'VE$%;=-&RQVHUYHGUHVLGXHVDUHVKRZQLQJUH\DQGYDULDEOHUHVLGXHVLQEODFN
GRLMRXUQDOSRQHJ
&RPSDUDWLYH$QDO\VLVRI.OHEVLHOODSQHXPRQLDH'VE$
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DOLJQPHQWRI.S'VE$ZLWK(F'VE$)9.cPROHFXOH%
DQG6H'VE$/6cJDYH506'YDOXHVcIRUWKH
LGHQWLFDO UDQJH RI  &Į DWRPV %\ FRPSDULVRQ KLJK
UHVROXWLRQ FU\VWDO VWUXFWXUHV RI GLVWDQWO\ UHODWHG 'VE$V KDYH
PXFKKLJKHU506'VFRYHULQJDVPDOOHUUDQJHRIHTXLYDOHQW&Į
DWRPV HJ 3D'VE$ 3'% FRGH + DQG (F'VE$ )9.
PROHFXOH%&ĮDWRPV506'RIc>@7KHVHKLJKHU
YDOXHVDUHD FRQVHTXHQFHRI VWUXFWXUDO GHYLDWLRQV LQFOXGLQJD
WUXQFDWHGKHOL[+DQGDVKRUWHQHGK\GURSKRELFJURRYH
7KH VWUXFWXUH RI WKH FDWDO\WLF VLWH RI .S'VE$ LV VWULFWO\
FRQVHUYHGZLWKWKDWRI(F'VE$FRPSULVLQJWKHDFWLYHVLWHPRWLI
&\V3UR+LV&\V ORFDWHG DW WKH1WHUPLQDO HQG RI KHOL[+
DQG WKHDGMDFHQWFLV3UR 9DO3UR / ORRS )LJXUH%7KH
F\VWHLQH UHVLGXHV &\V DQG &\V DUH SUHVHQW LQ WKH
UHGXFHGVWDWHLQWKHFU\VWDOVWUXFWXUH$K\GURSKRELFSDWFKDQG
D ODUJH JURRYH VXUURXQGV WKH QXFOHRSKLOLF &\V DV DOVR
RFFXUV LQ (F'VE$ DQG 6H'VE$ )LJXUH & $V H[SHFWHG
WKHVHVXUIDFHIHDWXUHVDUHOLQHGZLWKUHVLGXHVFRQWULEXWHGIURP
WKH//DQG/ORRSV
7KH VL[ LQGHSHQGHQW FRSLHV RI .S'VE$ LQ WKH FU\VWDO
VWUXFWXUH DOORZ DQ DQDO\VLV RI FRQIRUPDWLRQDO YDULDELOLW\ RI WKH
ORRS UHVLGXHV IRUPLQJ WKH ELQGLQJ VXUIDFH 7KLV UHYHDOHG WKDW
WKH VLGH FKDLQVRI+LV3KH /HX*OQ7KUDQG
0HWDGRSWYDULRXVURWDPHUFRQIRUPDWLRQVZKHUHDVWKHUHLV
QR HYLGHQFH RI FRQIRUPDWLRQDO YDULDELOLW\ LQ 7\U &\V
3UR 9DO 3UR DQG 3KH )LJXUH $ 7KH VLGH
FKDLQYDULDWLRQVGRQRWLQIOXHQFHWKHVXUIDFHDFFHVVLELOLW\RIWKH
K\GURSKRELFJURRYHZKLFKZDVFDOFXODWHGWREHcE\
&DVW3>@DFURVVWKHPROHFXOHV0RUHRYHUWKHK\GURSKRELF
QDWXUH RI WKH JURRYH LV XQDIIHFWHG E\ WKH VLGH FKDLQ
FRQIRUPDWLRQDO YDULDELOLW\ DV LQGLFDWHG E\ WKH SURSRUWLRQ RI
FDUERQDWRPVOLQLQJWKLVJURRYH>@
1056ROXWLRQ6WUXFWXUHRI.S'VE$LV6LPLODUWRWKH
&U\VWDO6WUXFWXUH
3UHYLRXV VWXGLHVKDYHGHPRQVWUDWHG WKDW WKHUHDUHPLQLPDO
GLIIHUHQFHV EHWZHHQ UHSRUWHG VWUXFWXUHV FU\VWDO DQG105 RI
R[LGL]HG DQG UHGXFHG (F'VE$ 7R GHWHUPLQH LI WKLV ZDV DOVR
)LJXUH.S'VE$UHGR[SURSHUWLHV$'LVXOILGHERQGUHGXFWLRQDFWLYLW\RI.S'VE$Ÿ(F'VE$Ŷ(F'VE&ƔDQGDFRQWURO
ZLWKRXWHQ]\PH△ZDVPRQLWRUHGVSHFWURSKRWRPHWULFDOO\6H'VE$DFWLYLW\KDVEHHQSXEOLVKHGHOVHZKHUH>@%5HGR[HTXLOLEULD
RI.S'VE$ZLWKJOXWDWKLRQH*6+*66*&'HWHUPLQDWLRQRIWKHQXFOHRSKLOLF&\V&;;&S.D7KHS+GHSHQGHQWDEVRUEDQFH
RIWKHWKLRODWHDQLRQDWQPZDVILWWHGWRWKH+HQGHUVRQ+DVVHOEDFKHTXDWLRQ'7HPSHUDWXUHLQGXFHGXQIROGLQJRIR[LGL]HGR[
ŶDQGUHGXFHGUHGƑ.S'VE$ZDVGHWHUPLQHGE\IDU89&'VSHFWURVFRS\VKRZLQJWKDWWKHUHGXFHGIRUPLVPRUHVWDEOHWKDQWKH
R[LGL]HGIRUP
GRLMRXUQDOSRQHJ
&RPSDUDWLYH$QDO\VLVRI.OHEVLHOODSQHXPRQLDH'VE$
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WKH FDVH IRU .S'VE$ D VHPLDXWRPDWHG105 DSSURDFKZDV
XVHG WRGHWHUPLQH WKHVWUXFWXUHRIR[LGL]HG.S'VE$3'% ,'
0%6 %05% ,'  )ROORZLQJ 81,2$7126$6&$1
PDQXDOYHULILFDWLRQDQGUHILQHPHQWHQDEOHGDVVLJQPHQWRI
RIWKHQRQODELOHSURWRQUHVRQDQFHVLQ.S'VE$7KHVHZHUH
XVHGWRJHQHUDWHWKH12(EDVHGGLVWDQFHFRQVWUDLQWV IRU ILQDO
VWUXFWXUH FDOFXODWLRQ 7ZHQW\ FRQIRUPHUV ZLWK ORZHVW WDUJHW
IXQFWLRQDQGOHDVWYLRODWLRQVRI LQSXWUHVWUDLQWVZHUHFKRVHQWR
UHSUHVHQWWKHVWUXFWXUHRIR[LGL]HG.S'VE$)LJXUH6$%,W
ZDV QRW SRVVLEOH WR DVVLJQ VHYHUDO EDFNERQH DPLGH
UHVRQDQFHVFRUUHVSRQGLQJWRUHVLGXHVLQWKHȕȕORRS,OH
*O\ *OX *OQ 9DO /HX VR WKDW WKLV UHJLRQ
DSSHDUV WR EH ODUJHO\ GLVRUGHUHG LQ WKH 105 HQVHPEOH
FRPSDUHGZLWKWKHUHVWRIWKHVWUXFWXUH7KHEDFNERQH1&Į
&¶DQGDOOKHDY\DWRP506'IRUWKHZHOOGHILQHGUHVLGXHV
±RIWKH.S'VE$FRQIRUPHUVZHUH
c DQG    c UHVSHFWLYHO\ 6WUXFWXUDO VWDWLVWLFV DUH
VXPPDUL]HGLQ7DEOH$VREVHUYHGIRURWKHU'VE$VWUXFWXUHV
WKH LQGLYLGXDO WKLRUHGR[LQ DQG KHOLFDO GRPDLQV FDQ EH
VXSHULPSRVHG ZLWK KLJKHU SUHFLVLRQ WKDQ WKH HQWLUH VWUXFWXUH
7KLV LVPRVW OLNHO\GXHWR LQWHUGRPDLQPRWLRQZKLFKKDVDOVR
EHHQ UHSRUWHG LQ WKH VWUXFWXUHV RI (F'VE$ >@ DQG 9F'VE$
>@ 5HVLGXHV ZKLFK IDOO LQWR GLVDOORZHG 5DPDFKDQGUDQ
UHJLRQV LQFOXGHWKHXQDVVLJQHGUHVLGXHV*OX*OQ9DO
DQG +LV DQG UHVLGXHV LQ ORRS UHJLRQV LH /\V 3KH
/HX$VQDQG0HW
7KH RYHUDOO FRQIRUPDWLRQ RI WKH 105 VWUXFWXUH RI R[LGL]HG
.S'VE$ LV VLPLODU WR WKDW RI WKH FU\VWDO VWUXFWXUH RI UHGXFHG
.S'VE$)LJXUH&)RUH[DPSOHVXSHUSRVLWLRQRIPROHFXOH$
LQ WKH FU\VWDO VWUXFWXUH RI UHGXFHG .S'VE$ ZLWK WKH ILUVW
)LJXUH   ,Q YLWUR SHSWLGH GLWKLRO R[LGDWLRQ  $ 'LWKLRO
R[LGDVHDFWLYLWLHVRI(F'VE$Ŷ6H'VE$ƔDQG.S'VE$➉
ZHUHPRQLWRUHGXVLQJDIOXRUHVFHQWO\ODEHOHGSHSWLGHVXEVWUDWH
6DPSOHV ODFNLQJ WKHSDUWQHUSURWHLQ(F'VE%.S'VE$SHSWLGH
△(F'VE$SHSWLGHƑ6H'VE$SHSWLGHż RU EXIIHU DORQHź
VKRZHGQRLQFUHDVHLQVLJQDORYHUWKHVDPHWLPHSHULRG
GRLMRXUQDOSRQHJ
VWUXFWXUH LQWKH105HQVHPEOHRIR[LGL]HG.S'VE$\LHOGVDQ
506' RI  c RYHU  &Į DWRPV 7R PDNH D VLPLODU
FRPSDULVRQWKHFU\VWDOVWUXFWXUHVRIR[LGL]HG)9.PROHFXOH
%DQGUHGXFHG$/PROHFXOH%(F'VE$KDYHDQ506'RI
 c RYHU  &Į DWRPV DQG WKH FU\VWDO VWUXFWXUH RI
R[LGL]HG(F'VE$)9.PROHFXOH%DQGWKHILUVWVWUXFWXUH LQ
WKH105HQVHPEOHRIUHGXFHG(F'VE$$KDYHDQ506'
RIcRYHU&ĮDWRPV>@
7KHVWUXFWXUHVRIWKHFDWDO\WLFVLWHVDQGK\GURSKRELFVXUIDFH
IHDWXUHVDUHVLPLODUFRQVLGHULQJWKDWWKHF\VWHLQHVRIWKH&;;&
PRWLI DUH R[LGL]HG LQ WKH 105 VWUXFWXUH DQG UHGXFHG LQ WKH
FU\VWDO VWUXFWXUH )LJXUH6& $V KDV EHHQ QRWHG SUHYLRXVO\
IRU RWKHU 'VE$ VROXWLRQ DQG FU\VWDO VWUXFWXUHV >@ / RI
.S'VE$LVDUHODWLYHO\IOH[LEOHSDUWRI WKHSURWHLQ LQERWK105
DQG FU\VWDO VWUXFWXUHV )LJXUH % DQG & 7KXV RYHUDOO WKH
VWUXFWXUHV RI R[LGL]HG DQG UHGXFHG .S'VE$ DUH VLPLODU
QRWZLWKVWDQGLQJ WKH GLIIHUHQW FRQGLWLRQV DQG DSSURDFKHV XVHG
IRUVWUXFWXUHGHWHUPLQDWLRQ
%LQGLQJ$IILQLW\RI'VE%SHSWLGHVLVVLPLODUIRU.S'VE$
DQG(F'VE$
7KH VLPLODU VXUIDFH IHDWXUHV DQG VLPLODU SUHGLFWHG ELQGLQJ
UHVLGXHV RI .S'VE$ DQG (F'VE$ VXJJHVWHG WKDW WKHVH
HQ]\PHV ZRXOG LQWHUDFW ZLWK ELQGLQJ SDUWQHUV ZLWK VLPLODU
DIILQLW\7KHFU\VWDOVWUXFWXUHVRIWKH(F'VE$(F'VE%FRPSOH[
VKRZHGWKDW WKHVHFRQGSHULSODVPLF ORRS3RI(F'VE%ELQGV
GLUHFWO\ WR (F'VE$ >@ 7KH ELQGLQJ UHVLGXHV DUH 
363)$7&' DQG WKHVH DUH KLJKO\ FRQVHUYHG LQ .S'VE%
363)47&' 7KHVH WZR 3 SHSWLGHV ZHUH
V\QWKHVL]HGDQGLVRWKHUPDOWLWUDWLRQFDORULPHWU\,7&ZDVXVHG
WRDVVHVVWKHLUELQGLQJDIILQLW\ IRUERWKHQ]\PHV.S'VE$DQG
(F'VE$ ZHUH IRXQG WR ELQG WR 363)$7&' DQG 363)47&'
ZLWKVLPLODUDIILQLWLHV .G07DEOH)LJXUH6$:H
LQYHVWLJDWHG WKH LQWHUDFWLRQ RI .S'VE$ ZLWK 363)47&' E\
VWUXFWXUDO VXSHUSRVLWLRQ RI .S'VE$ RQWR WKH VWUXFWXUH RI
(F'VE$ LQ WKH (F'VE$(F'VE% FRPSOH[ VWUXFWXUH 5HVLGXH
$OD RI (F'VE% 363)$7&' ZDV PXWDWHG LQ VLOLFR WR
363)47&' XVLQJ WKHPRVW FRPPRQO\ REVHUYHG URWDPHU IRU
JOXWDPLQH7KHVXSHULPSRVHGPRGHOVKRZHG WKDW WKH3 ORRS
PDWFKHG WKH VXUIDFH RI .S'VE$ YHU\ ZHOO ZLWK QR FODVKHV
DSSDUHQWEHWZHHQWKH3UHVLGXHVDQG.S'VE$)LJXUH6%
'LVFXVVLRQ
:H KDYH VKRZQ WKDW WKH VWUXFWXUDO VXUIDFH UHGR[ DQG
ELQGLQJSURSHUWLHVRI(F'VE$6H'VE$DQG.S'VE$HQ]\PHV
DUH KLJKO\ FRQVHUYHG DQG WKDW WKHVH WKUHH 'VE$V DQG IRXU
RWKHU 'VE$V IURP (QWHUREDFWHU FORDFDH &LWUREDFWHU NRVHUL
6KLJHOOD IOH[QHUL DQG &URQREDFWHU VDND]DNLL PLJKW EH
FRQVLGHUHG DQ (QWHUREDFWHULDFHDH VXEFODVV RI 'VE$
&DUEDSHQHPUHVLVWDQW(QWHUREDFWHULDFHDH DUH UHVSRQVLEOH IRU
D ODUJHSURSRUWLRQRIGLIILFXOW WR WUHDWFRPPXQLW\DQGKRVSLWDO
DFTXLUHGLQIHFWLRQV>@DQGWKHUHLVDQXUJHQWQHHGWRGHYHORS
QRYHO WKHUDSHXWLF VWUDWHJLHV WR WDFNOH WKHVH VRFDOOHG µVXSHU
EXJV¶>@
2QHDSSURDFKWRJHQHUDWHQHZFODVVHVRIDQWLEDFWHULDOVLVWR
WDUJHW YLUXOHQFH UDWKHU WKDQ YLDELOLW\ RI EDFWHULD $Q
DQWLYLUXOHQFH DSSURDFK LV SUHGLFWHG WR OHDG WR OHVV VHOHFWLYH
&RPSDUDWLYH$QDO\VLVRI.OHEVLHOODSQHXPRQLDH'VE$
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)LJXUH &U\VWDOVWUXFWXUHRI.S'VE$ $6XSHUSRVLWLRQRIFU\VWDOVWUXFWXUHVRI.S'VE$F\DQ3'%,G0&8DQG(F'VE$
PDJHQWD 3'% LG )9. 7KH1 DQG&WHUPLQL KHOLFHV +   DQG VWUDQGV ȕ DUH LQGLFDWHG 6XUIDFH ORRSV / ± / DUH
ODEHOHG LQ UHG DQG DFWLYH VLWH F\VWHLQHV DUH VKRZQDV RUDQJH VSKHUHV% (OHFWURQ GHQVLW\ LQ WKH DFWLYH VLWH UHJLRQ RI.S'VE$
LQGLFDWHV WKDW WKH F\VWHLQHV DUH UHGXFHG 7KH )R  )F PDS ZDV FUHDWHG XVLQJ 3KHQL[ PRGHOPDS FRUUHODWLRQV >@ DQG LV
FRQWRXUHG DW  ı & (OHFWURVWDWLF VXUIDFH UHSUHVHQWDWLRQ RI (F'VE$ 6H'VE$ DQG .S'VE$ OHIW PLGGOH ULJKW 3RVLWLYH DQG
QHJDWLYH HOHFWURVWDWLF SRWHQWLDOV DUH FRQWRXUHG IURP EOXH  N7H WR UHG  N7H 7KH K\GURSKRELF JURRYHV RI DOO WKUHH
HQ]\PHVDUHLQGLFDWHGE\DGDVKHGRYDO>@
GRLMRXUQDOSRQHJ
&RPSDUDWLYH$QDO\VLVRI.OHEVLHOODSQHXPRQLDH'VE$
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SUHVVXUH IRU UHVLVWDQFH GHYHORSPHQW VLQFH PRVW YLUXOHQFH
WUDLWVDUHQRWHVVHQWLDOIRUVXUYLYDO>@7DUJHWLQJYLUXOHQFHPD\
DOVRH[SDQGWKHUHSHUWRLUHRIDQWLPLFURELDOWDUJHWVSUHVHUYHWKH
HQGRJHQRXV KRVW PLFURELRPH DQG H[WHQG WKH OLIHVSDQ RI
FRQYHQWLRQDO DQWLELRWLFV >@ 0RVW DQWLYLUXOHQFH VWUDWHJLHV
GHYHORSHG WR GDWH WDUJHW LQGLYLGXDO YLUXOHQFH IDFWRUV >@
DQG WKLV KDV \LHOGHG VRPH VXFFHVVHV >@ +RZHYHU WKH
DUPRU\ RI 'VE$ VXEVWUDWH YLUXOHQFH IDFWRUV H[SUHVVHG LQ
GLIIHUHQW (QWHUREDFWHULDFHDH YDULHV )LJXUH  VR WKDW GUXJV
WDUJHWLQJVSHFLILFYLUXOHQFHIDFWRUVPD\QRWEHHIIHFWLYHDJDLQVW
DOO (QWHUREDFWHULDFHDH 2Q WKH RWKHU KDQG 'VE$ LWVHOI
FDWDO\]HV DVVHPEO\ RI PDQ\ YLUXOHQFH IDFWRUV >@ DQG
'VE$ NQRFNRXWV VHYHUHO\ DWWHQXDWH YLUXOHQFH LQ LQIHFWLRQ
PRGHOV >@ 7DUJHWLQJ 'VE$ LV WKHUHIRUH D FRPSHOOLQJ
DSSURDFK IRU WKH GHYHORSPHQW RI DQWLYLUXOHQFH DJHQWV
EHFDXVH 'VE$ LQKLELWRUV VKRXOG LQKLELW D UDQJH RI YLUXOHQFH
WUDLWV 6LJQLILFDQWO\ RXU ILQGLQJV SRLQW WR WKH RSSRUWXQLW\ WR
)LJXUH&RQIRUPDWLRQDOYDULDELOLW\LQ;UD\DQG105VWUXFWXUHVRI.S'VE$$6XSHULPSRVLWLRQRIWKHVL[.S'VE$PROHFXOHV
EOXH LQWKHDV\PPHWULFXQLWVKRZVWKH OLPLWHGFRQIRUPDWLRQDOYDULDELOLW\ LQWKHVLGHFKDLQVRIDFWLYHVLWHDQG//DQG/ORRS
UHVLGXHVVWLFNUHSUHVHQWDWLRQ%&DUWRRQUHSUHVHQWDWLRQRIWKH.S'VE$FU\VWDOVWUXFWXUH0ROHFXOH'ZLWK&ĮDWRPVFRORUHGE\
WHPSHUDWXUHIDFWRU%IDFWRU0ROHFXOH'ZDVVHOHFWHGDVLWVWHPSHUDWXUHIDFWRUGLVWULEXWLRQLVWKHPRVWSURQRXQFHGGXHWRPLQLPDO
FU\VWDOORJUDSKLFFRQWDFWV,QSDUWLFXODUWKHKLJK%IDFWRURIORRS/LQGLFDWHVPRELOLW\LQWKDWUHJLRQFRQVLVWHQWZLWKWKH105GDWD&
6WHUHRGLDJUDPRI UHSUHVHQWDWLYHVWDWHVRI UHGXFHG ;UD\F\DQDQGR[LGL]HG 105\HOORZVWUXFWXUHVRI.S'VE$5HGDUURZV
KLJKOLJKWGLIIHUHQFHVLQWKHVWUXFWXUHVDW1WHUPLQDODQG/ORRSUHJLRQV
GRLMRXUQDOSRQHJ
&RPSDUDWLYH$QDO\VLVRI.OHEVLHOODSQHXPRQLDH'VE$
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GHYHORS D VLQJOH DQWLYLUXOHQFH GUXJ HIIHFWLYH DJDLQVW 'VE$V
HQFRGHGE\DWOHDVWVHYHQ(QWHUREDFWHULDFHDHSDWKRJHQV
7KHFU\VWDOVWUXFWXUHDQG105VROXWLRQVWUXFWXUHRI.S'VE$
WKH ODWWHU GHULYHG E\ VHPLDXWRPDWHG DSSURDFKHV UHSRUWHG
KHUH DUH LQ H[FHOOHQW DJUHHPHQW 7KH DYDLODELOLW\ RI VWUXFWXUDO
GDWD IRU .S'VE$ RSHQV XS WKH SRVVLELOLW\ RI XVLQJ VWUXFWXUH
EDVHGDSSURDFKHV WRJHQHUDWH'VE$ LQKLELWRUV0RUHRYHU WKH
FORVHVLPLODULW\RIWKHFU\VWDODQG105VWUXFWXUHVDQGWKHXVH
RIVHPLDXWRPDWHG105KLJKOLJKWVKRZ105FDQEHXVHGDV
DQ HIILFLHQW ILUVW VFUHHQ LQ HJ GUXJOLNH IUDJPHQW FDPSDLJQV
%\ FRQWUDVW WKH VL[ PROHFXOHV LQ WKH DV\PPHWULF XQLW RI
.S'VE$ FU\VWDO VWUXFWXUH LV IDU IURP LGHDO IRU UDSLG IUDJPHQW
VFUHHQLQJ EXW LV QHYHUWKHOHVV DGYDQWDJHRXV IRU IROORZ XS
DQDO\VLV
7DNHQ WRJHWKHURXUGDWDVKRZ WKDW'VE$HQ]\PHVVKDULQJ
! VHTXHQFH LGHQWLW\ ZLWK (F'VE$ DOVR VKDUH DOPRVW
LGHQWLFDO UHGR[ DQG VXUIDFH SURSHUWLHV DQG FDQ WKXV EH
FDWHJRUL]HGDVDGLVWLQFW'VE$VXEFODVV)XUWKHUDQDO\VHVZLOO
EHUHTXLUHGWRGHWHUPLQHKRZPDQ\VXEFODVVHVRI'VE$H[LVW
DQGZKHWKHU'VE$VZLWKORZHUWKDQVHTXHQFHLGHQWLW\ZLOO
IDOOLQWRWKH(F'VE$OLNHFODVV,PSRUWDQWO\RXUUHVXOWVVXJJHVW
WKDWFRPSRXQGVGHVLJQHGWRLQKLELW(F'VE$ZLOOOLNHO\LQKLELWDOO
'VE$V ZLWKLQ WKH VDPH FODVV )LQDOO\ ZH SURSRVH WKDW
FRPSRXQGVWKDWELQG.S'VE$PLJKWEHLGHQWLILHGUDSLGO\XVLQJ
VHPLDXWRPDWHG 105 DSSURDFKHV DQG WKDW GHYHORSPHQW RI
µKLWV¶ WR RSWLPLVH SRWHQF\ FDQ EH DFKLHYHG XVLQJ D SLSHOLQH
FRPSULVLQJELRFKHPLFDO DQG VWUXFWXUDO DVVD\V VLPLODU WR WKRVH
RXWOLQHGKHUHLQ
6XSSRUWLQJ,QIRUPDWLRQ
)LJXUH6 7KHUPDOXQIROGLQJRI6H'VE$$7HPSHUDWXUH
LQGXFHG XQIROGLQJ RI R[LGL]HG R[ Ȟ DQG UHGXFHG UHG ș
6H'VE$ZDVPRQLWRUHGE\IDU89&'VSHFWURVFRS\8QIROGLQJ
ZDVPRQLWRUHG LQ.VWHSV IURP. WR.1RUPDOL]HG
DYHUDJH GDWD SRLQWV RI WKUHH PHDVXUHPHQWV ZHUH ILWWHG WR D
WZRVWDWH IROGLQJPRGHO7KH UHGXFHGVWDWHRI6H'VE$ 
.LV.PRUHVWDEOHWKDQLWVR[LGL]HG.
IRUP
7,)
)LJXUH 6  6XPPDU\ RI LQ YLYR FRPSOHPHQWDWLRQ RI
.S'VE$DQG(F'VE$$(FROLFHOOVODFNLQJGVE$-&%
RU GVE$ GVE% -&% DUH QRQPRWLOH ([SUHVVLRQ RI
.S'VE$RU(F'VE$FDQ UHVFXH WKHVZDUPLQJRI(FROLGVE$
-&%EXWQRWRIGVE$GVE%FHOOV([SUHVVLRQRI.S'VE$
RU(F'VE$LVLQGXFHGE\LQFOXVLRQRIDUDELQRVHDUDE
7,)
)LJXUH6 %LQGLQJVWXGLHVRI363)47&' WR.S'VE$$
5HSUHVHQWDWLYH ,7& SURILOH IRU 363)47&' SHSWLGH ELQGLQJ WR
(F'VE$)RUDOOFRPELQDWLRQVWHVWHGVHH7DEOH%0RGHORI
)LJXUH   &RQVHUYDWLRQ RI 'VE$ VXEVWUDWH YLUXOHQFH IDFWRUV  &RPSDULVRQ RI WKH VHTXHQFH FRQVHUYDWLRQ RI 'VE$
R[LGRUHGXFWDVHV IURP( FROL (F6 HQWHULFD 7\SKLPXULXP 6H DQG. SQHXPRQLD .S DQG RI FKDUDFWHUL]HG 'VE$ VXEVWUDWH
YLUXOHQFHIDFWRUV6HTXHQFHLGHQWLWLHVUHODWLYHWRWKHFKDUDFWHUL]HGVXEVWUDWHSURWHLQDUHUHSUHVHQWHGLQGLIIHUHQWFRORXUVDVVKRZQ
LQWKHNH\:KLWHVTXDUHVLQGLFDWHWKHODFNRIDVHTXHQFHKRPRORJXHLQWKHVSHFLILFEDFWHULD<VF&DQG&DI0ZHUHLGHQWLILHGDV
'VE$VXEVWUDWHSURWHLQVLQ<HUVLQLDSHVWLV>@D>@E>@F>@G>@HI>@J>@KN>@L>@M>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WKH LQWHUDFWLRQ RI WKH .S'VE$ PROHFXOH $ ZLWK 363)47&'
JHQHUDWHGE\ VWUXFWXUDO VXSHUSRVLWLRQRQ WKH(F'VE$(F'VE%
FRPSOH[>@
7,)
)LJXUH6 105VWUXFWXUHRIR[LGL]HG.S'VE$$2YHUOD\
RI WKH105PRGHOV GLVRUGHUHG UHJLRQKLJKOLJKWHG LQEOXH
%ORZHVWHQHUJ\105FRQIRUPHUFPDJQLILFDWLRQRIWKHDFWLYH
VLWH UHJLRQ VKRZLQJ WKH GLVXOILGH ERQG IRUPHG EHWZHHQ WKH
F\VWHLQHV LQ WKH DYHUDJHG105 VROXWLRQ VWUXFWXUH RI R[LGL]HG
.S'VE$
7,)
$FNQRZOHGJHPHQWV
:H WKDQN WKH$XVWUDODVLDQ&U\VWDOORJUDSK\6FKRRO HVSHFLDOO\
3URI(OHDQRU'RGVRQ)56IRUKHUDGYLFHDQGVXSSRUWWR).LQ
VROYLQJ WKH PROHFXODU UHSODFHPHQW SUREOHP IRU .S'VE$ :H
WKDQNWKHEHDPOLQHVXSSRUWWHDPDWWKH$XVWUDOLDQ6\QFKURWURQ
IRU GDWD FROOHFWLRQ DGYLFH DQG DFNQRZOHGJH XVH RI WKH
8QLYHUVLW\RI4XHHQVODQG5HPRWH2SHUDWLRQ&U\VWDOOL]DWLRQDQG
;UD\ 8452&;'LIIUDFWLRQ)DFLOLW\DQG WKDQN0U.DUO%\ULHO
DQG0U*RUGRQ.LQJIRUWKHLUH[SHUWDVVLVWDQFH
$XWKRU&RQWULEXWLRQV
&RQFHLYHG DQG GHVLJQHG WKH H[SHULPHQWV ). .50-6 -/0
3HUIRUPHG WKHH[SHULPHQWV)..5/3%0:'0+656%+
$QDO\]HG WKH GDWD ). .5 /3 %0 :' 0+ %+ 0-6 -/0
&RQWULEXWHGUHDJHQWVPDWHULDOVDQDO\VLVWRROV)..5656'3)
0-6 -/0 :URWH WKH PDQXVFULSW ). .5 /3 0-6 -/0
3URYLGHG FULWLFDO FRPPHQW RQ WKHPDQXVFULSW -/0)..5/3
%0:'0+656%+'3)0-6
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Figure S1.Thermal unfolding of SeDsbA.
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Comparative Analysis of Klebsiella pneumoniae DsbA
JCB818 (dsbA- / dsbB-)JCB817 (dsbA-)
arab(-) arab(+) arab(-) arab(+)
KpDsbA
EcDsbA
Figure S2.Summary of in vivo complementation of KpDsbA and EcDsbA.
E. coli cells lacking dsbA- (JCB817) or dsbA- /dsbB- (JCB818) are non-motile. Expression of KpDsbA or 
EcDsbA can rescue the swarming of E. coli dsbA- (JCB817) but not of dsbA- /dsbB- cells. Expression of 
KpDsbA or EcDsbA is induced by inclusion of arabinose (arab).
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Figure S3.Binding studies of PSPFQTCD to KpDsbA.
A. Representative ITC profile for PSPFQTCD peptide binding to EcDsbA. For all combinations tested see 
Table 4. B. Model of the interaction of the KpDsbA (molecule A) with PSPFQTCD generated by structural 
superposition on the EcDsbA:EcDsbB complex [76].
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Figure S3.NMR structure of oxidized KpDsbA.
A. Overlay of the 20 NMR models; disordered region highlighted in blue. B. lowest energy NMR conformer. C. 
magnification of the active site region showing the disulfide bond formed between the cysteines in the aver-
aged NMR solution structure of oxidized KpDsbA.
CHAPTER III 
 
 57 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER III 
CHAPTER III                                                                                                                                              PMDSBA 
 
 58 
3 Crystal Structure of the Dithiol Oxidase DsbA Enzyme from Proteus 
Mirabilis Bound Non-covalently to an Active Site Peptide Ligand  
 
 
This Chapter has been published as a research article in the Journal of Biological 
Chemistry. It provides data for the hypothesis that compounds designed to bind to EcDsbA 
should also bind to close homologues – a topic introduced in the previous Chapter. In brief, 
it describes the structural and functional characterization of DsbA from P. mirabilis, which 
has 59% sequence identity with EcDsbA. Studies were complemented by the structure 
determination of PmDsbA-C30S active site mutant and a non-covalent complex between a 
synthetic peptide (PWATCDS) and PmDsbA-C30S.  
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Crystal Structure of the Dithiol Oxidase DsbA Enzyme from
Proteus Mirabilis Bound Non-covalently to an Active Site
Peptide Ligand
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Fabian Kurth‡1,2, Wilko Duprez‡1,2, Lakshmanane Premkumar‡2, Mark A. Schembri§3, David P. Fairlie‡§4,
and Jennifer L. Martin‡§5
From the ‡Institute for Molecular Bioscience, Division of Chemistry and Structural Biology and §Australian Infectious Diseases
Research Centre, School of Chemistry andMolecular Biosciences, University of Queensland, St. Lucia, Queensland 4067, Australia
Background: DsbA enzymes assemble bacterial virulence factors and are targets for an entirely new drug class.
Results: Proteus mirabilis DsbA was characterized and its structure determined with a peptide bound non-covalently at the
active site.
Conclusion: The structure provides an important basis for future inhibitor design.
Significance: New drugs to treat superbugs are urgently needed. DsbA inhibitors could have antivirulence activity against
bacterial pathogens.
The disulfide bond forming DsbA enzymes and their DsbB
interaction partners are attractive targets for development of
antivirulence drugs because both are essential for virulence fac-
tor assembly inGram-negative pathogens. Here we characterize
PmDsbA from Proteus mirabilis, a bacterial pathogen increas-
ingly associated with multidrug resistance. PmDsbA exhibits
the characteristic properties of a DsbA, including an oxidizing
potential, destabilizing disulfide, acidic active site cysteine,
and dithiol oxidase catalytic activity. We evaluated a peptide,
PWATCDS, derived from the partner proteinDsbB and showed
by thermal shift and isothermal titration calorimetry that it
binds to PmDsbA. The crystal structures of PmDsbA, and the
active site variant PmDsbAC30S were determined to high reso-
lution. Analysis of these structures allows categorization of
PmDsbA into the DsbA class exemplified by the archetypal Esche-
richia coli DsbA enzyme. We also present a crystal structure of
PmDsbAC30S incomplexwith thepeptidePWATCDS.Thestruc-
ture shows that the peptide binds non-covalently to the active site
CXXC motif, the cis-Pro loop, and the hydrophobic groove adja-
cent to the active site of the enzyme. This high-resolution struc-
tural data provides a critical advance for future structure-based
design of non-covalent peptidomimetic inhibitors. Such inhibitors
would represent an entirely new antibacterial class that work by
switching off the DSB virulence assemblymachinery.
Proteus mirabilis is a significant Gram-negative extra-intes-
tinal human pathogen that belongs to the Enterobacteriaceae
family, which also includes other important pathogens such as
Escherichia coli, Klebsiella pneumoniae, and Enterobacter clo-
acae. Together, the Enterobacteriaceae account for the vast
majority of community-acquired and nosocomial urinary tract
infections (1, 2). P. mirabilis is a frequent cause of both compli-
cated and catheter-associated urinary tract infections (3, 4).
Multidrug-resistant strains of clinical pathogenic P. mirabilis
have been reported for several decades (1). For example, clinical
isolates of P. mirabilis resistant to streptomycin, tetracycline,
kanamycin, chloramphenicol, and polymyxin B were described
in the 1960s (5, 6) and since then reports of antibiotic resistance
have increased (7–16).
DsbA enzymes from Gram-negative bacteria are targets for
the development of anti-virulence drugs that could represent
an entirely new class of antimicrobial agents (17, 18). Drugs that
target bacterial virulence couldminimize the selective pressure
that generates antibiotic resistance and simultaneously pre-
serve the endogenous host microbiome (19). DsbA is a key tar-
get for such drugs because it is essential for the correct folding
or assembly ofmultiple virulence factors, including toxins, fim-
brial adhesins, flagella, and type II and type III secretion systems
(17). The mutation of dsbA results in the attenuation of viru-
lence factor production inmultiple pathogens (17), some exam-
ples, include P. mirabilis (20), uropathogenic E. coli (21), and
Burkholderia pseudomallei (21, 22), Vibrio cholerae (23), Shi-
gella flexneri (24), and Salmonella enterica serovar Typhimu-
rium (25).
DsbAenzymes are thioredoxin-fold proteins (26) localized to
the periplasm of Gram-negative bacteria where they catalyze
oxidative folding (27). This reaction involves the transfer of a
disulfide bond from the active site 30CXXC33 motif of DsbA to
cysteine thiols in newly translocated proteins (28). Through
this disulfide-exchange reaction, the active site cysteines of
DsbA become reduced. The enzymatic cycle is completed
through oxidation of DsbA by the inner membrane partner
The atomic coordinates and structure factors (codes 4OCE, 4OCF, and 4OD7)
have been deposited in the Protein Data Bank (http://wwpdb.org/).
1 Both authors contributed equally to this article.
2 Supported throughanAustralianResearchCouncil Australian Laureate Fellow-
ship FL0992138 to J. L. M.
3 Supported by an Australian Research Council Future Fellowship FT100100662.
4 Supported by National Health and Medical Research Council Senior Princi-
pal Research Fellowship 1027369.
5 Supported by Australian Research Council Australian Laureate Fellowship
FL0992138 and Honorary National Health and Medical Research Council
Research Fellowship 455829. To whom correspondence should be
addressed. E-mail: j.martin@imb.uq.edu.au.
THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 289, NO. 28, pp. 19810–19822, July 11, 2014
© 2014 by The American Society for Biochemistry and Molecular Biology, Inc. Published in the U.S.A.
19810 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 289•NUMBER 28•JULY 11, 2014
 at Univ of Queensland (CAUL) on July 15, 2014
http://www.jbc.org/
Downloaded from 
CHAPTER III                                                                                                                                              PMDSBA 
 
 61  
protein, DsbB (29). DsbA from E. coli (EcDsbA) is a highly pro-
miscuous enzyme that catalyzes disulfide bond formation in
many cysteine-containing proteins (28). In contrast, EcDsbB
has a very strict binding specificity for EcDsbA (29). The inter-
action between EcDsbA and EcDsbB involves the formation of
a mixed disulfide between Cys30 of the 30CXXC33 motif of
EcDsbA and Cys104 of EcDsbB in the P2 periplasmic loop,
which has the sequence 98PSPFATCDF106 (30). The crystal
structure of the complex between EcDsbA and EcDsbB also
revealed non-covalent binding of EcDsbB P2 loop residues to
the EcDsbA hydrophobic groove (30). The P2 periplasmic loop
sequence of P. mirabilis DsbB (PmDsbB) is identical to that of
EcDsbB, suggesting a similar interaction occurs between
PmDsbA and PmDsbB.
Here we characterize PmDsbA from P. mirabilis, which
shares 59% sequence identity with EcDsbA, and confirm its
activity as a DsbA enzyme.We demonstrate that the heptapep-
tide PWATCDS, derived from the DsbB P2 loop sequence,
binds to wild type PmDsbA and to a C30S active site variant
(PmDsbAC30S).We report three high-resolution crystal struc-
tures including the PmDsbAC30S!PWATCDS complex, which
represents to our knowledge the first reported example of a
peptide bound non-covalently to a DsbA structure. This non-
covalent complex provides the critical starting point for the
design of non-covalent drugs that act as anti-virulence agents
targeting Enterobacteriaceae DsbAs.
EXPERIMENTAL PROCEDURES
Protein Production and Molecular Biology—Codon-opti-
mized wild type P. mirabilis dsbA (GenBank" accession num-
ber CAR45574), lacking the sequence coding for the predicted
signal peptide (amino acids 1–19), was cloned into a modified
pMCSG7 (31) vector using ligation-independent cloning. The
cytoplasmic expressed PmDsbA contained an N-terminal
His6 affinity tag followed by a linker region including a
tobacco etch virus (TEV)6 protease cleavage site. The
PmDsbAC30S variant was generated from the wild type con-
struct using QuikChange" (Agilent Technologies). The fol-
lowing primers were used to introduce the point mutation,
forward, GAATTTTTCTCATTTTATTCTCCGCATTGT-
TACC and reverse, GGTAACAATGCGGAGAATAAAATG-
AGAAAAATTC. Transformed BL21(DE3)pLys cells contain-
ing plasmids for either PmDsbA or PmDsbAC30S were grown
(1 liter) at 30 °C in 2.5-liter baffled shaker flasks for 16–20 h
using autoinduction media (32). Cells were resuspended in 25
mM Tris, 150 mM NaCl (10 g of cells/100 ml of buffer), and
protease inhibitor mixture (diluted 1 in 1000 into the lysate)
(BioPioneer Inc., SanDiego, CA) andDNase (1300 units/100ml
of lysate) (Roche Applied Science) were added. Lysis was per-
formed in a Cell Disruptor (TS-Series, Constant Systems LTD.,
UK) applying a single run with a constant pressure of 25 Kpsi.
Cell debris was removed by centrifugation (18,500 rpm, 30min,
4 °C, rotor JM-25.5, Beckman Coulter, Brea, CA). The proteins
were further purified by immobilized metal ion affinity chro-
matography using 12 ml/1-liter cells of equilibrated Talon
(Clontech) and eluted with 25 mM Tris, 150 mM NaCl, 200 mM
imidazole after incubation of 30 min at room temperature.
Total protein was determined at 280 nm with a NanoDropTM
2000c (Thermo Fisher Scientific). The His6 affinity tag was
removed by TEV cleavage using a 50:1 (w/w) ratio (protein/
TEV-protease) incubated in a 50-ml Falcon tube including 1
mM !-mercaptoethanol for 2 h on a rotary mixer at room tem-
perature. After cleavage, the PmDsbA proteins had an addi-
tional two non-native residues (Ser!2–Asn!1) at the N termi-
nus. To remove imidazole, the mixture was rapidly buffer
exchanged into 25 mM Tris, 150 mM NaCl using a Sephadex
G-25 fine 16/60 column connected to an ÄKTA system (GE
Healthcare). The His6-tagged TEV protease was removed by
reverse metal ion affinity chromatography using Talon resin
(0.5 ml of resin/2 mg of TEV protease) (Clontech, Australia)
and the PmDsbA proteins were recovered in the flow through.
The final step of purification was performed using a Superdex
S75 gel-filtration column (GE Healthcare). Peak fractions were
then combined and the protein was oxidized using copper(II)/
1,10-phenanthroline at 1.7 mM final concentration or reduced
usingDTT at"25molar excess. To remove oxidizing or reduc-
ing agent, the mixture was then buffer-exchanged into 10 mM
HEPES pH 7.4 using a Sephadex G-25 fine 16/60 column.
Finally, the protein was concentrated to 100 mg/ml using Ami-
con Ultra filter devices with a 10-kDa cutoff (Millipore). Yield
was generally 120–150 mg/liter of culture. Protein quality was
assessed by SDS-PAGE (NuPAGE" system, 4–12% BisTris gel,
Invitrogen, Australia). Molar protein concentrations were
determined from calculated extinction coefficients derived
from ProtParam (33).
Purified EcDsbA (GenBank accession number CAA56736)
and EcDsbC (GenBank accession number AAA83074), lacking
the periplasmic leader signal were expressed and purified as
described above for PmDsbA. Yields were generally 120 and 80
mg/liter of culture, respectively.E. colimembrane extracts con-
taining over-expressed EcDsbB (GenBank accession number
AAC74269) were prepared as described previously (34), and
resuspended in PBS buffer containing 10% glycerol.
EcDsbA Complementation—E. coli #dsbA (JCB817) and
#dsbA/#dsbB (JCB818) non-motile strainswere used formotil-
ity assays as described previously (35). The gene sequence cod-
ing for mature PmDsbA (lacking the periplasmic signal
sequence) was cloned into pBAD33 under an arabinose-induc-
ible promoterwith anN-terminal EcDsbA signal sequence (36).
As a positive control, EcDsbA was expressed within the same
pBAD33 vector background. 2" 106 non-motile E. coli #dsbA
(JCB817) and#dsbA/#dsbB (JCB818) double-mutant (JCB818)
(27) cells harboring pBAD33(EcDsbA) or pBAD33(PmDsbA)
were spotted onto the center of a soft M63 minimal agar plate
containing 40 mg/ml of each amino acid (except L-cysteine) in
the absence or presence of 0.1% arabinose (negative control).
Plates were incubated at 37 °C and cell motility was monitored
after 4–5 h using aMolecular Imager"Gel DocTM system from
Bio-Rad. Complementation experiments were performed as
biological triplicates.
6 The abbreviations used are: TEV, tobacco etch virus; BisTris, 2-[bis(2-hy-
droxyethyl)amino]-2-(hydroxymethyl)propane-1,3-diol; HbtU, O-benzo-
triazole-N,N,N$,N$-tetramethyluroniumhexafluorophosphate; ITC, isother-
mal titration calorimetry; PDB, Protein Data Bank; r.m.s., rootmean square.
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Cysteine Thiol Oxidation Assay—A synthetic peptide sub-
strate of EcDsbA (CQQGFDGTQNSCK) with a europium
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid group
amide coupled to the N terminus and amethylcoumarin amide
coupled to the !-amino group of the C-terminal lysine was pur-
chased from AnaSpec (Fremont, CA) and prepared as previ-
ously reported (37).
Assays were performed using a Synergy H1 multimode plate
reader (BioTek) as described previously (38). In brief, fluores-
cence (excitation " ! 340 nm and emission " ! 615 nm) cor-
responding to disulfide formation in the substrate peptide was
measured in a white 384-well plate (PerkinElmer Life Sciences
OptiPlate-384, number 6007290) in 50 mM MES, 50 mM NaCl,
and 2 mM EDTA at pH 5.5 buffer. The total reaction volume in
each well was 50 #l, containing 40, 80, or 160 nM PmDsbA or
EcDsbA, 1.6 #M EcDsbB membrane, and 8 #M peptide sub-
strate (added last to initiate the reaction). Controls used were:
PmDsbA or EcDsbA" buffer" substrate (no DsbB); EcDsbB"
buffer " substrate (no DsbA); buffer " substrate (no DsbA or
DsbB); andno components (fluorescence backgroundof the plate,
which was subtracted from all othermeasurements). Three inde-
pendent experiments (biological replicates) were performed,
using three technical replicates for each measurement. The
reaction rate was estimated by calculating the increase in fluo-
rescence over the first 8min of reaction. The fluorescence rates
were plotted including the standard deviation calculated from
the three biological replicates.
Thermal Stability of PmDsbA—Temperature-induced unfold-
ing of native PmDsbA was recorded by UV circular dichroism as
previously reported for other DsbA enzymes (39) using a Jasco
J-810 spectropolarimeter (Jasco). The initial redox state of
PmDsbA was confirmed by Ellman’s assay (40). The maximum
difference in CD signal was determined by subtraction of the
CD spectra of the folded protein (25 °C) from the unfolded
(95 °C) protein, for the oxidized and the reduced forms of the
protein. Unfolding of oxidized PmDsbA (210 nm) and reduced
PmDsbA (213 nm) was monitored in a 1-mm quartz cuvette
using a heating rate of 1 °C/min from 25 to 95 °C. Measure-
ments were carried out using 10#M protein in a buffer contain-
ing 100 mM NaH2PO4/Na2HPO4, 1 mM EDTA, pH 7.0. To
ensure PmDsbA remained reduced throughout the entire
measurement, reduced samples contained 0.75 mM DTT. Data
were fitted to a two-state unfolding model and errors were cal-
culated using Prism 6 (GraphPad) as described previously (41).
Redox Properties of PmDsbA—The standard redox potential
of PmDsbAwasmeasured utilizing the intrinsic fluorescence of
tryptophan residues in PmDsbA, similar to themethod used for
EcDsbA (42). In brief, oxidized PmDsbA was equilibrated for
3 h at 25 °C in degassed 100mMNaH2PO4/Na2HPO4, pH 7.0, 1
mMEDTA, containing 1mMoxidized glutathione (GSSG) and a
range of reduced glutathione (GSH) concentrations (0–2000
#M). 200 #l of PmDsbA from each redox condition was dis-
pensed into a 96-well plate (TPP AG, Switzerland, number
92096) and tryptophan fluorescence was measured (excitation
wavelength 280 nm, emission 332 nm) using a Synergy H1
microplate reader and Gen5 2.0 software (Biotek). Data were
analyzed in Prism 6 (GraphPad) and the redox potential was
calculated as described previously for EcDsbA (42).
Determination of Cys30 pKa—Absorbance at 240 nm of the
catalytic thiolate anion is pH-dependent allowing the equilib-
rium between protonated and deprotonated Cys30 to be mea-
sured (43) using a UV-visible spectrophotometer (CARY 50,
Agilent Technologies). Absorbance at 240 and 280 nm were
measured over pHvalues starting at 6.5 and decreasing to 2.0, in
0.25 pH unit increments. Samples contained either oxidized or
reduced PmDsbA (40 #M) in composite buffer (10 mM Tris, 10
mM sodium citrate, 10 mM K2HPO4, 10 mM KH2PO4, 200 mM
KCl, and 1 mM EDTA) at 22 °C. The pKa value was calculated
from the fitted curves using the Henderson Hasselbalch equa-
tion (pH ! pKa # log ([A240/A280]red/[A240/A280]ox)). Average
and mean$ S.D. from triplicate measurements are plotted.
Disulfide Reductase Activity—DsbA enzymes can reduce the
intermolecular disulfide bonds between insulin chains A and B
under mild reducing conditions (27). Disulfide bond reduction
of insulin can be followed spectrophotometrically at " ! 650
nm (A650 nm). The A650 nm value gives a measure of turbidity,
which occurs as a result of the increase in production of insol-
uble B chain of insulin (44). Samples were prepared in 1-cm
cuvettes containing 10 #M protein (PmDsbA, EcDsbA, or
EcDsbC), 0.33mMDTT, and 2mMEDTA in 100mMNaH2PO4/
Na2HPO4, pH 7.0. Catalysis was initiated by the addition of
0.131 mM insulin (I0516, Sigma) to the mixture. The assay was
repeated three times and the mean$ S.D. of the measurement
at each time point was calculated.
Peptide Synthesis—Peptides were synthesized using solid-
phase peptide synthesis on rink-amide (4-methyl)benzhydryl-
amine resin (ChemImpex International, Wood Dale, IL) with a
loading of 0.65 mmol/g. De-protection of the resin and amino
acids was performed using an 80:20 (v/v) mixture of dimethyl-
formamide/piperidine (Rci Labscan, Bangkok Thailand/Aus-
pep, Australia) for 2 % 5 min. L-Amino acids (ChemImpex
International) were activated using 4 resin equivalents (eq) and
4 eq of HbtU (O-benzotriazole-N,N,N&,N&-tetramethyluro-
nium hexafluorophosphate, ChemImpex International) (500
mM) and 5 eq of N,N-diisopropylethylamine (Auspep, Austra-
lia) for 5 min before coupling to the de-protected resin for 60
min. After the final coupling, all peptides were acetylated at the
N terminus using 4 eq of acetic acid (ChemSupply, Australia), 4
eq of HbtU, and 5 eq ofN,N-diisopropylethylamine for 30 min.
Cleaving was executed using a 95:2.5:1.25:1.25 (v/v) mixture of
trifluoroacetic acid (TFA)/ethanedithiol/triisopropylsilane/
water (H2O) (chemicals fromSigma). Cleaved peptides resulted
in an amidated C terminus from the resin rink-amide and dried
using N2 gas, washed with diethyl ether (DEE, Ajax Finechem,
Sydney Australia), and dissolved in a 80:20 (v/v) mixture of
acetonitrile/H2O (RCI Labscan, Bangkok, Thailand) before
purification on HPLC. Purification was executed on a C18 col-
umn (Phenomenex, Torrance CA) using a gradient from 20 to
80% of acetonitrile and TFA 0.1%. Fractions were analyzed by
mass spectrometry (Waters Micromass LCT,Milford, CT) and
the purified peptide was lyophilized using a freeze drier (Christ,
Osterode am Harz, Germany).
Peptide-induced Thermal Shift Measurements—25 #M
PmDsbA in phosphate-buffered saline (PBS), pH 7.4, was incu-
bated with peptide PWATCDS at concentrations ranging from
125 #M to 4 mM for 1 h. Then Sypro Orange (S-6650, Invitro-
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gen) was added to a 5! final concentration (stock concentra-
tion!5000). Controls contained either no peptide, noDsbA, or
the dye alone. Measurements were conducted in a white 384-
well plate (Perkin Elmer OptiPlate-384, number 6007290) with
5 replicates. Fluorescence emission from SyproOrange binding
to unfolded protein was measured following a temperature
time course increasing from 25 to 95 °C (heat rate" 0.05 °C/s)
using a VIAA7 Real-time PCR system (Invitrogen) with a ! "
585 # 15 nm wavelength filter. Raw data were analyzed using
Prism 6 (GraphPad). Fluorescence emission was fitted to a clas-
sic Boltzmann sigmoidal curve, and the inflection point was
used as the melting temperature, Tm. To determine $Tm (the
shift in melting temperature in the presence of peptide), the
Tm value for the wild type protein was subtracted from
the Tm value for PmDsbA-PWATCDS and the Tm value for
the variant PmDsbAC30S was subtracted from the Tm value
for PmDsbAC30S-PWATCDS. $Tm values are presented as
the mean# S.D. from 5 replicates. A significant $Tm is con-
sidered to be greater than two times the S.D. of the Tm value
for the protein in the absence of ligand (45).
Isothermal Titration Calorimetry—Evaluation of affinity and
thermodynamicsof bindingbetweenPWATCDSandPmDsbAor
PmDsbAC30S were assessed by isothermal titration calorimetry
(ITC)using anAuto-iTC200 instrument (MicroCalTM,GEHealth-
care). The sample cell was loaded with 200 "l of purified protein
(oxidized PmDsbA or untreated PmDsbAC30S) at 100 "M con-
centration in 25 mM HEPES, pH 7.4, 50 mM NaCl, 0.8% dimethyl
sulfoxide (ITC buffer). The syringe was filled with purified pep-
tide PWATCDS in ITC buffer at a concentration of 4 mM.
Titrations were conducted at 25 °C using 19 consecutive injec-
tions of 2 "l each delayed by 180 s with a stirring speed of 1000
rpm. In every experiment an initial 0.5 "l of peptide was
injected to avoid slow leakage of titrant and this data point was
discarded for binding analysis. As a control for background
noise, titration of PWATCDS into a solution containing ITC
buffer only was performed. The association constant (Ka "
1/Kd), free energy ($G), and enthalpy change ($H) were calcu-
lated by fitting the data to a single-site binding model using the
MicroCalOrigin software (Origin 7.0 SR4 version 7.0552#) and
correcting peptide concentrations to adjust the stoichiometry
parameter close to 1.0. Entropy change ($S) was deduced from
the standard free energy equation$G"$H%T$S. Parameters
reported include the mean # S.D. across three replicates. The
calculated c-value for these measurements is 12.
Crystallization, Structure Determination, and Structural
Analysis—Crystallization screening was performed at the Uni-
versity of Queensland ROCX diffraction facility. Protein crys-
tallization trials were performed in 96-well plates using the
hanging drop vapor diffusion method at 8 or 20 °C. In general,
purified protein (200 nl) wasmixedwith crystallization solution
(200 nl) using a Mosquito crystallization robot (TTP Labtech,
UK), and trays were incubated and imaged in a RockImager
1000 (Formulatrix). Wild type PmDsbA was crystallized by
mixing a 1:3.3 molar ratio of the protein!peptide complex
PmDsbA!PSPWATCDF (3 mM protein, 10 mM peptide, 2%
dimethyl sulfoxide incubatedon ice for1h)with0.5"l of15%PEG
3350 and 0.4 M sodiummalonate, pH 5.0, and incubating the drop
over the same solution at 20 °C. The presence of the peptide per-
mitted crystallization but no densitywas evident for the peptide in
the phased data; the final refined structure from this condition is
referred to as native PmDsbA. Crystals were harvested in cryo
solution (25%PEG3350, 0.4M sodiummalonate, pH5.0, 20%PEG
400) and immediately flash frozen in liquid nitrogen.
PmDsbAC30S crystals appeared overnight at 8 °C in
0.2 M KSCN, 23% PEG 3350 using a 1:10 molar ratio of the
protein!peptide complex (1.5mMprotein and 15mMPWATCDS,
final concentrations of both, incubated on ice for 1 h); again the
presence of the peptide permitted crystallization but there was
no evidence of peptide binding in the electron density maps.
The cryo solution used was 0.2 M KSCN, 25% PEG 3350, and
20% PEG 400. The structure of the protein derived from this
condition is referred to as PmDsbAC30S.
PmDsbAC30S!PWATCDS co-crystals grew at 20 °C using a
1:10 molar ratio of the protein!peptide complex (3 mM protein,
30mMpeptide, final concentrations of both), with the two com-
ponents incubated on ice for 1 h prior to crystallization. The
protein!peptide solution was then mixed with an equal volume
of crystallization solution, which contained 0.2 M KSCN, 22%
PEG 3350, 0.2 M non-detergent sulfobetaine (NDSB-221). Dif-
ferences in crystallization conditions in comparison to the
PmDsbAC30S crystals that did not yield bound peptide
included higher concentrations of protein and peptide (but the
same molar ratio), the use of NDSB-221 as an additive and an
incubation temperature of 20 °C (rather than 8 °C). Crystals
were flash frozen in cryo solution consisting of 0.3 M KSCN,
30% PEG 3350, and 20% PEG 400.
Diffraction data for all three crystal structures were mea-
sured at the Australian Synchrotron MX2 beamline at a wave-
length of 0.9537 Å, and recorded with an ADSCQuantum 315r
detector controlled by BLU-ICE (46). Reflections were indexed
and integrated in Mosflm (47) or XDS (48), analyzed in Point-
less (49), and scaled in SCALA (49) from the CCP4 suite (50).
Phases for PmDsbA were obtained by molecular replacement
using PHASER (51) with EcDsbA as a template (PDB code
1FVK, sequence identity 59%). PmDsbAC30S!PWATCDSwere
solved using the wild type PmDsbA structure as the template.
Initial electron density maps from PHASER were improved by
cycles of iterative refitting of the model using the program
COOT (52) and PHENIX.refine (53). The refinement of the
complex structure was stalled at R-factor/R-free: 30/33%. Phe-
nix.xtriage analysis indicated that the diffraction data were
twinned with a twinning fraction of 0.49. The twin target
function implemented in PHENIX was applied in further
refinement cycles with the twinning operator %h&k, k, %l.
The final R-factor/R-free was 17.2/19.9%. For PmDsbAC30S!
PWATCDS, the density corresponding to the bound peptide
was modeled for all seven residues including N-terminal acety-
lation and C-terminal amidation. In addition, a malonate anion
was modeled into the crystal structure of PmDsbA and four
SCN molecules were modeled into the PmDsbAC30S!
PWATCDS crystal structure with one pair in each protomers A
and C. One thiocyanate molecule is buried between $1 and #2
of protomers A/C, whereas the secondmolecule binds between
Pro andPmDsbAC30Shelix$1, possibly forming aweak hydro-
gen bond with the Pro backbone carbonyl (distance N:O" 3.4
Å). Thiocyanate molecules do not appear to influence peptide
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binding, because the peptide binding site and conformation is
identical in protomer B, which lacks a bound thiocyanate.
Data processing and refinement statistics for all three crystal
structures are provided in Table 1. Molecular figures were gen-
erated using PyMOL (ThePyMOLMolecularGraphics System,
version 1.6.0.0 Schrödinger, LLC) and figures of the electro-
static potential were generated using APBS (54). r.m.s. devia-
tion calculations and structural alignments were conducted in
PyMOL and FATCAT (55). Interaction analyses were con-
ducted with the program COOT (52) and the PDBePISA (56)
and Cocomaps servers (57).
RESULTS
PmDsbA Catalyzes Disulfide Formation in Vitro and in Vivo—
DsbA enzymes catalyze oxidative folding, or the introduction of
disulfide bonds into proteins. To assess whether PmDsbA has
dithiol oxidase activityweassessed its activity in an in vitropeptide
oxidation assay. A europium-labeled peptide (CQQGFDGTQN-
SCK) fluoresces when the two cysteines are oxidized, but not
when the cysteines are reduced (37). We found that PmDsbA,
like EcDsbA, catalyzed peptide thiol oxidation as evident by an
increase in the fluorescent signal over time (Fig. 1A). The fluo-
rescence rate increased with increasing concentrations of
PmDsbA and EcDsbA (Fig. 1A). PmDsbA catalysis was a little
slower than that of EcDsbAat the same enzyme concentrations.
This slightly reduced activity may reflect the use of a peptide
derived fromanEcDsbA substrate.Nonetheless, the results estab-
lish that PmDsbA catalyzes dithiol oxidation in amodel substrate.
We also assessed the ability of PmDsbA to complement
EcDsbA in vivo. E. coli strains deficient in the P-ring protein
FlgI fail to assemble functional flagella (58). Moreover,
E. coli strains lacking EcDsbA, EcDsbB, or both, have the
same phenotype (59) because FlgI requires a disulfide bond
to function. The non-motile strains E. coli !dsbA (JCB817)
and !dsbA/!dsbB (JCB818) were therefore used for in vivo
DsbA complementation experiments. When EcDsbA or
PmDsbA were expressed in JCB817 following arabinose
induction, full rescue of motility was observed in JCB817
(Fig. 1B). However cells from the double knock-out (JCB818)
remained non-motile for both PmDsbA and EcDsbA. These
results demonstrate that PmDsbA can replace EcDsbA func-
tionally in vivo in the context of flagella assembly. Because
EcDsbB was also essential for complementation in this
experiment, the results confirm that PmDsbA and EcDsbB
can form a functionally competent system. This was
expected because the P2 loop sequence from PmDsbB is
identical to that of EcDsbB. Furthermore, the P. mirabilis
FlgI homologue shares 74% sequence identity with EcFlgI
including two conserved cysteine residues.
PmDsbA Shares the Same Characteristic Redox Properties as
EcDsbA—DsbA enzymes exhibit unique properties that con-
tribute to their ability to catalyze disulfide bond formation (28,
TABLE 1
X-ray data collection and refinement statistics
Data collection PmDsbA (4OCE)
PmDsbAC30S
(4OCF)
PmDsbAC30S ! PWATCDS
(4OD7)
Wavelength (Å) 0.95369 0.95369 0.95370
Resolution range (Å) 42.64–1.77 57.22–1.98 64.13–1.60
Highest resolution shell (Å) 1.86–1.77 2.09–1.98 1.68–1.60
Space group P 43212 P21 P32
Unit cell dimensions
a (Å) 37.8 37.9 74.06
b (Å) 37.8 80.2 74.06
c (Å) 298.4 114.4 93.27
!, ", # (°) 90, 90, 90 90, 91, 90 90, 90, 120
Total reflections 303398 176891 839517
Unique reflections 22817 47865 74969
Multiplicity 13.3 (13.6)a 3.7 (3.6)a 11.2 (10.2)a
Completeness (%) 100 (100) 99.7 (98.9) 98.6 (93.9)
Mean "I#/"$I# 16.1 (4.8) 14.3 (8.4) 16.3 (2.4)
Rmergea 0.127 (0.587) 0.073 (0.155) 0.080 (0.973)
Rp.i.m. 0.035 (0.157) 0.044 (0.095) 0.026 (0.327)
Refinement statistics
Rfree (%) 16.9 (21.9) 21.1 (24.0) 19.9 (29.2)
Rwork (%) 14.8 (17.3) 15.2 (15.2) 17.2 (30.3)
Unique reflections 22686 47846 74969
Number of non-H atoms
Protein 1492 5841 4506
Water 268 810 542
Protein residues 189 749 561
r.m.s. deviation bond
Lengths (Å) 0.009 0.012 0.017
Angles (°) 1.152 1.240 1.555
Ramachandran
Favored (%) 98.4 98.5 98.9
Outliers (%) 0 0 0
Average B-factor (Å2) 14.6 12.8 25.7
Wilson B-factor (Å2) 16.0 10.3 22.1
Molprobityb
Clashscore (percentile) 1.03 [100th, (839)] 2.32 [100th, (714)] 4.25 [97th, (699)]
Score (percentile) 0.80 [100th, (11193)] 1.01 [100th, (12309)] 1.21 [98th, (6780)]
a The values in parentheses refer to the highest resolution shell.
b 100th Molprobity (74) percentile is the best among the structures of comparable resolution. The percentile and the number of structures included in the comparison (N)
are given in parentheses within the square bracket.
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60). We next established whether these characteristics are
shared by PmDsbA. First, we investigated the relative thermo-
stability of the oxidized and reduced forms of the enzyme. In
most DsbAs, the reduced form of the CXXC active site is
more stable than the oxidized form. For instance, the melt-
ing temperature of reduced EcDsbA is almost 10 K higher
than that of the oxidized form (39). Similarly, we found that
reduced PmDsbA (Tmred 348.4 ! 0.1 K) is 10 K more stable
than oxidized PmDsbA (Tmox 338.4 ! 0.2 K) (Fig. 1C).
DsbAs are also highly oxidizing. The redox potential of
EcDsbA is "122 mV (42) and the range of values reported for
other DsbAs varies from "80 mV for NmDsbA1 (37) to "163
mV for WpDsbA (41). Nevertheless, closely related (#80%
sequence identity) homologues of EcDsbA such as SeDsbA and
KpDsbA have redox potential values very similar to that of
EcDsbA ("126 and "116 mV, respectively). We determined
the redox potential of PmDsbA to be"129mV (Fig. 1D), which
is consistent with those of other Enterobacteriaceae DsbAs.
The oxidizing nature of DsbA proteins is thought to be a
consequence of the highly acidic cysteine in the CXXC active
sitemotif. The pKa of 3.3 for this nucleophilic cysteineCys30 for
EcDsbA is unusually low for a cysteine (pKa 9.0) (61). Values
reported for other DsbAs vary from 3.0 (NmDsbA1) (62) to 5.1
(VcDsbA) (63).Wemeasured the pKa of the equivalent cysteine
in PmDsbA, bypH-dependent specific absorbance at!$240nm,
anddetermined thevalue tobe4.0 (Fig. 1E).Thus, thenucleophilic
FIGURE 1. Redox properties of PmDsbA. A, in vitro disulfide catalysis. Plot shows increase in fluorescence as a consequence of peptide disulfide formation
catalyzedbyEcDsbAor PmDsbA in thepresenceof EcDsbB.B, in vivodisulfide catalysis.%dsbA knock-out or%dsbA/Bdouble knock-out cells arenon-motile due
to their inability to fold FlgI. Expression of PmDsbAor EcDsbA restoresmotility in%dsbA, but not in%dsbA/B.C, thermalmelting curves of oxidized and reduced
PmDsbA shows that reduced PmDsbA (Tm
red 348.4! 0.1 K) is more stable than its oxidized counterpart (Tm
ox 338.4! 0.2 K). D,measurement of PmDsbA redox
potential. PmDsbA was equilibrated in glutathione (GSSG/GSH) redox buffers to measure the equilibrium constant Keq (187. 5! 6"M), which corresponds to
a redox potential of"129mV. E, absorbance of the catalytic thiolate anion is pH-dependent and this property was used to determine that the pKa of PmDsbA
Cys30 is 4.0. F, disulfide reductase activity measured by following A650 nm. PmDsbA has activity similar to that of EcDsbA, and much lower than that of the
isomerase EcDsbC. For panels A and C–F, data are presented as mean! S.D. from three biological replicates. The error bars for the DsbA-only and buffer-only
controls in panel A are essentially 0 as there was no increase in fluorescence over the period of the experiment.
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cysteine of PmDsbA, like that of other DsbAs, is likely to be in the
thiolate form at physiological pHwhen the enzyme is reduced.
Although DsbA proteins are dithiol oxidases they can cata-
lyze disulfide reduction in the presence of mild reducing agents
such as DTT. Typically, insulin is used as a substrate to study in
vitro disulfide bond reduction. The two chains of insulin are
linked by three disulfide bonds,which can be rapidly reduced by
disulfide reductases such as the disulfide isomerase EcDsbC.
This reduction leads to separation of the insulinA andB chains,
and precipitation of the insoluble B chain. Reduction can be
followed by measuring the increase in turbidity of the solution
over time. We found that PmDsbA is able to reduce the disul-
fide bonds of insulin as rapidly as EcDsbA (Fig. 1F), but more
slowly than the specialist reductant EcDsbC. In summary, the
redox properties of PmDsbA reported here place it in the same
class as EcDsbA and other Enterobacteriaceae DsbAs such as S.
entericaDsbA(SeDsbA)andK.pneumoniaeDsbA(KpDsbA) (18).
PWATCDS Binding to PmDsbA and PmDsbAC30S—We
were interested to understand how peptides interact with
PmDsbA, as the basis for future peptidomimetic inhibitor
development. The low resolution crystal structures and NMR
characterization of the EcDsbB!EcDsbA complex revealed that
the EcDsbB periplasmic loop P2 forms a mixed disulfide with
the nucleophilic cysteine of EcDsbA and binds to a hydropho-
bic groove near the active site (29, 30, 64, 65). The peptide
sequence of the EcDsbBP2 loop 98PSPFATCDF106 is conserved
in PmDsbB (99PSPFATCDF107) suggesting that a similar inter-
action occurs between PmDsbA and PmDsbB. From the
sequence of this P2 loop peptide, we developed a shorter, mod-
ified peptide PWATCDS optimized for solubility, binding
affinity, and inhibition of EcDsbA.7 Briefly, alanine scanning,
peptide length scouting, and substitution of specific residues
showed that the peptide PWATCDShad a good affinity tomass
ratio for binding to EcDsbA.We hypothesized that this peptide
would also interact with PmDsbA, and therefore evaluated its
binding using thermal shift assay and ITC.
Tm values for PmDsbA andPmDsbAC30S (a variant inwhich
the nucleophilic cysteine was replaced by serine) were mea-
sured in the presence and absence of the peptide PWATCDS,
with varying peptide concentrations. For PmDsbA,Tm values of
!2.0, !4.1, and !5.0 K were observed at peptide concentra-
tions of 1, 2, and 4mM, respectively, suggesting that PWATCDS
binds to PmDsbA. These data show that theTm shift continued
with increasing peptide concentration beyond saturation, as is
commonly observed in this assay (66). When the variant
PmDsbAC30S was used, thermal shifts ("Tm # !0.3 K) were
detectable at concentrations of PWATCDS ranging from 250 !M
to 4 mM. However, the maximum "Tm at 4 mM was significantly
lower than that at the sameconcentration forPmDsbA("Tm!1.5
K, compared with 5.0 K, respectively) (Fig. 2A). This difference in
"Tm suggests the possibility of different bindingmodes.
We also investigated the interaction using ITC. An exother-
mic reaction was observed when titrating PWATCDS into
PmDsbA (Fig. 2B). Analysis of the raw data using a 1:1 binding
model revealed a binding affinityKD of 8.3$ 0.4!Mwith a high
enthalpic contribution ("H % &13.7 $ 0.3 kcal/mol) and an
unfavorable entropy of binding ("S % &22.3 $ 1.1 cal/mol/
deg). When PmDsbAC30S was used, there was no evidence of
PWATCDS binding by ITC under these same conditions (Fig.
2C). Clearly, the C30S mutation reduced the affinity of peptide
binding, as evidenced by both thermal shift and ITC. Neverthe-
less, wewere able to generate a crystal structure of this complex
as described below. These differing outcomes for the appar-
ently weak complex of PmDsbAC30S!PWATCDS may be a
consequence of different experimental design (thermal shift
and crystallization used a 1-h preincubation of peptide with
PmDsbAC30S, ITC methodology does not allow this; ITC was
performed at 25 °C, whereas preincubation was done at 4 °C
7 W. Duprez, L. Premkumar, M. Halili, F. Lindahl, R. Reid, D. P. Fairlie, and J. L.
Martin, unpublished data.
FIGURE 2. Peptide PWATCDS interacts with PmDsbA. A, values of "Tm upon addition of increasing PWATCDS peptide for PmDsbA and PmDsbAC30S. Data
are shown as mean $ S.D. from 5 replicates. B, ITC data titrating PWATCDS into PmDsbA. The reaction was exothermic suggesting a dominant enthalpic
contribution to binding. C, ITC data titrating PWATDCS into PmDsbAC30S. Panels B and C show a representative example from three replicates.
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and crystallization at 20 °C) or different experimental condi-
tions (buffer, pH, and concentration of peptide as outlined
under “Experimental Procedures”).
Crystal Structure of PmDsbA—To investigate the different
binding modes further, we attempted to determine the crystal
structures of PmDsbA and PmDsbAC30S, in the presence of
the peptide PWATCDS.Wewere unable to generate a crystal of
a stable complex of PmDsbA with PWATCDS. However, crys-
tals of PmDsbA and PmDsbAC30S without peptide, and
PmDsbAC30S with peptide yielded high-resolution diffraction
data (PmDsbA, 1.77-Å resolution; PmDsbAC30S, 1.98-Å reso-
lution; and PmDsbAC30S-PWATCDS, 1.6-Å resolution).
PmDsbA crystallized in a tetragonal crystal system and was
solved (PDB code 4OCE) by molecular replacement using the
EcDsbA structure (PDB code 1FVK) as a template. One protein
chain is present in the asymmetric unit, and this has a typical
DsbA-like architecture, comprising a TRX core domain (!1,
!2,"1,!3,C-terminal region of"6,!4,!5, and"7), interrupted
by an "-helical domain ("2-"5 and the N-terminal region of
"6). This PmDsbA structure is structurally similar to other
Enterobacteriaciae DsbAs including EcDsbA (PDB code 1FVK
(67)), KpDsbA (PDB code 4MCU (18)), and SeDsbA (PDB code
3L9S (68)) (Fig. 3A). This is reflected in the r.m.s. deviation of
1.0–1.2 Å comparing 177 C" atoms from equivalent positions
of these enzymes. Fig. 3B shows a structure-based sequence
alignment of PmDsbA with homologous DsbA proteins from
clinically relevant pathogens that share !59% sequence
identity. Sequences are highly conserved, especially at the
active site CPHC motif. Sequence identity translates into
overall structural similarity between DsbA proteins from
these pathogens.
The sequence and structure of the active site motif (CPHC)
and the cis-Pro loop are identical in these DsbA homologues.
However, helix "1 and the loops connecting !1 and !2, and "3
and "4 differ in their relative positions. Most importantly loop
L3 that connects !3 and helix "7 varies across the structures.
The EcDsbA L3 residues Asp167, Thr168, and Ser169 are posi-
tioned closer to the active site helix "1 than the equivalent
residues (Ala167, Lys168, and Ser169) in PmDsbA. This region is
relatively hydrophobic in both PmDsbA and EcDsbA, although
more basic in PmDsbA than in EcDsbA due to the presence of
Lys159 in the former and Gln160 in the latter. Overall these dif-
ferences in structure are relatively minor compared with the
structures of other DsbA proteins, such as Pseudomonas
aeruginosa DsbA (25% identity with PmDsbA, r.m.s. deviation
2.2 Å, 175 C", PDB code 3H93 (35)), and Wolbachia pipientis
DsbA1 (16% identity with PmDsbA, r.m.s. deviation 3.6 Å, 151
C", PDB code 3F4R (41)).
Crystal Structure Determination of PmDsbAC30S and
PmDsbAC30S!PWATCDS—We solved the structure of the
active site mutant PmDsbAC30S (PDB code 4OCF). The
crystals grew in the presence of peptide, but no bound pep-
tide was evident in the electron density map. We therefore
used this structure of PmDsbAC30S to assess whether
replacement of Cys30 with Ser30 induced any structural
changes. The mutant crystallized in a monoclinic crystal sys-
tem containing 4 protomers in the asymmetric unit. The
structure was solved by molecular replacement using the
coordinates of PmDsbA described above. The average r.m.s.
deviation for comparison of the 6 combinations of the 4
protomers range from 0.3 to 0.7 Å for 177 equivalent C"
atoms (residues 6–181).
PmDsbAC30S in complex with peptide PWATCDS crystal-
lized in a trigonal crystal system, containing 3 protomers in the
asymmetric unit. The complex was solved by molecular
replacement using PmDsbA (PDB code 4OD7) as the template.
All three protomers (A, B, and C) reveal strong electron density
corresponding to bound PWATCDS. The average r.m.s. devia-
tion for the 3 comparisons of the protomers in this crystal struc-
ture range from 0.4 to 0.6 Å for 177 equivalent C" atoms
(residues 6–181). The r.m.s. deviation for comparison of
PmDsbAC30S with PmDsbAC30S!PWATCDS range from 0.5
to 0.9 Å (177 C") for the 12 combinations. Similarly, compar-
ison of the wild type PmDsbA structure with PmDsbAC30S
and PmDsbAC30S!PWATCDS gave r.m.s. deviation values
of 0.3–0.9 Å (177 C"). This result indicates there is no major
reorganization of the PmDsbAC30S structure upon interac-
tion with PWATCDS. However, there is evidence of rigid
body shifts for helix 1 and side chain adjustments for resi-
dues on helix 1 (His32, Tyr34, Gln35, Phe36, Ser37) and flexible
loop 3 (Ile165 and Ser166) that together form part of the pep-
tide binding site.
Active Site Structure Is Conserved after Peptide Binding—A
comparison of the active site motifs (CPHC and CPHS) and
the Val150/Pro151 residues of the cis-Pro loop across all the
protomers in the PmDsbA, PmDsbAC30S, and PmDsbAC30S!
PWATCDS crystal structures reveals a high degree of structural
conservation. The active site cysteines Cys30 and Cys33 in the
native PmDsbA structure were modeled as a mixture of oxi-
dized and reduced (ratio 0.7:0.3). In the oxidized state the two
sulfurs (Fig. 3C) are 2.2 Å apart, reflecting the typical length of a
covalent disulfide bond found in other oxidized DsbA struc-
tures (e.g.EcDsbA and SeDsbA, S-S distance 2.0Å) (26, 68). The
dithiol form of the cysteines is likely a consequence of radiation-
induced disulfide reduction. The distance between the dithiol sul-
furs is 3.4Å. In the PmDsbAC30S and PmDsbAC30S!PWATCDS
structures, the distance between the hydroxyl oxygen of Ser30
and the sulfur atom of Cys33 varies between 3.3 and 3.5 Å (Fig.
3D). These distances are in agreement with those of other
reducedDsbA structures (e.g.KpDsbA 3.3–3.8 Å) (18). Overall,
there is no apparent change in the active site upon binding of
the peptide.
Peptide Binding Mode and Interaction with PmDsbAC30S—
The binding mode of the peptide (Fig. 4, A and B) is highly
conserved across the three protomers (r.m.s. deviation 0.1–0.2
Å over all 82 atoms). The electron density from this high-reso-
lution structure provides strong evidence for both the position
and conformation of the bound peptide (Fig. 4C). The binding
site for PWATCDS (residues 1 to 7) includes the hydrophobic
groove and the active site regions (CXXC and cis-Pro motif) of
the enzyme. As expected, the hydrophobic residues Pro1 and
Trp2 (italics indicate peptide residues) interact with the hydro-
phobic groove, and the C-terminal residues interact with the
cis-Pro region of the active site.
However, the observed bindingmodewas not entirely as pre-
dicted. On the basis of the EcDsbA!EcDsbB covalent complex,
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Cys5 of the peptide should interact with PmDsbAC30S residue
30 (mutated fromCys to Ser). This was not the case. In all three
complexes in the asymmetric unit, Asp6 and not Cys5 interacts
with PmDsbAC30S Ser30 (Fig. 4D). The acidic side chain of
Asp6 is within hydrogen bond contact distance of Ser30 and
His32. Moreover, the backbone amide of Asp6 forms hydrogen
bonds with the backbone amide of Val149 of the PmDsbAC30S cis-
Pro loop (Fig. 4D).
Comparison of Peptide Binding Mode with DsbA-DsbB
Complexes—The EcDsbB P2 loop (sequence PSPFATCDF) and
the synthetic peptide we used (PWATCDS) share the same bind-
ing location on EcDsbA and PmDsbAC30S, respectively. The
EcDsbA-EcDsbB complex (3.7-Å resolution (30)), revealed
one possible hydrogen bond between P2 and the enzyme
(backbone oxygen of Arg148 of the EcDsbA cis-Pro loop with
the backbone nitrogen of EcDsbB Phe106). All other interac-
tions with the P2 loop, aside from the covalent disulfide, are
hydrophobic (28).
As indicated above, no interaction was observed between
Cys5 and Ser30 of PmDsbAC30S. Instead, hydrogen bond inter-
actions with Asp6 and hydrophobic interactions with Trp2
appear to dominate the PWATCDS binding mode. Residues
between these two anchor points, Cys5, Thr4, and Ala3, pro-
trude out of the binding site relative to the equivalent EcDsbB
loop residues (Fig. 4, E and F).
The r.m.s. deviation for comparison of PWATCDS with the
EcDsbB P2 loop conformation is relatively high (2.2 Å for 28
backbone atoms), because of the bulge in the peptide confor-
FIGURE 3. Crystal structure of PmDsbA and its comparison with close homologues. A, structural comparison of four closely related DsbA homologues,
PmDsbA (4OCE) in cyan, EcDsbA (1FVK protomer B) in white, KpDsbA (4MCU protomer E) in orange, and SeDsbA in green. Conserved structural regions are
annotated; the catalytic cysteines are shown as yellow spheres. B, structure based sequence alignment of EcDsbA (1FVK, chain A), SeDsbA (3L9S, chain A),
KpDsbA (4MCU, chain F), and PmDsbA (4OCE, chain A). Sequence identitywith EcDsbA is shownon the left, conserved residues are black, differing residues are
red. The TRX domain is highlighted in light gray, and the helical domain in dark gray. Red squaresmark the three loop regions L1/2/3. Amino acid conservation
code is shown beneath the sequences. The active site CXXC motif is highlighted in blue, and the cis-Pro region in green. Secondary structure elements are
indicatedabove the sequences. Residuesunderlined in EcDsbAbind to theEcDsbBP2 looppeptide (PISA server analysis).C, CXXCactive site of PmDsbA.D,CXXC
active site of PmDsbAC30S:PWATCDS. For panels C and D, the electron density is from 2F0! Fc FFT maps generated in Phenix (53) and contoured at 1.0 !.
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mation. Binding of PWATCDS results in an average buried sur-
face area (i.e. surface that becomes inaccessible to solvent) of
955! 12 Å or 9.0! 0.1% of the total surface of PmDsbAC30S
(values are mean! S.D. generated from the three molecules in
the asymmetric unit). This is similar in area to the EcDsbA
buried surface upon binding of the EcDsbB P2 loop (924 Å2)
(30). In both structures a major feature is the binding of an
aromatic residue in the hydrophobic groove. EcDsbB P2 loop
residue Phe101 forms a T-shaped !-! stacking interaction with
EcDsbA Phe174, whereas Trp2 of the PWATCDS peptide
forms a parallel !-! stacking interaction with PmDsbAC30S
Tyr173 and possible edge interactions with enzyme residues
Pro170 and Tyr40.
DISCUSSION
The increasing incidence of infections caused by multidrug-
resistant pathogens represents a serious global human health
issue. Indeed, the emergence of carbapenem-resistant Entero-
bacteriaceae threatens tomake common infections such as uri-
nary tract infections untreatable (69). Antibiotic resistance is
spreading rapidly and treatment options are becoming increas-
ingly limited. One possible approach to address the paucity of
FIGURE 4. Analysis of the interaction between peptide PWATCDS and PmDsbAC30S. A, superposition of the PWATCDS peptides from all three
protomer!peptide complexes in the asymmetric unit. Note the peptide includes an N-terminal acetyl and a C-terminal amide group. Carbon atoms are shown
in cyan, oxygens in red, nitrogens in blue, and sulfurs in yellow. B, location of the bound PWATCDS peptide on the surface of PmDsbAC30S (protomer A shown
in gray). Peptide residues are labeled and colored as for panel A. The yellow patch indicates the location of Ser30. C, electron densitymap of PWATCDS (chain F)
at the interface with PmDsbAC30S (chain B). The 2F0 " Fc map was generated in Phenix (53) and is contoured at 1.0 ". PmDsbAC30S residues forming the
binding site are labeled.D, interactions between the peptide (D–F, in cyan) and protein (chains A-C, in gray) are shown: hydrogen bonds are indicated as black
dashed lines; a circle highlights the stacking interaction between Trp2 and PmDsbAC30S Tyr173. E, superposition of the EcDsbB P2 periplasmic loop (PSPFATCD,
orange and black letters, PDB code 2ZUP) with PmDsbAC30S-PWATCDS (red letters, backbone in cyan). F, schematic representation of the interactions formed
between EcDsbB P2 loop binding to EcDsbA (top) in comparison to PWATCDS binding to PmDsbAC30S (bottom), showing the comparative shift in register.
Covalent bonds are shown as black lines, hydrogen bonds are indicated with red dashed lines, and hydrophobic interactions with black dotted lines.
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new antimicrobials in the developmental pipeline lies in the
generation of novel anti-virulence drugs (19, 70).
The Gram-negative DsbA/B system has been proposed as a
target for the development of novel anti-virulence drugs (17).
Targeting DsbA/B for development of inhibitors could be ben-
eficial in many ways. First, DsbA is not essential for bacterial
survival (27) although it plays an essential role in virulence (17).
Thus, inhibiting DsbA/B would not kill bacteria and this prop-
erty may reduce the selective pressure to develop resistance.
Second, structures of several DsbA homologues have been
solved (18, 28, 71), providing a framework for structure-based
drug design. Third, DsbA structures and properties are more
highly conserved than the structures and sequences of viru-
lence factors across pathogens (18). Therefore, inhibitors that
target one DsbA enzyme within a subclass are likely to block
DsbAs within the subclass offering the possibility of medium-
spectrum inhibitors (18).
Designing an inhibitor to block a protein-protein interface,
such as that of a DsbA, requires a comprehensive knowledge of
its binding interactions. Here we have used an innovative
approach to define the interaction surface of PmDsbA by
using knowledge from the low resolution crystal structure of
EcDsbA-EcDsbB.We characterized a peptide derived from the
sequence of DsbB, showed that it bound to PmDsbA and co-
crystallized it in a non-covalent complex with PmDsbAC30S.
This provides the first example of a high-resolution crystal
structure of a DsbA in complex with a non-covalently bound
peptide. Two previously published structures of DsbA in com-
plex with bound peptides include (i) EcDsbA bound covalently
with a substrate SigA-derived peptide; and (ii)Xyfella fastidiosa
DsbA also bound covalently with a peptide that co-crystallized
fortuitously.
P. mirabilis associated infections are often difficult to treat
due to its propensity to form biofilms (4). Two cell surface
organelles associated with P. mirabilis biofilm formation, man-
nose-resistant Proteus-like (MR/P) fimbriae (72) and flagella
(which mediate swarming) (4), require DsbA for their correct
assembly. Taken together, our data show that PmDsbA exhibits
redox, functional, and structural properties typical of the DsbA
class Ia enzymes (73), which extends to all DsbAs characterized
to date from Enterobacteriaceae (18).We expect that the struc-
tural details of the peptide binding mode and the interactions
observed will likely hold true for all of these enzymes. Specifi-
cally, the hydrophobic groove and the cis-Pro loop provide key
points of interaction that could be exploited further. The high-
resolution crystal structure of the non-covalent complex
between PmDsbAC30S and peptide may provide an important
platform for the development of peptidomimetic antivirulence
compounds targeting PmDsbA and by extension the DsbAs
from all Enterobacteriaceae.
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4 Optimization of the expression and purification of the 
transmembrane protein PmDsbB from Proteus mirabilis using GFP-
fusions 
 
4.1 Introduction 
 
Antibiotic resistance is spreading rapidly and treatment options are becoming increasingly 
limited. One possibility to address the paucity of new antimicrobials in the pharmaceutical 
pipeline lies in the generation of novel anti-virulence drugs. The Gram-negative DsbA/B 
system has been proposed as a target for the development of novel anti-virulence drugs 
(Heras et al., 2009, Heras et al., 2014). One current approach is to inhibit reoxidation of 
DsbA, which requires the interaction with DsbB (Inaba, Murakami, et al., 2006) (Chapter I, 
Figure 1-5, Figure 1-8, Figure 1-13).  
 
Figure 4-1. DsbA/B anti-virulence strategy. Small molecule inhibitors block the ubiquinone (Q) 
binding site, leading to accumulation of inactive DsbA in its reduced state. In contrast, inhibition of 
DsbA, by synthetic peptides/peptidomimetics could directly block its interaction with substrates or 
DsbB. In both scenarios virulence factor maturation would be disrupted, leading to cells unable to 
establish or maintain an infection. 
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Another option is disruption of ubiquinone (essential DsbB co-factor) binding to DsbB, 
which should prevent electron transfer (reoxidation) between DsbA and DsbB. As a result 
inactive oxidized DsbA would accumulate in the periplasm, preventing virulence factor 
maturation. The success of targeting DsbB for anti-virulence therapy is supported by 
animal models showing that knockouts of either DsbA or DsbB attenuate the infection and 
pathogenesis of Gram-negative bacteria (Ireland et al., 2014, Rosadini et al., 2008, Totsika 
et al., 2009).  
 
Unfortunately, only low-resolution (3.3 - 3.7 Å) structural data is available for the DsbB 
protein from E. coli (Inaba et al., 2009, Inaba, Murakami, et al., 2006, Malojcic et al., 
2008). However high-resolution information is urgently needed for ongoing drug design 
efforts against the ubiquinone co-factor binding site in DsbB. To date, only two structures 
of the EcDsbB/EcDsbA complex (PDB ID: 2ZUP, 3E9J) have been deposited in the RCSB 
PDB. Both were solved at a moderate resolution of 3.7 Å (Malojcic et al., 2008, Inaba, 
Murakami, et al., 2006). In addition a 3.3 Å structure exists between EcDsbB and a 
monoclonal FAB-fragment (PDB ID: 2ZUQ) (Inaba et al., 2009). Due to the absence of 
structural information from DsbB homologues as well as high-resolution data, structure-
based drug design studies targeting DsbB for novel anti-virulence therapies remains 
limited. 
 
In order to expand our structural knowledge on DsbB proteins, I chose to examine the 
EcDsbB homologue from Proteus mirabilis (PmDsbB). A high-resolution structure of 
PmDsbB would be advantageous for future drug development against this important class 
of proteins and provide further insights into structural variations of DsbB proteins from 
Gram-negative bacteria. In addition, purified PmDsbB could then be used in the 
identification and screening process of small synthetic compounds, which target the 
ubiquinone-binding site.  
 
PmDsbB shares 52.5% sequence identity with canonical EcDsbB (Figure 4-2). The crystal 
structure of EcDsbB revealed four transmembrane helices and one short horizontal α-helix 
located in the second (flexible) periplasmic loop (P2) (Inaba, Murakami, et al., 2006). DsbB 
from E. coli contains 6 native cysteine residues (Cys8, Cys41, Cys44, Cys49 Cys104 and 
Cys130), in which Cys41-44 and Cys104-130 each form a reversible covalent disulfide 
bond. In contrast, PmDsbB includes four native cysteines, which are located at 
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homologous positions to Cys41-44 and Cys104-130 in EcDsbB. The CXXC motif differs 
between EcDsbB and PmDsbB (CVLC in EcDsbB and CVMC in PmDsbB). In addition a 
methionine residue is inserted in PmDsbB at position 70, located in the cytoplasmic loop 
region in EcDsbB. Importantly the majority of the residues located in proximity of the 
cofactor ubiquinone (Ala29, Gln33, Pro40, Glu47, Leu51, His 91, Met142, Pro143, Leu146 
and Phe150) are conserved in PmDsbB. Hence, small molecule inhibitors designed for the 
UQ binding pocket in EcDsbB are predicted to bind to the co-factor binding site in 
PmDsbB. A topology-based comparison of PmDsbB (UniProt ID: B4EXU5) with canonical 
EcDsbB (UniProt ID: P0A6M2) is shown in Figure 4-2.  
 
Figure 4-2. Side by side comparison of EcDsbB with PmDsbB. A. Topology diagram of 
EcDsbB, based on crystal structure coordinates (Inaba, Murakami, et al., 2006). 
Unstructured/flexible loop regions are in gray (P1/2 = periplasmic loop regions). Residues 
integrated into the lipid bilayer are in white. Cysteines are highlighted in red. The P2 loop peptide 
sequence that binds to the hydrophobic pocket/active site region in EcDsbA is colored in green. 
Yellow amino acids correspond to the horizontal α-helix and orange residues form the UQ co-factor 
binding pocket. B. Topology model of PmDsbB from a sequence based alignment with EcDsbA. 
Color code is identical to A. In addition methionine (purple) indicates an amino acid insertion in the 
cytoplasmic loop. Amino acids surrounded by red circles show sequence alterations compared to 
EcDsbB. 
 
The first high resolution structure (2 Å) of a soluble protein (myoglobin, an abundant iron- 
and oxygen-binding protein found in the muscle tissue of vertebrates) was reported in 
1960 (Kendrew et al., 1960). Ever since, technological advances led to an exponential 
increase of the deposition of soluble high-resolution structures in the protein data bank 
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(RCSB PDB, www.rcsb.org). Today, 54 years later, more than 80,000 soluble structures 
have been deposited. In comparison, the first crystal structure (3 Å) of a transmembrane 
protein (photosynthetic reaction center of Rhodopseudomonas) was solved 25 years later 
in 1985 (Deisenhofer et al., 1985). Since then, crystal structures of unique MPs have been 
scarce (Bill et al., 2011). The lack of structural knowledge of membrane proteins provides 
a severe bottleneck, in particular for the field of drug development, since estimations 
indicated that that over half (~ 60%) of all available drugs, target membrane proteins 
(Overington et al., 2006). Today, 29 years after the first report from Deinsenhofer et al., 
only 455 unique MP structures have been solved (http://blanco.biomol.uci.edu/mpstruc/), 
which is significantly less than the number of soluble structures generated within the same 
time (White, 2004) (Figure 4-3). 
 
 
Figure 4-3: Number of unique membrane protein crystal structures. Graph shows cumulative 
number of unique membrane protein structures solved since 1985. Red line represents the 
effective cumulative exponential growth rate of membrane protein structures. Plot of the red 
dashed line indicates the cumulative exponential growth rate of soluble protein structures within 
the same period of time. Starting point for the calculations is 1960, when the first soluble crystal 
structure was solved. Figure adopted from Prof. Stephen White 
(http://blanco.biomol.uci.edu/mpstruc/, UC Irvine). 
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The progress of MP structure determination has been hampered due to many obstacles, 
including the fact that the majority of MPs are only present at low abundance in native 
tissues (Tate, 2001). For example, G-protein coupled receptors (GPCRs), which play an 
essential role in cell signaling of many cellular pathways (Oldham & Hamm, 2008) are 
present on the cell surface in very low copy numbers under physiological conditions. 
Hence, GPCRs and most other MPs need to be overexpressed recombinantly (Schertler, 
1992, Tate, 2001, Grisshammer & Tate, 1995), which is more difficult compared with 
soluble proteins. Membrane proteins need to be inserted properly into the membrane, 
which is an intricate process (von Heijne, 2006, White & von Heijne, 2004, Hessa et al., 
2005, White & von Heijne, 2005). In addition, cells are more sensitive to the 
overproduction of MPs, leading to toxicity and disruption of cell growth (Wagner et al., 
2007). Also, membrane protein stability can be susceptible to secondary modifications, 
such as glycosylation or phosphorylation (Watanabe et al., 2004, Petrecca et al., 1999, 
Webster et al., 1997). Thus, different expression systems and hosts including mammalian, 
insect, yeast or bacterial cell lines need to be considered for MP expression. Different 
constructs of the MP of interest must also be designed to add signal peptides, and/or 
remove flexible regions of the proteins. This means it can take a significant time to 
optimize and screen hundreds of MP constructs in order to increase the expression levels 
of a single membrane protein.  
 
Even after the successful expression of a MP construct, its extraction from the 
phospholipid bilayer constitutes another hurdle. In most cases it requires the reconstitution 
of the desired membrane-construct in an artificial environment, consisting of detergent 
micelles. Detergents are bifunctional, amphipathic molecules that can form micelle 
structures above a critical concentration termed “the critical micelle concentration (cmc)” 
(Lichtenberg et al., 2013). They consist of a non-polar hydrocarbon rich tail, covalently 
linked to an ionic or polar head group. The hydrophobic tail regions interact with each 
other and prompt the formation of a globular micelle, which contains a hydrophobic core. 
Detergent molecules can displace phospholipids from the native lipid bilayer and thereby 
facilitate the solubilisation of the membrane protein by decorating the hydrophobic 
transmembrane region while, at the same time, using the hydrophilic head groups to keep 
the protein in solution.  
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Another layer of complexity is the selection of the correct type of detergent for 
crystallization. For example detergents such as LDAO (lauryldimethylamine-oxide) with a 
shorter aliphatic chain (forming a smaller micelle) are usually preferred since crystal 
contacts need to be established between exposed regions of the protein to produce high 
resolution protein crystals. However the application of smaller detergents can generate a 
harsher environment resulting in destabilization of the membrane protein (Tate, 2010). In 
contrast, detergents such as DDM (n-dodecyl-β-D-maltoside) form larger micelles that 
readily accommodate membrane proteins of various sizes. But the increased dimension of 
DDM micelles can interfere with crystal contact formation and frequently result in low-
resolution diffracting crystals. Therefore it is important to screen different detergents for 
their suitability for crystallization.  
 
Despite the obstacles described above, the pace of structure determination is accelerating 
due to recent technological advances, innovations in protein engineering and the use of 
advanced microfocus X-ray beams (Bill et al., 2011). In particular the stability of MPs is 
critical for crystallization. Generating and screening single amino acid point mutants for 
increased thermostability of the protein has led to increased protein stability for some 
GPCRs (Serrano-Vega et al., 2008). For instance, the β1-adrenergic receptor, β1AR-m23 
(Warne et al., 2011) was successfully solved using this method and the concept of 
thermostabilizing mutations can be extended to other types of MPs. Another recently 
developed technique relies on the insertion of a stabilising fusion protein (e.g. T4 
lysozyme, flavoredoxin, xylanase, rubredoxin or cytochrome b562 RIL) into a disordered 
intracellular loop region of the desired membrane protein, or more recently, at the N-
terminus of the protein (Chun et al., 2012, Zou et al., 2012). The addition of the fusion 
protein, such as T4 lysozyme, stabilises the flexible loop and increases the hydrophilic 
surface of the membrane protein (Cherezov et al., 2007) thereby increasing the formation 
of crystal contacts. In addition, highly specific monoclonal Fab and Fv fragments of 
antibodies can be generated, which can form a highly stable complex with a discontinuous 
exposed epitope of the membrane protein. This method was successfully applied to solve 
the structure of the electron transfer catalyst EcDsbB (Inaba et al., 2009) or the K+ channel 
from Steptomyces lividans (Zhou et al., 2001). 
 
Furthermore new techniques have been developed that influence the outcome of 
membrane protein crystallization. One such approach uses the formation of the lipidic 
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cubic phase (LCP), which is a liquid crystalline phase that assembles spontaneously when 
lipids are mixed with water/buffer at specific conditions (Landau & Rosenbusch, 1996, 
Caffrey, 2009). Three different subforms of bicontinous LCPs have been described in the 
literature (Cherezov, 2011). Altogether they contain an array of lipid bilayers that form 
different structural arrangements, depending on the composition of the lipid to water ratio. 
Membrane proteins can be embedded into the LCP. Buffers and solutes can diffuse 
through existing channels in the LCP, while the MP is integrated in an orderly fashion in 
the lipid bilayer. The MP can diffuse along the plane and form crystal contacts with 
neighbouring molecules and molecules from another bilayer, leading to a three 
dimensional stacking-interaction, which can eventually form a crystallization nucleation 
point. Several LCP-derived MP structures have been reported over the last few years 
(Manglik et al., 2012, Wu et al., 2012).  
 
Figure 4-4: Selection of membrane proteins obtained by LCP crystallization. The resolution 
and PDB code for each structure is shown. Compared to common detergent based crystallization, 
LCP has generated many sub 2.5 Å structures. Figure taken from (Cherezov, 2011).  
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Another recent development is the generation of discrete nanodiscs (Ritchie et al., 2009, 
Bayburt & Sligar, 2010, Bayburt et al., 2006, Raschle et al., 2009, Nath et al., 2007, 
Denisov & Sligar, 2011), which are soluble phospholipid islands in the form of a disc, 
whose dimensions are restricted by the length of the membrane scaffold protein, which 
surrounds the disc and lead to the formation of a ring like structure. Nanodiscs provide a 
promising approach to accommodate membrane proteins in their native lipid environment 
while being retained in solution in their active state. At present, no crystal structure has 
been reported of a membrane protein embedded in a nanodisc bilayer. However the 
technology has been vital for membrane enzymology. Also small angle X-ray scattering is 
currently used to investigate the shape and structure relation of nanodisc-integrated 
proteins such as bacteriorhodopsin (Kynde et al., 2014, Skar-Gislinge et al., 2010).  
 
To optimise membrane protein expression of PmDsbB, I employed a new technology that 
utilizes a green-fluorescent protein (GFP) fusion that was developed by Dr. David Drew 
(Drew et al., 2001, Drew et al., 2002, Drew et al., 2005, Drew et al., 2006). The method 
provides a relatively quick, efficient way to optimize membrane protein expression, 
production and selection of the appropriate detergent. The GFP is incorporated C-
terminally to the MP of interest, and does not fold or fluoresce unless the upstream MP is 
properly folded and fully membrane-integrated. Therefore fluorescence measurement 
allows direct monitoring of membrane protein integration, overexpression, solubilisation 
and purification. That is, MP expression levels can be directly compared and quantified by 
in-gel fluorescence or from whole cell samples using the fluorescence signal of the GFP-
fusion tag (Newstead et al., 2007, Geertsma et al., 2008). The GFP-fusion tag allows the 
determination of the solubilisation efficiency and therefore provides a platform to quickly 
screen a selection of different detergents. Furthermore it can be used in line with gel-
filtration chromatography (fluorescence-detection size exclusion chromatography = FSEC), 
which requires only small quantities of crude membrane extracts to evaluate the degree of 
monodispersity of the membrane protein sample (Kawate & Gouaux, 2006). This strategy 
can be applied to determine the integrity of the MP in various detergents without the need 
for protein purification.  
 
In summary, structure determination of MPs has been relatively slow, compared to their 
soluble counterparts. However several new technologies have recently emerged involving 
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(1) the stabilization of MPs by specific amino acid point mutations, (2) the generation of 
fusion constructs with soluble proteins such as T4 lysozyme, (3) the generation of antibody 
FAB fragments to facilitate crystallization, (4) the development of promising crystallization 
methods such as LCP or nanodiscs and (5) a GFP fusion method that enables efficient 
screening of the expression and purification of various MP constructs in parallel. In 
combination these approaches provide a powerful platform to overcome the bottlenecks in 
the field of membrane protein crystallization and might accelerate the process of 
membrane protein production and structure determination in the future.  
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4.2 Materials and Methods 
 
4.2.1 Molecular cloning of PmDsbB-GFP and GFP-His8 
 
PmDsbB (UniProt ID: B4EXU5) was cloned into the bacterial GFP fusion vector pWaldo-
GFPd (Waldo et al., 1999, Drew et al., 2006) provided by Dr. David Drew (Stockholm 
University) using 5’ NdeI and 3’ BamHI (New England Biolabs, USA) restriction sites. For 
quantification of expression levels and purification yields, the GFP sequence derived from 
the fusion-Tag of pWaldo-GFPd was sub-cloned into pET20b(+) from Novagen (EMD 
Millipore, USA) using 5’ NdeI and 3’ BamHI. PCR amplification of GFP was performed with 
KOD DNA polymerase according to the manufacturers instruction manual (EMD Millipore, 
USA). The gene sequence of PmDsbB including flanking (NdeI / BamHI) restriction sites 
was purchased from GenScript (GenScript USA Inc.). Table 4-1 provides the primer pairs 
that were used for PCR DNA-fragment amplification. Lastly, DNA was inserted into the 
linearized vector backbone with T4 DNA Ligase (Roche, Australia) to generate the final 
recombinant vector constructs (F010 and F027) listed in Table 4-2. 
 
Table 4-1. Oligonucleotides used for cloning. 
# Sequence Comment 
P017 GCGCACTCATATGAGCAAAGGAGAAGAACT pWaldo GFP (FW) 
P018 TATATGGATCCCAGCCGGATCTCAGTGGT pWaldo GFP (REV) 
 
Table 4-2. Plasmids. 
# Inserted gen Vector Restriction sites Tag 
F010 PmDsbB [B4EXU5] pWaldo-GFPd NdeI, BamHI PmDsbB- TEV–GFP–His8 
F011 - pWaldo-GFPd MCS empty- TEV–GFP–His8 
F026 - pET20b(+) Novagen MCS pelB-MCSa-C-His6 
F027 pWaldo-GFP pET20b(+) Novagen NdeI, BamHI C-His8 – TEVb 
a MCS = multiple cloning site; b TEV = Tobacco etch virus protease 
 
4.2.2 Protein expression, screening and optimization 
 
The bacterial strains listed in Table 4-3 were used for plasmid mini-preps (Top10 E. coli 
cells), expression of GFP (BL21-DE3-pLysS) and transmembrane PmDsbB-GFP 
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(BL21(DE3)-pLysS, C43 and C42 cells). Optimization of expression was solely performed 
in BL21(DE3)-pLysS cells. 
 
Table 4-3. E. coli cloning and expression strains. 
Strain Description Source 
E. coli Top10 cloning, plasmid replication Invitrogen (Australia) 
E. coli BL21-(DE3)-pLysS protein expression Invitrogen (Australia) 
C41(DE3) toxic and / membrane protein expression  Lucigen (Lucigen Inc., USA) 
C43(DE3) toxic and / membrane protein expression Lucigen (Lucigen Inc., USA) 
 
In the case of GFP-His8, F027 was freshly transformed into BL21-(DE3)-pLysS cells 
following the instructions for the transformation of chemically competent cells of the 
Invitrogen manual (Life Technologies Australia, Document Part Number: 280126). A single 
colony was used to inoculate a 5 mL LB-media culture (including 0.5 mg ampicillin [AMP] 
and 0.17 mg chloramphenicol [CAM]), which was incubated overnight at 37 ºC on a shaker 
(200 rpm). The overnight culture was diluted 1:1000 (1 mL into 1 L of fresh LB-media 
containing 100 mg AMP, 34 mg CAM) and incubated at 37 ºC (220 rpm) until OD600 
reached 0.5. The temperature was subsequently reduced to 25 ºC and protein over-
expression induced upon addition of 0.4 mM IPTG (final concentration). The main culture 
was then incubated at 220 rpm for another 4 h; cells were harvested by centrifugation 
(5000g, 15 min) and snap frozen in liquid nitrogen for long term storage at -80 ºC.  
 
Screening and comparison of expression levels of PmDsbB involved a three-step process. 
First, I assessed the ability of BL21-(DE3)-pLysS, C41 and C43 to overexpress PmDsbB-
GFP. Therefore F010, was transformed (as described above) into three different types of 
cells (BL21-(DE3)-pLysS = AMP, KAN, CAM; C41/C43 = kanamycin [KAN]), which were 
spread onto 1.5% LB-agar plates containing the appropriate antibiotic. A single colony was 
inoculated into a 5 ml LB-culture containing the appropriate antibiotic and grown overnight 
at 37 ºC, 220 rpm. On day two, six different medium sized cultures (160 mL fresh LB-
media in 1 L flasks) were inoculated with 500 µL of the overnight culture. 2x 160 mL for 
each cell line, screening two different IPTG concentrations (0.1 mM / 0.4 mM final). All six 
cultures were grown at 37 ºC until cells reached an OD600 of 0.5 and then temperature was 
reduced to 25 ºC for IPTG induction. Every hour, a 1 mL sample was removed to measure 
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cell density and whole cell fluorescence (section 4.2.4.). Cells were harvested 4 h post-
induction and analyzed using a confocal fluorescence microscope (Nikon SMZ1500). 
 
The second step involved a narrow grid screen using the cell line that produced the 
highest expression levels in the previous step (i.e. BL21-(DE3)-pLysS). This time an 
overnight culture of BL21-(DE3)-pLysS transformed with PmDsbB-pWaldo-GFPd was 
used to inoculate 6 x 15 mL LB-medium cultures. Two cultures were placed at three 
different temperatures (18/25/30 ºC) (6 in total). IPTG induced expression was conducted 
using two concentrations (0.1 mM and 0.4 mM final) at each temperature. A 500 µL 
sample of cells was withdrawn after 1/ 2/ 4 and 20 h. Also an additional culture containing 
empty pWaldo-GFP vector (F011) was grown as a negative control. Expression levels 
were then analyzed using whole cell fluorescence, in gel fluorescence and fluorescence 
microscopy. 
 
In the third step, the most suitable condition from the previous step was applied to scale up 
the expression reaction to a 1 L culture volume. Final expression of PmDsbB-GFP was 
performed starting from a single bacterial colony from a fresh overnight transformation 
(PmDsbB-GFP in BL21-(DE3)-pLysS), which was used to inoculate 20 mL LB-media 
containing  50 µg/mL KAN + 34 µg/mL CAM. The pre-culture was incubated with shaking 
at 37 ºC, 220 rpm overnight. On the next day, the entire 20 mL from the overnight culture 
(50-fold dilution) was added to 1 L LB-media (50 µg/ml KAN + 34 µg/mL CAM) pre-
warmed in a 2.5 L baffled shaker flask. Cells were grown at 37 ºC, 220 rpm till OD600 
reached 0.8 (after 2-3 hours). Then cells were quickly chilled on ice for 15 min, induced 
with 0.4 mM IPTG and grown at 25 ºC for 20 hours. Cells were harvested by centrifugation 
at 5,000 g for 15 min. Usually 6 L of culture were expressed in parallel. At this point the 
supernatant was disposed, and cells derived from a 6 L expression culture were 
resuspended in 200 mL PBS. The liquid was then either removed by centrifugation (5,000 
g for 15 min) and cells snap frozen in liquid nitrogen or used immediately for isolation of 
cell membranes (4.2.5).  
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4.2.3 GFP (F027) protein purification and quantification 
 
Table 4-4 summarizes all buffers used to purify GFP / PmDsbB-GFP. 
 
Table 4-4. Overview of purification buffers and their composition. 
Name Composition 
1x PBSa 8.1 mM Na2HPO4, 1.9 mM KH2PO4, 2.68 mM KCl, 136 mM NaCl 
Lysis buffer 1x PBS + PI (1:1000), DNase (1300 U per 100 mL lysate), 1 mM MgCl2 
1x SECb  20 mM Tris-HCl 7.5, 5 mM EDTA, 100 mM NaCl 
a PBS = phosphate buffered saline, b SEC = size exclusion 
  
Soluble GFP was expressed as described in section 4.2.2. Essentially, 40 mL of lysis 
buffer was added to a frozen cell pellet (derived from 1 L of LB-culture), including protease 
inhibitor (PI) cocktail (diluted 1:1000 into the lysate) (BioPioneer Inc., San Diego, CA), 
DNase (1300 U per 100 mL Lysate) (Roche, Australia) and 1 mM MgCl2. Cells were 
thawed in a 50 mL falcon tube, which was incubated on a test tube rotator for 15 – 20 min 
at room temperature [RT]. Next, cells were transferred to a pre-chilled 200 ml beaker and 
an additional 60 mL of lysis buffer (total pellet weight 9 g -> 10 mL lysis buffer / 1g cell 
pellet -> 90 mL total) was added and cells vigorously resuspended. Cell lysis was 
performed in a Cell Disruptor (TS-Series, Constant Systems LTD., UK) applying a single 
run with a constant pressure of 25 Kpsi. Cell debris was then removed by centrifugation 
(18.500 rpm, 35 min, 4 ºC, rotor JM-25.5, Beckman Coulter, Brea, CA). GFP was 
extracted from the cell lysate by immobilized metal ion affinity chromatography (IMAC) 
using 6 mL (= 1 column volume = CV) of Talon (Clontech, Australia). The resin was 
washed with 20 CV (120 ml) of 1x PBS + 50 mM imidazole and protein was eluted with 1x 
PBS + 250 mM imidazole. Total protein (20 mg) was determined at A280nm with a 
NanoDrop™ 2000c (Thermo Fisher Scientific, USA). To remove imidazole, the mixture 
was rapidly buffer-exchanged and further purified into 1x SEC using a Superdex S75 gel-
filtration column (GE Healthcare, USA) connected to an ÄKTA system (GE Healthcare, 
USA). Peak fractions were combined and protein aliquots (1.5 mg/mL) snap frozen in 
liquid nitrogen. 
 
Purified GFP was used as a standard to estimate expression levels in entire cells. In order 
to determine protein expression yields, a linear correlation between the intensity of GFP 
fluorescence with respect to a series of precise GFP dilutions was measured. Therefore 
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GFP was diluted into 20 mM Tris-HCl 7.5, 5 mM EDTA, 100 mM NaCl generating a set of 
14 concentrations (25 ng – 1500 ng / 50 µL well solution). Fluorescence of GFP was 
measured in 50 µL volume of a white 384-well plate (Perkin Elmer OptiPlate-384, Part #: 
6007290). Measurements were performed with a Synergy H1 multimode plate reader 
(BioTek, USA) using the tungsten light source, 510 nm top read and the sensitivity set to 
30. Values were exported and analyzed in Prism 6.0 (GraphPad Software, USA). 
 
4.2.4 PmDsbB-GFP in-gel fluorescence  
 
12 µL of each sample, taken throughout the purification was mixed with 6 µL of 3x SDS 
running buffer (New England Biolabs, USA). Samples were incubated for 5 min at 37 ºC. A 
standard 10% Tris-Glycine gel was prepared. The Benchmark Fluorescence Marker 
(Invitrogen, Australia) was used (8 µL) and the entire sample volume of 20 µL was loaded 
into separate gel-chambers. Gels were usually run in two steps, first for 15 min at 80 V and 
then for 60 min at 160 V. The entire system was placed in a box of ice to keep the 
temperature at 4 ºC. Protein fluorescence was then determined using a Typhoon scanner 
(Typhoon Trio, GE Healthcare).  
 
4.2.5 PmDsbB-GFP membrane isolation, detergent screening, IMAC and FSEC 
 
Membrane Isolation 
 
Protease inhibitor cocktail (diluted 1 in 1000 into the lysate) (BioPioneer Inc., San Diego, 
CA), DNase (1300 U per 100 mL Lysate) (Roche, Australia) and 1 mM MgCl were added 
to resuspended cells in 200 ml 1x PBS obtained from a 6 L expression batch (section 
4.2.2). Cell lysis was performed in a Cell Disruptor (TS-Series, Constant Systems LTD., 
UK) using two consecutive runs each with a constant pressure of 25 Kpsi. After cell 
breakage, lysate was spun down (14 000 rpm, 15 min, 4 ºC, rotor JLA-16.250, Beckman 
Coulter, Brea, CA) to remove unbroken cells and debris. To collect the cell membrane 
fraction in the supernatant, cleared lysate was ultra-centrifuged (41 000 rpm, 2h, 4 ºC, 
rotor 45 Ti, Beckman Optima XL-100R Ultra-centrifuge, Brea, CA) and the supernatant 
disposed. The remaining membrane fraction was carefully resuspended in 20 ml ice-cold 
1x PBS using a 10 ml syringe with a 21-gauge needle.  
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Detergent screening 
 
Isolated membranes were used to determine the solubilisation efficiency of PmDsbB-GFP 
in different detergents. First the total amount of protein was estimated with a NanoDrop™ 
2000c (Thermo Fisher Scientific, USA). The suspension was adjusted with 1x PBS to a 
protein concentration of 3.5 mg/mL. Nine different detergents were screened (Triton X-
100, LDAO, DM, NM, OM, UDM, OG, NG, DDM, also see Figure 4-11). 900 µL of 
membrane suspension was transferred into pre-chilled 1.5 ml eppendorf tubes, mixed with 
100 µL of detergent (10% w/v stock solution in 1x PBS) and incubated at 4 ºC for 1 h with 
mild agitation. Next, samples were centrifuged (18.000 g, 45 min, 4 ºC, Beckman Coulter 
BenchTop centrifuge) to remove non-solubilized material. The supernatant was then used 
to determine the fluorescence as described in (4.2.3), as well as by in gel fluorescence 
(4.2.4). 
 
To identify the ideal ratio between the selected detergent and the membrane fraction an 
experiment was conducted, exploring different protein:detergent ratios. The isolated 
membrane fractions were diluted to a range of concentrations (3-10 mg/mL) and 900 µL of 
the stock was mixed with 100 µL of 10% w/v NM detergent. Then the same protocol was 
applied to screen remaining detergents (Table 4-5). Solubilization efficiency was 
determined using fluorescence as described in (4.2.3), as well as by in gel fluorescence 
(4.2.4). 
 
Table 4-5. Summary of detergents used during purification optimization of PmDsbB-GFP. 
Abbreviation Chemical nomenclature  
Triton X-100 polyethylene glycol p-(1,1,3,3-tetramethylbutyl)-phenyl ether 
LDAO n-dodecyl-N,N-dimethylamine-N-oxide  
OG n-octyl ß-D-glucopyranoside  
NG n-nonyl β-D-glucopyranoside 
DM n-decyl ß-maltoside 
NM n-nonyl β-maltoside 
DDM n-dodecyl β-D-maltoside 
OM n-octyl-β-D-maltoside 
UDM n-undecyl-β-maltoside 
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Selection of Immobilized metal ion affinity chromatography (IMAC) resin 
 
The stock of isolated membranes was diluted to 3 mg/ml in a final volume of 150 mL, in 
PBS containing 1% w/v NM and protease inhibitor cocktail (diluted 1:1000) (BioPioneer 
Inc., San Diego, CA). The mixture was incubated at 4 ºC for 1 h with mild agitation and 
then centrifuged at 100,000g (4 ºC, 30 min). Imidazole was added (10 mM final 
concentration) to the supernatant containing detergent solubilized PmDsbB-GFP. The 
solution was split into 3x 50 mL to test binding to three different types of IMAC resin (Ni-
NTA HisTrap FF (GE Healthcare, USA); Talon (Clontech, Australia) and PrepEase 
(Affymetrix, USA). 1 mL (1 CV) of each resin was equilibrated with 5 CV of 1x PBS, 1% 
w/v NM (the critical micelle concentration [cmc] for NM is 0.2% w/v; 1% w/v = 5x cmc of 
NM was used throughout the residual steps of the purification). Talon and PrepEase were 
mixed with 50 mL of detergent solubilized membranes in a falcon tube for 2 h on a rotating 
wheel at 4 ºC. Ni-NTA resin was loaded with a constant flow rate of 0.5 ml/min using a 
peristaltic pump. Talon and PrepEase material was transferred into a 25 ml maxi column. 
All three resins were washed stepwise, with an increasing concentration of imidazole in 1x 
PBS, 1% NM w/v (i.e. 20 CV + 20 mM imidazole, 5 CV + 35 mM imidazole, 5 CV + 50 mM 
imidazole and in addition Ni-NTA with another 5 CV + 100 mM imidazole). Finally protein 
was eluted with 1x PBS, 1% w/v NM, 250 mM imidazole.  
 
Fluorescence-detection size-exclusion chromatography was performed to analyze the 
purity and monodispersity of PmDsbB-GFP. The eluted protein from the IMAC purification 
was loaded on to a Superdex 200 300/10 analytical column (equilibrated with 1x PBS 1% 
w/v NM) connected to an ÄKTA system (GE Healthcare, USA), which contained a JASCO 
FP-2020 Plus (Intelligent Fluorescence Detector). The flow rate was set to 0.5 mL/min and 
absorbance at A280nm as well as GFP fluorescence (λ = 510 nm) was monitored. Peak 
fractions were identified and concentrated in a 30 kDa cut-off concentrator (Amicon Ultra-
30, Millipore). Protein was immediately used for crystallization trials (4.2.7).  
 
4.2.6 Isolation of PmDsbB-GFP in DDM and TEV-cleavage 
 
Isolated membranes from a 3 L expression culture (18 mg/ml) (prepared as described in 
section 1.2.5) were mixed with DDM (1% w/v final concentration) and incubated at 4 ºC for 
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1 h under mild agitation. Supernatant containing the soluble fraction of PmDsbB-GFP in 
detergent micelles was obtained by ultra-centrifugation (100,000g, 4 ºC, 30 min). The 
solution was diluted 1:2 with ice-cold PBS containing 20 mM imidazole (10 mM final). 
PrepEase was added and the mixture was incubated overnight at 4 ºC. The resin was 
washed with 20 CV 1x PBS, 0.03% w/v DDM and 35 mM imidazole, and an additional 20 
CV of the same buffer containing 50 mM imidazole. Elution was performed using 1x PBS, 
0.03% w/v DDM and 250 mM imidazole. For TEV cleavage, 4.5 mg of TEV was added to 9 
mg PmDsbB-GFP (1:2 w/w ratio) including 5 mM EDTA and 1 mM β-mercaptoethanol. 
Digestion was performed for 18 h at 4 ºC. All subsequent steps (FSEC, FPLC SDS-PAGE) 
were performed as described in 4.2.5 for PmDsbB-GFP in NM (except that 0.03% w/v 
DDM was used in the buffer). 
 
4.2.7 Crystallization screening of PmDsbB 
 
Crystallization trials were conducted using the hanging drop vapor diffusion method. 
Seven of the commercially available 96-well screening plates (JCSG, Morpheus, PACT, 
ProPlex; Molecular Dimentions, UK) (Peg/Ion, PEGRx; Hampton Research, USA) 
(Precipitant Synergy; Jena Bioscience, USA) were prepared with a mosquito crystallization 
robot (TTP Labtech) by mixing 200 nL purified PmDsbB-GFP (3.2 mg/mL) in PBS 1% w/v 
NM with 200 nL of well solution. Screens were incubated and monitored in a RockImager 
1000 (Formulatrix, USA). In addition two Index screens (incubated at 8 or 20 ºC) and one 
PEGRx screen (both from Hampton Research, USA) (8 ºC) were prepared as described 
above but with a higher protein concentration of 9.1 mg/mL. Crystal growth was analyzed 
for 4-6 weeks. 
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4.3 Results 
4.3.1 GFP purification and quantification 
 
The native sequence of PmDsbB was inserted into the pWaldo-GFP plasmid (F010), 
which contains a C-terminal GFP fusion protein, a His8-tag and a TEV protease cleavage 
site to recover the native protein during purification. (Drew et al., 2001). Construct design 
is depicted in Figure 4-5A. To enable the quantification of PmDsbB-GFP, the ORF of GFP 
was subcloned including the His8-tag (F027) into pET20b(+) (Figure 4-5B). 
 
Figure 4-5: PmDsbB-GFP and GFP-His8 construct design. A. Construct design of PmDsbB, 
which was cloned into pWaldo-GFP using NdeI and BamHI restriction sites. The resulting ORF 
contains the sequence of native PmDsbB fused to a downstream linker sequence containing the 
TEV protease recognition sequence (cutting site is indicated by a small red cross) followed by the 
coding region of GFP and finally a C-terminal His8-tag. B. The GFP coding sequence of pWaldo-
GFP including the His8-tag was subcloned into pET20b(+) using NdeI and BamHI restriction sites. 
 
GFP was expressed and purified (as per section 4.2.3) and a total yield of 7.5 mg of 
purified GFP was obtained from a 1 L culture (Figure 4-6). GFP expressing cells are a 
bright yellow/green after being induced with 0.4 mM IPTG and overnight incubation at  
30 ºC (Figure 4-6).  
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Figure 4-6: GFP purification profile. A. Top and bottom picture shows the yellow/green color of 
GFP-His8 expressed in BL21(DE3)pLysS cells after overnight incubation. B. A typical GFP 
purification profile is shown. GFP-His8 elutes as a monomer at ~68 ml from a Superdex S75 gel-
filtration column (GE Healthcare, USA). On the left besides the peak is the SDS-PAGE lane for 
purified GFP protein. C. 15 ml falcon tube including 5 ml of purified (1.5 mg/ml) GFP-His8.  
 
Purified GFP was then used as a quantification standard for subsequent expression and 
purification trials of PmDsbB-GFP. Therefore whole-cell GFP fluorescence (WCF) as well 
as in gel-fluorescence (IGF) was analyzed using specific amounts of purified GFP (Figure 
4-7). Both methods provide a highly sensitive approach to detect GFP alone or GFP when 
properly folded and fused to PmDsbB. Protein quantification conducting IGF experiments 
is suitable to detect protein amounts up to 25 ng of GFP, which correspond to the signal of 
the faint band shown in the last lane of Figure 4-7B. WCF is ~ 5x more sensitive since a 
significant fluorescence signal can be detected for protein amounts as low as 5 ng.  
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Figure 4-7: Quantification of purified GFP. A. Determination of fluorescence of 14 different 
dilutions of purified GFP using a 96-well plate and a Synergy H1 multimode plate reader (excitation 
488 nm emission 520 nm). A linear regression curve was fitted through all data points with an r2 of 
0.93. B. Bands of a serial dilution obtained from an unstained SDS-PAGE gel. A Typhoon scanner 
(Typhoon Trio, GE Healthcare) was configured to detect GFP fluorescence. The signal strength 
correlates with the amount of protein loaded and represents an ideal detection range from 1000 ng 
– 25 ng.  
 
4.3.2 Optimizing expression levels of PmDsbB-GFP 
 
Expression levels of PmDsbB-GFP were analyzed using three cell types 
(BL21(DE3)pLysS, C41(DE3) and C43(DE3)) often used for membrane protein 
overexpression. Several soluble and membrane proteins can be toxic to BL21(DE3) cells. 
C41(DE3) was originally derived from BL21(DE3) and contains a mutation which prevents 
cell death associated with expression of many recombinant toxic proteins. C43(DE3) is a 
variant of C41(DE3), which contains further mutations to resist a different set of toxic 
proteins (Dumon-Seignovert et al., 2004). However PmDsbB-GFP was solely expressed in 
BL21(DE3)pLysS cells as summarized in Figure 4-8. Expression levels were measured 
after 20 h analysing the GFP fluorescence signal of whole cell samples. As shown in 
Figure 4-8, specific amounts of purified GFP were measured in parallel. After 
normalization of the OD600 = 1.0 between cultures and the subtraction of the fluorescence 
background from non-induced cells an estimate of ~ 5 mg expressed PmDsbB-GFP per 1 
L culture was calculated for BL21(DE3)pLysS (0.4 mM IPTG).  
 
Expression of PmDsbB-GFP, GFP-His8 as well as non-induced cells (F011) was examined 
using a fluorescent microscope (Figure 4-9). PmDsbB-GFP cells were clearly visible as 
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light green dots (Figure 4-9A). At the same exposure time of 40 ms, GFP-His8 producing 
cells generate an even stronger signal. No fluorescence was detected at 2.5x (100 ms) the 
exposure of non-induced cells.  
 
Figure 4-8: Whole cell fluorescence detecting PmDsbB-GFP expression levels in 
BL21(DE3)pLysS, C41(DE3) and C43(DE3) cells. Cell densities were normalized to an OD600 = 
1.0. Fluorescence signal of C41(DE3) and C43(DE3) were very weak (< 100 µg/1L expression 
culture) compared with BL21(DE)pLysS cells (> 6 mg/1L expression culture). 0.32/64 µg of GFP 
were measured for comparison.  
 
 
Figure 4-9: Fluorescent microscopy images of PmDsbB-GFP / GFP-His8 expressing cells. A. 
Sample of PmDsbB-GFP cells, after 20 h of IPTG induction. Fluorescence signal clearly shows 
that PmDsbB is overexpressed in BL21(DE3)pLysS cells. B. BL21(DE3)pLysS cells expressing 
GFP-His8 analyzed at an identical exposure time (40 ms) as in A. Fluorescence signal is stronger 
as expected for highly expressed GFP. C Cells transformed with an empty pWaldo-GFP vector 
(F011), showing no intrinsic background fluorescence of BL21(DE3)pLysS cells. 
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In the next step, a more narrow expression screen focusing on BL21(DE3)pLysS cells was 
conducted varying three different parameters (IPTG concentration, time of PmDsbB-GFP 
expression and incubation temperature). The highest yield was derived from cells that 
were incubated for 20 h at 25 ºC upon induction with 0.4 mM IPTG. The amount of 
expressed protein was estimated as 9.6 mg / 1 L expression culture based on whole cell 
fluorescence data (using the linear regression equation from Figure 4-6), and 7.5 mg / 1 L 
assuming an identical band intensity between the best expressing cells (lane 4) and the 
300 ng GFP band in Figure 4-10B. These values indicate that expression was further 
increased compared with results from Figure 4-8 by simply extending the expression time. 
 
Figure 4-10: Expression screen of PmDsbB-GFP in BL21(DE3)pLysS. A. Summary of whole 
cell fluorescence of BL21(DE3)pLysS cells overexpressing PmDsbB-GFP. GFP fluorescence of 
whole cells was measured after 1, 2, 4 and 20 h post induction comparing two different 0.1 / 0.4 
mM IPTG concentrations and three different temperatures (18/25/30 ºC). All values were 
normalized to OD600 = 1.0. B. In gel fluorescence of cell samples from the expression screen 
confirmed the strongest signal obtained for cells incubated at 25 ºC and 0.4 mM IPTG. The fusion 
construct runs faster than full length GFP, since membrane proteins run typically at 70-85% of their 
expected molecular weight (Drew et al., 2006). (gs = culture from cells grown from a glycerol 
stock), F011 = empty pWaldo-GFP vector (negative control). 
 
Figure 4-10A includes a sample of PmDsbB-GFP expressing cells that were inoculated 
from a frozen glycerol stock (gs, sample). The overall expression levels at 4/20 h were 
significantly lower compared with freshly transformed cells exposed to identical conditions. 
Thus for optimal expression levels the main expression cultures were always inoculated 
from a fresh overnight transformation. F011 was used as a negative control, which only 
contains the empty pWaldo-GFP vector transformed into BL21(DE3)pLysS cells. The cells 
showed no significant fluorescence. Figure 4-10B exhibits the in-gel fluorescence result for 
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cell samples from the expression screen in Figure 4-10B. Less obvious than in Figure 
4-10A, PmDsbB-GFP gives the strongest signal in lane 4 (starting from the left). 
 
4.3.3  Detergent screen for PmDsbB-GFP  
 
The selection of an appropriate detergent is critical in membrane protein solubilisation. 
Therefore the extraction of PmDsbB-GFP from its native phospholipid environment was 
optimized. As described in section 4.1 different detergents have different abilities to 
solubilize membrane proteins of various sizes. Nine different detergents were analyzed for 
their ability to incorporate PmDsbB-GFP into their micelle environment. Each of the 
detergents shown in Figure 4-11 was incubated with 3 mg/ml of the isolated membrane 
fraction, containing PmDsbB-GFP among other cell membrane proteins. As a general rule 
membrane protein solubilization is conducted at 2-10x the cmc (e.g. cmc for NM = 0.2% 
w/v, 1% w/v  = 5x the cmc for NM) (1% w/v final concentration for each detergent was 
used to ensure the formation of a saturated micelle environment) (Hjelmeland, 1990). 
 
Figure 4-11: Selection of detergents used to solubilize PmDsbB-GFP. A total of 9 different 
detergents were used in the solubilisation screen of PmDsbB-GFP. Solubilisation efficiency 
strongly depends on the type of membrane protein and detergent. Triton X-100, LDAO = n-
dodecyl-N,N-dimethylamine-N-oxide, OG = n-octyl ß-D-glucopyranoside, NG = n-nonyl β-D-
glucopyranoside, DM = n-decyl ß-maltoside, NM = n-nonyl β-maltoside, DDM = n-dodecyl β-D-
maltoside, OM = n-octyl-β-D-maltoside, UDM = n-undecyl-β-maltoside. 
  
After centrifugation and separation of the insoluble fraction, fluorescence of the 
supernatant was determined. Without the addition of any detergent, the majority of 
PmDsbB-GFP remains in the insoluble fraction (left bar, Figure 4-12A). The majority of 
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detergents significantly increased the solubility of PmDsbB-GFP, however DDM, DM, 
UDM, LDAO, NM and Triton X-100 are more effective than NG, OG and OM. NM was 
used in all successive steps of the purification since NM has been applied successfully to 
determine the crystal structure of EcDsbB (Malojcic et al., 2008). Figure 4-12B compares 
the band intensity between 1% NM solubilized PmDsbB-GFP and the no detergent sample 
by in gel fluorescence. It becomes clear (no detergent lane) that the single band is the 
result of two independent bands, which migrate in close proximity, suggesting the 
presence of two different (ox/red) redox states of PmDsbB, reminiscent of EcDsbB 
(Kobayashi & Ito, 1999). 
 
 
Figure 4-12: PmDsbB-GFP detergent solubilisation screen. A. Diagram displays measured 
florescence of PmDsbB-GFP in the supernatant after detergent solubilisation (after centrifugation 
and separation of the insoluble fraction). Nine different detergents were compared for their ability 
to incorporate PmDsbB-GFP in their micelle environment. The solubilisation efficiency of PmDsbB-
GFP was very similar for the majority of detergents tested. The lowest signal was obtained for the 
sample without any detergent (left). B. In gel fluorescence of PmDsbB-GFP solubilized in 1% w/v 
NM (left) compared with the PmDsbB-GFP sample without any detergent (right). Two bands can 
be identified (right), which may represent the reduced and oxidized redox states of PmDsbB. 
  
Generally the choice of detergent can significantly influence the efficiency of solubilization. 
In particular, protein can be lost if the concentration of detergent is not adjusted properly 
(Hjelmeland, 1990). An excess of detergent can lead to the fomation of empty micelles 
which might reduce binding to IMAC material and inhibit TEV-cleavage, unnecessarily 
increase costs and lead to detergent crystals. If the concentration is too low, membrane 
proteins may precipitate along with the insoluble fraction. One approach to optimize the 
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detergent-protein ratio is to keep the detergent concentration constant; about 5x above the 
cmc (here 1% NM) and continously increase the concentration of the isolated membrane 
protein fraction (Drew et al., 2006). Ideally fluorescence increases (more solubilized 
material) till saturation is reached. At the point of saturation, fluorescence (solubilization) 
will remain constant since the amount of detergent becomes the limiting factor. Figure 4-13 
shows the results for PmDsbB-GFP and 1% NM. 3 mg/ml of isolated membrane fraction 
leads to a similar signal as all other samples containing higher concentrations (4-10 
mg/ml) of PmDsbB-GFP. In this case 1% of NM might suffice to solubilize the entire 
fraction of 3 mg/ml PmDsb-GFP. An increase in protein doesn’t translate into a higher 
signal in GFP fluorescence. Thus a dilution of 3 mg/ml or even less should be used in 
combination with 1% NM to effectively solubilize PmDsbB-GFP from isolated membranes. 
Using dilutions significantly lower than 3 mg/ml will result in very large sample volumes 
and therefore will increase the cost for a purification dramatically. 
  
 
Figure 4-13: PmDsbB-GFP:detergent ratio determination. To identify the amount of PmDsbB-
GFP that is still effectively solubilized by 1% NM, different concentrations of isolated membrane 
protein fractions were incubated with 1% NM. After centrifugation, fluorescence of the remaining 
supernatant was measured. Solubilization of 3 mg/ml is similar to higher concentrated sample. An 
increase above 3 mg/ml does not increase the amount of solubilized PmDsbB-GFP. 
 
4.3.4 IMAC testing and FPLC/FSEC analysis of PmDsbB-GFP 
 
The ideal ratio of 3 mg/ml of isolated membrane fraction in combination with 1% NM in 1x 
PBS was used in the following steps to solubilize the entire membrane fraction. The 
insoluble fraction was discarded after centrifugation and binding experiments were 
initiated. In total three different types of IMAC resin (Talon, PrepEase, Ni-NTA) were 
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compared for their ability to bind to PmDsbB-GFP. Resin was charged as described in 
section 4.2.5. Surprisingly Ni-NTA didn’t show any binding to PmDsbB-GFP (data not 
shown). The nickel resin material that was used had passed its expiry date, which could 
explain why binding was not detected. Experiments with Ni-NTA should be repeated in the 
future using fresh resin. However both PrepEase and Talon were able to bind PmDsbB-
GFP effectively. As shown in Figure 4-14 PmDsbB-GFP bound very tightly to PrepEase 
resin. Even at 50 mM imidazole (in 1x PBS), the protein did not elute from the column 
material. On the other hand, strong binding also led to an increased background through 
contaminants Figure 4-14. Several other proteins co-eluted with PmDsbB-GFP (lane7-10). 
In contrast, PmDsbB-GFP associated more weakly with Talon, since protein eluted using 
35 mM imidazole in 1x PBS. Also, Talon resin samples showed less background binding of 
impurities. However less protein was loaded in the case of the Talon SDS-PAGE samples, 
and the elution fractions were more dilute. Overall both methods generated highly pure 
protein, through the application of a single affinity purification step. PmDsbB-GFP binding 
to Talon resulted in ~ 50% less yield in total protein after elution, as estimated through 
PmDsbB-GFP fluorescence considering both samples/elution fraction volumes.  
 
Figure 4-14: SDS-PAGE purification profile of PmDsbB-GFP using Talon or PrepEase. From 
left to right, protein standard, UC = ultracentrifugation pellet + 1% NM detergent = solubilized 
membrane extract with 1% NM, flow through of the solubilized membrane fraction during loading 
step of the IMAC resin. Increased imidazole concentrations in 1x PBS buffer to remove 
contaminants and at higher concentrations elute bound protein from the IMAC material. The profile 
for PrepEase is on the left, for Talon on the right.  
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In the final purification step, PmDsbB-GFP was analyzed by FPLC (GE Superdex 200 gel 
filtration column) in combination with FSEC (Fluorescence size-exclusion chromatography) 
detection. The eluent from the size-exclusion column was passed through a fluorometer 
fitted with a flow cell. The resulting shape of the curve reflects the monodispersity 
(homogeneity of a system) and therefore the quality and integrity of the membrane protein 
sample (Kawate & Gouaux, 2006). The graph in Figure 4-15 shows a black curve, 
representing the A280nm protein specific UV absorption (y-axes) versus the retention time 
(x-axes). Some aggregated protein eluted at ~ 7.5 ml. The second peak at 13.5 ml 
represents purified PmDsbB-GFP. The fluorescence signal increased in parallel with the 
second elution fraction, and showed a symmetrical monodisperse peak. 
 
Figure 4-15: FSEC / FPLC diagram of PmDsbB-GFP. A. Elution fractions from the PrepEase 
purification step were pooled and analyzed on a GE Superdex200 300/10 and a JASCO 
fluorometer. Two main black peaks can be identified, the first at 7.5 mL represents aggregated 
protein, and the second at 13.5 mL is purified PmDsbB-GFP. The red line indicates the FSEC 
signal, which shows a monodisperse peak for PmDsbB-GFP in 1% NM. B. 96-well plate after 
collection of PmDsbB-GFP fractions from the FPLC / FSEC run, which were excited with blue light. 
The peak fractions of PmDsbB-GFP are clearly visible. 
 
4.3.5 TEV protease digest of PmDsbB-GFP in DDM 
 
The detergent NM was selected for the purification of PmDsbB-GFP (described above), 
however NM is very costly and has a high cmc of 6 mM (0.28%) in H2O. Therefore ≥ 1% of 
NM are recommended during the initial steps of the purification process. At later stages 
(e.g. size exclusion chromatography) the detergent concentration can be reduced closer to 
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the cmc (Hjelmeland, 1990, Arnold, 2008). In contrast the cmc for DDM in H2O is ~ 30x 
less (0.2 mM, 0.0087% in H2O) and therefore only 0.01-0.1% (depending on the buffer 
composition and working temperature) is required throughout the purification process. In 
addition solubilisation efficiency of PmDsbB-GFP is very similar comparing DDM with NM. 
 
Figure 4-16: FSEC peak for PmDsbB-GFP in 0.03% DDM. Graph represents GFP fluorescence 
(GFP excitation: 488 nm / emission: 520 nm) of 96-well plate samples containing 100µL elution 
fractions from a Superdex S75 gel-filtration run. The peak is not as symmetrical as that for NM in 
Figure 4-15.  
 
Preliminary experiments using DDM to solubilize PmDsbB-GFP from crude membrane 
fractions were conducted, and protein purified in DDM according to the results described 
for PmDsbB-GFP and NM (section 4.2.6). However PmDsbB-GFP in DDM did not show 
the highly symmetrical peak found using NM. One of the reasons could be the difference in 
diameter of the detergent micelles in DDM, which are bigger and might be more suitable to 
accommodate larger membrane proteins. Nevertheless DDM purified PmDsbB-GFP was 
used in a first attempt to cleave the GFP-tag from the native PmDsbB sequence (Figure 
4-16). Figure 4-17 summarizes the results of the removal of the C-terminal GFP sequence 
from PmDsbB-GFP. Lane 2 (post-TEV) from the SDS-PAGE in Figure 4-17A reveals, that 
overnight incubation of PmDsbB-GFP with TEV (2:1, w/w) at 4 ºC leads to proteolytic 
cleavage. However the FPLC graph in Figure 4-17B reveals that a small fraction of full 
length PmDsbB-GFP protein remained, which co-eluted with PmDsbB including additional 
high molecular weight impurities.  
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Figure 4-17: TEV cleavage of PmDsbB-GFP and gel filtration of PmDsbB in DDM. A. SDS-
PAGE summarizing the TEV-cleavage of PmDsbB-GFP. Elution = sample after eluting PmDsbB-
GFP from PrepEase resin with 250 mM imidazole in PBS, post-TEV = after overnight digest of 
PmDsbB-GFP with TEV (2:1 w/w), post-TEV conc. FT = sample from the flow through of the 50 
kDa cut-off Millipore concentrator, PrepEase resin = protein remaining on resin after elution with 
250 mM imidazole in PBS, C11/D10/D6/D4 and F10 = sample of FPLC fractions. (* indicates 
impurities introduced by TEV) B. FPLC UV-trace of PmDsbB after TEV cleavage. TEV-protease 
elutes later in the second peak (~75 ml) and can be separated as well as most of the uncleaved 
PmDsbB-GFP. FPLC fractions from A are highlighted. 
 
These data highlight that TEV-cleavage needs further optimization. A common problem 
with membrane proteins is ineffective TEV cleavage even at a ratio of 1:2 w/w 
(TEV:protein). In comparison TEV cleavage of PmDsbA (see chapter III), at a molar ratio 
of 1:50 (TEV:PmDsbA) was sufficient to cleave the entire protein fraction within 2 h. It was 
shown previously that TEV cleavage can be affected by the presence of detergents 
(Mohanty et al., 2003). Also high imidazole concentrations can significantly decrease TEV 
proteolysis. In addition the concentration of the protein sample has an influence on kinetics 
of TEV digestion, i.e. the higher the protein concentration the higher the cleavage rate. To 
obtain complete cleavage a further increase in TEV concentration might be necessary for 
future experiments, e.g. a 1:1 (mg/mg) ratio or an excess of TEV should be considered for 
complete cleavage. However, the use of large TEV quantities has the risk of introducing 
contamination if the TEV-protease sample is not pure. For example lane 5/6 of the SDS-
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PAGE gel Figure 4-17A shows a high molecular weight contaminant ~ 97 kDa introduced 
by the addition of TEV (indicated by *).  
 
4.3.6 Crystallization trials of PmDsbB-GFP 
 
Purified PmDsbB-GFP (pooled fractions: 12.5 – 14 ml Figure 4-15A) was concentrated to 
various concentrations (section 4.2.7) and commercially available 96-well screening plates 
(JCSG, Morpheus, PACT, ProPlex, Peg/Ion, PEGRx) were setup using the Mosquito 
crystallization robot. 400 µL drops were either incubated at 8 ºC or 20 ºC. Several crystals 
appeared within a week (Figure 4-18). All four crystals were harvested using 
perfluoropolyether cryo oil (Hamton Research, UK) and flash frozen in liquid nitrogen for 
storage and shipment to the Australian synchrotron. The quality of the four crystals shown 
in Figure 4-18 was assessed at the MX2 beamline at the Australian Synchrotron. The 
crystal in Figure 4-18A showed low-resolution diffraction (> 25 Å, see Figure 4-18E), 
whereas the remaining three B-D showed no diffraction. In the future UV-imaging of the 
crystals screens should be considered since this technology can discriminate between 
protein and detergent crystals. This technique uses tryptophan (PmDsbB contains 8 
tryptophan residues), which when excited by UV light will fluoresce between 300-350 nm. 
In theory, protein crystals are very dense arrangements of protein, and glow brightly when 
illuminated with UV light. The UV imaging thus allows to locate small protein crystals and 
to distinguish them from other material, such as salt crystals or detergent crystals. In 
addition lowering the detergent concentration during the last size exclusion 
chromatography step might reduce the likelihood for detergent crystal formation.  
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Figure 4-18: Crystallization screening results for PmDsbB-GFP. A. Index, 9.1 mg/ml, size: 130 
x 50 µm, 8 ºC, 0.1 M Tris pH 7.5, 0.01 M CoCl2 – 6H2O, 20% w/v polyvinylpyrrolidone K15. B. 
PegRX, 9.1 mg/ml, size: 25 x 25 µm, 8 ºC, 0.1 M sodium citrate tribasic dihydrate pH 7.5, PEG 
20.000 10% w/v, 0.2 M MgCl2 – 6H2O C. PegIon, 3.2 mg/ml, size: 100 x 5-10 µm, 8 ºC 0.02 M 
ZnCl2, 20% w/v PEG 3350. D. PegRX, 3.2 mg/ml, size: 60 x 30 µm, 8 ºC 0.1 M sodium acetate 
trihydrate pH = 7.5, 10% w/v PEG 4000. E. Diffraction image of crystal A. Low resolution diffraction 
visible up to 25 Å. Ice rings are present at 3.67 Å, suggesting non-ideal cryo conditions of the 
mother liquor.  
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4.4 Discussion 
 
In recent years DsbA/B proteins have received major attention as targets for the 
development of novel antivirulence drugs (Heras et al., 2009). Many substrate proteins of 
DsbA are virulence factors, which are non-functional without stabilizing disulfide bonds. 
Gene deletion experiments in bacteria to remove DsbA or DsbB revealed that these 
bacterial strains were highly attenuated (Ireland et al., 2014, Rosadini et al., 2008, Totsika 
et al., 2009). Inhibition of pathogenic strains may be achieved by inhibition of DsbB, which 
would prevent reoxidation of DsbA and consequently inhibit virulence factor maturation. 
However, we lack high-resolution structural information on DsbB. Therefore I integrated 
PmDsbB into the GFP-fusion pipeline (Drew et al., 2006) to optimize its expression and 
purification, with the final aim to obtain pure protein that can be used in crystallization trials 
and biochemical assays. Figure 4-19 summarizes the steps that were conducted to 
optimize the expression and purification of PmDsbB using the GFP fusion technique. 
 
Figure 4-19: Flow diagram of the PmDsbB expression and purification optimization pipeline.  
Within four weeks, PmDsbB-GFP and GFP-His8 were synthesized and cloned. GFP-His8 was 
expressed, purified and applied as quantification standard. Over the next 2 months, expression of 
PmDsbB-GFP was optimized from sub-milligram amounts to 6-9 mg of protein / 1 L expression 
culture. Then the expression volume was increased to 6 L and a suitable detergent was selected 
for PmDsbB-GFP solubilisation. Different types of IMAC resin were tested and the full-length 
construct crystallized.  
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The GFP-fusion pipeline enabled quick optimization of expression levels of PmDsbB-GFP 
(6-9 mg/1L) without the necessity to engineer different variants of the protein or to screen 
different heterologous expression systems. Generally overexpression of membrane 
proteins typically yield ≤ 1 mg/L (Bernaudat et al., 2011) and therefore cells from several 
litres of an expression culture need to be purified to obtain sufficient protein amounts for 
crystallization trials. In comparison expression levels of PmDsbB were relatively high, 
possibly due to its moderate size (containing only 4 TM helices) and prokaryotic origin. In 
comparison human GPCR receptors contain 7 TM helices and commonly show much 
lower expression yields ≤ 1 mg/L (O'Malley et al., 2009). In addition membrane proteins 
from higher organisms frequently contain posttranslational modifications. For example 
glycosylation of the Kv1.4 potassium channel has an influence on its stability (Watanabe et 
al., 2004). Several membrane proteins can be regulated by phosphorylation, including 
mechanisms that involve conformational changes (Webster et al., 1997). Knowledge about 
stabilization of membrane proteins upon ligand binding can be vital in the purification and 
crystallization process (Palczewski et al., 2000). However binding of the ubiquinone co-
factor had no influence on the stability of the DsbA/B complex (Yazawa et al., 2013). 
These differences between more complex membrane proteins and PmDsbB might explain 
its relatively high expression levels. 
 
After expression optimization, different types of detergents were assessed for their ability 
to solubilize PmDsbB from the native lipid bilayer. In general detergents that form larger 
micelles, provide a more stabilizing environment and are therefore commonly used during 
the initial steps of the purification process. DDM (n-dodecyl-β-D-maltopyranoside) is 
considered one of the most widely used detergents belonging to the class of maltosides, 
which contain a hydrophilic maltose unit and a hydrophobic alkyl chain (C12). Frequently 
DDM is replaced by smaller detergents that are more suitable for crystallization, i.e. that 
form a more compact micelle structure such as LDAO or NM, which can result in an 
increase of exposed regions of the membrane protein, necessary for the formation of 
crystal contacts. NM is a shorter non-ionic detergent containing a C9-aliphatic chain 
connected to a maltopyranoside moiety. It forms a smaller detergent micelle compared to 
DDM (Seddon et al., 2004). PmDsbB-GFP in NM revealed a highly symmetrical peak in 
the FSEC experiments (Figure 4-15), consistent with a monodisperse (homogenous) 
sample. However ~ 1/3 of the total protein fraction was precipitated and eluted in the 
column void volume. This indicates that NM provides a suitable environment to preserve 
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the integrity of PmDsb-GFP, however future experiments need to identify ways to minimize 
the fraction of precipitated protein to increase protein yields. Several approaches for how 
the latter could be achieved are summarized in the last section of this chapter (4.5, future 
directions). In addition the cmc for NM is relatively high (6 mM), compared to DDM (0.2 
mM, 30x less) which requires the usage of 1% NM throughout the entire purification 
process. Ideally DDM should be used for the initial steps and be replaced by NM during 
the final size exclusion chromatography step. However, Figure 4-16 indicates that 
PmDsbB-GFP is not highly monodisperse in DDM (n=1), although this experiment should 
be repeated as the protein was stored overnight at 4 ºC before the FSEC run was 
conducted, which could have an impact on its stability. Additional detergents might be 
considered in future experiments, such as UDM, which was successfully used in the 
structure determination of the complex between EcDsbA and EcDsbB (Inaba, Murakami, 
et al., 2006). UDM is a variant of NM containing a C11 versus a C9 aliphatic hydrocarbon 
tail. UDM showed almost identical solubilisation rates for PmDsbB compared to NM 
(Figure 4-12) and therefore could be a promising candidate for future crystallization trials 
to generate better diffracting crystals.  
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4.5 Future directions 
 
Whilst the GFP fusion approach described here provided a quick and efficient means of 
producing sufficient amounts of PmDsbB for crystallization studies, several aspects of 
protein expression and purification of PmDsbB could be optimized in the future. For 
example, changing the expression media from LB to TB rich media could increase cell 
density and overall expression rates. Fermenter systems optimized for bacterial cell 
growth to high density, could also be considered. Specialized expression systems such as 
the pLEMO system (Wagner et al., 2008), in which cell expression can be precisely titrated 
could further enhance expression. It is worthwhile to explore some variations to the 
standardized induction procedure such as inducing cells for a much shorter time (only 1-2 
h) at a much higher OD600 (6-8), or grow cells to an OD600 = 0.8 – 1.0 then place cells on 
ice (cold shock) for half an hour, induce at a lower temperature (15-18 ºC) and incubate for 
several hours/overnight (Qing et al., 2004, Sivashanmugam et al., 2009).  
 
During protein purification, it is critical to minimize the time and handling of MPs. Thus, one 
could eliminate the TEV protease cleavage step using a common pET vector system 
instead. For example pET21a has been successfully used for the purification of WpDsbB 
without the GFP protein attached, removing the necessity for TEV cleavage (Walden et al., 
2013). Handling time could be further decreased by an exchange of dialysis (imidazole 
removal) by a quick desalting step using an FPLC Äkta system in combination with a 
desalting column (GE Sephadex GE-25 superfine). These aspects could accelerate and 
minimize the steps involved in the purification of PmDsbB. They might also increase the 
probability to generate proteins crystals since the handling time of the protein is greatly 
reduced.  
 
Encouragingly, initial crystallization trials produced low-resolution (> 25 Å) diffracting 
crystals of PmDsbB that were tested at the microfocus beamline (MX2, optimal for 
shooting small crystals) at the Australian synchrotron. At this stage, optimization of 
PmDsbB crystallization is far from exhausted, with only traditional vapor diffusion methods 
being conducted to date. In particular, techniques specifically developed for membrane 
proteins, such as LCP or bicelles (section 4.1) should be employed in the future.  
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It is important to note that previous attempts to crystallize EcDsbB alone were 
unsuccessful. No extracellular domains are present in the structure of DsbB, and only a 
highly flexible P2 loop region connects TM helix 3 and 4 (Figure 4-2). This is concerning as 
the generation of crystal contacts requires stable interactions between exposed 
residues/domains. Hence formation of a complex between EcDsbA(Cys33Ala) and 
EcDsbB(Cys130Ser) or EcDsbB(Cys41Ser) and a monoclonal FAB-fragment was 
essential in the past to determine the crystal structure of EcDsbB (Inaba, Murakami, et al., 
2006, Inaba et al., 2009, Malojcic et al., 2008). EcDsbA and the EcDsbB specific FAB 
fragment greatly increased the surface for crystal contact formation as evident by the 
crystal packing arrangement of both structures.  
 
A similar strategy should be employed for PmDsbB, which would require the formation of a 
complex between PmDsbA(Cys33Ala) and PmDsbB(Cys130Ser) or the generation of a 
monoclonal antibody. The structure of PmDsbA(Cys33Ala) was solved during the course 
of this PhD thesis (data not shown), hence complex formation should be explored in the 
first instance since it is much more cost effective than the production of a monoclonal 
antibody. Also the complex will provide more valuable structural information, in particular, 
whether the interaction between EcDsbA/B is preserved in PmDsbA/B. The main focus of 
this project is to get a high-resolution structure of PmDsbB that will enable more accurate 
docking experiments and also facilitate structural based design of small molecules that 
could target the ubiquinone-binding pocket. Since it is very unlikely that PmDsbB will 
crystallize on its own, complex formation with PmDsbA might be the solution. However it is 
not clear if co-crystallization experiments will be successful using the complex, especially if 
the ubiquinone-binding pocket will be accessible in the PmDsbA(Cys33Ala) / 
PmDsbB(Cys130Ser) complex. 
 
Additional engineering based approaches such as the fusion of T4 lysozyme, 
Flavoredoxin, Xylanase, Rubredoxin or Cytochrome b562 RIL into one of the two flexible 
periplasmic loops (P1/2) from PmDsbB (Figure 4-2) could be explored as an alternative 
(Chun et al., 2012). Fusion proteins might have the advantage to leave the UQ binding 
pocket accessible for potential small molecule inhibitors. Also it might be possible to lock 
PmDsbB in a different conformation that could provide further clues on the mechanism of 
action of PmDsbB. Since PmDsbB is only 174 amino acids, screening of thermostabilizing 
mutations might be another valid option, but keeping in mind that only a more stable 
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version of the protein might not be sufficient to obtain protein crystals which require 
significant crystal contacts. Presumably a thermostabilized version of the protein will only 
crystallize in combination with some of the approaches stated above.  
 
In summary, the future looks bright for obtaining the crystal structure of PmDsbB. 
Optimization of protein production and purification using the GFP-fusion strategy has 
resulted in high protein yields of up to 2-4 mg/L of PmDsbB, which is excellent for MPs. 
Secondly, initial crystallization attempts have already produced some promising hits, and 
we are left with many avenues to explore. For example, engineering of fusion proteins with 
T4 lysozyme into PmDsbB, the formation of a complex between PmDsbB and PmDsbA, 
and the generation of antibodies against PmDsbB should be considered. Novel 
crystallization techniques such as LCP or bicelles should now be explored for 
crystallization. The structure of PmDsbB will be instrumental for the design of inhibitors by 
providing a detailed atomic picture of the interface that can be used for future rational drug 
design studies.  
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5 The multidrug resistance IncA/C transferable plasmid encodes a 
novel domain swapped dimeric protein disulfide isomerase 
 
 
This chapter has been published as a research article in the Journal of Biological 
Chemistry. It describes the structural and functional characterization of a novel Dsb 
member DsbP, which is a highly conserved disulfide-bond isomerase encoded on mobile 
genetic elements. DsbP plays a crucial role in the dissemination of antibiotic resistance 
genes. 
 
Contributions 
 
Experiments were conceived and designed by myself, Premkumar Lakshmanane, Simon 
Neyer and Jenny Martin. The manuscript resulted from a collaboration with Premkumar 
Lakshmanane, who refined all three crystal structures of DsbP and primarily drafted the 
first manuscript. I conducted the crystallization and biochemical characterization of DsbP 
and contributed to the drafting of the manuscript. Simon Neyer purified and crystallized 
seleno-methionine labeled DsbP, which resulted in the determination of the initial DsbP 
structure. Simon Neyer was a Masters student from the Ludwig Maximilians University 
Munich supervised by me during his six month research project at the University of 
Queensland. As an expert in the field, Mark Schmbri contributed valuable input for the 
discussion section. Jenny Martin supervised the project. All authors provided critical 
comments on the manuscript and assisted during editing.  
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Lakshmanane Premkumar‡1, Fabian Kurth‡1, Simon Neyer‡2, Mark A. Schembri§3, and Jennifer L. Martin‡4
From the ‡Institute for Molecular Bioscience, Division of Chemistry and Structural Biology and §School of Chemistry andMolecular
Biosciences University of Queensland, St. Lucia, Queensland 4067, Australia
Background: Bacterial IncA/C plasmids distribute antibiotic resistance genes and encode a conserved thioredoxin-fold
protein (DsbP).
Results:DsbP shuffles incorrect disulfide bonds in misfolded proteins, and its structure diverges from previously characterized
disulfide isomerases.
Conclusion: Plasmid-encoded DsbP is a novel domain-swapped protein-disulfide isomerase.
Significance: IncA/C plasmidsmay encode this protein proofreadingmachinery to ensure horizontal gene transfer of antibiotic
resistance genes.
The multidrug resistance-encoding IncA/C conjugative
plasmids disseminate antibiotic resistance genes among clin-
ically relevant enteric bacteria. A plasmid-encoded disulfide
isomerase is associated with conjugation. Sequence analysis
of several IncA/C plasmids and IncA/C-related integrative
and conjugative elements (ICE) from commensal and patho-
genic bacteria identified a conserved DsbC/DsbG homolog
(DsbP). The crystal structure of DsbP reveals an N-terminal
domain, a linker region, and a C-terminal catalytic domain. A
DsbP homodimer is formed through domain swapping of two
DsbP N-terminal domains. The catalytic domain incorporates
a thioredoxin-fold with characteristic CXXC and cis-Promotifs.
Overall, the structure and redox properties of DsbP diverge
from the Escherichia coli DsbC and DsbG disulfide isomerases.
Specifically, the V-shaped dimer of DsbP is inverted compared
with EcDsbC and EcDsbG. In addition, the redox potential of
DsbP (!161mV) ismore reducing than EcDsbC (!130mV) and
EcDsbG (!126 mV). Other catalytic properties of DsbP more
closely resemble those of EcDsbG than EcDsbC. These catalytic
differences are in part a consequence of the unusual active site
motif of DsbP (CAVC); substitution to the EcDsbC-like (CGYC)
motif converts the catalytic properties to those of EcDsbC.
Structural comparison of the 12 independent subunit structures
of DsbP that we determined revealed that conformational
changes in the linker region contribute to mobility of the cata-
lytic domain, providingmechanistic insight into DsbP function.
In summary, our data reveal that the conserved plasmid-en-
coded DsbP protein is a bona fide disulfide isomerase and sug-
gest that a dedicated oxidative folding enzyme is important for
conjugative plasmid transfer.
The global prevalence of multidrug-resistant bacteria is
increasing at an alarming rate (1). Both the spread of antibiotic-
resistant bacteria (2) and the transmission of resistance genes
between the same and different species (3), contribute to the
increase in antibiotic resistance. For example, since the
initial identification of the New Delhi metallo-!-lactamase-1
(NDM-1) gene in Klebsiella pneumoniae, the gene has been
identified in a number of other bacterial genera (4). It is now
clear that plasmids or integrative and conjugative elements
(ICE)5 (a chromosomally integrated mobile genetic element (5,
6)), are important drivers of the dissemination of antibiotic
resistance in bacteria (7).
Bacterial cell surface pili, belonging to a subfamily of the type
IV conjugation system (known as the type IV secretion system)
mediate the transfer of conjugative plasmids and ICE between
bacteria (8, 9). The type IV secretion system is a multiple pro-
tein component system. Its core functional components com-
prise: (i) cell surface pili that establish contact with recipient
cells; (ii) a multiprotein secretion channel that facilitates trans-
fer of the plasmid across the bacterial cell envelope; and (iii) a
type IV coupling protein receptor that recognizes protein-
coated conjugative plasmids at the cytoplasmic face and deliv-
ers them into the secretion channel (9). The large extrachromo-
somal conjugative plasmids or ICEs contain a subset of genes
located in the transfer (tra) region that encode protein compo-
nents (Tra proteins) required for building and assembling the
complete conjugative machinery (10). In addition to these
essential genes and several genes encoding regulatory proteins,
the F plasmids andmany other drug-resistant conjugative plas-
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The atomic coordinates and structure factors (codes 4ML1, 4ML6, and 4MLY)
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mids also contain a gene that encodes a thioredoxin (TRX)-like
disulfide oxidoreductase (10–13).
Bacterial disulfide isomerases are periplasmic TRX-like oxi-
doreductase chaperones that proofread and shuffle incorrect
disulfide bonds in secreted proteins harboring multiple cys-
teines, or protect periplasmic proteins with a single cysteine
from oxidative damage (14–18). The best-studied disulfide
isomerases are Escherichia coli DsbC and DsbG (EcDsbC and
EcDsbG) (18–20). Both have a catalytic domain comprising a
TRX-fold with a canonical redox-active CXXC active site motif.
Both form a V-shaped protein structure through homodimeriza-
tion of the N-terminal cystatin-like domains of each subunit. A
connectinghelix links theN-terminal domainwith theC-terminal
catalytic domain (16, 17). However, other TRX-like disulfide
isomerases are also used by bacteria. For example, a!160-residue
F-plasmid encoded disulfide reductase and isomerase TrbB,
whose sequence remotely resembles that of the extracytoplasmic
monomeric thioredoxin ResA (16% identity) (21), is essential for
the folding and assembly of components of the conjugative secre-
tion system (13).
In recent years, the incompatibility group IncA/C-conjuga-
tive plasmids have receivedmajor attention as a consequence of
their presence in awide range of bacterial hosts and their ability
to support the spread of multidrug resistance (3, 22). The
IncA/C plasmid was first identified in a fish pathogen Aeromo-
nas hydrophila in the 1970s (23, 24). Sequencing analysis of
plasmid lineages of blaCMY-2 (extended-spectrum !-lacta-
mase gene) and blaNDM-1 (New Delhi metallo-!-lactamase-1
gene) showed that IncA/C plasmids are highly disseminated
across animal and human bacterial pathogens (4, 25–27). Our
sequence trawling of several IncA/C plasmids revealed that the
tra region encodes a conserved protein, which we named DsbP
based on its similarity to other disulfide oxidoreductases and its
frequent plasmid location (see Table 1 for a compiled list). The
DsbP sequence is remotely related to EcDsbC and EcDsbG
(18–20% identity over 214 residues) and is not recognized as
homologous with TrbB because it lacks the N-terminal
dimerization domain (35% identity, over just 32 residues
around the CXXC motif).
IncA/C plasmids also contain mobile elements that facilitate
their integration into the bacterial chromosome (22). Conse-
quently, a gene coding for DsbP is also located in ICEs isolated
from Proteus mirabilis, K. pneumoniae, Salmonella enterica
serovars Typhimurium and Newport, and Acinetobacter bau-
mannii (100% sequence identity to DsbP). Importantly, dele-
tion of a DsbP homolog (47% identity and 71% similarity) in the
SXT/R391 family of ICE (closely related to IncA/C plasmids)
abolished conjugative transfer (5).
Here, we present three crystal structures of the IncA/C
plasmid-encoded DsbP from independent crystal forms. The
resulting six structural models of homodimeric DsbP were com-
pared with the structures of chromosomally encoded disulfide
isomerases to report on structural diversity, domain motion, and
redox state-dependent changes at the active site. We also evalu-
ated the redox activity profiles of DsbP and active site variants
in dithiol oxidase, disulfide isomerase, and disulfide reductase
assays in comparison with the prototypical EcDsbC and
EcDsbG disulfide isomerase enzymes. The results show that
DsbP is a novel domain-swapped dimeric disulfide isomerase.
EXPERIMENTAL PROCEDURES
Protein Production—A codon-optimized synthetic gene
corresponding to plasmid-encoded DsbP (e.g. H9TIR9 and
A6GV51, residues 22–235), lacking the predicted secretion
signal sequence was engineered into the bacterial expression
vector pMCSG7 (28) by ligation-independent cloning. Resi-
TABLE 1
DsbP gene carrying multidrug-resistant IncA/C plasmids or ICE
The plasmid/ICE size in kilobases (kb) and the number of predicted open reading frames (ORFs), where available, are given in the first column in parentheses. Also provided
are names of the organism from which the plasmid/ICE were isolated (second column) and the Uniprot protein ID for DsbP (third column in parentheses).
Plasmid/ICE Organism Uniport ID/anotation
pSH111_166 (166kb, 201 ORFs) S. enterica serovar Heidelberg DsbC thiol:disulfide involved in conjugative transfer (H9TIR9)
pSH163_135 (135 kb, 163 ORFs) pSH696_135
(135 kb, 161 ORFs)
pNDM102337 (166 kb, 191 ORFs) E.coli DsbC protein-disulfide isomerase (C4NUX8)
pNDM-1_Dok01 (196 kb, 224 ORFs)
pAR060302 (167 kb, 179 ORFs)
pNDM10505 (167 kb, 193 ORFs)
pAPEC1990_61 (161 kb, 173 ORFs)
peH4H (148 kb, 173 ORFs)
pUMNK88 (161 kb, 173 ORFs)
pPG010208 (136 kb, 148 ORFs)
pCC416 (24 kb) K. pneumoniae DsbC thiol:disulfide interchange protein (A6GV51)
AOCV01000044.1 (ICE) K. pneumoniae DsbC (M7P3V0)
pNDM-KN (163 kb)
pNDM10469 (138 kb, 169 ORFs)
pR55 (171 kb, 180 ORFs)
pSN254 (176 kb, 198 ORFs) Salmonella newport Uncharacterized protein (A4IVF4)
pSD_174 (174 kb, 198 ORFs) Salmonella dublin Thiol:disulfide interchange protein DsbC (F5BPS8)
pIP1202 (183 kb, 221 ORFs) Yersinia pestis biovar Orientalis DsbC (A4IUW6)
pTC2 (29 kb) Providencia stuartii DsbC (K0HF62)
pP99–018 (150 kb, 187 ORFs) Pasteurella piscicida DsbC (A0PB07)
pP91278 (132 kb, 161 ORFs)
pRA1 (144 kb, 158 ORFs) A. hydrophila DsbC (C6GA31)
AB525688.1 (ICE) Proteus mirabilis DsbC (D0FZX2)
AB571791.1 (ICE) S. typhimurium Putative uncharacterized protein (F2Z7X1)
AMDF01000024.1 (ICE) A. baumannii Disulfide bond isomerase protein (K5QUC4)
DQ164214.1 (ICE) Salmonella newport DsbC (Q3S5B8)
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due numbering used here is for the predicted mature DsbP
protein (Ser1-Ser2-Lys3-Leu4 correspond to residues 22–235
of the unprocessed gene-encoded protein). Active site vari-
ants “CGYC” (DsbP (103CAVC106 3 103CGYC106)) and
“CPYC” (DsbP (103CAVC1063 103CPYC106)) were generated
by QuikChangeTM site-directed mutagenesis using the wild-
type construct, and the non-catalytic cysteine mutant (Cys1443
Ala, Cys1683 Ala) was made by ligation-independent cloning
of a synthetic gene into pMCSG7. Proteins were expressed in
BL21(DE3)pLys cells using autoinduction media (29) and puri-
fied by immobilized metal affinity chromatography using
Talon! resin (Clontech) and standard procedures. Selenome-
thionine-labeled DsbP was expressed in BL21(DE3)pLys cells
grown in M63 minimal media supplemented with 0.05 mg/ml
of DL-selenomethionine and induced for 14 h with 0.1 mM iso-
propyl 1-thio-!-D-galactopyranoside at 30 °C. TheHis6 tag was
removed by tobacco etch virus protease, leaving three vector-
derived residues (Ser!2-Asn!1-Ala0) at theDsbPN terminus. A
final size exclusion chromatography step using a Superdex 75
column was performed to yield the purified DsbP enzyme used
in all steps described below. Oxidized or reduced DsbP was
prepared using a 25-fold molar excess of copper(II)/1,10-phe-
nanthroline or dithiothreitol (DTT), respectively. The oxidiz-
ing/reducing agentwas then removed and the buffer exchanged
to 10 mMHEPES, pH 7.4, using Sephadex 25 resin. E. coliDsbB
membrane extracts for the peptide oxidation assay were pre-
pared as described previously (30) and resuspended in phos-
phate-buffered saline containing 10% glycerol.
Crystallization and Diffraction Data Collection—Oxidized
DsbP samples aliquoted and stored at !80 °C were used for
crystallization trials. DsbP crystals were grown by the hanging
drop vapor diffusion method at 293 K, set up using a Mosquito
crystallization robot (TTP Labtech) and incubated and imaged
in a RockImager 1000 (Formulatrix). Selenomethionine-la-
beled DsbP crystals and the native orthorhombic crystals (Ox1)
were grown from a protein sample (25 mg/ml) in 15–16%
PEG3350 and 0.1 M sodiummalonate, pH 6.6. Of the twomono-
clinic crystal forms, DsbP(Red) crystals were grown using a
protein concentration of 25 mg/ml in 10% (w/v) PEG8000, 20%
(v/v) ethylene glycol, and 0.1 M MOPS/HEPES, pH 7.5. The
other monoclinic DsbP(Ox2) crystals were grown using a pro-
tein concentration of 50 mg/ml and precipitant solution con-
taining 10%PEG4000, 20% (v/v) glycerol, 0.1MMES/imidazole,
pH 6.5, and 20 mM each of 1,6-hexanediol, 1-butanol, 1,2-pro-
panediol (racemic), 2-propanol, 1,4-butanediol, and 1,3-pro-
panediol (Morpheus screen, Molecular Dimensions). DsbP
crystals grown in PEG3350 based conditions were cryopro-
tectedwith perfluoropolyether oil (HamptonResearch) and the
crystals grown in glycerol and ethylene glycol were directly fro-
zen in liquid nitrogen without additional cryo-protectant.
Data Collection and Structure Determination—Diffraction
data sets were measured at the Australian Synchrotron MX1
and MX2 beamlines using the BLU-ICE data collection inter-
face (31). All data sets were integrated in iMosflm (32) or XDS
(33), space group possibilities were analyzed and scaled using
Pointless/Scala or Aimless from the CCP4 suite (34). The
orthorhombic crystal form (Ox1) was processed from 93° data
giving a reflection multiplicity of 3.5. The monoclinic crystal
forms were processed from 220° (Ox2) and 180° (Red) data
yielding comparable multiplicities (Ox2, 4.5 and Red, 3.7) to
that of Ox1. Data for Ox2 were processed to the edge of the
detector; data beyond 2.21 Å were not recorded. Red crystals
diffracted to 2.07 Å resolution. However, these data exhibited
significant anisotropy along the c* direction and the data were
therefore truncated to 2.3 Å resolution, following the data sig-
nificance assessment using the CC1/2 criteria. The initial
phases were determined using HYSS, SOLVE, and RESOLVE
implemented in the AutoSol routine of the PHENIX software
suite by the Se-SAD method (35). Identification of all 32 sele-
nium sites (the four protomers in the asymmetric unit contain
eight sites each) resulted in a figure of merit of 0.39 for reflec-
tions to 2.2 Å resolution. Density modification and automated
model building traced 765 of 868 residues resulting in an R-fac-
tor/R-free of 0.25/0.29 and a mapmodel correlation coefficient
of 0.83. Electron density was poor for residues "160- 175 and
the automated model therefore was not built in 3 of the 4 mol-
ecules in the asymmetric unit. This initial DsbP model was
improved by manual building into the experimental map using
Coot (36).
The three DsbP native data sets (Ox1, Ox2, and Red) were
solved by molecular replacement with PHASER (37) using as a
search model of the DsbP structure solved by SAD-phasing.
Iterative manual building and refinement were carried out in
PHENIX (35) and COOT (36). Each structure contains four
DsbPmolecules in the crystallographic asymmetric unit, giving
a total of 12 monomer subunit structures of DsbP and 6 inde-
pendent copies of the biological dimers. The active site cysteine
residues were modeled in the oxidized form for each of the
three structures initially. However, negative difference density
between the sulfur atoms of the catalytic cysteines in one of the
three structures suggested that the disulfide had become
reduced. In the final refinements, the reduced and oxidized
forms of the active site cysteines were modeled with occupan-
cies of 0.7 and 0.3, respectively. This structure is referred to as
the reduced structure, Red.
Electron density was absent for the 3 vector-derived residues
and theN-terminal 11 residues andC-terminal 2 residues of the
DsbP construct in most of the modeled molecules. Judging
from the quality of electron density and the relatively high
B-factor values, the region comprising residues 165–170 is the
most flexible in DsbP. In molecules A and D of the Red struc-
ture, the main chain electron density for this region is con-
nected only at low contour levels (0.5–0.8 "). The same resi-
dues could not be modeled in Ox2 molecule A and electron
density for residues 171–172 of molecule B is also poorly
ordered. Several surface-exposed side chains could not be built
into Red (16 residues) and Ox2 (6 residues) structures with
confidence and were therefore excluded from the final model.
A summary of the data processing and refinement statistics are
presented in Table 2. The stereochemical quality of DsbPmod-
els were assessed using AutoDepInputTool (38), MolProbity
(39), and SF check (40). The final Red structure has a high aver-
age atomic B value (53 Å2 for all atoms (of which molecule D
alone contributes 73 Å2)) consistent with anisotropic diffrac-
tion of the crystal along c* direction. The quality of the electron
density is shown in Fig. 2, F–H. The coordinates and structure
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factors have been deposited with the Protein Data Bank (PDB
codes 4ML1 (Ox1), 4ML6 (Red), and 4MLY (Ox2)).
Disulfide Reductase Activity—Many TRX-fold proteins includ-
ing the disulfide-bond isomerase EcDsbC can reduce the inter-
molecular disulfide bonds formed between insulin chain A and
B in the presence of a mild reducing agent such as DTT (41).
The rate of insulin disulfide reduction was spectroscopically
monitored at 650 nm by an increase in turbidity resulting from
the production of insoluble insulin chain B. The reaction was
initiated by the addition of 0.131mM insulin to the samplemix-
ture containing 10!M enzyme, 0.33mMDTT, and 2mM EDTA
in 100 mM sodium phosphate, pH 7.0. Measurements were
repeated three times and the resulting mean! S.D. were used
in plots.
Scrambled RNaseA Isomerization Assay—In vitro disulfide
isomerase activity was monitored using scrambled RNaseA as
substrate (42). Inactive scrambled RNaseA was produced as
previously described (43). Disulfide isomerization of incor-
rectly formed disulfides in scrambled RNaseA (40 !M) was car-
ried out in a reaction volume of 750 !l containing 100 mM
sodium phosphate buffer, pH 7.0, 1 mM EDTA, 10 mM DTT,
and 10 !M enzyme at 298 K. At various time intervals, a 50-!l
sample was withdrawn andmixed with 150 !l of 3 mM cytidine
3",5"-cyclic monophosphate (cCMP4) to measure RNaseA
activity. Hydrolysis of cCMP4 was measured using a Synergy
H1 multimode plate reader (BioTek) at 296 nm. Samples con-
taining native RNaseA and scrambledRNaseA in the absence of
any other enzyme served as positive and negative controls,
respectively.
Dithiol Oxidation Assay—The ability of DsbP and variants to
catalyze dithiol oxidation was assessed using a model peptide
substrate (CQQGFDGTQNSCK) described previously (44).
Intramolecular disulfide bond formation was followed fluoro-
metrically using a SynergyH1multimode plate reader (BioTek)
with excitation set to 340 nm and emission to 615 nm.A 150-!s
delay before reading and 100-!s reading time was used for
time-resolved fluorescence. The reaction mixture (50 !l final
volume) contained 80 or 160 nM enzyme (DsbP, EcDsbC, and
EcDsbG) and 1.6 !M membrane extract of EcDsbB in 50 mM
MES, 50mMNaCl, and 2mMEDTAat pH5.5. Peptide substrate
(8 !M) was added to initiate the reaction. The reaction in the
absence of enzyme was used as negative control, and in the
presence of EcDsbAwas used as a positive control.Mean! S.D.
were calculated from three replicates.
Determination of Redox Potential—The redox potential of
DsbP was measured with a method described previously (45)
and using a DsbP variant in which the non-catalytic cysteines
were mutated to alanine (Cys1443 Ala, Cys1683 Ala). Briefly,
2 !M DsbP (or EcDsbA as control) was incubated with various
ratios of oxidized and reduced glutathione (GSSG (1mM)/GSH
(4!M to 15mM)) for#12 h at 24 °C in degassed 100mM sodium
phosphate buffer, pH 7.0, and 1 mM EDTA. Protein samples
TABLE 2
Data collection and refinement statistics
Statistics for the highest resolution shell are shown in parentheses.
Orthorhombic (Ox1) Monoclinic (Ox2) Monoclinic (Red) Se-SAD
Wavelength (Å) 0.9537 0.9537 0.9537 0.9793
Resolution range (Å) 54.14–1.98 42.79–2.21 47.67–2.30 19.6–2.20
Higher resolution shell (Å) 2.09–1.98 2.27–2.21 2.38–2.30 2.27–2.20
Space group P 21 21 21 P 21 P 21 P 21
Unit cell
a 54.3 54.6 54.7 54.1
b 108.3 110.5 110.6 111.3
c 139.0 74.1 80.7 72.7
" 90 90 90 90
# 90 93.1 96.8 95.5
$ 90 90 90 90
Total reflections 204,119 197,792 155,050 652,058
Unique reflections 58,014 (8,315) 43,861 (3,564) 42,056 (4,162) 43,382 (3,732)
Multiplicity 3.5 (3.4) 4.5 (4.0) 3.7 (3.8) 15.0 (14.3)
Completeness (%) 99.7 (99.2) 99.4 (93.4) 99.2 (100) 99.8 (99.5)
Mean I/%(I) 8.9 (2.5) 16.2 (5.0) 16.0 (3.4) 16.5 (1.9)
Wilson B-factor (Å2) 24.5 34.6 38.4 29.7
R-merge 0.079 (0.465) 0.049 (0.244) 0.047 (0.366) 0.158 (1.7)
R-pim 0.050 (0.293) 0.028 (0.157) 0.033 (0.247) 0.047 (0.475)
Refinement statistics
R-work (%) 19.2 (23.4) 18.6 (26.4) 19.0 (26.0)
R-free (%) 24.3 (29.2) 23.4 (33.1) 24.4 (32.4)
Unique reflections 57,718 43,816 41,826
No. of non-H atoms
Protein 6,278 6,231 6,233
Water 686 354 326
Protein residues 811 800 807
Root mean square bond lengths (Å) 0.014 0.015 0.013
Root mean square bond angles (°) 1.47 1.54 1.27
Ramachandran
Favored (%) 99.4 98.5 98.3
Outliers (%) 0 0.25 0.4
Average B-factor (Å2) 33.9 43.7 53.2
Molprobity
Clashscore (percentile) 3.1 (99th (714))a 3.51 (99th (456)) 3.13 (100th (355))
Score (percentile) 1.10 (100th (12309)) 1.14 (100th (10167)) 1.10 (100th (8909))
a 100th Molprobity (39) percentile is the best among the structures of comparable resolution. The percentile and the number of structures included in the comparison (n)
are given in parentheses.
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were precipitated with 10% trichloroacetic acid and washed
with ice-cold acetone prior to labeling the free thiols with 2mM
4-acetamido-4!-maleimidylstilbene-2,2!-disulfonic acid in 50
mM Tris-HCl, pH 8.0, and 1% SDS. Reduced/oxidized forms of
the protein were separated on a 12% non-reducing SDS-PAGE
(SDS-NuPAGE) and stainedwithCoomassie Brilliant Blue. The
fraction of reduced protein was quantified using ImageJ (46).
The equilibrium constant Keq was calculated using the equa-
tion: Y" ([GSH]2/[GSSH])/(Keq# ([GSH]2/[GSSH])), where Y
is the normalized fraction of reduced protein at equilibrium
(47). The redox potential of the protein was then calculated
using the Nernst equation: E0! " E0!GSH/GSSG$ (RT/nF)lnKeq,
where E0!GSH/GSSG is the standard potential of$240mV (48),R
is the universal gas constant 8.314 JK$1mol$1,T is the absolute
temperature in K, n is the number of electrons transferred, F is
the Faraday constant 9.648% 104 Cmol$1, and Keq is the equi-
librium constant. The mean redox potential was calculated
from four independent measurements.
RESULTS
Overall Structure—TheDsbPmolecular structure comprises
anN-terminal subdomain connected to a C-terminal TRX-fold
catalytic domain by a linker region (residues 60–83) (Fig. 1A).
It is assembled as a homodimer (Fig. 1B). The appearance of
FIGURE1.DsbP formsan invertedVcomparedwithDsbG.A,eachDsbP subunit consists of three structural regions: anN-terminal subdomain (violet), a linker
segment (cyan), andacatalyticdomain (yellow). Cysteine sulfurs are indicatedbygreen spheres,with thecatalytic cysteines identifiedbyanasterisk. Comparison
of the crystal structures of the (B) DsbP (yellow) and (C) EcDsbG homodimers (green). The relative orientation of DsbP and EcDsbG are defined by structural
alignmentof theN-terminal subdomain. EcDsbChas the sameV-arrangement asDsbG,with a shorter linker. The inter-subunit interface in the crystal structures
of DsbP (D) and EcDsbG (E) are shown. The interface region forming the subunit interaction, as analyzed in PISA (79), is shown in pink. The green spheres show
cysteine sulfurs, with the catalytic cysteines indicated by an asterisk.
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DsbP dimer is that of an “inverted” V-shaped protein, by com-
parison to the previously characterized disulfide isomerases
EcDsbC and EcDsbG (Fig. 1C) (16, 17). However, themolecular
size of DsbP is comparable with EcDsbC/G with the inner dis-
tance measuring 41 Å between the two opposing distal ends,
and 24 Å from the distal end to the V-shaped cleft (by compar-
ison, EcDsbC measures 39 and 25 Å and EcDsbG measures 58
and 31 Å).
Strikingly, all three regions contribute to the extensive dimer
interface (2076! 44Å2 buried surface area) in the crystal struc-
ture (Fig. 1D). In contrast, the subunit interaction in EcDsbG
and other characterized bacterial disulfide isomerases
(EcDsbC,Haemophilus influenzaeDsbC and S. enterica serovar
Typhimurium DsbC) are mediated only through the N-termi-
nal domain (Fig. 1E), with the buried surface area (790–1000
Å2, PDB codes 1v57, 1eej, and 1t3b) measuring half that of
DsbP.
DsbP Forms a Domain-swapped Dimer—The N-terminal
domains of bacterial disulfide isomerases that have been char-
acterized structurally contain a cystatin-like fold comprising a
helix packing against a twisted 4-stranded antiparallel !-sheet
(1–2-3–4, Fig. 2B) (16, 17). In the dimer, the !4 strands from
subunits A and B interact to form an up and down 8-stranded
dimerization domain (Fig. 2, B andD). This dimerizationmedi-
ating structure of EcDsbG is conserved in EcDsbC and other
disulfide isomerases (16, 17, 49–51).
DsbP does not follow this pattern. Instead, a domain-
swapped dimer is formed through an exchange of !1 strands
between subunits A and B (Fig. 2A). Following a low complexity
N-terminal region (1–14 residues), theDsbP chain of subunit A
forms the !1 strand that augments the !2" end of the
3-stranded antiparallel!-sheet (2"-3"-4") of subunit B. Through
a linker loop (L1), the !1 strand then enters the 3-stranded
antiparallel !-sheet (2–3-4) that augments the !1" end of sub-
unit B. Themain chain hydrogen bonding interactions between
!4 strands of subunits A and B completes the 8-stranded
dimerization domain (Fig. 2, A and C). Remarkably, the archi-
tecture of the dimerization domain between DsbP and EcDsbG
is similar with a root mean square deviation of 2.0 Å for 58 C"
equivalent atoms. The key difference being that the three-di-
mensional domain swapping forms the dimerization domain in
DsbP (Fig. 2). Additionally, the conserved helix found at the N
termini of EcDsbG and other disulfide isomerases is absent in
DsbP (Fig. 2). The intersubunit hydrogen bonding interaction
between !4 strands appears to be a highly conserved structural
feature among TRX-fold disulfide isomerases (Fig. 2I).
DsbP Has Two Canonical Catalytic Domains—The C-termi-
nal region of each DsbP chain contains a canonical “DsbC/
DsbGC-terminal domain-like fold” comprised of a non-contig-
uous TRX domain encompassing a helical domain (Fig. 3A).
The structure of DsbP is architecturally similar, but nonethe-
less, different from the EcDsbC/DsbG catalytic domains (e.g.
root mean square deviation betweenmolA of Ox1 andmolA of
EcDsbG (PDB code 1v57) is 2.9 Å for 127 C" atoms). Themajor
differences occur within the helical domain (H3-H5) and the
C-terminal helix of the TRX-fold, H6, among these three pro-
teins (Fig. 3A). A TRX-fold CXXC catalytic motif is present at
the N terminus of helix H2 (Figs. 1A and 3D), and a second
non-catalytic disulfide bond is present at a point similar to that
of EcDsbC, between the C-terminal end of helix H3 and the
connecting loop between helices H4 and H5 (Fig. 1A).
The catalytic motif and the adjacent cis-proline (cis-Pro)
motif together form the active site of TRX-fold redox proteins
(Fig. 3, D–F). In both EcDsbC and EcDsbG, the catalytic and
cis-Pro motifs are Cys-Gly/Pro-Tyr-Cys and Thr-Pro, respec-
tively. However, the residues forming these important regions
are different in DsbP: the catalytic motif is Cys103-Ala104-
Val105-Cys106 and the cis-Pro motif is Val188-Pro189. Interest-
ingly, a Cys-Ala-Val-Cys motif is present in some structurally
characterized FAD/NAD(P)-dependent TRX reductases (52)
although there are no NADP or FAD binding sites evident in
DsbP. Moreover, the Val-cis-Pro motif is typically found in
disulfide oxidases (DsbAs) rather than isomerases of Gram-
negative bacteria (53). We determined the standard redox
potential of DsbP at pH 7.0 and 25 °C (Fig. 4A) and found that
DsbP (#161 mV) is more reducing than EcDsbA (#122 mV),
EcDsbC (#130 mV (54)), and EcDsbG (#126 mV, (55)).
The catalytic disulfide bond of disulfide oxidoreductases is
susceptible to synchrotron radiation reduction. Themixed cat-
alytic disulfide bond observed in the Red structure is therefore
not completely unexpected and allowed us to capture both
redox states ofDsbP. Structural comparison of the oxidized and
reduced forms of DsbP do not indicate any major conforma-
tional changes at the catalytic site (Fig. 3, B andC). Distances of
2.1 Å (oxidized form) and 3.5 Å (reduced form) between the
sulfur atoms of the cysteine residues are consistent with those
in EcDsbC and EcDsbG structures (16, 17).
Reduced EcDsbC/DsbG is thought to be energetically favored
asaconsequenceofunfavorablecontacts in theoxidized form(17).
One proposed destabilizing interaction in the oxidized enzyme
structures occur between the sulfur of the first Cys in the active
site CXXCmotif and themain chain nitrogen of the secondCys
(3.1 Å). A second unfavorable contact occurs between the sul-
fur of the first Cys and the side chain oxygen of Thr motif (3.4
Å). Analysis of oxidized DsbP structures yielded a similar dis-
tance of 3.1 Å between Cys103 sulfur and the main chain nitro-
gen of Cys106. However, the natural variation of Val188 in place
of Thr in the DsbP cis-Pro motif may relieve the second desta-
bilizing interaction. Intriguingly, mutation of Thr for Val in the
EcDsbC cis-Pro motif imparted a more reducing character on
the enzyme (56).
DsbP Is a Disulfide Isomerase—We next explored the redox
characteristics of DsbP in standard dithiol oxidase, disulfide
isomerase, and disulfide reductase assays.
The ability to isomerize disulfide bonds was tested using
scrambled RNaseA as described under “Experimental Proce-
dures.” Under the conditions of the assay, DsbP restored 60%
of RNase activity within 5 h (Fig. 4B). In comparison, proto-
typical EcDsbC restored full RNaseA activity in 2 h, whereas
EcDsbG restored 45% activity in 5 h. Similarly, EcDsbC
exhibited high disulfide reductase activity in an insulin
reduction assay, whereas both DsbP (marginally active) and
EcDsbG (inactive) were poor reductants in this assay (Fig.
4C). All three enzymes were inactive in the in vitro dithiol
oxidation assay (Fig. 4D).
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FIGURE 2.DsbP formsadomain-swappeddimerizationdomain.Comparisonof theN-terminal regions ofDsbP (A) andEcDsbG (B). Topology and foldofDsbP (C)
and EcDsbG (D). E, domain-swappedhuman cystatin C. Three-dimensional domain swappingofDsbP andhuman cystatin C (PDB code 1G96) aremediated through
anexchangeof thestrand!1.BothEcDsbGandhumancystatinCcontain thecystatinC-fold.Thehelixconserved in thedimerizationdomainofEcDsbC/Gandhuman
cystatinC isabsent inDsbP. Inter-subunit interactionprimarily involvesstrand!1 (humancystatinC)or!4 (EcDsbG)orbothstrands!1and!4 (DsbP). The2mFo!DFc
map(m, figureofmerit;D is"-Aweighting factor) isdisplayedaroundan interfacingregionbetweensubunitsAandBata1.2-"contour.F,DsbPOx1;G,DsbPOx2;and
H, DsbP Red. I, structure-based sequence alignment. Structurally equivalent positions (uppercase), variable regions (lowercase), and insertions (dash) are shown.
Secondarystructureassignments forDsbP(top)andEcDsbG(bottom)arepresented.Residuescontributingto inter-subunithydrogenbonding interactionsareshown
in blue. The!4 strand (boxed) mediating subunit interaction is conserved betweenDsbC/G andDsbP.
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The effect of specific CXXC motifs on redox activity was
tested using DsbP active site substitution variants. The DsbP
variants were created to mimic the active site of EcDsbC
(CGYC, DsbP (CGYC)) or EcDsbG (CPYC, DsbP (CPYC)). The
active site variant CGYC almost matched the RNaseA isomer-
ization activity of EcDsbC (Fig. 4B) but only moderately
improved the insulin reductase activity. In comparison, the
EcDsbG-like CPYC variant exhibited almost equivalent activi-
ties to those of the wild-type DsbP (Fig. 4, B-D). Overall, these
results show that the plasmid-encoded putative DsbP is a disul-
fide isomerase, and a less efficient insulin reductant than
EcDsbCdespite having aVal-cis-Promotif and amore reducing
redox potential.
Orientation of the Linker Helix Alters the Shape of DsbP—To
understand the basis for the inverted V-shape of DsbP, we ana-
lyzed the 24-residue linker segment (residues 60–83) connect-
ing the dimerization and catalytic domains. Structural align-
ment suggested that the linker helix (H1) of DsbP is oriented in
the opposite direction compared with the equivalent linker
helix of EcDsbG (Fig. 5A).
Close examination of the DsbP linker (Fig. 5B) reveals that
four hydrophobic and two polar side chains of H1 (Met61,
Met64, Val67 and Ala68; Gln63 and Arg65) engage in interactions
with the twisted !-sheet closing this end of the dimerization
domain. Similarly, helixH1! seals the other end of the dimeriza-
tion domain, resembling a closed hemi-cylinder shape. Follow-
ing helix H1, the segment continues at the interface between
the dimerization domain and the catalytic domain before form-
ing a 310-helix and a turn that connects to the catalytic domain.
These structural elements contribute six hydrophobic side
chains (Ile71, Phe73 Met76, Met78, Val80, and Leu83) that insert
and fill the gap between the !-sheet (5–7-6–8-9) and helix H5
of the catalytic domain. Thus, the linker segmentmediates tight
interdomain interactions unique to DsbP (Fig. 5B).
In both EcDsbC and EcDsbG, the surface formed on the flex-
ible linker helices (H2 and H2!) and the “upper” surface of the
cleft created on the dimerization domain (Fig. 5C) are proposed
to be involved in substrate recognition (16, 57). By analogy, we
hypothesize that the inverted V-shaped DsbP also uses the
“bottom” surface of the dimerization domain for substrate rec-
ognition. Connecting loops H1-!1 and !2-!3 as well as strand
!4 form the V-shaped cleft in EcDsbC/DsbG (Fig. 5, E and F).
However, in DsbP, the corresponding cleft is formed by con-
necting loops !1-!2 (loop L1) and !3-!4 (Fig. 5D). Notably,
DsbP strand !4 is located on the opposite face of the putative
binding region.
Surface structures of the clefts differ considerably among
these three proteins due to variations in length, conformation,
and residue composition of loops (Fig. 6, A–C). Despite these
differences, DsbP and EcDsbG display an overall negative elec-
trostatic surface potential in their putative substrate binding
regions, whereas EcDsbC is largely neutral. Additionally, all
three proteins show a positive electrostatic surface potential
around the catalytic cysteine, with DsbP displaying the most
extended positive potential arising from four basic residues on
the catalytic face of the enzyme (Arg102, Lys200, Arg202, and
Lys204, see Fig. 3D).
DsbP Catalytic Domain Exhibits Domain Motion—The flex-
ibility of linker helix (H2) has been proposed to allow EcDsbC
and EcDsbG to accommodate various sizes and shapes of sub-
strate proteins in the cleft (16, 51). However, structural superpo-
sition of the linker segments derived from 12 DsbP molecules
(independently refined from three high-resolution x-ray diffrac-
tion data sets (Ox1, Ox2, and Red, see “Experimental Procedures”
for details)) revealed that the equivalent linker is largely unper-
turbed, albeit a small progressive conformational change was
apparent, starting near the 310-helix and running toward the cata-
lytic domain (Fig. 6D). In a similar analysis of the catalytic domain,
the TRX domain was found to retain the same overall conforma-
FIGURE3.DsbPhas a canonicalDsbC/DsbG-like catalytic domain.A, struc-
tural superposition of the catalytic domains of DsbP (yellow), EcDsbG (green),
and EcDsbC (cyan). The structural deviation in helix H6 of DsbP and the equiva-
lent helix H7 of EcDsbC/G is outlined. Active site of oxidized (B) and reduced (C)
states of DsbP is shown. The catalyticmotif (Cys103-Ala104-Val105-Cys106) and the
cis-Promotif (Val188-Pro189) are labeled. For clarity, only the reduced form of the
catalytic cysteines is shown in panel C, although the refined Red structure
includes both reduced (70%) and oxidized (30%) forms. The structure of the cat-
alytic faceofDsbP (D), EcDsbG (E), andEcDsbC (F) is shown. Residues in the vicin-
ityofcatalytic residuesareshown.NoteDsbPcontains fourbasic residuesaround
the catalytic site (Arg102, Lys200, Arg202, and Lys204), a feature absent in EcDsbG
and EcDsbC (cf. panel D with panels E and F). In each panel, the position of the
catalytic cysteine is indicated by a green asterisk.
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tion in each monomer, whereas the embedded helical domain
can undergo significant conformational changes, including
extension of helix H5 (Fig. 6E). Despite the presence of a (non-
catalytic) disulfide bond between Cys143 and Cys168 bridging
helix H3 and the loop preceding helix H5 in the helical domain,
the residues in this region are highly flexible (see “Experimental
Procedures”). The corresponding region in EcDsbC, which also
has a disulfide, is also flexible as indicated by high B-factors.
Structural superposition of the N-terminal domains of the 12
DsbP molecules revealed that conformational changes in the
310-helix are translated to the catalytic domain causing a “wob-
bly” motion of the catalytic domain (Fig. 6F) that we propose
may contribute to enzymatic activity of DsbP.
DISCUSSION
Genetic plasticity through horizontal gene transfer is a key
contributor in the rapid adaptation of bacteria to different envi-
ronmental challenges (58, 59). The acceleration of reported
multidrug resistance strains appears to be one such bacterial
response to inappropriate use of antibiotics (60–62). Bacteria
FIGURE 4. Redox characterization of DsbP. A, determination of the redox equilibrium constant (Keq) of DsbP with glutathione at pH 7.0 and 25 °C. A
representative plot of four independent experiments showing the normalized fraction of reduced DsbP at various ratios of reduced:oxidized glutathione. The
mean Keq (2.0 ! 0.18 mM) was obtained from nonlinear curve fits and the redox potential ("160.6 ! 1.0 mV) calculated as described under “Experimental
Procedures.” B, scrambled RNaseA disulfide isomerization activity. 100% activity corresponds to the averaged catalytic rate of native RNaseA. C, enzyme
catalyzed insulin precipitation as a result of intermolecular disulfide reduction.D,percent of peptide dithiol oxidase activity relative to control EcDsbA activity.
Oxidation rateswere calculatedover the first 15min (see “Experimental Procedures”). 100%activity corresponds to the catalytic rate of EcDsbA. Forpanels B–D,
the average and S.D. for each data point were calculated from three replicates; DsbP (square), CGYC (inverted triangle), CPYC (triangle), EcDsbC (diamond), and
EcDsbG (circle).
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disseminate antibiotic resistance genes from one bacterium to
another by multiple mechanisms, including a conjugation
secretion system that is encoded by a conjugative plasmid or
ICE (6).
Plasmid/ICE-encoded disulfide isomerases appear to play an
important role in folding and assembly of the conjugative
machinery (10, 13). The current body of knowledge of bacterial
TRX-fold redox proteins is derived from chromosomally
encoded proteins. Accordingly, disulfide oxidase (DsbA in con-
junction with its redox partner DsbB) functions as the primary
disulfide forming enzyme and is required for oxidative folding
of cell-surface and exported proteins including toxins and vir-
ulence factors (15). On the other hand, disulfide isomerases
(EcDsbC/DsbG) proofread and shuffle incorrect disulfides or
protect single cysteine containing proteins fromoxidative dam-
age (14–18).
The data presented here reveal the structural and functional
details of a conserved plasmid-encoded disulfide isomerase
DsbP from a group of multidrug resistance conjugative IncA/C
plasmids. We showed that DsbP is atypical due to a domain-
swapped dimerization domain, a linker that mediates interdo-
main interactions, an inverse putative binding site, and a rare
CXXC active site motif in the canonical EcDsbC/G-like cata-
lytic domain.
Three-dimensional domain swapping is generally regarded
as being independent of protein sequence or secondary struc-
ture (63). Interestingly, there are common features between
DsbP and human cystatin C, an amyloidogenic cystatin-fold
protein that also participates in domain swapping (64). In both
proteins it is the !1 strand that is exchanged between the two
subunits (Fig. 2E). However, DsbP lacks the N-terminal helix
that is otherwise conserved in cystatin and the dimerization
interface differs between the two proteins. A structural conse-
quence of three-dimensional domain swapping in DsbP is a
much larger subunit interface compared with EcDsbC/DsbG.
This may have important implications for function because
dimerization is essential for both chaperone and isomerase
activities of bacterial disulfide isomerases (65, 66).
FIGURE 5. The putative DsbP substrate-binding surface differs from that of EcDsbC/G. A, comparison of the orientation of the linker (arrows) in DsbP
(yellow) and EcDsbG (green). B, the linker segment of DsbP forms a tight interaction with the dimerization (DD) and catalytic (CD) domains. C, schematic
representation showing how the upper and lower surfaces of the dimerization domain form the cleft in V-shaped EcDsbC/G and inverse V-shaped DsbP,
respectively. Structure ofDsbP (D), EcDsbG (E), and EcDsbC (F) vieweddown the cleft. All three structures are similarly oriented such that strand!4 (blue) points
upand the catalytic domainspoint outof thepage. Loops forming the cleft are shown in redand the catalytic cysteine residues are shownasgreen spheres. Note
that strand !4 in DsbP is behind loop L1, which is not the case for EcDsbC/G.
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A hallmark of disulfide isomerases, including eukaryotic
protein-disulfide isomerase, are two catalytic domains that
face each other across the putative substrate-binding cleft.
Motion of the catalytic domains was shown to be essential
for function (16, 51, 67). Our crystal structures of DsbP are
consistent with the interpretation that the catalytic domains
move relative to the dimerization domain, despite the linker
segment being uniquely engaged in inter-domain interac-
tions. Moreover, we speculate that the flexibility/disorder in
the region around the non-catalytic disulfide bond may
point to this being an important site for substrate binding or
regulation of DsbP.
FIGURE 6. Comparison of electrostatic surface properties and conformational changes. Electrostatic surface comparison of DsbP (A), EcDsbG (B), and
EcDsbC (C). Electrostatic surface potential is contoured from!7 (red) to"7 (blue) kT/e. The catalytic domain (CD), dimerization domain (DD), and the catalytic
Cys (greenasterisk) of each subunit are indicated. Theorientations of themolecules inpanels A–C showboth the catalytic face and thedimerization cleft andare
not intended to present the 2-fold axis. D, E, and F, DsbP catalytic domain undergoes conformational changes and wobbly domain motion. Structural
superpositionof 12monomers found in theDsbPcrystal structures (Ox1,Ox2, andRed1):D, the linker segment, the catalytic domain (E), and the completeDsbP
subunit (F) which is aligned to the N-terminal subdomain. The conformational change in the hinge region (around the 310-helix of the linker segment, marked
with a circle and black arrow in panels D and F) results in movement of the catalytic domain. The two distinct conformers that showed helix H5 extension are
shown in blue (E and F).
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DsbP has in vitro disulfide isomerase activity that is moder-
ately better than that of EcDsbG (60 versus 45% in RNaseA
refolding activity). Substitution of the active sitemotif to that of
EcDsbC (CGYC) improved isomerase activity almost to that of
EcDsbC. The XX dipeptide in the CXXC active site motif and
the residue preceding the cis-proline have been shown previ-
ously to affect redox properties and catalytic activities of TRX-
fold oxidoreductases (68–73). However, the difference in activ-
ity between DsbP (CGYC) and EcDsbC in the insulin reductase
assay suggests that other elements also contribute to the cata-
lytic activities of these enzymes.
The relatively acidic surface on the inverted dimerization
domain and an extended positive potential surrounding the
catalytic site of DsbP compared with EcDsbC/DsbG may sug-
gest different substrate binding specificities for these enzymes.
In support of this, a virulence plasmid-encoded DsbA-like
enzyme (SrgA from plasmid pStSR100 in Salmonella typhimu-
rium), essential for the oxidative folding of the plasmid-en-
coded fimbriae major subunit protein (PefA), also exhibited
overlapping in vitro activities but different substrate specificity
compared with DsbA (74, 75).
Several Tra proteins required for the structure and assembly
of conjugative pili contain multiple cysteine residues (10), and
are therefore candidate substrates for DsbP. Analysis of func-
tional links for DsbP in the STRING database (76) supports
these possibilities (data not shown). Previous attempts to detect
substrates for EcDsbC and EcDsbG using two-dimensional gel
electrophoresis identified two substrates for EcDsbC (RNase I
andMepA) but none forDsbG (77). Another successful strategy
employed to trap substrate proteins was through mutagenesis
of cis-Pro loop residues (78). Similar approaches may now be
used to identify substrates ofDsbP.Taken together, our structural
and functional studiesofDsbPprovidea framework tounderstand
the roles of plasmid-mediated disulfide oxidoreductases in the
assembly processes of type IV secretion systems and may lead to
novel approachesaimedatpreventingplasmid-and ICE-mediated
transfer of drug resistance genes.
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6 Structural and Functional Characterization of secreted ScsC from 
pathogenic Proteus mirabilis  
 
6.1 Introduction 
 
6.1.1 Redox proteins from the scs locus involved in copper sensitivity 
 
Using genetic studies, a novel TRX-related protein cluster consisting of four scs 
(suppressor of copper sensitivity) genes (scsABCD) has been identified, and shown to 
confer copper tolerance in Salmonella enterica serovar Typhimurium (S. Typhimurium) 
(Gupta et al., 1997). It was proposed that the scs locus is divided into two functional 
operons (scsA and scsBCD), which are both required for copper-tolerance. The scs locus 
is absent in the genome of E. coli. However, when the scsABCD genes were introduced 
into a copper sensitive E. coli strain they conferred a phenotype of enhanced survival to 
elevated copper concentrations (Gupta et al., 1997).  
 
In S. Typhimurium, ScsA comprises a 120 residue predicted integral membrane protein 
with two putative transmembrane helices, containing an N-terminal C13-L-A-C16 motif as 
well as a potential copper-binding motif (M1-A-K-Q-Q-R-M7). Its structure, cellular function 
and role within the scs cluster remains undefined (Figure 6-1). ScsB in the model organism 
C. crescentus (628 residues) has been identified as a membrane electron transporter 
homologous to DsbD (Cho et al., 2012). Bioinformatic analysis by the same authors 
demonstrated the presence of ScsB in a wide variety of bacteria (proteobacteria, 
cyanobacteria, chlamydiae and planctomycetes). Sequence based secondary structure 
analysis revealed a hydrophobic transmembrane (TM) domain containing eight predicted 
TM helices and two soluble periplasmic domains, located at the N/C-terminus respectively 
(Figure 6-1). Reminiscent of E. coli DsbD, all three domains contain a pair of cysteines 
presumably involved in electron transport from the cytoplasm to ScsB substrate proteins. 
Nevertheless, ScsB differs significantly from DsbD in its N-terminal domain (nScsB), which 
is considerably longer in ScsB. The latter led to the hypothesis that nScsB could interact 
with a set of distinct substrate proteins (Cho et al., 2012). Overexpression of ScsB in a 
scsB null strain resulted in the reduction of the active site cysteines of two periplasmic 
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proteins, ScsC and PrxL, indicating their potential role as putative substrate proteins of 
ScsB. However it was shown that only ScsC is a direct substrate of ScsB. PrxL (the first 
secreted peroxiredoxin identified in bacteria) was found to be a substrate of Trx-like 
protein TlpA (Trx-like protein A) that directly obtains its electrons from ScsB (Cho et al., 
2012). 
 
 
Figure 6-1: Overview of ScsA-D, the four proteins encoded by the scs operon. Based on 
sequence analysis and hydrophobicity plots ScsA (yellow) contains two transmembrane helices. 
ScsB (green) has two periplasmic domains, one each at its N- and C-terminus, which are 
connected by a transmembrane domain (8TM). This topology is highly reminiscent of DsbD. ScsD 
(orange) contains a single TM anchor at its N-terminus, similar to CcmG/DsbE from E. coli. In S. 
Typhimurium (St), ScsC is a monomer as evident from its crystal structure (blue). In C. crescentus 
(Cc), ScsC is predicted to form a dimer (light blue) and the next sections of this chapter will 
address the oligomeric state of P. mirabilis (Pm) ScsC. Sequences of the redox active sites are 
highlighted in yellow/red. In C. crescentus, ScsB keeps PrxL, TlpA and ScsC reduced. Further, 
TlpA reduces PprX, which is involved in peroxide reduction. The function of PrxL is unknown. 
Modified from (Gupta et al., 1997, Cho et al., 2012). 
 
ScsC from C. crescentus was classified as a disulfide isomerase, since it catalysed folding 
of RNase I and RcsF, both of which contain non-consecutive disulfide bonds. Interestingly, 
ScsC was predicted to form a dimer in solution due to the presence of an extended N-
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terminal α-helical segment, which is absent in the prototypical homologue from S. 
Typhimurium. ScsC from S. Typhimurium (St) was predicted to be an outer-membrane 
protein (Gupta et al., 1997). However, a recent publication clearly demonstrated that 
StScsC is a monomeric soluble periplasmic protein (Shepherd et al., 2013b). The structure 
of StScsC revealed a typical Trx-fold including a CPYC active site motif and an overall 
similarity with StDsbA, however two key differences were observed (Heras et al., 2010). 
First, the α-helical insertion domain (α2-5), lacks helix α5, solely present in the StDsbA 
homolog and second, strand β1 is hydrogen-bonded to β3 instead of β5. Further, redox 
characteristics of StScsC revealed DsbA-like properties such as a destabilised Cys30 of 
the active site and an oxidizing redox potential similar to EcDsbA. Lastly a copper sensitive 
phenotype of an scsC null mutant was shown to be dependent on extra-chromosomal 
expression of wild type ScsC (Shepherd et al., 2013b). This finding is consistent with the 
work of Gupta et al., which postulated that the presence of all four genes is required to 
confer copper resistance (Gupta et al., 1997). It is also clear that the N-terminus in ScsC 
exhibits significant diversity. In particular, comparison of StScsC and CcScsC illustrate that 
the length and amino acid composition of the N-terminus might be a determinant of their 
different oligomeric states (Figure 6-2). The fourth protein, ScsD from S. Typhimurium, is a 
short 168 amino acid protein that contains a predicted N-terminal TM anchor. ScsD shows 
sequence similarity with TlpA from B. japonicum and its secondary structure prediction is 
almost identical to CcmG (DsbE) from E. coli. These findings implicate ScsD as a possible 
interaction partner for ScsB and indicate a potential role in cytochrome biogenesis, 
reminiscent of the CcmG-DsbD system (Figure 6-1). 
 
P. mirabilis contains a genome integrated cluster, containing homologues to all four Scs 
proteins from S. Typhimurium (Genbank ID: CAR41088, PmScsA = 24.8%; CAR41090, 
PmScsB = 51%; CAR41092, PmScsC = 41.4%; CAR41094, PmScsD = 45.2%). Unlike 
StScsC, PmScsC contains a 37 aa N-terminal helical extension reminiscent of the N-
terminus in CcScsC (Figure 6-2). However, the N-termini of PmScsC and CcScsC share 
very low sequence identity (< 26.5%). To shed light on this class of ScsC proteins a 
detailed structural and functional analysis of PmScsC was performed and is described in 
the following sections of this chapter.  
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Figure 6-2: Sequence alignment and comparison of PmScsC with StScsC and CcScsC. A. 
Sequence alignment comparing PmScsC (UniPro ID: C2LPE2) with StScsC (UniPro ID: H9L4C1) 
without the N-terminal secretion signal sequence. Identical residues are highlighted in red, the 
active site CXXC motif is shaded in gray and the cisPro region is indicated in yellow. Topology of 
StScsC was extracted from PDB = 4GXZ (StScsC) and is displayed underneath both sequences. 
B. Sequence alignment of PmScsC with CcScsC (UniPro ID: Q9A747). Identical residues are 
colored in red, the active site CXXC motif is in blue, the cisPro region is in yellow and the signal 
secretion sequence is shaded in gray. Predicted secondary structure elements (PSIPred, (Buchan 
et al., 2013) for both proteins are presented above the alignment. 
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6.2 Materials and Methods 
 
6.2.1 Protein production 
 
Two codon-optimized constructs (GenScript, USA) of P. mirabilis ScsC (GenBank® 
accession number EEI46301) were generated for this study. The first (PmScsC) lacks the 
sequence coding for the predicted periplasmic secretion sequence (21 amino acids). The 
second construct (PmScsCt) lacks the first 63 residues (starting at A1Q2F3…), which 
removes approximately half of the predicted helical domain at the N-terminus. Both were 
cloned into a modified pMCSG7 (Midwest Center for Structural Genomics) vector 
compatible with ligation-independent cloning. This plasmid encodes a leader sequence 
consisting of an N-terminal His6-tag followed by a linker region containing the tobacco-etch 
virus (TEV) protease recognition sequence (ENLYFQ^S). PmScsC and PmScsCt were 
expressed in BL21(DE3)pLys cells at 30 ºC for 16-20 h using auto-induction media 
(Studier, 2005).  
 
Figure 6-3: PmScsC construct design. A. Construct design of PmScsC and PmScsCt including 
secondary structure prediction (PSIPred, (Buchan et al., 2013) displayed on top of the protein 
sequence. Alpha helical regions are indicated with H (red) and beta sheet sites are highlighted with 
E in blue. Coding sequence for PmScsC (green) and PmScsCt (brown) used for cloning are 
shown. The 21 amino acids of the secretion signal sequence (yellow) were removed for cloning. B. 
Construct architecture of PmScsC and PmScsCt. The ORF was flanked by ligation-independent 
cloning (LIC) sites. The N-terminus contained six consecutive histidine residues followed by a 
linker region including the TEV cleavage site.  
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Both constructs were essentially purified as described in chapter III. In brief, cells were 
lysed (10 g cells per 100 mL buffer, 25 mM Tris pH = 7.5, 150 mM NaCl) and purified with 
Talon resin (Clontech Laboratories, USA). After elution (25 mM Tris pH = 7.5, 150 mM 
NaCl, 200 mM imidazole), the His6-tag was removed by TEV protease, leaving 
recombinant PmScsC/PmScsCt with two additional amino acids (S–1 and N0) at the N-
terminus. In the final step, size-exclusion chromatography was performed using a 
Superdex75 column (GE Healthcare, USA). Oxidized or reduced forms of both proteins 
were generated using 1.7 mM copper-(II)-1,10-phenanthroline or a 25-fold molar excess of 
DTT, respectively. Reagents were removed during a buffer-exchanged step into 10 mM 
HEPES, pH 7.4, using GE-25 Sephadex desalting resin. Protein yields were typically 35-
50 mg per L culture.  
 
Selenomethionine-labelled PmScsC (mature PmScsC containing 4 native methionine 
sites) was expressed in BL21(DE3)pLysS cells grown in minimal media (M63), which was 
supplemented with 0.05 mg/ml D/L-selenomethionine. Recombinant protein expression 
was induced by the addition of 0.1 mM IPTG overnight at 30 ºC. Protein purification was 
performed as described above for native PmScsC.  
 
Preparation of E. coli DsbA (CAA56736), E. coli DsbC (AAA83074), and E. coli DsbG 
(AAC45785), lacking the periplasmic leader signal were purified as described for PmScsC. 
For peptide oxidation experiments, E. coli DsbB (AAC74269) membrane extracts were 
prepared as described previously (Bader et al., 1998) and re-suspended in phosphate 
buffered saline (PBS, 137 mM NaCl, 2.7 mM KCl, Na2HPO4 10 mM and KH2PO4, pH 7.4) 
containing 10% glycerol. 
 
6.2.2 PmScsC genomic sequence analysis  
 
Clinical isolates of P. mirabilis were obtained from urine and blood cultures of patient 
samples from the Princess Alexandria Hospital (Prof. Graeme P. Nimmo, Dr David Looke) 
or Sullivan Nicolaides Pathology (Tony Jennings and Rodney McDougall). All strains were 
de-identified, and individual informed consent was not required. Genomic DNA isolation 
was performed using the UltraClean Microbial DNA Isolation Kit (MO-BIO Laboratories, 
#12224) according to the manufacturer’s instructions. Yields varied between 100-500 ng/µl 
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of DNA. PCR amplification of the scsC gene from P. mirabilis strains was performed using 
a sequence specific primer pair (5’-GTGCCGTTTAACCAGATTTATG) and (5’-
CGTAGATAAATCAGTAAGTTCTG) in combination with Phusion High-Fidelity DNA 
Polymerase (New England BioLabs Inc., MA, USA). DNA was initially denatured in a 
single step at 98 ºC for 30 s followed by 30 cycles of denaturation (98 ºC, 10 s), annealing 
(50 ºC, 20 s) and elongation (72 ºC, 30 s). In a final step fragment elongation was 
completed at 72 ºC for 7 min. PCR samples were loaded on a 1.5% DNA agarose gel and 
fragments were visualized with ethidium bromide (1:10.000 v/v).  
 
6.2.3 Cross linking 
 
150 µM of purified PmScsC (in 50 mM Hepes buffer pH 8.5) was reacted with 3 mM 
homobifunctional dithiobis(sulfosuccinimidylpropionate) (DTSSP, Pierce) for different time 
intervals (30 sec – 30 min) at 23 ºC. DTSSP contains an amine-reactive N-
hydroxysulfosuccinimide (sulfo-NHS) ester at each side of its eight carbon spacer arm. 
The sulfo-NHS reacts preferentially with amines (from lysine residues) at pH = 7-9, to form 
a stable amide bond. DTSSP contains a disulfide bond between both spacer arms, which 
is readily cleaved by DTT. 
 
Aliquots were removed at various time points and mixed with (NH4)HCO3 (50 mM final), to 
stop the reaction through hydrolysis of the remaining functional ester groups in DTSSP. 
Samples were then run on a non-reducing SDS-PAGE and subjected to Coomassie 
staining. As control, 50 mM DTT was added to selected samples, which led to cleavage of 
the internal disulfide bond in DTSSP, and consequently disruption of cross-links between 
ScsC protomers.  
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6.2.4 Multi-angle laser light scattering 
 
A combined approach, using analytical size exclusion chromatography (SEC) and 
multiangle laser light scattering (MALLS) was utilized to determine and compare the 
stoichiometry of PmScsC with PmScsCt, EcDsbC and EcDsbG in solution. A LC20 high-
performance liquid chromatography (HPLC) system (Shimadzu, Rydalmere, Australia) in 
combination with a DAWN® HELEOS® II laser light detector connected to an Optilab® T-
rEX™ refractive index detector (Wyatt Technology, Dernbach, Germany) was used. A 
Superdex™ 200 or Superdex™ 75 10/300 GL analytical column (GE healthcare, USA) 
was connected to the LC20 HPLC system and equilibrated with 25 mM Tris and 150 mM 
NaCl pH = 7.5 over night. Purified proteins were injected (500 µl of 3 mg/ml at a flow rate 
of 1.0 mL/min) into the SEC-/MALLS system for analysis. To calibrate the detector, 500 µl 
of 5 mg/mL bovine serum albumin (BSA) (Sigma-Aldrich, Australia) was used in 25 mM 
Tris and 150 mM NaCl pH = 7.5, at a flow rate of 1.0 mL/min. Wyatt Astra V software was 
used for data collection and analysis. 
 
6.2.5 Small angle X-ray scattering  
 
Small angle X-ray scattering (SAXS) data of PmScsC were collected and analyzed by Dr 
Andrew Whitten, in both oxidized and reduced form, on the SAXS-WAXS beamline at the 
Australian Synchrotron (N. M. Kirby, 2013). The sample to detector distance was set at 
1576 mm and the X-ray wavelength was λ = 1.033 Å, allowing access to a q-range 
spanning ~0.01-0.55 Å-1 (q = (4πsinθ)/λ, where θ is half the scattering angle). The A280 of 
the stock solution was determined, from which the concentration was estimated to be 8.85 
mg/mL (ε280 = 13075 cm-1mol-1, molecular mass = 24.7 kDa). Two dilutions of the stock 
solution were made (with 25mM Tris pH 7.5, 150mM NaCl), yielding three different 
concentrations (2.15, 4.50, and 8.85 mg/mL). Immediately prior to loading, all samples 
were centrifuged at 10,000 g to remove large particles from the solution. To minimize the 
effects of radiation damage, samples were flowed (100 µL) past the beam in 1.5 mm 
quartz capillaries (Hampton Research) at 10 °C, measuring 14 frames (each with a 2 sec 
exposure time). Data reduction was carried out using the Australian Synchrotron 
Scatterbrain software (DJ, 2007) averaging all 14 measured frames and correcting for 
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solvent scattering, sample transmission, detector sensitivity and background radiation. 
Data were placed on an absolute scale, by normalisation against a water standard 
(Orthaber D, 2000). 
 
Data quality was assessed by inspection of the linearity of the Guinier region of the data 
(qRg < 1.3), estimated molecular mass of the protein complex, and concentration 
dependence of the scattering. The estimated molecular mass was determined as outlined 
in (Orthaber D, 2000), where the contrast and partial specific volume were estimated from 
the protein sequence (Whitten A. E., 2008) The pair-distance distribution function (p(r)) 
was generated from the experimental data using GNOM (Svergun, 1992) from which I(0), 
Rg and Dmax were determined. Rigid body modelling was performed using the 
program SASREF (Petoukhov & Svergun, 2005). Here, C3 symmetry was assumed, and 
the starting model was oriented such the 3-fold axis was parallel with the z-axis, and 
passed through the centre of the oligomization domain. Two rigid bodies were then defined 
for each monomer: residues 3-45 (oligomerisation domain); 46-224 (catalytic domain). 
The position of the oligerization domain was fixed, and the position and orientation of the 
catalytic domain was then optimized against the measured scattering data. The program 
was run 10 times and the best model was chosen. Data is summarized in Table 6-1. 
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Table 6-1: SAXS data collection and analysis details for the reduced form of PmScsC 
Data Collection Parameters  
Instrument SAXS-WAXS (Australian Synchrotron) 
Beam geometry Point 
Wavelength (Å) 1.033 
q-range (Å-1) 0.01-0.55 
Exposure time (s) 28 (14 × 2 sec. exposures) 
Protein concentration (mg/mL) 2.15 
Temperature (°C) 10 
Standard Water 
Structural parameters  
I(0) (cm-1) [from p(r)] 0.1006 ± 0.0002 
Rg (Å) [from p(r)] 36.0 ± 0.1 
I(0) (cm-1) [from Guinier] 0.1010 ± 0.0005 
Rg (Å) [from Guinier] 36.5 ± 0.3 
Dmax (Å) 110 ± 5 
Porod volume (Å3) 97800 ± 9000 
Rg (Å) [crystal structure] 30.4 
Dmax (Å) [crystal structure] 95 
Dry volume (Å3) [crystal structure] 87300 
Molecular mass determination  
Partial specific volume (cm3g-1) 0.73 
Contrast, Δρ (1010 cm-2) 2.75 
Molecular mass Mr [from I(0)]* 69900 ± 3500 
Molecular mass Mr [crystal structure] 74100 
Software employed  
Primary data reduction SAXS15ID 
Data processing PRIMUS and GNOM 
Rigid body modelling SASREF 
Three-dimensional graphics representations PyMOL 
*Data were also collected at protein concentrations of 4.50 and 8.85 mg/mL. The corresponding 
I(0) values for these concentrations are 0.2120 and 0.4060 cm-1. These values yield molecular 
mass estimates of 70.3 kDa and 68.6 kDa. Thus, there is no evidence of significant interparticle 
interactions in the measured concentration range. 
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6.2.6 Crystallization and structure determination 
 
Protein crystallization was performed at the UQ ROCX facility (uqrocx.imb.uq.edu.au) 
using commercially available screening kits and the hanging-drop vapor diffusion method. 
Frozen aliquots of concentrated truncated PmScsC (PmScsCt) (in 25 mM Tris 7.5, 150 
mM NaCl = SEC) were diluted in SEC to a final concentration of 25 mg/ml. Then 200 µL 
protein were mixed with 200 µL crystallization solution, containing 0.1 M sodium acetate 
trihydrate pH = 4.5 and 30% w/v PEG-monomethylether 5000 using a Mosquito robot (TTP 
LabTech Ltd.). 96-well plates were imaged and incubated at 20 ºC in a RockImager 1000 
(Formulatrix, MA, USA). Rod shaped crystals appeared within 1-2 days. For diffraction 
data measurement, crystals were frozen in liquid nitrogen and cryoprotected with 
perfluoropolyether (Hampton Research). Diffraction data were measured at the Australian 
Synchrotron micro-focus MX2 beamline using BlueIce software (McPhillips et al., 2002). 
PmScsCt crystals diffracted to 2.1 Å resolution. Reflections were processed in XDS 
(Kabsch, 2010), analyzed and converted to MTZ in Pointless (Evans, 2006) and scaled in 
SCALA (Evans, 2006). Phases were obtained by molecular replacement (MR) using 
PHASER (McCoy et al., 2007) using StScsC as template (PDB ID: 4gxz). The initial model 
was improved by iterative model building in COOT (Emsley et al., 2010) and refinement in 
PHENIX (Adams et al., 2010). The stereochemical quality of the final model was assessed 
using MolProbity (Chen et al., 2010). A summary of the data processing and refinement 
statistics are provided in Table 6-2. 
 
For full-length PmScsC and selenomethionine-labeled PmScsC crystals, 400 µL drops 
were setup at 20 ºC containing 200 µL of 30 mg/ml purified protein (in 10 mM HEPES pH 
= 7.4) and 200 µL of 2.85 M sodium malonate pH = 5.8 and 0.1 M cobalt(II)chloride 
hexahydrate. Crystals grew over a period of 2-3 days. In general selenomethionine-labeled 
protein resulted in the formation of larger crystals than native PmScsC. A 3-wavelength 
MAD data set at the Se-edge was collected under cryogenic conditions at the Australian 
Synchrotron MX2 beamline using BluIce interface (McPhillips et al., 2002). Data 
processing and refinement was performed by Dr Premkumar Lakshmanane. Data were 
processed in XDS (Kabsch, 2010) and scaled to space group P21212 in AIMLESS (Evans 
& Murshudov, 2013). Both 3-wavelength and 2-wavelength MAD experiments were 
unsuccessful because of the poor correlation of the anomalous signal. A single wavelength 
SAD experiment using Peak data identified 87 sites in Autosol (Phenix), but the resulting 
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map quality was poor as indicated by low skew value 0.08. In addition, molecular 
replacement with ScsC from Salmonella enterica serovar Typhimurium (PDB ID: 4gxz; 
52% sequence identity to the catalytic domain of PmScsC) or a homology model 
corresponding to the catalytic domain of ScsC using PHASER (McCoy et al., 2007) was 
unsuccessful probably due to difficulties arising from the large cell dimensions with many 
PmScsC molecules in the asymmetric unit (based on Mathews coefficient 12 or more 
copies expected), inaccuracy in the homology model and presence of pseudo-translational 
symmetry. Therefore a manually guided molecular replacement approach was performed 
using MOLREP (Vagin & Teplyakov, 2000). A combination of molecular replacement in 
MOLREP and manual selection of solutions based on observed packing allowed placing of 
six molecules in the asymmetric unit. This solution was improved in the subsequent MR 
runs in MOLREP, allowing the addition of eight molecules in the second trial and a total of 
nine molecules in the third run. A SAD-MR approach in PHENIX (Adams et al., 2010), by 
combining PEAK data and the partial MR solution (9 molecules), and subsequent density 
modifications resulted in a significantly improved electron density map with a better skew 
value of 0.82 (1826 residues (190 side chain built) in 250 fragments). Successive runs of 
Autobuild run in PHENIX built 1557 residues (806 side chain) and dropped the R/Rfree 
values to 38 and 41.5. Extensive manual building was required to complete one copy of 
PmScsC. Molecular replacement using this model as template in PHASER allowed placing 
of 12 molecules in the asymmetric unit. After several rounds of manual building in coot and 
PHENIX refinements R/Rfree values dropped to 29.1 and 32.3, but further refinement 
cycles were unsuccessful. Careful examination of Ctruncate (Dauter, 2006) indicated the 
presence of twinning and led to a reconsideration of space group P212121. Reprocessing 
PEAK data set to 2.6 angstrom in space group P21 yielded lower R-merge compared to 
data processing in P212121 (0.072 vs 0.097). Ctruncate output indicated a high probability 
for twinning (-h,-k,l). A new molecular replacement run using the reprocessed data in P21 
space group and the PmScsC template with a resolution cut off of set to 3.2 angstrom 
finally identified 24 copies. Rigid body refinement in Refmac (Vagin et al., 2004) showed 
that refinement considering the twin operator (-h,-k,l) produced better R-factors (37 vs 
42%, no twinning). After manual correction of two chains that were placed inaccurately 
during molecular replacement by PHASER, and several rounds of refinement the present 
R/Rfree values are 24.1/28.7 at 2.6 Å resolution. Further refinements are currently in 
progress.  
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Table 6-2: X-ray data measurement and refinement statistics for PmScsCt/PmScsC  
Data collection PmScsCt PmScsC 
Space group P 32  P 21 
Unit cell dimensions   
a (Å) 105.5 137.5 
b (Å) 105.5 163.9 
c (Å) 35.1 181.9 
α, β, γ (º) 90, 90, 120 90, 90, 90 
Wavelength (Å) 0.95370 0.9792 
Resolution (Å) 35.12 - 2.15  (2.22 - 2.15) 91.2 – 2.6 (2.74 – 2.6) 
Number measured 
reflections 
265709 935709 
Number of unique 
reflections  
12203 243466 
Rmergea 0.130 (0.861) 0.072 (0.617) 
Rp.i.m. 0.043 (0.273) 0.055 (0.419) 
<I>/<σI> 21.6 (4.9) 11.0 (2.0) 
Redundancy 21.8 (20.5) 3.8 (3.7) 
Completeness (%) 99.7 (97.0) 98.6 (95.4) 
Refinement statistics    
Resolution (Å) 35.13 - 2.15  (2.22 - 2.15) 91.15 – 2.6 
Rfree (%) 20.4 (22.1) 24.1 
Rwork (%) 16.8 (20.5) 28.7 
Number of monomers in a/u 
a.u. 
1 24 
Number of protein atoms 2738 40862 
Number of waters 78  553 
B factors (Å2)   
Wilson 29.7 44 
Protein atoms 47.9 57 
Waters 51.8 39 
RMSD Bond length (Å) 0.014 0.018 
RMSD Bond angles (º) 1.380 1.8 
Ramachandran favored / 
outlier (%) 98 / 0.5  94/1.4 
Molprobity clashscore / 
scoreb 
1.88 [100th(483)] / 1.02 
[100th(10544)] 
23.6 [65th(227)] / 1.02 
[71st(6237)]c 
a The values in parentheses refer to the highest resolution shell. b 100th Molprobity (Chen et al., 
2010) percentile is the best among structures of comparable resolution; 0th percentile is the worst. 
The number of structures included in the comparison is given in parentheses within square 
brackets. c Refinement still in progress. 
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6.2.7 Measurement of PmScsC Redox Potential and pKa values 
 
The redox equilibrium of PmScsC was measured as described in chapter V. In brief, the 
pH-dependent absorbance of the catalytic thiolate anion of PmScsC was determined at 
240 nm (Nelson & Creighton, 1994) using a CARY 50 UV/VIS spectrophotometer (Agilent 
Technologies, USA). The pH titration measurements of oxidized or reduced PmScsC (40 
µM) were conducted at 22 ºC in 2 mL reaction buffer (10 mM Tris, 10 mM sodium citrate, 
10 mM K2HPO4, 10 mM KH2PO4, 200 mM KCl, and 1 mM EDTA). Absorbance (λ = 240 
and 280 nm) was measured between pH 6.5 and 1.5 in 0.25 increments. The pKa value 
was calculated from the fitted curves of three replicates using the Henderson-Hasselbalch 
equation (pH = pKa - log ([A240 ⁄A280]red ⁄ [A240 ⁄A280]oxid)). Redox potential and pKa experiments 
were repeated at least three times. Plotted data represent average values including the 
standard deviations across all replicates. 
 
6.2.8 Thermal melting analysis of PmScsC and PmScsCt  
 
Unfolding of PmScsC and PmScsCt was determined applying a thermal gradient (25 ºC – 
95 ºC) as described previously (Heras et al., 2008). Ellman’s reagent was used to confirm 
the redox state of both proteins (Ellman, 1959). The largest difference in molar ellipticity for 
oxidized or reduced enzymes was calculated from initial far-UV CD spectra (from 250 nm 
to 190 nm) recorded at 25 ºC and 95 °C using a Jasco J-810 circular dichroism (CD) 
spectropolarimeter (Jasco, USA), respectively. The unfolding of oxidized and reduced 
protein (PmScsCox = 221.5 nm, PmScsCred = 220.0 nm and PmScsCtox = 222.5 nm, 
PmScsCtred = 219.5 nm) was monitored at a constant heat rate of 1 K / min starting from 
298 K to 368 K in a 1 mm quartz cuvette. Unfolding reactions were performed using 10 µM 
protein in 100 mM NaH2PO4 / Na2HPO4, 1 mM EDTA at pH 7.0. Reduced enzyme samples 
contained 0.75 mM DTT. Unfolding data were analyzed in Prism (GraphPad Software, 
USA) and fitted to a two-state unfolding model as described previously (Kurz et al., 2009). 
The average values are plotted including the standard deviation derived from three 
replicates. 
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6.2.9 PmScsC: Disulfide Reductase Activity 
 
The rate of disulfide bond reduction of PmScsC and PmScsCt was recorded and 
compared to other thioredoxin-fold proteins (EcDsbA, EcDsbC). Briefly, reduction of 
disulfide bonds in insulin was spectroscopically monitored at OD650nm by an increase in 
turbidity resulting from denaturation of the insoluble insulin chain B (Holmgren, 1979). 
Individual samples were prepared in 1 cm cuvettes containing 10 µM of protein, 2 mM 
EDTA and 0.33 mM DTT in phosphate buffer (100 mM NaH2PO4 / Na2HPO4, pH 7.0). 
Catalysis was initiated by the addition of 0.131 mM insulin (I0516, Sigma-Aldrich, 
Australia) to the sample mixture. The assay was repeated three times and the mean value 
was plotted including the standard deviation.  
 
6.2.10 Scrambled RNaseA disulfide bond isomerization assay 
 
Bovine pancreatic ribonuclease A (RNaseA) contains 4 native disulfide bonds, necessary 
for its function. Starting with “scrambled” RNaseA (= inactive, containing non-native 
disulfide linkages), one can determine the ability to shuffle / isomerize disulfides by 
measuring RNaseA activity through spectroscopical analysis of the hydrolysis of 3’,-5’-
cyclic monophosphate (cCMP4), a synthetic substrate of ribonuclease. Here in vitro 
disulfide isomerase activity was monitored using scrambled RNaseA as substrate (Hillson 
et al., 1984). Inactive scrambled RNaseA was produced as described previously (Heras et 
al., 2008). The total reaction volume consisted of 750 µl containing 100 mM sodium 
phosphate buffer pH 7.0, 1 mM EDTA, 10 mM DTT, and 10 µM PmScsC, PmScsCt, 
EcDsbC or PmDsbA and 40 µM of scrambled RNaseA. At various time intervals, the 
progress of isomerization of incorrectly formed disulfides was measured by removing a 50 
µl sample which was then mixed with 150 µl of 3 mM cytidine 3’,-5’-cyclic monophosphate 
(cCMP4) to measure RNaseA activity. Hydrolysis of the cyclic phosphate ester bond in 
cCMP4 was monitored at 296 nm using a Synergy H1 multimode plate reader (BioTek, 
USA). Samples containing native RNaseA and scrambled RNaseA in the absence of any 
other enzyme served as positive and negative controls, respectively. Plotted data 
represent the average values from three replicates including the standard deviation of the 
mean.  
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6.2.11 PmScsC complementation of EcDsbA  
 
To investigate the ability of PmScsC to replace EcDsbA’s oxidoreductase function in vivo, 
complementation assays were performed with non-motile E. coli dsbA null (JCB817) and 
dsbA/dsbB double-null (JCB818) strains, in which cell swarming is disrupted (Shouldice, 
Heras, et al., 2010). Mature PmScsC was cloned into pBAD33 fused to the EcDsbA 
periplasmic signal sequence. The plasmid contains a tightly regulated arabinose inducible 
promotor. As positive control, EcDsbA was cloned into pBAD33. Non-motile E. coli dsbA 
deficient (JCB817) or dsbA/dsbB double-mutant (JCB818) (Bardwell et al., 1991) cells 
(2x106) were transformed with either PmScsCpBAD33 or EcDsbApBAD33 and spotted onto the 
center of a soft M63 minimal agar plate containing 40 mg/mL of each amino acid (except 
L-cysteine) and 0.1% arabinose. Plates were incubated at 37 ºC and motility of cells was 
monitored over a time period of 4-5 h. Complementation experiments were repeated three 
times to provide biological replicates. 
 
6.2.12 PmScsC Dithiol Oxidation Activity 
 
The potential of PmScsC / PmScsCt to catalyze disulfide bond formation in vitro was 
assessed using a synthetic model peptide (CQQGFDGTQNSCK) as described before 
(Vivian et al., 2009). Dithiol oxidation was determined fluorometrically, using a Synergy H1 
multimode plate reader (BioTek, USA) with the excitation wavelength set to 340 nm and 
emission adjusted to 615 nm. A 150 µs delay before reading and 100 µs reading time were 
used for time-resolved fluorescence. The reaction buffer contained 50 mM MES, 50 mM 
NaCl and 2 mM EDTA at pH 5.5. The reaction consisted of a 50 µL solution in each well of 
a white 384-well plate (Perkin Elmer OptiPlate-384, Part #: 6007290), including increasing 
concentrations (80-320 nM) of EcDsbA, EcDsbC, PmScsC, or PmScsCt and either 1.6 µM 
EcDsbB (crude membrane extracts, containing ubiquinone) or 2 mM glutathione (GSSG, 
conducted by Maria Halili) as oxidant. Lastly 8 µM peptide substrate was added to initiate 
the reaction. The EcDsbA sample was used as positive control. As negative control, 
reactions in the absence of enzymes were used. Rates were calculated as fluorescence 
increase per minute integrating the linear range of the raw data. Data were measured for 
three replicates and are presented as mean values, with the standard error of the mean 
indicated by error bars. 
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6.3 Results 
 
6.3.1 Sequence conservation of scsC in P. mirabilis 
 
The presence of the scsC gene in P. mirabilis (GENE ID: EEI46301; PmscsC) was 
analyzed in 96 clinical isolates. Samples were collected from patients in Brisbane. 
Genomic DNA of all clinical strains was isolated and the scsC gene sequence was PCR 
amplified using a pair of genomic upstream (5’) and downstream (3’) specific primers. The 
scsC gene was present in 94/96 strains (98%; Figure 6-4). Further, the sequence of 25 
randomly selected scsC amplification products was determined. The scsC sequences 
were highly conserved. Only one nonsynonymous nucleotide change was identified; this 
change resulted in an amino acid alteration converting alanine to valine at residue 7 (GCA 
- GTA within the secretion signal sequence). All remaining mutations were synonymous 
and only represented single base pair alterations in codon triplets that did not alter the 
amino acid sequence. This suggests that the amino acid sequence of PmScsC (including 
the N-terminal α-helical domain) is highly conserved within the cohort of clinical isolates. 
Additional strains of P. mirabilis from a larger cross section of geographical sources 
including genetic linkage studies could provide further insight into the conservation of 
PmScsC on a global scale.  
 
Figure 6-4: Agarose gel, screening the presence of the P. mirabilis scsC ORF in 96 clinical 
isolates. PCR was performed using genomic DNA from 96 strains (genomic DNA extraction for 
91/96 failed) running a 1.5% agarose gel. The resulting DNA fragment was 970 bp in size. A clear 
band for 94 out of 96 samples was observed. As control, 1 kb plus ladder from Life Technologies 
was used for comparison.  
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6.3.2 PmScsC forms a stable homo-trimeric complex in solution.  
 
At least two different variants of ScsC exist. The first class lacks the N-terminal extension 
and is similar to monomeric StScsC from S. Typhimurium (Shepherd et al., 2013a). The 
second class contains an extended N-terminus. For example in CcScsC, an N-terminal 
helical dimerization domain was predicted (Cho et al., 2012). Bioinformatic analysis 
revealed homologues of CsScsC (26.4 kDa) in all major classes of proteobacteria. 
Sequence comparison of PmScsC (26.7 kDa) and CcScsC (26.5% sequence identity) 
revealed an N-terminus of similar length, however the sequence identity between the two 
N-termini is low (< 27% for amino acids 22-69). Nevertheless the secondary structure 
predictions for both proteins are almost identical. This ambiguity encouraged me to 
investigate the role of the N-terminus in PmScsC. 
 
First I assessed whether the N-terminal region in PmScsC results in dimerization of the 
protein. During purification of full length mature PmScsC, which lacks the 21 amino acids 
of the periplasmic secretion signal, a peak fraction was obtained ranging from 52-54 ml on 
a Superdex75 16/60 size exclusion column (Figure 6-5A). The elution profile corresponds 
to a molecular mass range of 70-75 kDa, indicating a possible homo-trimer (= 74.3 kDa) 
rather than a dimer of PmScsC in solution. Dimeric EcDsbC (47.3 kDa) eluted at the 
expected lower molecular range (~ 61 ml) of a dimer compared with PmScsC. Next 
purified PmScsC was applied to non-denaturing NATIVE-PAGE. A single protein band was 
obtained for PmScsC at a molecular range correlating well with a protein of > 66 kDa 
(Figure 6-5B).  
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Figure 6-5: FPLC trace / NATIVE-PAGE of PmScsC. A PmScsC was injected into a Superdex75 
16/60 size exclusion column and eluted at ~ 52-54 ml. In comparison EcDsbC eluted later at ~ 61 
ml. The retention time of PmScsC correlated with the mass of a PmScsC trimer in solution (74 
kDa). B Non-denaturing gel comparing oxidized (lane 3) and reduced (lane 4) PmScsC with 
monomeric PmDsbA (lane 2) (see chapter III). Monomeric PmDsbA with a molecular weight of 21 
kDa runs close to the 20 kDa band, while both PmScsC samples run between the 66-146 kDa 
marker bands. Native mark from Life Technologies was used as size standard in lane 1.  
 
Cross-linking experiments were then conducted using DTSSP as a modifying agent. 
These experiments clearly showed the formation of a homo-trimer of PmScsC in solution 
(Figure 6-6). Figure 6-6A, indicates that the majority of PmScsC was cross-linked to its 
trimeric state within 30 seconds of reaction time. The intramolecular reaction between 
DTSSP cross-linking agent and protein lysine residues was much faster than the inter-
molecular reaction (2x trimer = hexamer band Figure 6-6A top row), resulting in almost 
fully cross-linked trimeric PmScsC after 5 min. Over time a second faint band appeared at 
a higher molecular weight presumably reflecting two cross-linked trimeric units (149 kDa) 
of PmScsC (intermolecular cross-link, slow, since statistically less likely). To obtain 
accurate molecular weight values for PmScsC in solution Multiangle Laser Light Scattering 
(MALLS) experiments were performed. PmScsC eluted after 21.5 min corresponding to a 
molecular mass of 73.9 ± 0.3 kDa (theoretical value for a trimer of PmScsC = 74.3 kDa). 
This value is in good agreement with a homo-trimeric arrangement of PmScsC in solution 
Figure 6-6B.  
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Figure 6-6: PmScsC forms a homo-trimer in solution. A. Denaturing SDS-PAGE (-DTT) of 
purified PmScsC, incubated at different time intervals (30 s – 30 min) with DTSSP, cross-linking 
agent. The reactive sulfo-NHS group of DTSSP reacts with primary amines e.g. from lysine side 
chains and links them together by the formation of a covalent amide bond. Within 30 s the majority 
of PmScsC was cross-linked (lanes 3-8). Cross-links were disrupted after 30 min through the 
addition of 50 mM DTT, which cleaved an internal disulfide-bond present in DTSSP (lane 2). As a 
result PmScsC runs as a single monomeric band. Molecular weight marker is shown on the left 
(lane 1). B. Molecular size of PmScsC, EcDsbC and EcDsbG measured by the SEC-MALLS 
approach are plotted against the retention time with the refractive index overlaid. PmScsC peaked 
at a significantly shorter retention time (21.5 min) from an analytical S75 gel filtration column 
compared to EcDsbC (23.5 min) and EcDsbG (23.3 min). A highly stable scattered light signal 
across the peak in all three gel-filtration profiles is indicative of a single species. The degree of 
scattering revealed molecular weights consistent with a homo-trimer of PmScsC (74 ± 0.3 kDa) 
and a homo-dimer for EcDsbC (48.0 ± 0.2 kDa) and EcDsbG (51.7 ± 0.3kDa) in solution. 
 
For comparison, MALLS was performed with dimeric EcDsbC and EcDsbG, which 
exhibited a longer retention time (23.5 min / 23.3 min) consistent with a molecular weight 
corresponding to their dimeric forms (EcDsbC 47.3 kA, MALLS = 48.0 ± 0.2 kDa; EcDsbG 
52.5 kDa, MALLS = 51.7 ± 0.3 kDa) (Figure 6-6B). To investigate whether trimerization 
was due to the presence of the N-terminal extension, a truncated construct lacking the first 
42 amino acids was designed (= PmScsCt). Analysis of the MALLS data of PmScsCt 
revealed a protein with a molecular weight of 18.3 ± 0.2 kDa (retention time = 27.2 min), 
which reflects the size of the catalytic core domain in its monomeric form of the protein 
(18.1 kDa theoretical mass) ( Figure 6-7A). In addition, PmScsCt eluted much later (ΔV = 
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20 ml, 74 ml PmScsCt versus 54 ml for PmScsC) from a Superdex75 gel filtration column  
Figure 6-7B.  
 
 Figure 6-7: MALLS / FPLC analysis of truncated PmScsC. A. SEC-MALLS profile of PmScsCt, 
showing a longer retention time for PmScsCt compared to full length PmScsC (27.2 min vs 21.5 
min). Molecular size of PmScsCt calculated from the MALLS data indicated a protein of 18.3 ± 0.3 
kDa in size, consistent with a monomer of PmScsCt in solution. B. Comparison of the elution 
profiles of PmScsC/PmScsCt performed on a Superdex75 16/60 size exclusion column. Clearly 
PmScsCt elutes much later (ΔV ~ 20 ml) indicative of a monomer.  
 
Moreover small-angle X-ray scattering (SAXS) was collected for PmScsC at the Australian 
synchrotron beamline indicating a protein with a molecular mass of 74 kDa, which would 
be consistent with a trimer in solution (see Table 6-1). 
 
6.3.3  Crystal structure of PmScsCt  
 
The monomeric truncated form (PmScsCt) crystallized in the trigonal space group P312 
and contained a single molecule in the asymmetric unit. PmScsCt was refined to an Rfree 
of 20.4 (Rwork = 16.8) (Table 6-2). Its structure is similar to ScsC from S. Typhimurium 
(Shepherd et al., 2013b). The superposition of PmScsCt and StScsC (protomer A) 
revealed an RMSD of 1.02 Å over 170 of 182 Cα aligned. The overall architecture is 
conserved with some subtle structural variations located in the loop regions between 
α7/α8, β3/α5, β5/α9 as well as the N-terminus and the site surrounding the β1 sheet 
(Figure 6-8A). The core of PmScsCt revealed an archetypal Trx-fold, which consists of the 
βαβ motif (β2, α4 and β3) comprising amino acids 92-129 as well as the N-terminal region 
of connecting helix (α8) and the ββα motif (β4/5, and α9, aa 201-240) (Figure 6-8B).  
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Figure 6-8: Structural analysis of the catalytic core domain of PmScsCt. A. Superposition of 
PmScsCt (green) with StScsC (cyan, PDB: 4GXZ). The overall architecture is conserved with 
subtle structural variations indicated with black arrows, located in the loop regions between α7/α8, 
β3/α5, β5/α9 as well as the N-terminus and the site surrounding the β1 sheet. CXXC active site 
cysteines are highlighted as yellow spheres B. Structural overview of PmScsCt in cartoon 
representation, including secondary structure annotation. The core of PmScsCt revealed an 
archetypal Trx-fold, consisting of the βαβ motif (β2, α4 and β3, in cyan), the N-terminal region of 
connecting helix (α8) and the ββα motif (β4/5, and α9, in green) and the α-helical region (α5-7, 
dark grey). Location of the active site cysteines is highlighted as yellow spheres. C. Structural 
superposition of PmScsCt, StScsC, (PDB: 4GXZ) EcDsbC (PDB: 1EEJ), EcDsbG (PDB: 1V57), 
DsbP (PDB: 4ML1), PmDsbA (PDB: 4OCE) and EcDsbA (PDB: 1FVK). β1* from EcDsbA/PmDsbA 
is highlighted in yellow, which forms an antiparallel beta sheet with β5* (magenta). In comparison 
β1 (cyan) from PmScsCt/StScsC/EcDsbC/EcDsbG/DsbP interacts with β3 (green), resulting in a 
different topology compared to DsbA class Ia enzymes. D. Similar to C, with a different orientation 
highlighting the key difference in the α-helical insertion domain. The class of ScsC (PmScsCt, 
StScsC, green) can be distinguished from DsbA (EcDsbA, PmDsbA, yellow) and isomerases 
(EcDsbC/G and DsbP, cyan) by the number of α-helices present in the α-helical insertion domain. 
ScsC proteins contain three α-helices, while isomerases only contain two in the helical insertion 
domain.* Indicates the fourth helix only found in DsbA proteins. 
 
However, structural superposition of Trx (PDB: 2TRX) with PmScsCt yielded an RMSD of 
2.44 Å (comparing 74 Cα equivalent positions) indicating several differences. The 
antiparallel β-sheet between β1 and β3 in PmScsCt revealed limited backbone hydrogen 
bond interactions between P84 / V125 and I86 / I127 compared to extensive interaction 
found between β1 and β3 in Trx. In addition an α-helical domain is inserted between β3 
and α8, disrupting the canonical Trx-fold. The connecting helix (α8) in PmScsCt is ~3x 
longer than in Trx. In this regard PmScsCt shares more similarity with Dsb redox proteins. 
For instance the catalytic domain of DsbG from E. coli shares a similar overall architecture 
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with PmScsCt with an RMSD of 1.82 Å (comparing 170 Cα equivalent positions) (Table 
6-3). 
 
Table 6-3: Structural and redox comparison of several secreted TRX-fold proteins. 
 
 
Minor differences are represented by a shorter C-terminal helix and the absence of α7 in 
the α-helical domain. Other secreted disulfide bond isomerase such as DsbC and DsbP 
also share significant structural similarity with PmScsCt (Table 6-3). In addition to disulfide 
bond isomerase enzymes, PmScsCt is related to DsbA disulfide bond formation proteins 
such as DsbA from E. coli (EcDsbA) and its homologue from Proteus mirabilis (PmDsbA, 
chapter III). One of the major structural variations between PmScsCt, the family of 
isomerases (DsbC/G/P) and prototypical DsbA proteins is the divergence of the topology 
in the location of the β1 strand. In PmScsCt as well as the isomerases β1 forms an 
antiparallel β-sheet arrangement with β3 resulting in a 1-3-2-4-5 β-sheet topology, 
whereas in class I DsbA proteins (McMahon et al., 2014) β1 forms hydrogen bonds with 
β5 giving a 3-2-4-5-1 topology (Figure 6-8C). However class II DsbA enzymes (WpDsbA, 
MtbDsbA and DsbAs from Gram positive bacteria) show a β1 topology similar to PmScsCt 
(McMahon et al., 2014). Nonetheless PmScsCt can be clearly distinguished from both the 
isomerases and DsbA proteins by the number of α-helices present in the α-helical insertion 
domain (Figure 6-8D). Only two α-helices are found in DsbC/G and DsbP whereas StScsC 
and PmScsC contain three α-helices and all DsbA proteins have four α-helices. A 
comparison of the active sites of PmScsCt, StScsC, the isomerases (DsbC/G/P) and DsbA 
(Ec/Pm) revealed high conservation between all enzymes highlighting the importance of 
the precise positioning of the CXXC motif (N-terminal site of helix α4) with respect to the 
cisPro loop region between β5 and α4 Figure 6-9.  
 
CHAPTER VI                                                                                                                                        RESULTS 
 
 152 
 
Figure 6-9: Active site structure comparison of PmScsCt, DsbA proteins and disulfide bond 
isomerases. Structural superposition of the CXXC / cisPro region from PmScsCt, StScsC, (PDB: 
4GXZ) EcDsbC (PDB: 1EEJ ), EcDsbG (PDB: 1V57), DsbP (PDB: 4ML1), PmDsbA (PDB: 4OCE) 
and EcDsbA (PDB: 1FVK). The geometry is highly conserved across all seven proteins. 
 
6.3.4 Crystal structure of PmScsC  
 
The PmScsC molecular structure comprises an N-terminal helical subdomain (α1/2) and a 
catalytic domain (= α-helical insertion domain: α5-7, connecting helix: α8, canonical Trx-
fold: β1-5, α4/9) connected by linker helix α3 (Figure 6-10A). Three protomers form a 
homotrimeric arrangement facilitated by the N-terminal helical subdomain (Figure 6-10B). 
The quaternary structure resembles that of a mushroom, with the N-terminal trimerization 
domain representing the stem (Figure 6-10B). A comparison of PmScsC with 260 bacterial 
homo-trimeric assemblies, published in the PDB database (RCSB) revealed no significant 
similarity, in particular examining the trimerization (stem-) domain. The tertiary structure of 
the stem is unique, however arrangement of the globular domains is similar to other 
published structures such as Aryl Esterase from Pseudomonas (PDB: 3T4U). In PmScsC, 
the active sites are located on the upper rear side of the complex are solvent exposed and 
located ~ 40 Å apart from each other, similar to the distance between the active sites of 
dimeric DsbC/P (see chapter V). Compared to DsbC/G/P, PmScsC provides a shallower 
surface with a funnel shaped pocket in the middle. The complex spans 80 Å at its longest 
distance and is approximately 50 Å in width (Figure 6-10B/C). The surface representation 
of the complex clearly shows that residues of the Trx-fold provide most of the surface on 
the upper side reaching all the way to the edge of the complex, whereas the region of the 
α-helical insertion domain is mostly accessibly from the opposite (rear) side of the complex 
(Figure 6-10B). Residues of helices α1 and α2 form the central stem of the complex.  
CHAPTER VI                                                                                                                                        RESULTS 
 
 153 
 
Figure 6-10: Structure of homotrimeric PmScsC. A. Cartoon representation of a single 
protomer of PmScsC. Secondary structure elements are annotated (Trx-fold in green, α-helical 
domain in gray, α3 linker helix in cyan, N-terminus in pink) as well as the angles between α3/2 and 
α2/1. The N-terminal helix is convexly bent (~25º, dashed line in α1). The active site CXXC 
cysteines are represented as yellow spheres. B. Semitransparent surface representation showing 
the PmScsC trimer from the top and rear view. Color code is identical to A. Active site cysteines 
are shown as orange spheres located in a surface exposed triangle and form the midpoint of each 
protomer. Distance between the active site regions (~ 40 Å) is indicated with dashed lines. The 
complex spans 80 Å at its longest point. C. Cartoon cylindrical representation of the complex 
shown from a side view displaying its width of 50 Å. In each of the three protomers, the N-terminal 
helix α1/2 and the connecting helix α3 are highlighted in different colors (starting with pink α1-3, 
the helices of the protomer oriented in clockwise direction are indicated by ‘ = α1’-3’ in green, and 
the counterclockwise helices from the third protomer are α1‘‘-3‘‘, in cyan). The N-terminal 
trimerization domain constitutes a right-handed twisted helical arrangement formed by α1/2, α1’/2’, 
α1’’/2’’. The Trx-fold forms the majority of the surface on the top, whereas the α-helical insertion 
domain is mostly accessible from the rear side of PmScsC. D. Overview of the interaction surface 
between protomer A’ (gray) and protomer C (pink) / L’’ (green). Surface region of A’ that interacts 
with C is colored pink. Region of A’ interacting with L’’ are shown in green and sites that are shared 
between A’ and C/L’’ are in yellow. Representation shows three interaction hotspots (1) α2’ of A’ 
interacts with α7’’, α5’’ of the α-helical insertion domain and α8’’ the connecting helix of L’’ (2) its 
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α1’ region interacts with both α1 and α1’’, and (3) its own α-helical domain and α8 bind to α2 from 
C. In summary one protomer links itself to its neighboring protomers, via its α-helical insertion 
domain, connecting helix (α8) and its N-terminal region. 
 
Helix α1/2 and α3 form a clockwise (right handed) twisted helical arrangement in PmScsC 
(Figure 6-10C). In DsbC and DsbG the interface that is involved in dimerization is limited to 
the N-terminal dimerization domain (buried surface area 790 - 1000 Å2) (see chapter V). In 
contrast, in DsbP the linker region and residues from the connecting helix of the catalytic 
core domain contribute to an extended dimerization interface (2076 ± 44 Å2) (see chapter 
V). However trimerization of PmScsC results in a more complex interaction (Figure 6-10D). 
Helix α2 of protomer C (annotation of protomer that is located clockwise to C will be 
indicated with ’) interacts with α2’/5’/7’/8’ of protomer A’. The N-terminal helix α1 of 
protomer C forms an interface with α1’/2’ and α1’’/8’’ from protomer A’ and L’’, respectively 
(annotation of protomer that is located anti-clockwise to C is highlighted with ’’) (Figure 
6-10D). Therefore each protomer forms an extended interface with its neighbor on its right 
hand side as well as its left-hand-neighbor. Figure 6-10D shows a surface representation 
of protomer A’ and its interactions with protomer C and L’’. The pink area represents the 
inaccessible surfaces, which are solely shared between protomer A’ and C (750 Å2). The 
green area reflects the surface formed between A’ and L’’ (560 Å2) and in yellow regions of 
chain A’ are highlighted that share contacts with chain C and chain L’’ (1275 Å2), 
respectively. The total buried surface area of chain A’ is 2580 Å2 and thus is much larger 
compared to the dimerization interface of DsbC/G and DsbP (see chapter V). 
Approximately half of the buried surface area is shared between A’ and C/L’’, while 
exclusive contacts between A’ and C cover about 1/3 more surface than A’ and L’’.  
 
6.3.5 How the trimeric arrangement in PmScsC is stabilized 
 
Dimeric DsbC/G contain both a linker helix, which connects the N-terminal dimerization 
domain with the globular catalytic Trx-domain. The linker region is absent in monomeric 
DsbA proteins. The length and orientation of the linker helix determine the dimensions of 
the cavity that is created by the two protomers. It also influences the relative distance of 
the active sites to each other and the surface of the protein which is accessible for 
substrate binding (McCarthy et al., 2000b, Heras et al., 2004) (see chapter V). Similarly in 
PmScsC a linker helix (α3) exists that connects the rear side (opposite side of the CXXC 
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motif) of the protein (the β1 sheet) with the N-terminal trimerization domain (α1/2). The 
linker helix revealed some unique characteristics. For example helix α3 forms a central 
part of a hydrophobic pocket generated by several of its own residues and side chains 
from β4, the loop region between α8 and β4, and the C-terminal section of α8 (F47, L51, 
L58, L183, L186, I 188, A194, V196). This conformation is further stabilized by an intra-
molecular salt bridge between E54 (α8) and K186 (α3) (Figure 6-11A.1/2). 
 
 
Figure 6-11: Interactions identified in PmScsC’s trimeric arrangement. A. Cartoon 
representation of a single PmScsC protomer in gray including the α1’’/2’’ helical segment of 
another protomer in green. Four important interaction sites are highlighted by numbers 1-4. A1/2. 
Close-up of a hydrophobic pocket (light-green sphere) that stabilizes the conformation of the linker 
helix α3, and at the same time positions it next to the C-terminal end of α8. Solely hydrophobic 
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residues coming from α3, β4, the loop region between α8 / β4 and the C-terminal part of α8, line 
the inside of the pocket. In addition a salt bridge between K186 and E54 support the conformations 
between α3 and α8. A3. Hydrogen bond (red dashed line) / salt bridge network (black dashed line) 
that is formed between key residues of the α-helical region (α5/7) and α2’’ (C-terminal part) as well 
as α2/8 and α2’’ (N-terminal part). On the bottom, the network of the N-terminal region of α1/2 is 
shown. In particular hydrogen bonds are formed between α1/2 and α1’’/2’’. This network is present 
in each of the three protomers to enable an intimate trimeric arrangement. A4. Top view along the 
three-fold axis depicting a hydrophobic core formed by residues of α1/ α1’/ α1’’ and the N-terminal 
region of α2/ α2’/ α2’’. Helix α2’’/1’’ are colored in green for clarification. On the right, side-chain 
residues are shown in balls and stick representation, which coat the surface of the N-terminal 
region of the trimerization domain, shielding the hydrophobic core from the hydrophilic periplasmic 
environment. 
 
The linker helix is kinked (approx. 120°) after one turn, which enables it to enfold the C-
terminal end of α8 (Figure 6-11A.1/2). A short loop region between α3 and α2 provides a 
85° angle between the two helices, enabling helix α2 to fold back on α8. This arrangement 
is unique among other multimeric Trx-fold proteins and is stabilized through interactions 
with the N-terminal end of α2’’ from an adjacent protomer (Figure 6-11A.3). Further an 
array of salt bridges and hydrogen-bond interactions (as defined by PDBeFold, EMBL-EBI, 
(Krissinel & Henrick, 2004)) are formed (E26’’, E29’’, K38, K39, Q178, R185) between α2, 
α2’’ and α8, to stabilize the tertiary structure between the linker helix and the N-terminal 
domain. Simultaneously the C-terminal region of α2’’ connects to the helical domain of 
chain A (Q44’’, D42’’, N152, K120). Adjacent α2 is connected through a short 90º turn to 
the N-terminal helix α1 (Figure 6-11A.3 and Figure 6-10A). The conformation is highly 
rigidified and stabilized by hydrogen bonds and salt bridges between α2 and α1’’ (E26, 
E30, R18’’) and α1 with α1’’ (Q9, D19, T20, S23, A4’’, R14’’). This intricate network of 
interactions is conserved across all three protein chains and connects the helical N-
terminal domain of each protomer to the α-helical region (α7’/5’), helix α8’ and helix α1’/2’ 
of the downstream protomer as well as the α1’’/2’’ region of the upstream protomer. 
Besides salt bridges and hydrogen bonds the trimeric arrangement is supported by 
exclusive hydrophobic interactions formed between residues lining the inside of α2, α2’, 
α2’’ and all along α1, α1’ and α1’’ (L5, V13, L16, V17, L21, I27, L28, A31, I32, L35). 
Altogether these residues form a large hydrophobic core (Figure 6-11A.4, left). The latter is 
protected from the hydrophilic environment by polar and ionic amino acids that face 
outwards and decorate the surface of the stem structure (Figure 6-11A.4, right).  
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6.3.6 SAXS data of PmScsC reveals a more extended molecule in solution 
 
It is important to note that the crystal structures revealed some significant deviation from 
the SAXS data. In particular, the pair distance distribution function derived from the 
scattering data, revealed a maximum dimension of the particles in solution of ~110 Å 
suggesting a molecule that was far more extended compared to PmScsC in the crystal 
structure (80 Å) (Figure 6-12A/B). A comparison of the PmScsC crystal structure and the 
rigid body structure optimized against the SAX scattering is shown in Figure 6-12C. This 
difference indicates the possibility of a dynamic architecture in PmScsC, which might be 
required to accommodate different substrates and allow for binding to ScsB. 
 
 
Figure 6-12: Comparison PmScsC crystal structure and the rigid body structure optimized 
against the SAX scattering data. A. Small-angle X-ray scattering data collected from PmScsC 
(gray) and calculated scattering profile of an optimized PmScsC model overlayed in black. The 
agreement between the experimental data and the model is good, yielding χ2=1.08 (inset) Guiner 
region of the scattering data is linear, consistent with a homogenous solution. B. Pair distance 
distribution function derived from the scattering data, showing the maximum dimension of the 
particles in solution are 110 Å. C. 3D model was obtained by rigid body refinement starting with the 
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PmScsC crystal structure. A number of rigid domains were defined and their positions optimized 
against the scattering data. This shows that the trimeric structure is much less compact in solution 
than observed in the crystal structure.   
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6.3.7 Redox characteristics of PmScsC  
 
Trx-fold proteins share several characteristic properties. One of them is their ability to 
oxidize or reduce their substrate proteins. The oxidizing or reducing power of these 
enzymes can be measured at equilibrium using glutathione as a standard with a known 
redox potential of -240 mV. The redox potential of PmScsC was determined at equilibrium 
with glutathione (Figure 6-13A) and gave a equilibrium constant of 34 µM, corresponding 
to a redox potential of –108 mV. EcDsbA was used as positive control, showing a redox 
potential of –123 mV, which is in agreement with previously reported data (Wunderlich & 
Glockshuber, 1993b). So far the only ScsC characterized is that from S. Typhimurium, 
which showed a slightly less oxidizing redox potential of -132 mV. PmScsC therefore has a 
similar redox potential to highly oxidizing Dsb proteins such as KpDsbA (-116 mV, (see 
chapter III), PaDsbA (-94 mV, (Shouldice, Heras, et al., 2010)), and to isomerases 
EcDsbC (-130 mV, (Zapun et al., 1995)) and EcDsbG (-129-126 mV, (Bessette et al., 
1999, van Straaten et al., 1998)) and other DsbA-related proteins e.g. SeDsbL (-97 mV, a 
homologue of SeDsbA, (Heras et al., 2010)) from S. Typhimurium.  
 
Figure 6-13: Redox properties and stability of PmScsC. A. Measurement of PmScsC redox 
potential. PmScsC was equilibrated in a range of glutathione (GSSG/GSH) redox buffers to 
measure the equilibrium constant Keq (34 µM), which corresponds to a redox potential of -108 mV. 
B. Determination of the pKa of the first cysteine from the CXXC active site motif. Presence of the 
catalytic thiolate anion is pH-dependent and can be spectroscopically monitored. The pKa of 
PmScsC CXXC is 3.1. C. Thermal unfolding of the catalytic core domain PmScsCt, clearly showing 
that its reduced state (Tmred = 357.8 K) is more stable than its oxidized (Tmox = 344.7 K) form. 
 
In part, the oxidizing nature of these proteins is due to the presence of a highly acidic, 
solvent exposed cysteine (Cys30), from the active site motif CXXC, which is characterized 
by an unusual low pKa (pKaCys30 = 3.0 - 4.0, typical pKa of a free Cys ~ 8.5, (Nelson & 
CHAPTER VI                                                                                                                                        RESULTS 
 
 160 
Creighton, 1994)). The pKa of PmScsC was determined (pKaPmScsC = 3.1) using pH-
dependent absorbance of the Cys30 catalytic thiolate anion (Figure 6-13B). Findings 
indicate a highly acidic Cys30 residue, consistent with previously reported pKa values for 
StScsC (pKaStScsC = 3.4,(Shepherd et al., 2013b)) as well as slightly less acidic EcDsbC 
(pKaEcDsbC = 4.3, (Sun & Wang, 2000)), EcDsbG (pKaEcDsbG = 3.5, (Ren et al., 2009)) and 
DsbA enzymes (pKaDsbA 3.0 -5.1, see chapter II). 
 
An additional factor that has great impact on the oxidizing nature of Trx-fold proteins is a 
significant increase in stability upon reduction of the active site cysteines (Zapun et al., 
1993). This property is rare since the vast majority of proteins are significantly stabilized 
through the formation of a covalent disulfide linkage (Doig & Williams, 1991, Taniyama et 
al., 1991, Wetzel et al., 1988). Since no unfolding data is available for ScsC proteins, 
thermal stability measurements of PmScsC were conducted using circular dichroism 
spectroscopy. Due to the trimeric nature of PmScsC unfolding was initially measured on 
PmScsCt, the monomeric catalytic core domain (Figure 6-13C). The reduced form of 
PmScsCt is highly (ΔTm = 14 K) stabilized (TmPmScsCt-red = 356.0 K) over its oxidized form 
(TmPmScsCt-ox = 342.0 K). These values indicate that PmScsC in its reduced state is as 
stable as DsbA from Vibrio cholerae (Walden et al., 2012) and most other DsbA proteins 
(see chapter II). Interestingly, when PmScsC full length is used (Figure 6-14), the unfolding 
profile reveals two phases. First, at lower temperatures the N-terminal trimerization domain 
starts to unfold, (ascending slope not observed in the PmScsCt profile) until it reaches a 
short plateau at ~ 335 K. Above > 340 K the curves for oxidized and reduced protein 
separate, which suggests unfolding of the catalytic core domain of PmScsC (= PmScsCt) 
in the second step (Figure 6-14A). These observations are consistent with the idea that 
intermolecular interactions between the individual protomers are weaker than interactions 
within a folded globular domain. It was possible to calculate unfolding temperatures 
starting from the plateau region. Calculated values (TmPmScsC-red = 357.8 K, TmPmScsC-ox = 
344.7 K) are consistent with the unfolding temperatures of PmScsCt (Figure 6-13C). Thus 
trimer formation of PmScsC does not provide any additional stabilizing effects over the 
monomeric form. 
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Figure 6-14: Thermal melting of full length PmScsC. A. Comparison of native unfolding data 
between PmScsC and PmScsCt. PmScsC makes a sharp transition from folded to unfolded, 
whereas PmScsC already starts to unfold at much lower temperatures. The reduced form of both 
constructs is significantly more stable. B. Thermal unfolding profile of PmScsC. Data were 
integrated starting at the plateau region ~ 335 K to calculate unfolding temperatures of the oxidized 
and reduced forms of PmScsC. 
 
6.3.8 Trimeric state of PmScsC is required for its disulfide isomerase activity   
 
EcDsbC isomerase is highly active in the insulin reduction assay, since it reduces disulfide 
bonds efficiently. In contrast StScsC was less active than EcDsbA, which is considered to 
show mild activity in this assay. Consequently PmScsC (more similar to CcScsC) was 
compared to PmScsCt (more similar to StScsC) in the insulin reduction assay to clarify 
whether trimerization of the protein has an impact on its reducing activity. Indeed, as 
shown in Figure 6-15A, full length PmScsC is almost as active as EcDsbC in the insulin 
reduction assay. However truncation of the protein to its monomeric form (PmScsCt), 
leads to a significant reduction in activity, below the rate of EcDsbA. These data explain 
the previous findings from the literature. StScsC lacks the N-terminal domain, which is 
essential for the enzymes reducing activity under conditions of the insulin reduction assay.  
 
In the next step PmScsC was analyzed in the RNaseA I (bovine) refolding assay (Hillson 
et al., 1984). StScsC did not show any activity in this assay (Shepherd et al., 2013b). In 
contrast, RNase I activity depends on the presence of the scsC locus in C. crescentus 
(Cho et al., 2012). Data measured for PmScsC indicated strong disulfide isomerase 
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activity, since PmScsC catalyzes disulfide bond formation as rapid as EcDsbC Figure 
6-15B. However using solely the catalytic domain (PmScsCt) the activity drops significantly 
(PmScsCt, 50% refolding after 250 min versus PmScsC, 50% refolding after 15 min). This 
clearly suggests that trimerization of PmScsC plays a key role for its function to catalyze 
disulfide bond isomerization and refolding of a model substrate (bovine RNaseA I). 
 
Figure 6-15: Trimeric PmScsC is a disulfide-bond isomerase. A. Absorbance measurement of 
the increase in turbidity caused by denatured insulin. PmScsC similar to EcDsbC rapidly reduces 
intramolecular disulfides between insulin chains, whereas EcDsbA is only moderately active and 
monomeric PmScsCt is highly impaired in its reductase function. B. Disulfide isomerase assay 
results showing that full length PmScsC () is able to recover activity of scrambled RNase A as 
quickly as EcDsbC (☐). Catalysis of monomeric PmScsCt (ο) is similar to EcDsbA () but reduced 
compared to PmScsC (PmScsCt, 50% refolding after 250 min versus PmScsC, 50% refolding after 
15 min).  
 
6.3.9 PmScsC, differentiation from the canonical oxidative folding pathway 
 
In the oxidative folding (DsbA/B) pathway free cysteines become oxidized and resulting 
electrons are transferred via quinones into the cytoplasm. In contrast, the isomerization 
(DsbC/D) pathway depends on electrons that are provided by cytoplasmic thioredoxin. To 
prevent futile redox cycles, it was reported that dimerization of DsbC is one crucial 
element. A monomeric DsbC mutant, was found to rescue a dsbA null phenotype (Bader 
et al., 2001). To investigate the possibility of PmScsC cross-talk with the oxidative folding 
system, peptide oxidation assays were performed, comparing catalysis rates of PmScsC, 
PmScsCt, EcDsbA and EcDsbC. A fluorescently labeled EcDsbA derived substrate 
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peptide was used in combination with either EcDsbB or GSSG as electron donor for 
enzyme reoxidation (Paxman et al., 2009). In the presence of EcDsbB, peptide oxidation 
was absent in PmScsC, EcDsbC and PmScsCt at 160 nM concentration (Figure 6-16A). 
Kinetics for EcDsbA-mediated peptide oxidation was rapid as reported previously (Paxman 
et al., 2009). However, significant rates were detected for PmScsCt at protein 
concentrations above 320 nM (Figure 6-16B). These data agree with previous findings for 
monomeric DsbC, which was able to mimic DsbA activity in the context of EcDsbB (Bader 
et al., 2001). Interestingly when DsbB is replaced by the oxidant GSSG, PmScsCt reacts 
with the model peptide in a concentration dependent manner, showing similar reaction 
rates to EcDsbA, while PmScsC and EcDsbC remain inactive (Figure 6-16C). This is 
remarkable since only the oligomeric state of the protein determines whether PmScsC 
predominantly acts as an oxidase or reductase. It was also noted that the overall catalysis 
rates dropped when EcDsbB was replaced with GSSG suggesting that EcDsbB is a much 
better oxidant than GSSG for these enzymes.  
 
Lastly, the mature sequence of PmScsC was fused with the EcDsbA secretion signal and 
expressed in non-motile E. coli dsbA null (JCB817) and dsbA/dsbB double-null (JCB818) 
cells. No rescue of motility was observed for PmScsC in both JCB817 and JCB818, 
however dsbA null cells transformed with wild type EcDsbA were highly motile after 3-5 h 
upon induction with arabinose (Figure 6-16D). EcDsbA homologues with a sequence 
identity as low as 30% (PaDsbA) have been shown to complement EcDsbA in vivo 
(Shouldice, Heras, et al., 2010). However several others with very low sequence identity 
such as MtbDsbA (13.8% with EcDsbA) are unable to restore motility (Premkumar et al., 
2013).  
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Figure 6-16: PmScsC does not cross-react with EcDsbB. A. Rate of peptide dithiol oxidase 
activity of PmScsC, PmScsCt and EcDsbC relative to the control enzyme EcDsbA. EcDsbB was 
used as electron donor. The increase of fluorescent signal per minute is shown. All enzymes are 
inactive at 160 nM, except EcDsbA. B. Peptide oxidation assay raw data comparing 160nM / 320 
nM of PmScsCt with the signal from EcDsbA 160 nM and EcDsbB. At the highest concentration 
PmScsCt begins to show some activity compared to the EcDsbB control (purple line) C. Similar to 
A. but GSSG used as electron donor. In addition different concentrations of EcDsbA and PmScsCt 
were compared. PmScsCt becomes highly active in a concentration dependent manner, similar to 
EcDsbA, whereas trimeric PmScsC and dimeric EcDsbC are still inactive at 160 nM D. Restoration 
of motility in E. coli DsbA null (JCB817) and DsbA/DsbB double null (JCB818) mutant cells. 
Expression of PmScsC or EcDsbA was controlled by an arabinose inducible promoter. Only 
EcDsbA (control) was able to restore motility in DsbA null (JCB817) cells. Expression of PmScsC 
had no effect. 
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6.4 Discussion 
 
The structure of ScsC from pathogenic Proteus mirabilis presents the first example of a 
homo-trimeric Trx-fold protein identified in the bacterial periplasm. This chapter 
demonstrates that PmScsC forms a highly stable trimer in solution and in the crystal 
structure. Previous reports about two different homologs of ScsC, from S. Typhimurium 
and C. crescendes, indicated variability in the N-terminal domain. StScsC is monomeric 
and lacks residues of the α-helical N-terminal region, whereas a comparison of FPLC 
retention profiles of EcDsbC and CcScsC suggested a dimer in solution (Cho et al., 2012) 
(Figure 6-17). However secondary structure predictions as well as the length of the N-
terminal helical domain is similar between PmScsC and CcScsC (Figure 6-2). My studies 
of PmScsC provide compelling evidence that its N-terminal α-helical domain leads to 
trimerization of the enzyme, which is essential for its isomerase function and ability to 
reduce disulfide bonds in vitro (Figure 6-17). PmScsC was as active as DsbC in the 
refolding of RNaseA, whereas its truncated form (PmScsCt) shows significantly reduced 
activity similar to weakly active EcDsbA. 
 
Figure 6-17: Overview of the scs operon including PmScsC. Same illustration as Figure 6-1, 
however PmScsC was added. At this stage the class of ScsC proteins constitute monomeric ScsC 
from S. Thyphimurium, trimeric ScsC from P. mirabilis and predicted dimeric ScsC from C. 
crescentus. 
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StScsC did not show any activity in this assay under similar conditions (Shepherd et al., 
2013b), further suggesting a direct role in copper resistance, rather than disulfide 
isomerization. However, PmScsC isomerase activity agrees with findings for CcScsC, 
which when mutated showed reduced levels of CcRNase I activity in a zymogram assay 
(Cho et al., 2012). Thus, it appears that isomerase function is an exclusive feature of the 
subclass of ScsC proteins that contain the extended helical N-terminus.  
 
It is interesting to note that the dimensions of PmScsC in the crystal structure were about 
30 Å smaller compared to the model of PmScsC calculated from SAXS data. This 
difference indicates the possibility of a highly dynamic architecture in PmScsC, which 
might be required to accommodate different substrates and allow for binding to ScsB. For 
DsbC it was demonstrated previously that both protomers exhibit substantial flexibility, as 
shown by the comparison of the reduced and oxidized crystal structure of DsbC in H. 
influenza as well as the EcDsbC-αDsbD complex (McCarthy et al., 2000a, Banaszak et al., 
2004, Zhang et al., 2004, Haebel et al., 2002). In addition domain motion in DsbC was 
suggested to facilitate binding of differently sized substrate proteins. It is also believed that 
flexibility is crucial in EcDsbC’s role to function as a chaperone (Liu & Wang, 2001). 
Similar mechanisms might exist for PmScsC providing one explanation for the discrepancy 
between the SAXS data and the crystal structure. An alteration of PmScsC between a 
more extended and more compact state might constitute a means to regulate its activity. 
Molecular dynamic simulations performed in future experiments might provide valuable 
insights in the dynamics of the complex. In addition, mutation of appropriate residues in 
combination with cross-linking experiments could lock PmScsC in one particular 
conformation (active state), which then could be used in activity screens. However future 
work is required to prove these hypotheses. 
 
Interestingly the Trx-fold enables the catalysis of a diverse array of enzymatic reactions 
(Ren et al., 2009, Pan & Bardwell, 2006) (see chapter I). For example oxidized DsbA 
introduces disulfide bonds into substrate proteins and therefore becomes reduced 
(Bardwell et al., 1991). DsbB as a strong oxidant reoxidizes DsbA to restore its activity 
(Bardwell et al., 1993, Kobayashi et al., 1997, Bader et al., 1999). In contrast, isomerases 
like DsbC are active in their reduced state (Missiakas et al., 1994, Rietsch et al., 1996) 
enabling the enzyme to attack disulfide bonds in misfolded periplasmic proteins. To keep 
the active site cysteines reduced in the highly oxidizing environment of the periplasm 
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isomerases such as DsbC/G require a strong reductant, provided by DsbD, which acquires 
its electrons from cytosolic Trx (Rietsch et al., 1997, Stewart et al., 1999). A similar 
catalytic dyad has been reported between CsScsC and CsScsB (Cho et al., 2012). A tight 
barrier between these antero-/retro-grade electron networks is required to prevent futile 
redox cycles. One explanation of how separation can be achieved came from random 
mutagenesis studies in DsbC from E. coli. Here a point mutant (G49R) located in the 
dimerization domain transformed the enzyme into a monomer, which was impaired in its 
isomerase function (now present in its oxidized state in vivo) and behaving as a DsbA-like 
protein. The switch in activity was facilitated by oxidation of DsbC by DsbB (Bader et al., 
2001). Also, DsbB oxidation of non-native substrates such as cytosolic Trx and eukaryotic 
PDI has been shown before (Jonda et al., 1999, Debarbieux & Beckwith, 1998). These 
findings suggested that dimerization of DsbC was developed during evolution to prevent 
cross-talk and counteract futile redox cycles. It is tempting to speculate that trimerisation in 
PmScsC restricts cross-talk with the oxidative folding pathway in a similar way. This 
hypothesis is supported by the complementation data, where PmScsC was not able to 
restore motility in non-motile dsbA cells. However, PmScsCt in combination with EcDsbB 
exhibited an increased activity in the peptide oxidation assay at significantly higher protein 
concentrations showing DsbA-like oxidase activity. The combination of PmScsC and 
GSSG showed no enzymatic activity, which indicated that only the monomeric form of 
PmScsC can be converted to an oxidoreductase. However these findings can’t explain a 
hypothetical interaction between monomeric StScsC and StDsbB, which point towards an 
additional or alternative mechanism that must exist in S. Typhimurium to preserve the 
interplay between the network of redox pathways.  
 
Comparable to the interplay between αDsbD and DsbC in E. coli an interaction of CcScsC 
with CcScsB has been identified (Cho et al., 2012). Furthermore experiments showed that 
CcScsC was reduced by EcDsbD, however the reverse, reduction of DsbC by ScsB was 
not possible. These findings suggest that a different domain organization is required for an 
interaction between CcScsC/B and possibly PmScsC/B. The N-terminal domain differs 
substantially between αDsbD and αCcScsB/αPmScsB. However the crystal structure of 
αPmScsB will be required to gain more insight into likely interactions between both 
proteins.  
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Proteins of the scs cluster have been reported to confer copper resistance to cells of S. 
Typhimurium (Gupta et al., 1997). Additional evidence came from mutational studies in S. 
Typhimurium where a StScsC knock-out strain showed increased sensitivity to copper 
relative to the wild type strain. The sensitivity phenotype was rescued by expression of 
StScsC from a plasmid reintroduction into the scsC mutant strain (Shepherd et al., 2013b). 
However the observed phenotype could solely be due to secondary effects. Currently no 
substrates or protein targets of ScsC have been identified. The trace element copper is an 
essential co-factor of many enzymes, but free copper requires tight cellular regulation 
since it is toxic to living cells (Rademacher & Masepohl, 2012). Previous data has shown 
the ability of Cu(II) to catalyze disulfide bond formation in combination with molecular 
oxygen similar to DsbA (Hiniker et al., 2005). Copper mediated disulfide bond formation is 
a random process and can lead to formation of the incorrect disulfide linkages in secreted 
proteins containing more than 2 cysteines. In addition copper cations can strongly bind to 
free thiol groups disturbing redox-homeostasis and displacing other transition metals from 
their native binding sites (Mikolay et al., 2010). This can result in impaired function, and 
unfolding of enzymes. Deleterious effects of elevated copper levels could justify the 
presence of the Scs locus. In particular one could imagine a mechanism that specifically 
counteracts copper stress directly or indirectly by providing ScsC isomerase that binds to 
substrate/target proteins that would be affected particularly during copper stress. These 
proteins however remain to be identified. It was previously shown that DsbC becomes 
upregulated during copper stress. DsbC isomerase confers copper resistance to E. coli 
cells to bind and refold misoxidized proteins caused by copper-mediated disulfide bond 
formation (Hiniker et al., 2005). Strong isomerases such as PmScsC could fulfil a similar 
role, however it is not clear why two independent pathways have evolved with potentially 
overlapping functions.  
 
Another explanation why the scs locus might be present in several pathogens, is the 
development of a defence mechanism to circumvent eukaryotic antimicrobial strategies 
using copper ions (Hodgkinson & Petris, 2012). For example recent work has implicated 
copper ions as a defence mechanism in the innate immune response, where copper ions 
are transported to phagosomes in macrophages, potentially playing an antimicrobial role 
(Wang et al., 2012). Additional data about gene regulation and expression of individual scs 
proteins is required to address the influence of different environmental cues. A 
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combination of mass-spectrometry and proteomics could be applied in the future to identify 
proteins that are affected by the absence of different scs proteins.  
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7 Conclusions and Future Directions 
7.1 Summary of findings 
 
Figure 7-1 provides an overview of the results presented in chapters II-VI. This thesis 
aimed to characterize the structure and function of four distinct bacterial Trx-fold proteins 
(KpDsbA, PmDsbA, DsbP and PmScsC) as well as to optimize protein production for 
transmembrane protein DsbB from P. mirabilis. These proteins can be assigned to three 
distinct bacterial periplasmic pathways. DsbA/B enzymes described in chapter II-IV belong 
to the oxidative folding pathway. Chapter V highlights the discovery of DsbP, which shares 
highly unique features with DsbC and DsbG from the isomerization pathway. The final 
results chapter VI describes the first homo-trimeric Trx-fold protein, ScsC from P. mirabilis, 
which belongs to the cluster of suppressor of copper sensitivity proteins. 
 
Figure 7-1: Research chapters II-VI overview. Cartoon representation of eight protein structures 
(highlighted by an asterisk*), which were solved during the course of my thesis. PmDsbB was 
crystallized but its structure remains to be elucidated, hence it is colored but lacks an asterisk. 
Highlighted in different colors are the chapter numbers, in which the detailed description of each 
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protein was provided. Enzymes can be assigned to three distinct periplasmic pathways as depicted 
at the bottom. 
 
7.2 Suitability of Enterobacteriaceae DsbA proteins as antivirulence targets 
 
Classical antimicrobial drugs target bacterial viability. However killing bacteria accelerates 
the selection process to generate resistant strains. The widespread deployment of 
antibiotics during the last few decades has produces multiple resistant strains at an 
alarming rate. One approach to generate new classes of antibacterials is to target 
virulence rather than viability of bacteria (Heras et al., 2014, Clatworthy et al., 2007, Rasko 
& Sperandio, 2010). This strategy was suggested to induce less selective pressure on 
bacteria to develop resistance, since most virulence traits are not essential for survival. 
Currently the majority of antivirulence strategies focus on individual virulence factors 
(Alksne & Projan, 2000, Lee et al., 2003, Clatworthy et al., 2007, Barczak & Hung, 2009, 
Rasko & Sperandio, 2010), which has yielded some success (Pinkner et al., 2006, Felise 
et al., 2008). However one crucial outcome of chapter II is that DsbA virulence factor 
substrates vary significantly among closely related pathogens while their DsbA proteins 
are highly conserved. Supporting this notion the structural and biochemical elucidation of 
KpDsbA, as an example of a close homolog (KpDsbA, 81% sequence identity to EcDsbA) 
of EcDsbA revealed significant structural and functional overlap. The identity was 
particularly high in important regions relevant for drug design, such as the active site, loop 
region L1-3 and the hydrophobic pocket. In addition I proposed that at least 5 other DsbAs 
(S. Typhimurium, S. flexneri, E. cloaceae, C. koseri, and C. sakazakii) are part of the same 
structural class (see chapter II). This provides a unique opportunity to combine structural 
data of DsbA homologues from different important pathogens, i.e. the family of 
Enterobacteriaceae and develop compounds likely to inhibit DsbAs within the same class. 
In summary chapter II set the requirements to initiate a drug discovery approach targeting 
DsbA proteins from the family of Enterobacteriaceae.  
 
Chapter III represents the continuation of the concept introduced in the previous section. It 
was of interest to assess how similar the sequence of a particular DsbA from the same 
family has to be in comparison to EcDsbA, without resulting in significant structural and 
functional alterations. This is important to identify the range of pathogens which could be 
targeted with a single drug. KpDsbA and all other DsbAs described in chapter II share  
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> 80% sequence identity. To challenge this idea DsbA from P. mirabilis, which shares 59% 
sequence identity with EcDsbA was examined in chapter III. Indeed PmDsbA exhibited the 
same characteristic redox properties as EcDsbA. Additionally its crystal structure was 
overall conserved compared to other Enterobacteriaceae DsbA proteins. However, minor 
alterations were noticed, for example in the loop region between β3 and helix α7. Thus 
PmDsbA might represent the border of this DsbA subclass, suggesting that EcDsbA 
homologues that share >59% sequence identity share sufficient structural and functional 
overlap to be regarded as a common drug target framework. Nevertheless, to test this 
hypothesis compounds remain to be identified which can equally bind to different 
Enterobacteriaceae DsbA subclass members.  
 
It was demonstrated previously that the EcDsbB periplasmic loop P2 (C130) forms a mixed 
disulfide with the nucleophilic cysteine (C30) of EcDsbA and binds to its hydrophobic 
groove near the active site (Inaba, Murakami, et al., 2006). The peptide sequence of the 
EcDsbB P2 loop (PSPFATCDF) is identical in PmDsbB and highly conserved in KpDsbB 
(PSPFQTCD) suggesting that a similar interaction occurs between KpDsbA/B and 
PmDsbA/B (see chapter II/III). Thus from the EcDsbB P2 loop sequence, a modified 
peptide (PWATCDS) was synthesized with an increased solubility and affinity profile. 
Interestingly this peptide was originally optimized against EcDsbA. Nevertheless it bound 
with similar affinity to PmDsbA. In addition the native P2 loop sequence of either KpDsbB 
or EcDsbB bound to KpDsbA or EcDsbA with similar affinity, suggesting that these 
peptides bind to the entire range of the Enterobacteriaceae DsbA subclass. To identify the 
interaction between PWATCDS and PmDsbA, both were co-crystallized. It required the 
generation of an active site mutant (PmDsbAC30S) of PmDsbA, most likely because the 
covalently linked intermediate is quickly resolved through nucleophilic attack of PmDsbA 
C33. Active site mutants have been utilized before to stabilize protein-protein interaction 
between Dsb proteins, for example in the formation of the EcDsbA/B complex (Inaba, 
Murakami, et al., 2006). Cys30 in PmDsbA was mutated to serine for co-crystallization 
studies. Thus we obtained the first complex between a non-covalently bound peptide and 
DsbA. Even though the peptide bound to a similar site as the EcDsbB P2 loop to EcDsbA, 
a frame shift was observed. The cysteine from the peptide did not reach into the active 
site, it pointed outwards in the solvent space. In addition, the majority of the interactions 
between PWATCDS and PmDsbAC30S were nonspecific backbone interactions. 
Moreover the N-terminal peptide residues were locked into place by hydrophobic 
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interactions. The latter makes it more difficult to use ITC to determine binding affinities and 
most importantly hydrophobic interactions contribute much less to specificity. Generally, 
free energy contributions from hydrogen bonds and ionic interactions are much larger than 
from hydrophobic interaction and hence influence binding more strongly. At this point, we 
only have peptides that represent the native P2 loop sequences or minor variations to its 
sequence. Therefore studies are currently a significant step away from drug like 
compounds, which would require high affinity scaffolds with reduced size and increased 
stability. In the next step it will be critical to extend the screening process to identify 
compounds that can bind specifically to conserved binding sites in this subclass of DsbA 
proteins, and block its activity. However DsbA will remain a particularly challenging drug 
target since evolution has optimized its architecture to bind to hundreds of different 
substrates. Thus a surface providing highly specific interactions would limit DsbAs 
substrate range. Additional structural information from several different peptides bound to 
DsbA could be very useful to determine a common motif to describe how these peptides 
utilize their binding surface effectively. If attempts in the future fail to identify an inhibitory 
compound against DsbA, inhibition of DsbB might be an equally promising alternative 
since DsbA’s enzymatic activity is dependent on DsbB. In comparison to DsbA, DsbB 
contains a defined binding site for its cofactor ubiquinone (see 7.3), which might facilitate 
the development of a small molecule compound against this site. 
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7.3 Milligram scale purification of PmDsbB using GFP-fusions 
 
The absence of DsbB prevents reoxidation of DsbA and consequently inhibits virulence 
factor maturation, similar to the approach described in 7.2. We currently lack high-
resolution structural information on DsbB. In addition no information is available about 
EcDsbB homologues and their structural conservation, especially of the ubiquinone-
binding site. Thus protein expression and production of DsbB from P. mirabilis, a homolog 
of EcDsbB (52.5 % sequence identity) was optimized using a novel GFP fusion approach. 
The major advantage of this technique was a relatively quick and efficient process to 
increase the expression and protein yields of PmDsbB. After several rounds of 
optimization, the protein yield was increased from sub-milligram to 2-4 mg of purified 
protein, from a 1 L bacterial culture. This allowed for the initiation of crystallization trials 
and provided an economic way to produce sufficient amount of membrane protein for 
crystallization and inhibitor screenings. At this stage only the PmDsbB-GFP fusion 
construct was subject to crystallization trials. In the future additional strategies such as 
LCP or bicelles should be explored, to increase the probability of well diffracting crystals. 
One of the major challenges to overcome in the future is the limited amount of accessible 
surface available in PmDsbB, which is necessary for crystal contact formation. It will be 
critical to focus on approaches to increase the extracellular region of PmDsbB to facilitate 
crystal contact formation by using a T4 lysozyme fusion approach, the formation of a 
stable PmDsbA/B complex, or the generation of a monoclonal antibody against an epitope 
of PmDsbB. Therefore it will be necessary to switch vector systems and generate new 
constructs that lack the GFP fusion anchor. However the question remains, whether the 
protocol derived for PmDsbB-GFP can be applied to novel constructs of PmDsbB while 
retaining high expression and protein yields.  
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7.4 IncA/C plasmid encoded DsbP, a novel target against the spread of resistance 
genes? 
 
Horizontal gene transfer, for example of antibiotic resistance genes, occurs through a 
highly conserved needle like secretion system (type IV), which is encoded in the tra locus 
of autonomous conjugative plasmids or integrative and conjugative elements (ICE). We 
have identified and characterized a conserved disulfide isomerase, found on IncA/C 
plasmids and ICE found in many different bacteria. Importantly a deletion of a DsbP 
homologue in the SXT/R391 family of ICE prevented conjugative transfer. Three 
independent crystal structures of DsbP were solved, revealing an N-terminal domain, a 
linker region and a C-terminal catalytic domain, which incorporated a thioredoxin fold with 
its characteristic CXXC and cisPro motifs. The DsbP homodimer is formed through unique 
domain-swapping of two DsbP N-terminal domains. Its redox properties and reductase 
function deviate from previously characterized disulfide bond isomerase enzymes 
(EcDsbC and EcDsbG). We found that mutation of the active site CXXC motif from the 
native DsbP sequence (CAVC) to CGYC from EcDsbC rendered its activity towards 
EcDsbC (see chapter V).  
 
The discovery of DsbP evokes several exciting questions. For example, is DsbP absolutely 
essential in the conjugative process and dissemination of IncA/C / ICE elements, similar to 
its homolog in SXT/R391 (Wozniak et al., 2009)? Deletion experiments of DsbP could 
reveal its importance in conjugation and dissemination of IncA/C / ICE elements. Second, 
why did evolution create an isomerase in addition to DsbC/G enzymes? DsbP constitutes 
a domain-swapped V-shaped dimer, which contains a unique surface charge distribution 
compared to DsbC/G. Moreover its dimensions differ from DsbC/G. One explanation could 
be that DsbP has been optimized to bind to substrate proteins encoded on conjugative 
plasmids. Valuable information might come from mutational experiments that could use 
cisPro mutants of DsbP to trap the enzyme in combination with substrates, such as 
performed successfully previously for EcDsbA substrate complexes (Kadokura et al., 
2004). It is unknown if DsbP performs a direct role during conjugation or influences 
conjugation indirectly through the interaction with substrate proteins. At this point it is 
completely unclear how it is regulated and in particular how it is maintained in its reduced 
functional state. One hypothesis is that genome encoded proteins from the host, such as 
DsbD or ScsB could adopt this role. Most importantly, if it is an essential protein for the 
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dissemination of mobile genetic elements, can we target DsbP and block its function to 
prohibit the spread of resistance genes?  
 
7.5 ScsC from P. mirabilis constitutes a new structural class of Trx-fold proteins 
 
A novel cluster of Trx-fold proteins, consisting of four scs (suppressor of copper sensitivity) 
proteins (A-D) was previously identified. The presence of the gene locus was shown to 
confer copper tolerance to S. Typhimurium cells. ScsC is the only soluble protein within 
the cluster. Sequence analyses of ScsA/B/D predict their integration/anchoring into the 
bacterial inner-membrane (Gupta et al., 1997). Interestingly sequence comparison of ScsC 
between different bacteria revealed a highly variable N-terminus. For example ScsC from 
Proteus mirabilis and another recently reported ScsC homologue from Caulobacter 
crescentus contain a 37 amino acid helical extension at the N-terminus compared to 
archetypal ScsC from S. Typhimurium, which lacks the extension (Cho et al., 2012, 
Shepherd et al., 2013b). It was shown that StScsC forms a monomer while CcScsC was 
suggested to form a dimer. Chapter VI describes the structural and functional study of 
PmScsC, which revealed a unique homotrimer facilitated by a twisted α-helical 
arrangement of the N-terminus from three PmScsC protomers. MALLS, cross-linking and 
SAXS data clearly demonstrated its trimeric state in solution. PmScsC is a strong disulfide 
isomerase, similar to EcDsbC, however its activity is highly dependent on the presence of 
its N-terminus, since a truncated construct (PmScsCt) was strongly impaired in its 
isomerase and reductase function. Since secondary structure predictions are identical 
between PmScsC and CcScsC, it is likely that CcScsC forms a trimer in its native state in 
contrast to the FPLC profile reported previously (Cho et al., 2012). SAXS data indicated a 
more open (extended) arrangement of PmScsC, indicating mobility and dynamics in the 
catalytic domains. Structural plasticity could reflect the possibility to adapt to different 
substrates. However substrates for PmScsC remain to be identified. One idea is to utilize 
cisPro or active site mutants that could trap PmScsC substrate intermediates. In addition it 
is not clear how PmScsC is maintained in its active reduced state. Experiments in C. 
crescentus revealed that CcScsB was required to keep CcScsC reduced (Cho et al., 
2012). A similar mechanism might exist for PmScsC. Interestingly the N-terminal domain 
of PmScsB, which constitutes a possible interaction site for PmScsC, varies significantly 
from the sequence of the N-terminal domain of PmDsbD, indicating that its architecture 
might have been optimized to interact with a trimeric protein rather than a dimer. Why 
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several ScsC proteins might form a trimer, while others are monomeric needs future 
clarification. Furthermore does monomeric ScsC perform the same function as its trimeric 
homolog in vivo? Knock out strains are required to shed some light on potential roles of 
PmScsC in vivo. No data has been published on the regulation of the gene cluster itself. 
The latter could provide information on whether scs proteins are constitutively expressed 
or specifically upregulated due to environmental cues. In addition, have scs proteins 
developed as a bacterial defense mechanism? For example a recent study has shown that 
in macrophages copper is transported to phagosomes, potentially providing an 
antimicrobial effect. Scs proteins might provide a bacterial system to tolerate and 
counteract these cellular defense strategies.  
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7.6 Concluding remarks 
 
In summary this work provides a compelling structural and functional exploration of 
secreted bacterial Trx-fold proteins, which constitute important targets for antivirulence 
strategies, dissemination of resistance genes and possibly bacterial defense against the 
innate immune response. For the successful continuation for this work, I propose the 
following objectives. DsbA proteins from the family of Enterobacteriaceae should be 
subject to additional orthogonal inhibitor screening approaches, such as screening of 
natural compound libraries or phage display to identify scaffolds that can inhibit their 
activity. Moreover compound screenings against DsbB proteins should be intensified, 
since they provide an attractive alternative to DsbA with a more discrete target site, 
increasing the likelihood to develop an effective inhibitor. The identification of DsbP 
provides exciting new possibilities to develop strategies to combat the dissemination of 
resistance genes. Therefore future investigations should elucidate its suitability as a new 
drug target. Finally, PmScsC knockout strains could be utilized to analyze their survival in 
macrophages to determine PmScsC’s potential as a protein target in pathogenicity.
BIBLIOGRAPHY 
 
 180 
8 Bibliography 
 
Adams, P. D., Afonine, P. V., Bunkoczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. 
J., Hung, L. W., Kapral, G. J., Grosse-Kunstleve, R. W., McCoy, A. J., Moriarty, N. 
W., Oeffner, R., Read, R. J., Richardson, D. C., Richardson, J. S., Terwilliger, T. C. 
& Zwart, P. H. (2010). Acta crystallographica. Section D, Biological crystallography 
66, 213-221. 
Alksne, L. E. & Projan, S. J. (2000). Curr Opin Biotechnol 11, 625-636. 
Andersen, C. L., Matthey-Dupraz, A., Missiakas, D. & Raina, S. (1997). Mol Microbiol 26, 
121-132. 
Arner, E. S. & Holmgren, A. (2000). Eur J Biochem 267, 6102-6109. 
Arnold, T. L., D; (2008). Curr. Protoc. Protein Sci. 53, 4.8.1-4.8.30. 
Bader, M., Muse, W., Ballou, D. P., Gassner, C. & Bardwell, J. C. (1999). Cell 98, 217-227. 
Bader, M., Muse, W., Zander, T. & Bardwell, J. (1998). The Journal of biological chemistry 
273, 10302-10307. 
Bader, M. W., Hiniker, A., Regeimbal, J., Goldstone, D., Haebel, P. W., Riemer, J., 
Metcalf, P. & Bardwell, J. C. (2001). EMBO J 20, 1555-1562. 
Bader, M. W., Xie, T., Yu, C. A. & Bardwell, J. C. (2000). The Journal of biological 
chemistry 275, 26082-26088. 
Baker, N. A., Sept, D., Joseph, S., Holst, M. J. & McCammon, J. A. (2001). Proc Natl Acad 
Sci U S A 98, 10037-10041. 
Balmer, Y., Vensel, W. H., Tanaka, C. K., Hurkman, W. J., Gelhaye, E., Rouhier, N., 
Jacquot, J. P., Manieri, W., Schurmann, P., Droux, M. & Buchanan, B. B. (2004). 
Proc Natl Acad Sci U S A 101, 2642-2647. 
Banaszak, K., Mechin, I., Frost, G. & Rypniewski, W. (2004). Acta crystallographica. 
Section D, Biological crystallography 60, 1747-1752. 
Barczak, A. K. & Hung, D. T. (2009). Curr Opin Microbiol 12, 490-496. 
Bardwell, J. C., Lee, J. O., Jander, G., Martin, N., Belin, D. & Beckwith, J. (1993). Proc 
Natl Acad Sci U S A 90, 1038-1042. 
Bardwell, J. C., McGovern, K. & Beckwith, J. (1991). Cell 67, 581-589. 
Battye, T. G., Kontogiannis, L., Johnson, O., Powell, H. R. & Leslie, A. G. (2011). Acta 
crystallographica. Section D, Biological crystallography 67, 271-281. 
Bayburt, T. H., Grinkova, Y. V. & Sligar, S. G. (2006). Arch Biochem Biophys 450, 215-
222. 
Bayburt, T. H. & Sligar, S. G. (2010). FEBS Lett 584, 1721-1727. 
Beard, N. A., Laver, D. R. & Dulhunty, A. F. (2004). Prog Biophys Mol Biol 85, 33-69. 
Berkmen, M., Boyd, D. & Beckwith, J. (2005). The Journal of biological chemistry 280, 
11387-11394. 
Bernaudat, F., Frelet-Barrand, A., Pochon, N., Dementin, S., Hivin, P., Boutigny, S., Rioux, 
J. B., Salvi, D., Seigneurin-Berny, D., Richaud, P., Joyard, J., Pignol, D., Sabaty, 
M., Desnos, T., Pebay-Peyroula, E., Darrouzet, E., Vernet, T. & Rolland, N. (2011). 
PloS one 6, e29191. 
Bertini, R., Howard, O. M., Dong, H. F., Oppenheim, J. J., Bizzarri, C., Sergi, R., Caselli, 
G., Pagliei, S., Romines, B., Wilshire, J. A., Mengozzi, M., Nakamura, H., Yodoi, J., 
Pekkari, K., Gurunath, R., Holmgren, A., Herzenberg, L. A., Herzenberg, L. A. & 
Ghezzi, P. (1999). J Exp Med 189, 1783-1789. 
Bessette, P. H., Cotto, J. J., Gilbert, H. F. & Georgiou, G. (1999). The Journal of biological 
chemistry 274, 7784-7792. 
BIBLIOGRAPHY 
 
 181 
Bessette, P. H., Qiu, J., Bardwell, J. C., Swartz, J. R. & Georgiou, G. (2001). J Bacteriol 
183, 980-988. 
Bill, R. M., Henderson, P. J., Iwata, S., Kunji, E. R., Michel, H., Neutze, R., Newstead, S., 
Poolman, B., Tate, C. G. & Vogel, H. (2011). Nat Biotechnol 29, 335-340. 
Blaser, M. (2011). Nature 476, 393-394. 
Blaser, M. J. & Falkow, S. (2009). Nat Rev Microbiol 7, 887-894. 
Bleves, S. & Cornelis, G. R. (2000). Microbes Infect 2, 1451-1460. 
Borisov, V. B., Gennis, R. B., Hemp, J. & Verkhovsky, M. I. (2011). Biochim Biophys Acta 
1807, 1398-1413. 
Boucher, H. W., Talbot, G. H., Bradley, J. S., Edwards, J. E., Gilbert, D., Rice, L. B., 
Scheld, M., Spellberg, B. & Bartlett, J. (2009). Clin Infect Dis 48, 1-12. 
Bouckaert, J., Berglund, J., Schembri, M., De Genst, E., Cools, L., Wuhrer, M., Hung, C. 
S., Pinkner, J., Slattegard, R., Zavialov, A., Choudhury, D., Langermann, S., 
Hultgren, S. J., Wyns, L., Klemm, P., Oscarson, S., Knight, S. D. & De Greve, H. 
(2005). Mol Microbiol 55, 441-455. 
Brusselaers, N., Vogelaers, D. & Blot, S. (2011). Ann Intensive Care 1, 47. 
Buchan, D. W., Minneci, F., Nugent, T. C., Bryson, K. & Jones, D. T. (2013). Nucleic acids 
research 41, W349-357. 
Caffrey, M. (2009). Annu Rev Biophys 38, 29-51. 
Chae, H. Z., Kang, S. W. & Rhee, S. G. (1999). Methods Enzymol 300, 219-226. 
Charbonnier, J. B., Belin, P., Moutiez, M., Stura, E. A. & Quemeneur, E. (1999). Protein 
Sci 8, 96-105. 
Chen, V. B., Arendall, W. B., 3rd, Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. 
J., Murray, L. W., Richardson, J. S. & Richardson, D. C. (2010). Acta 
crystallographica. Section D, Biological crystallography 66, 12-21. 
Cherezov, V. (2011). Curr Opin Struct Biol 21, 559-566. 
Cherezov, V., Rosenbaum, D. M., Hanson, M. A., Rasmussen, S. G., Thian, F. S., Kobilka, 
T. S., Choi, H. J., Kuhn, P., Weis, W. I., Kobilka, B. K. & Stevens, R. C. (2007). 
Science 318, 1258-1265. 
Cho, S. H. & Beckwith, J. (2006). J Bacteriol 188, 5066-5076. 
Cho, S. H., Parsonage, D., Thurston, C., Dutton, R. J., Poole, L. B., Collet, J. F. & 
Beckwith, J. (2012). MBio 3. 
Cho, S. H., Porat, A., Ye, J. & Beckwith, J. (2007). EMBO J 26, 3509-3520. 
Christensen, L. D., van Gennip, M., Jakobsen, T. H., Alhede, M., Hougen, H. P., Hoiby, N., 
Bjarnsholt, T. & Givskov, M. (2012). J Antimicrob Chemother 67, 1198-1206. 
Chun, E., Thompson, A. A., Liu, W., Roth, C. B., Griffith, M. T., Katritch, V., Kunken, J., Xu, 
F., Cherezov, V., Hanson, M. A. & Stevens, R. C. (2012). Structure 20, 967-976. 
Clatworthy, A. E., Pierson, E. & Hung, D. T. (2007). Nat Chem Biol 3, 541-548. 
Collet, J. F. & Messens, J. (2010). Antioxid Redox Signal 13, 1205-1216. 
Collet, J. F., Riemer, J., Bader, M. W. & Bardwell, J. C. (2002). The Journal of biological 
chemistry 277, 26886-26892. 
Cooper, M. A. & Shlaes, D. (2011). Nature 472, 32. 
Cornelis, G. R. (2006). Nat Rev Microbiol 4, 811-825. 
Crow, A., Lewin, A., Hecht, O., Carlsson Moller, M., Moore, G. R., Hederstedt, L. & Le 
Brun, N. E. (2009). The Journal of biological chemistry 284, 23719-23733. 
Dailey, F. E. & Berg, H. C. (1993). Proc Natl Acad Sci U S A 90, 1043-1047. 
Darby, N. J., Raina, S. & Creighton, T. E. (1998). Biochemistry 37, 783-791. 
Dauter, Z. (2006). Acta crystallographica. Section D, Biological crystallography 62, 867-
876. 
Debarbieux, L. & Beckwith, J. (1998). Proc Natl Acad Sci U S A 95, 10751-10756. 
Deisenhofer, J., Epp, O., Miki, K., Huber, R. & Michel, H. (1985). Nature 318, 618-624. 
BIBLIOGRAPHY 
 
 182 
Denisov, I. G. & Sligar, S. G. (2011). Biochim Biophys Acta 1814, 223-229. 
Deponte, M. (2013). Biochim Biophys Acta 1830, 3217-3266. 
Depuydt, M., Leonard, S. E., Vertommen, D., Denoncin, K., Morsomme, P., Wahni, K., 
Messens, J., Carroll, K. S. & Collet, J. F. (2009). Science 326, 1109-1111. 
Depuydt, M., Messens, J. & Collet, J. F. (2011). Antioxid Redox Signal 15, 49-66. 
Dillet, V., Dyson, H. J. & Bashford, D. (1998). Biochemistry 37, 10298-10306. 
DJ, C. (2007). Argonne National Laboratory, (Argonne IL). 
Doig, A. J. & Williams, D. H. (1991). J Mol Biol 217, 389-398. 
Drew, D., Lerch, M., Kunji, E., Slotboom, D. J. & de Gier, J. W. (2006). Nat Methods 3, 
303-313. 
Drew, D., Sjostrand, D., Nilsson, J., Urbig, T., Chin, C. N., de Gier, J. W. & von Heijne, G. 
(2002). Proc Natl Acad Sci U S A 99, 2690-2695. 
Drew, D., Slotboom, D. J., Friso, G., Reda, T., Genevaux, P., Rapp, M., Meindl-Beinker, N. 
M., Lambert, W., Lerch, M., Daley, D. O., Van Wijk, K. J., Hirst, J., Kunji, E. & De 
Gier, J. W. (2005). Protein Sci 14, 2011-2017. 
Drew, D. E., von Heijne, G., Nordlund, P. & de Gier, J. W. (2001). FEBS Lett 507, 220-
224. 
Dumon-Seignovert, L., Cariot, G. & Vuillard, L. (2004). Protein Expr Purif 37, 203-206. 
Duncan, M. C., Linington, R. G. & Auerbuch, V. (2012). Antimicrob Agents Chemother 56, 
5433-5441. 
Dyson, H. J., Tennant, L. L. & Holmgren, A. (1991). Biochemistry 30, 4262-4268. 
ECDC/EMEA (2009). 
Ellman, G. L. (1959). Arch Biochem Biophys 82, 70-77. 
Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. (2010). Acta crystallographica. 
Section D, Biological crystallography 66, 486-501. 
Evans, P. (2006). Acta crystallographica. Section D, Biological crystallography 62, 72-82. 
Evans, P. R. & Murshudov, G. N. (2013). Acta crystallographica. Section D, Biological 
crystallography 69, 1204-1214. 
Felise, H. B., Nguyen, H. V., Pfuetzner, R. A., Barry, K. C., Jackson, S. R., Blanc, M. P., 
Bronstein, P. A., Kline, T. & Miller, S. I. (2008). Cell host & microbe 4, 325-336. 
Feng, J. N., Model, P. & Russel, M. (1999). Mol Microbiol 34, 745-755. 
Fernandes, A. P. & Holmgren, A. (2004). Antioxid Redox Signal 6, 63-74. 
Fernebro, J. (2011). Drug Resist Updat 14, 125-139. 
Foloppe, N., Sagemark, J., Nordstrand, K., Berndt, K. D. & Nilsson, L. (2001). J Mol Biol 
310, 449-470. 
Freire-Moran, L., Aronsson, B., Manz, C., Gyssens, I. C., So, A. D., Monnet, D. L. & Cars, 
O. (2011). Drug Resist Updat 14, 118-124. 
Fruh, V., Zhou, Y., Chen, D., Loch, C., Ab, E., Grinkova, Y. N., Verheij, H., Sligar, S. G., 
Bushweller, J. H. & Siegal, G. (2010). Chem Biol 17, 881-891. 
Geertsma, E. R., Groeneveld, M., Slotboom, D. J. & Poolman, B. (2008). Proc Natl Acad 
Sci U S A 105, 5722-5727. 
Georgescu, R. E., Li, J. H., Goldberg, M. E., Tasayco, M. L. & Chaffotte, A. F. (1998). 
Biochemistry 37, 10286-10297. 
Gleason, F. K. & Holmgren, A. (1988). FEMS Microbiol Rev 4, 271-297. 
Goldstone, D., Haebel, P. W., Katzen, F., Bader, M. W., Bardwell, J. C., Beckwith, J. & 
Metcalf, P. (2001). Proc Natl Acad Sci U S A 98, 9551-9556. 
Goulding, C. W., Sawaya, M. R., Parseghian, A., Lim, V., Eisenberg, D. & Missiakas, D. 
(2002). Biochemistry 41, 6920-6927. 
Grauschopf, U., Fritz, A. & Glockshuber, R. (2003). EMBO J 22, 3503-3513. 
Grisshammer, R. & Tate, C. G. (1995). Q Rev Biophys 28, 315-422. 
Guddat, L. W., Bardwell, J. C. & Martin, J. L. (1998). Structure 6, 757-767. 
BIBLIOGRAPHY 
 
 183 
Guilhot, C., Jander, G., Martin, N. L. & Beckwith, J. (1995). Proc Natl Acad Sci U S A 92, 
9895-9899. 
Gupta, S. D., Wu, H. C. & Rick, P. D. (1997). J Bacteriol 179, 4977-4984. 
Ha, U. H., Wang, Y. & Jin, S. (2003). Infect Immun 71, 1590-1595. 
Haebel, P. W., Goldstone, D., Katzen, F., Beckwith, J. & Metcalf, P. (2002). EMBO J 21, 
4774-4784. 
Hentzer, M., Riedel, K., Rasmussen, T. B., Heydorn, A., Andersen, J. B., Parsek, M. R., 
Rice, S. A., Eberl, L., Molin, S., Hoiby, N., Kjelleberg, S. & Givskov, M. (2002). 
Microbiology 148, 87-102. 
Hentzer, M., Wu, H., Andersen, J. B., Riedel, K., Rasmussen, T. B., Bagge, N., Kumar, N., 
Schembri, M. A., Song, Z., Kristoffersen, P., Manefield, M., Costerton, J. W., Molin, 
S., Eberl, L., Steinberg, P., Kjelleberg, S., Hoiby, N. & Givskov, M. (2003). EMBO J 
22, 3803-3815. 
Heras, B., Edeling, M. A., Schirra, H. J., Raina, S. & Martin, J. L. (2004). Proceedings of 
the National Academy of Sciences of the United States of America 101, 8876-8881. 
Heras, B., Kurz, M., Jarrott, R., Shouldice, S. R., Frei, P., Robin, G., Cemazar, M., Thony-
Meyer, L., Glockshuber, R. & Martin, J. L. (2008). The Journal of biological 
chemistry 283, 4261-4271. 
Heras, B., Kurz, M., Shouldice, S. R. & Martin, J. L. (2007). Curr Opin Struct Biol 17, 691-
698. 
Heras, B., Scanlon, M. J. & Martin, J. L. (2014). Br J Clin Pharmacol. 
Heras, B., Shouldice, S. R., Totsika, M., Scanlon, M. J., Schembri, M. A. & Martin, J. L. 
(2009). Nat Rev Microbiol 7, 215-225. 
Heras, B., Totsika, M., Jarrott, R., Shouldice, S. R., Guncar, G., Achard, M. E., Wells, T. J., 
Argente, M. P., McEwan, A. G. & Schembri, M. A. (2010). The Journal of biological 
chemistry 285, 18423-18432. 
Hessa, T., Kim, H., Bihlmaier, K., Lundin, C., Boekel, J., Andersson, H., Nilsson, I., White, 
S. H. & von Heijne, G. (2005). Nature 433, 377-381. 
Hillson, D. A., Lambert, N. & Freedman, R. B. (1984). Methods Enzymol 107, 281-294. 
Hiniker, A. & Bardwell, J. C. (2003). Biochemistry 42, 1179-1185. 
Hiniker, A. & Bardwell, J. C. (2004). The Journal of biological chemistry 279, 12967-12973. 
Hiniker, A., Collet, J. F. & Bardwell, J. C. (2005). The Journal of biological chemistry 280, 
33785-33791. 
Hiniker, A., Ren, G., Heras, B., Zheng, Y., Laurinec, S., Jobson, R. W., Stuckey, J. A., 
Martin, J. L. & Bardwell, J. C. (2007). Proc Natl Acad Sci U S A 104, 11670-11675. 
Hirakawa, H. & Tomita, H. (2013). Front Microbiol 4, 114. 
Hizukuri, Y., Yakushi, T., Kawagishi, I. & Homma, M. (2006). J Bacteriol 188, 4190-4197. 
Hjelmeland, L. M. (1990). Methods Enzymol 182, 253-264. 
Ho, J., Tambyah, P. A. & Paterson, D. L. (2010). Curr Opin Infect Dis 23, 546-553. 
Hodgkinson, V. & Petris, M. J. (2012). The Journal of biological chemistry 287, 13549-
13555. 
Holmgren, A. (1979). The Journal of biological chemistry 254, 9627-9632. 
Holmgren, A. (1981). Trends in Biochemical Sciences 6, 26-29. 
Holmgren, A. (1985). Annu Rev Biochem 54, 237-271. 
Holmgren, A., Soderberg, B. O., Eklund, H. & Branden, C. I. (1975). Proc Natl Acad Sci U 
S A 72, 2305-2309. 
Horne, J., d'Auvergne, E. J., Coles, M., Velkov, T., Chin, Y., Charman, W. N., Prankerd, 
R., Gooley, P. R. & Scanlon, M. J. (2007). J Mol Biol 371, 703-716. 
Houk, J., Singh, R. & Whitesides, G. M. (1987). Methods Enzymol 143, 129-140. 
Huber-Wunderlich, M. & Glockshuber, R. (1998). Fold Des 3, 161-171. 
BIBLIOGRAPHY 
 
 184 
Hung, D. T., Shakhnovich, E. A., Pierson, E. & Mekalanos, J. J. (2005). Science 310, 670-
674. 
Inaba, K., Murakami, S., Nakagawa, A., Iida, H., Kinjo, M., Ito, K. & Suzuki, M. (2009). 
EMBO J 28, 779-791. 
Inaba, K., Murakami, S., Suzuki, M., Nakagawa, A., Yamashita, E., Okada, K. & Ito, K. 
(2006). Cell 127, 789-801. 
Inaba, K., Takahashi, Y. H., Fujieda, N., Kano, K., Miyoshi, H. & Ito, K. (2004). The Journal 
of biological chemistry 279, 6761-6768. 
Inaba, K., Takahashi, Y. H. & Ito, K. (2005). The Journal of biological chemistry 280, 
33035-33044. 
Inaba, K., Takahashi, Y. H., Ito, K. & Hayashi, S. (2006). Proc Natl Acad Sci U S A 103, 
287-292. 
Ireland, P. M., McMahon, R. M., Marshall, L. E., Halili, M., Furlong, E., Tay, S., Martin, J. L. 
& Sarkar-Tyson, M. (2014). Antioxid Redox Signal 20, 606-617. 
Ito, K. & Inaba, K. (2008). Curr Opin Struct Biol 18, 450-458. 
Jacob-Dubuisson, F., Pinkner, J., Xu, Z., Striker, R., Padmanhaban, A. & Hultgren, S. J. 
(1994). Proc Natl Acad Sci U S A 91, 11552-11556. 
Jensen, K. S., Hansen, R. E. & Winther, J. R. (2009). Antioxid Redox Signal 11, 1047-
1058. 
Joly, J. C. & Swartz, J. R. (1997). Biochemistry 36, 10067-10072. 
Jonda, S., Huber-Wunderlich, M., Glockshuber, R. & Mossner, E. (1999). EMBO J 18, 
3271-3281. 
Kabsch, W. (2010). Acta crystallographica. Section D, Biological crystallography 66, 125-
132. 
Kadokura, H. & Beckwith, J. (2002). EMBO J 21, 2354-2363. 
Kadokura, H. & Beckwith, J. (2009). Cell 138, 1164-1173. 
Kadokura, H. & Beckwith, J. (2010). Antioxid Redox Signal 13, 1231-1246. 
Kadokura, H., Tian, H., Zander, T., Bardwell, J. C. & Beckwith, J. (2004). Science 303, 
534-537. 
Katzen, F. & Beckwith, J. (2000). Cell 103, 769-779. 
Katzen, F. & Beckwith, J. (2003). Proc Natl Acad Sci U S A 100, 10471-10476. 
Kauppi, A. M., Nordfelth, R., Uvell, H., Wolf-Watz, H. & Elofsson, M. (2003). Chem Biol 10, 
241-249. 
Kawate, T. & Gouaux, E. (2006). Structure 14, 673-681. 
Kelley, R. F. & Richards, F. M. (1987). Biochemistry 26, 6765-6774. 
Kendrew, J. C., Dickerson, R. E., Strandberg, B. E., Hart, R. G., Davies, D. R., Phillips, D. 
C. & Shore, V. C. (1960). Nature 185, 422-427. 
Keynan, Y. & Rubinstein, E. (2007). Int J Antimicrob Agents 30, 385-389. 
Kishigami, S., Akiyama, Y. & Ito, K. (1995). FEBS Lett 364, 55-58. 
Kishigami, S., Kanaya, E., Kikuchi, M. & Ito, K. (1995). The Journal of biological chemistry 
270, 17072-17074. 
Kline, K. A., Dodson, K. W., Caparon, M. G. & Hultgren, S. J. (2010). Trends Microbiol 18, 
224-232. 
Kobayashi, T. & Ito, K. (1999). EMBO J 18, 1192-1198. 
Kobayashi, T., Kishigami, S., Sone, M., Inokuchi, H., Mogi, T. & Ito, K. (1997). 
Proceedings of the National Academy of Sciences of the United States of America 
94, 11857-11862. 
Krause, G., Lundstrom, J., Barea, J. L., Pueyo de la Cuesta, C. & Holmgren, A. (1991). 
The Journal of biological chemistry 266, 9494-9500. 
Krissinel, E. & Henrick, K. (2004). Acta crystallographica. Section D, Biological 
crystallography 60, 2256-2268. 
BIBLIOGRAPHY 
 
 185 
Kurokawa, Y., Yanagi, H. & Yura, T. (2000). Appl Environ Microbiol 66, 3960-3965. 
Kurz, M., Iturbe-Ormaetxe, I., Jarrott, R., Shouldice, S. R., Wouters, M. A., Frei, P., 
Glockshuber, R., O'Neill, S. L., Heras, B. & Martin, J. L. (2009). Antioxid Redox 
Signal 11, 1485-1500. 
Kynde, S. A., Skar-Gislinge, N., Pedersen, M. C., Midtgaard, S. R., Simonsen, J. B., 
Schweins, R., Mortensen, K. & Arleth, L. (2014). Acta crystallographica. Section D, 
Biological crystallography 70, 371-383. 
Lafaye, C., Iwema, T., Carpentier, P., Jullian-Binard, C., Kroll, J. S., Collet, J. F. & Serre, 
L. (2009). J Mol Biol 392, 952-966. 
Landau, E. M. & Rosenbusch, J. P. (1996). Proc Natl Acad Sci U S A 93, 14532-14535. 
LaSarre, B. & Federle, M. J. (2013). Microbiol Mol Biol Rev 77, 73-111. 
Lasica, A. M. & Jagusztyn-Krynicka, E. K. (2007). FEMS Microbiol Rev 31, 626-636. 
Laurent, T. C., Moore, E. C. & Reichard, P. (1964). The Journal of biological chemistry 
239, 3436-3444. 
Lee, Y. M., Almqvist, F. & Hultgren, S. J. (2003). Curr Opin Pharmacol 3, 513-519. 
Levin, B. R., Perrot, V. & Walker, N. (2000). Genetics 154, 985-997. 
Lichtenberg, D., Ahyayauch, H., Alonso, A. & Goni, F. M. (2013). Trends Biochem Sci 38, 
85-93. 
Lillig, C. H. & Holmgren, A. (2007). Antioxid Redox Signal 9, 25-47. 
Lin, T. Y. & Kim, P. S. (1989). Biochemistry 28, 5282-5287. 
Liu, X. & Wang, C. C. (2001). The Journal of biological chemistry 276, 1146-1151. 
Lu, J. & Holmgren, A. (2012). Antioxid Redox Signal 17, 1738-1747. 
MacLean, R. C., Hall, A. R., Perron, G. G. & Buckling, A. (2010). Nat Rev Genet 11, 405-
414. 
Malojcic, G., Owen, R. L., Grimshaw, J. P. & Glockshuber, R. (2008). FEBS Lett 582, 
3301-3307. 
Manglik, A., Kruse, A. C., Kobilka, T. S., Thian, F. S., Mathiesen, J. M., Sunahara, R. K., 
Pardo, L., Weis, W. I., Kobilka, B. K. & Granier, S. (2012). Nature 485, 321-326. 
Martin, J. L., Bardwell, J. C. & Kuriyan, J. (1993). Nature 365, 464-468. 
Mavridou, D. A., Stevens, J. M., Ferguson, S. J. & Redfield, C. (2007). J Mol Biol 370, 643-
658. 
McCarthy, A. A., Haebel, P. W., Torronen, A., Rybin, V., Baker, E. N. & Metcalf, P. 
(2000a). Nat Struct Biol 7, 196-199. 
McCarthy, A. A., Haebel, P. W., Torronen, A., Rybin, V., Baker, E. N. & Metcalf, P. 
(2000b). Nature structural biology 7, 196-199. 
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C. & Read, 
R. J. (2007). Journal of Applied Crystallography 40, 658-674. 
McMahon, R. M., Premkumar, L. & Martin, J. L. (2014). Biochim Biophys Acta. 
McPhillips, T. M., McPhillips, S. E., Chiu, H. J., Cohen, A. E., Deacon, A. M., Ellis, P. J., 
Garman, E., Gonzalez, A., Sauter, N. K., Phizackerley, R. P., Soltis, S. M. & Kuhn, 
P. (2002). J Synchrotron Radiat 9, 401-406. 
Miki, T., Okada, N. & Danbara, H. (2004). The Journal of biological chemistry 279, 34631-
34642. 
Mikolay, A., Huggett, S., Tikana, L., Grass, G., Braun, J. & Nies, D. H. (2010). Appl 
Microbiol Biotechnol 87, 1875-1879. 
Missiakas, D., Georgopoulos, C. & Raina, S. (1993). Proc Natl Acad Sci U S A 90, 7084-
7088. 
Missiakas, D., Georgopoulos, C. & Raina, S. (1994). The EMBO journal 13, 2013-2020. 
Missiakas, D., Schwager, F. & Raina, S. (1995). EMBO J 14, 3415-3424. 
Mohanty, A. K., Simmons, C. R. & Wiener, M. C. (2003). Protein Expr Purif 27, 109-114. 
Mossner, E., Huber-Wunderlich, M. & Glockshuber, R. (1998). Protein Sci 7, 1233-1244. 
BIBLIOGRAPHY 
 
 186 
N. M. Kirby, S. T. M., A. M. Hawley, D. J. Cookson, H. D. T. Mertens, N. Cowieson and V. 
Samardzic-Boban (2013). J. Appl. Cryst. 46, 1670-1680  
Nakamoto, H. & Bardwell, J. C. (2004). Biochim Biophys Acta 1694, 111-119. 
Nakamura, H., Nakamura, K. & Yodoi, J. (1997). Annu Rev Immunol 15, 351-369. 
Nakamura, T., Nakamura, H., Hoshino, T., Ueda, S., Wada, H. & Yodoi, J. (2005). Antioxid 
Redox Signal 7, 60-71. 
Nath, A., Atkins, W. M. & Sligar, S. G. (2007). Biochemistry 46, 2059-2069. 
Nelson, J. W. & Creighton, T. E. (1994). Biochemistry 33, 5974-5983. 
Newstead, S., Kim, H., von Heijne, G., Iwata, S. & Drew, D. (2007). Proc Natl Acad Sci U 
S A 104, 13936-13941. 
O'Malley, M. A., Mancini, J. D., Young, C. L., McCusker, E. C., Raden, D. & Robinson, A. 
S. (2009). Protein Sci 18, 2356-2370. 
Oldham, W. M. & Hamm, H. E. (2008). Nat Rev Mol Cell Biol 9, 60-71. 
Orthaber D, B. A. a. G. O. (2000). J. Appl. Cryst. 33, 218-225. 
Ouyang, N., Gao, Y. G., Hu, H. Y. & Xia, Z. X. (2006). Proteins 65, 1021-1031. 
Overington, J. P., Al-Lazikani, B. & Hopkins, A. L. (2006). Nat Rev Drug Discov 5, 993-
996. 
Palczewski, K., Kumasaka, T., Hori, T., Behnke, C. A., Motoshima, H., Fox, B. A., Le 
Trong, I., Teller, D. C., Okada, T., Stenkamp, R. E., Yamamoto, M. & Miyano, M. 
(2000). Science 289, 739-745. 
Pan, J. L. & Bardwell, J. C. (2006). Protein Sci 15, 2217-2227. 
Paxman, J. J., Borg, N. A., Horne, J., Thompson, P. E., Chin, Y., Sharma, P., Simpson, J. 
S., Wielens, J., Piek, S., Kahler, C. M., Sakellaris, H., Pearce, M., Bottomley, S. P., 
Rossjohn, J. & Scanlon, M. J. (2009). The Journal of biological chemistry 284, 
17835-17845. 
Petoukhov, M. V. & Svergun, D. I. (2005). Biophys J 89, 1237-1250. 
Petrecca, K., Atanasiu, R., Akhavan, A. & Shrier, A. (1999). J Physiol 515 ( Pt 1), 41-48. 
Piek, S., Wang, Z., Ganguly, J., Lakey, A. M., Bartley, S. N., Mowlaboccus, S., Anandan, 
A., Stubbs, K. A., Scanlon, M. J., Vrielink, A., Azadi, P., Carlson, R. W. & Kahler, C. 
M. (2014). PloS one 9, e106513. 
Pinkner, J. S., Remaut, H., Buelens, F., Miller, E., Aberg, V., Pemberton, N., Hedenstrom, 
M., Larsson, A., Seed, P., Waksman, G., Hultgren, S. J. & Almqvist, F. (2006). Proc 
Natl Acad Sci U S A 103, 17897-17902. 
Porat, A., Cho, S. H. & Beckwith, J. (2004). Res Microbiol 155, 617-622. 
Powis, G., Mustacich, D. & Coon, A. (2000). Free Radic Biol Med 29, 312-322. 
Premkumar, L., Heras, B., Duprez, W., Walden, P., Halili, M., Kurth, F., Fairlie, D. P. & 
Martin, J. L. (2013). Acta crystallographica. Section D, Biological crystallography 69, 
1981-1994. 
Prinz, W. A., Aslund, F., Holmgren, A. & Beckwith, J. (1997). The Journal of biological 
chemistry 272, 15661-15667. 
Qing, G., Ma, L. C., Khorchid, A., Swapna, G. V., Mal, T. K., Takayama, M. M., Xia, B., 
Phadtare, S., Ke, H., Acton, T., Montelione, G. T., Ikura, M. & Inouye, M. (2004). 
Nat Biotechnol 22, 877-882. 
Quan, S., Schneider, I., Pan, J., Von Hacht, A. & Bardwell, J. C. A. (2007). Journal of 
Biological Chemistry 282, 28823-28833. 
Rademacher, C. & Masepohl, B. (2012). Microbiology 158, 2451-2464. 
Raschle, T., Hiller, S., Yu, T. Y., Rice, A. J., Walz, T. & Wagner, G. (2009). Journal of the 
American Chemical Society 131, 17777-17779. 
Rasko, D. A. & Sperandio, V. (2010). Nat Rev Drug Discov 9, 117-128. 
Regeimbal, J. & Bardwell, J. C. (2002). The Journal of biological chemistry 277, 32706-
32713. 
BIBLIOGRAPHY 
 
 187 
Ren, G., Stephan, D., Xu, Z., Zheng, Y., Tang, D., Harrison, R. S., Kurz, M., Jarrott, R., 
Shouldice, S. R., Hiniker, A., Martin, J. L., Heras, B. & Bardwell, J. C. (2009). The 
Journal of biological chemistry 284, 10150-10159. 
Rice, L. B. (2008). J Infect Dis 197, 1079-1081. 
Rietsch, A., Belin, D., Martin, N. & Beckwith, J. (1996). Proc Natl Acad Sci U S A 93, 
13048-13053. 
Rietsch, A., Bessette, P., Georgiou, G. & Beckwith, J. (1997). J Bacteriol 179, 6602-6608. 
Ritchie, T. K., Grinkova, Y. V., Bayburt, T. H., Denisov, I. G., Zolnerciks, J. K., Atkins, W. 
M. & Sligar, S. G. (2009). Methods Enzymol 464, 211-231. 
Roos, G., Foloppe, N., Van Laer, K., Wyns, L., Nilsson, L., Geerlings, P. & Messens, J. 
(2009). PLoS Comput Biol 5, e1000461. 
Rosadini, C. V., Wong, S. M. & Akerley, B. J. (2008). Infect Immun 76, 1498-1508. 
Rozhkova, A. & Glockshuber, R. (2008). J Mol Biol 380, 783-788. 
Rozhkova, A., Stirnimann, C. U., Frei, P., Grauschopf, U., Brunisholz, R., Grutter, M. G., 
Capitani, G. & Glockshuber, R. (2004). EMBO J 23, 1709-1719. 
Russel, M. & Model, P. (1986). The Journal of biological chemistry 261, 14997-15005. 
Schertler, G. F. X. (1992). Curr. Opin. Struct. Biol. 2, pp. 534-544. 
Schwaller, M., Wilkinson, B. & Gilbert, H. F. (2003). The Journal of biological chemistry 
278, 7154-7159. 
Seddon, A. M., Curnow, P. & Booth, P. J. (2004). Biochim Biophys Acta 1666, 105-117. 
Segatori, L., Murphy, L., Arredondo, S., Kadokura, H., Gilbert, H., Beckwith, J. & Georgiou, 
G. (2006). The Journal of biological chemistry 281, 4911-4919. 
Segatori, L., Paukstelis, P. J., Gilbert, H. F. & Georgiou, G. (2004). Proc Natl Acad Sci U S 
A 101, 10018-10023. 
Serrano-Vega, M. J., Magnani, F., Shibata, Y. & Tate, C. G. (2008). Proc Natl Acad Sci U 
S A 105, 877-882. 
Shao, F., Bader, M. W., Jakob, U. & Bardwell, J. C. (2000). The Journal of biological 
chemistry 275, 13349-13352. 
Shepherd, M., Heras, B., Achard, M. E., King, G. J., Argente, M. P., Kurth, F., Taylor, S. L., 
Howard, M. J., King, N. P., Schembri, M. A. & McEwan, A. G. (2013a). Antioxid 
Redox Signal. 
Shepherd, M., Heras, B., Achard, M. E., King, G. J., Argente, M. P., Kurth, F., Taylor, S. L., 
Howard, M. J., King, N. P., Schembri, M. A. & McEwan, A. G. (2013b). Antioxid 
Redox Signal 19, 1494-1506. 
Shouldice, S. R., Cho, S. H., Boyd, D., Heras, B., Eser, M., Beckwith, J., Riggs, P., Martin, 
J. L. & Berkmen, M. (2010). Mol Microbiol 75, 13-28. 
Shouldice, S. R., Heras, B., Jarrott, R., Sharma, P., Scanlon, M. J. & Martin, J. L. (2010). 
Antioxid Redox Signal 12, 921-931. 
Shouldice, S. R., Heras, B., Walden, P. M., Totsika, M., Schembri, M. A. & Martin, J. L. 
(2011). Antioxid Redox Signal 14, 1729-1760. 
Sivashanmugam, A., Murray, V., Cui, C., Zhang, Y., Wang, J. & Li, Q. (2009). Protein Sci 
18, 936-948. 
Skar-Gislinge, N., Simonsen, J. B., Mortensen, K., Feidenhans'l, R., Sligar, S. G., Lindberg 
Moller, B., Bjornholm, T. & Arleth, L. (2010). Journal of the American Chemical 
Society 132, 13713-13722. 
Soto, G. E. & Hultgren, S. J. (1999). J Bacteriol 181, 1059-1071. 
Souli, M., Galani, I. & Giamarellou, H. (2008). Euro Surveill 13. 
Stenson, T. H. & Weiss, A. A. (2002). Infect Immun 70, 2297-2303. 
Stewart, E. J., Aslund, F. & Beckwith, J. (1998). EMBO J 17, 5543-5550. 
Stewart, E. J., Katzen, F. & Beckwith, J. (1999). EMBO J 18, 5963-5971. 
BIBLIOGRAPHY 
 
 188 
Stirnimann, C. U., Grutter, M. G., Glockshuber, R. & Capitani, G. (2006). Cell Mol Life Sci 
63, 1642-1648. 
Stirnimann, C. U., Rozhkova, A., Grauschopf, U., Bockmann, R. A., Glockshuber, R., 
Capitani, G. & Grutter, M. G. (2006). J Mol Biol 358, 829-845. 
Stirnimann, C. U., Rozhkova, A., Grauschopf, U., Grutter, M. G., Glockshuber, R. & 
Capitani, G. (2005). Structure 13, 985-993. 
Studier, F. W. (2005). Protein Expr Purif 41, 207-234. 
Sun, X. X. & Wang, C. C. (2000). Journal of Biological Chemistry 275, 22743-22749. 
Svergun, D. I. (1992). J. Appl. Cryst. 25, 495-503. 
Taniyama, Y., Kuroki, R., Omura, F., Seko, C. & Kikuchi, M. (1991). The Journal of 
biological chemistry 266, 6456-6461. 
Tapley, T. L., Eichner, T., Gleiter, S., Ballou, D. P. & Bardwell, J. C. (2007). The Journal of 
biological chemistry 282, 10263-10271. 
Tate, C. G. (2001). FEBS Lett 504, 94-98. 
Tate, C. G. (2010). Methods Mol Biol 601, 187-203. 
Terpe, K. (2006). Appl Microbiol Biotechnol 72, 211-222. 
Tinsley, C. R., Voulhoux, R., Beretti, J. L., Tommassen, J. & Nassif, X. (2004). The Journal 
of biological chemistry 279, 27078-27087. 
Totsika, M., Heras, B., Wurpel, D. J. & Schembri, M. A. (2009). J Bacteriol 191, 3901-
3908. 
Totsika, M., Kostakioti, M., Hannan, T. J., Upton, M., Beatson, S. A., Janetka, J. W., 
Hultgren, S. J. & Schembri, M. A. (2013). J Infect Dis 208, 921-928. 
Touaibia, M. & Roy, R. (2007). Mini reviews in medicinal chemistry 7, 1270-1283. 
Vagin, A. & Teplyakov, A. (2000). Acta crystallographica. Section D, Biological 
crystallography 56, 1622-1624. 
Vagin, A. A., Steiner, R. A., Lebedev, A. A., Potterton, L., McNicholas, S., Long, F. & 
Murshudov, G. N. (2004). Acta crystallographica. Section D, Biological 
crystallography 60, 2184-2195. 
van Straaten, M., Missiakas, D., Raina, S. & Darby, N. J. (1998). FEBS Lett 428, 255-258. 
Vertommen, D., Depuydt, M., Pan, J., Leverrier, P., Knoops, L., Szikora, J. P., Messens, 
J., Bardwell, J. C. & Collet, J. F. (2008). Mol Microbiol 67, 336-349. 
Vivian, J. P., Scoullar, J., Rimmer, K., Bushell, S. R., Beddoe, T., Wilce, M. C., Byres, E., 
Boyle, T. P., Doak, B., Simpson, J. S., Graham, B., Heras, B., Kahler, C. M., 
Rossjohn, J. & Scanlon, M. J. (2009). J Mol Biol 394, 931-943. 
von Heijne, G. (2006). Nat Rev Mol Cell Biol 7, 909-918. 
Wagner, S., Baars, L., Ytterberg, A. J., Klussmeier, A., Wagner, C. S., Nord, O., Nygren, 
P. A., van Wijk, K. J. & de Gier, J. W. (2007). Mol Cell Proteomics 6, 1527-1550. 
Wagner, S., Klepsch, M. M., Schlegel, S., Appel, A., Draheim, R., Tarry, M., Hogbom, M., 
van Wijk, K. J., Slotboom, D. J., Persson, J. O. & de Gier, J. W. (2008). Proc Natl 
Acad Sci U S A 105, 14371-14376. 
Waksman, G. & Hultgren, S. J. (2009). Nat Rev Microbiol 7, 765-774. 
Walden, P. M., Halili, M. A., Archbold, J. K., Lindahl, F., Fairlie, D. P., Inaba, K. & Martin, J. 
L. (2013). PloS one 8, e81440. 
Walden, P. M., Heras, B., Chen, K. E., Halili, M. A., Rimmer, K., Sharma, P., Scanlon, M. 
J. & Martin, J. L. (2012). Acta crystallographica. Section D, Biological 
crystallography 68, 1290-1302. 
Waldo, G. S., Standish, B. M., Berendzen, J. & Terwilliger, T. C. (1999). Nat Biotechnol 17, 
691-695. 
Walker, K. W. & Gilbert, H. F. (1997). The Journal of biological chemistry 272, 8845-8848. 
Wang, Y., Zhu, S., Hodgkinson, V., Prohaska, J. R., Weisman, G. A., Gitlin, J. D. & Petris, 
M. J. (2012). Am J Physiol Gastrointest Liver Physiol 303, G1236-1244. 
BIBLIOGRAPHY 
 
 189 
Warne, T., Moukhametzianov, R., Baker, J. G., Nehme, R., Edwards, P. C., Leslie, A. G., 
Schertler, G. F. & Tate, C. G. (2011). Nature 469, 241-244. 
Watanabe, I., Zhu, J., Recio-Pinto, E. & Thornhill, W. B. (2004). The Journal of biological 
chemistry 279, 8879-8885. 
Webster, J. C., Jewell, C. M., Bodwell, J. E., Munck, A., Sar, M. & Cidlowski, J. A. (1997). 
The Journal of biological chemistry 272, 9287-9293. 
Wellens, A., Garofalo, C., Nguyen, H., Van Gerven, N., Slattegard, R., Hernalsteens, J. P., 
Wyns, L., Oscarson, S., De Greve, H., Hultgren, S. & Bouckaert, J. (2008). PloS 
one 3, e2040. 
Wetzel, R., Perry, L. J., Baase, W. A. & Becktel, W. J. (1988). Proc Natl Acad Sci U S A 
85, 401-405. 
White, S. H. (2004). Protein Sci 13, 1948-1949. 
White, S. H. & von Heijne, G. (2004). Curr Opin Struct Biol 14, 397-404. 
White, S. H. & von Heijne, G. (2005). Curr Opin Struct Biol 15, 378-386. 
Whitten A. E., C. S., J. Trewhella (2008). J. Appl. Cryst. 41, 222-226. 
Wozniak, R. A., Fouts, D. E., Spagnoletti, M., Colombo, M. M., Ceccarelli, D., Garriss, G., 
Dery, C., Burrus, V. & Waldor, M. K. (2009). PLoS Genet 5, e1000786. 
Wright, K. J., Seed, P. C. & Hultgren, S. J. (2007). Cell Microbiol 9, 2230-2241. 
Wu, H., Song, Z., Hentzer, M., Andersen, J. B., Molin, S., Givskov, M. & Hoiby, N. (2004). 
J Antimicrob Chemother 53, 1054-1061. 
Wu, H., Wacker, D., Mileni, M., Katritch, V., Han, G. W., Vardy, E., Liu, W., Thompson, A. 
A., Huang, X. P., Carroll, F. I., Mascarella, S. W., Westkaemper, R. B., Mosier, P. 
D., Roth, B. L., Cherezov, V. & Stevens, R. C. (2012). Nature 485, 327-332. 
Wunderlich, M. & Glockshuber, R. (1993a). The Journal of biological chemistry 268, 
24547-24550. 
Wunderlich, M. & Glockshuber, R. (1993b). Protein Sci 2, 717-726. 
Yazawa, K., Furusawa, H. & Okahata, Y. (2013). The Journal of biological chemistry 288, 
35969-35981. 
Yu, J. & Kroll, J. S. (1999). Microbes Infect 1, 1221-1228. 
Zapun, A., Bardwell, J. C. & Creighton, T. E. (1993). Biochemistry 32, 5083-5092. 
Zapun, A., Missiakas, D., Raina, S. & Creighton, T. E. (1995). Biochemistry 34, 5075-
5089. 
Zhang, H. Z. & Donnenberg, M. S. (1996). Mol Microbiol 21, 787-797. 
Zhang, M., Monzingo, A. F., Segatori, L., Georgiou, G. & Robertus, J. D. (2004). Acta 
crystallographica. Section D, Biological crystallography 60, 1512-1518. 
Zhang, P., Liu, B., Kang, S. W., Seo, M. S., Rhee, S. G. & Obeid, L. M. (1997). The 
Journal of biological chemistry 272, 30615-30618. 
Zhang, Z., Li, Z. H., Wang, F., Fang, M., Yin, C. C., Zhou, Z. Y., Lin, Q. & Huang, H. L. 
(2002). Protein Expr Purif 26, 218-228. 
Zhao, Z., Peng, Y., Hao, S. F., Zeng, Z. H. & Wang, C. C. (2003). The Journal of biological 
chemistry 278, 43292-43298. 
Zhou, Y., Cierpicki, T., Jimenez, R. H., Lukasik, S. M., Ellena, J. F., Cafiso, D. S., 
Kadokura, H., Beckwith, J. & Bushweller, J. H. (2008). Mol Cell 31, 896-908. 
Zhou, Y., Morais-Cabral, J. H., Kaufman, A. & MacKinnon, R. (2001). Nature 414, 43-48. 
Zou, Y., Weis, W. I. & Kobilka, B. K. (2012). PloS one 7, e46039. 
 
APPENDIX A 
 
 190 
 
 
 
 
 
 
 
APPENDIX A 
 
 
 
9 Appendix A 
 
 
 
APPENDIX A 
 
 191 
 
Heras and Jennifer L. Martin
Gordon J. King, Maria A. Halili, Begoña
Wilko Duprez, Morten K. Grøftehauge, 
Lakshmanane Premkumar, Fabian Kurth,
  
Interaction Site
Factor EF-Tu Reveals a Novel Protein
Dithiol Oxidase DsbA Bound to Elongation 
Acinetobacter baumanniiStructure of the 
Protein Structure and Folding:
doi: 10.1074/jbc.M114.571737 originally published online May 23, 2014
2014, 289:19869-19880.J. Biol. Chem. 
  
 10.1074/jbc.M114.571737Access the most updated version of this article at doi: 
  
.JBC Affinity SitesFind articles, minireviews, Reflections and Classics on similar topics on the 
 Alerts: 
  
 When a correction for this article is posted•  
 When this article is cited•  
 to choose from all of JBC's e-mail alertsClick here
  
 http://www.jbc.org/content/289/29/19869.full.html#ref-list-1
This article cites 84 references, 31 of which can be accessed free at
 at Univ of Queensland (CAUL) on July 24, 2014
http://www.jbc.org/
Downloaded from 
 at Univ of Queensland (CAUL) on July 24, 2014
http://www.jbc.org/
Downloaded from 
APPENDIX A 
 
 192  
Structure of the Acinetobacter baumanniiDithiol Oxidase
DsbA Bound to Elongation Factor EF-Tu Reveals a Novel
Protein Interaction Site
Received for publication,April 6, 2014, and in revised form, May 19, 2014 Published, JBC Papers in Press,May 23, 2014, DOI 10.1074/jbc.M114.571737
Lakshmanane Premkumar1,2, Fabian Kurth1, Wilko Duprez1, Morten K. Grøftehauge3, Gordon J. King,
Maria A. Halili, Begon˜a Heras4, and Jennifer L. Martin5
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Background: DsbA is a master virulence determinant of bacterial pathogens and a target for antivirulence drugs.
Results:AbDsbA is a class I dithiol oxidase that binds EF-Tu-derived and DsbB-derived peptides on different enzyme surfaces.
Conclusion: Discovery of high affinity peptide interaction sites provides a platform for inhibitor design.
Significance: AbDsbA inhibitors could have anti-biofilm activity against multidrug resistant Acinetobacter baumannii.
The multidrug resistant bacterium Acinetobacter baumannii
is a significant cause of nosocomial infection. Biofilm formation,
that requires both disulfide bond forming and chaperone-usher
pathways, is a major virulence trait in this bacterium. Our bio-
chemical characterizations show that the periplasmic A. bau-
mannii DsbA (AbDsbA) enzyme has an oxidizing redox poten-
tial and dithiol oxidase activity. We found an unexpected
non-covalent interaction between AbDsbA and the highly con-
served prokaryotic elongation factor, EF-Tu. EF-Tu is a cyto-
plasmic protein but has been localized extracellularly in many
bacterial pathogens. The crystal structure of this complex
revealed that the EF-Tu switch I region binds to the non-cata-
lytic surface of AbDsbA. Although the physiological and patho-
logical significance of a DsbA/EF-Tu association is unknown,
peptides derived from the EF-Tu switch I region bound to
AbDsbA with submicromolar affinity. We also identified a sev-
en-residue DsbB-derived peptide that bound to AbDsbA with
low micromolar affinity. Further characterization confirmed
that the EF-Tu- and DsbB-derived peptides bind at two distinct
sites. These data point to the possibility that the non-catalytic
surface of DsbA is a potential substrate or regulatory protein
interaction site. The two peptides identified in this work
together with the newly characterized interaction site provide a
novel starting point for inhibitor design targeting AbDsbA.
The global increase inmultidrug- or pandrug-resistantAcin-
etobacter baumannii infections poses a major risk to public
health. A. baumannii is one of the “ESKAPE” pathogens
(Enterococcus faecium, Staphylococcus aureus,Klebsiella pneu-
moniae, Pseudomonas aeruginosa, and Enterobacter species),
so-called because of their ability to “escape” the effects of clin-
ically useful antibiotics by biofilm formation and rapid acquisi-
tion of resistance genes (1). Collectively, these ESKAPE patho-
gens are a major cause of hospital- and community-acquired
infections, morbidity, andmortality. New targets and strategies
are needed to combat infections caused by these pathogens.
A. baumannii (colloquially known as Iraqibacter) is a Gram-
negative, opportunistic pathogen that can cause a wide range of
diseases, including pneumonia,meningitis, bacteremia, urinary
tract infections, and wound infections (2, 3). This microbe has
been responsible for multiple outbreaks around the world,
including Australia and among United States military personal
deployed in the Middle East (5–9). There is a high incidence of
A. baumannii infection among immunocompromised patients,
especially those who have experienced long stays in hospital
(10). Multidrug-resistant A. baumannii such as the AYE strain
have accumulated a large cluster of resistance genes via hori-
zontal gene transfer. Both itsmultidrug resistance and its ability
to survive on highly desiccated abiotic surfaces (e.g. plastic and
glass medical devices) have been linked to its success as a nos-
ocomial pathogen (11, 12). Currently, there is no vaccine
against A. baumannii (4).
A. baumannii can invade host cells, but little is known
about its pathogenic mechanism. Biofilm formation is a
major virulence trait contributing to bacterial colonization
on tissue and persistence in the hospital environment (13).
Electron and fluorescence microscopy experiments showed
that cell surface fimbriae are necessary for A. baumannii
attachment and initiation of biofilm formation on abiotic
and biotic surfaces (14). Fimbriae are filamentous, multisub-
unit protein assemblies. Each fimbrial subunit contains an
evolutionarily invariant disulfide bridge (15) that requires
both the oxidative folding and the chaperone-usher path-
ways for assembly (13, 14, 16, 17).
Theatomic coordinates and structure factors (code4P3Y) havebeendeposited in
the Protein Data Bank (http://wwpdb.org/).
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The disulfide bond-forming system of Gram-negative bacte-
ria typically comprises DsbA (a soluble, periplasmic, thiore-
doxin-fold dithiol oxidoreductase) and DsbB (an integral inner
membrane protein). DsbA catalyzes the formation of disulfide
bonds in nascent substrate proteins as they are translocated
into the periplasm. Through this reaction, the active site CXXC
motif of DsbA becomes reduced and is restored to its function-
ally competent oxidized state through interaction with DsbB.
DsbA is considered a master regulator of virulence and viru-
lence traits (14, 18–21). Deletion or mutation of dsbA attenu-
ates virulence factor maturation in bacterial pathogens includ-
ing Proteus mirabilis (22), uropathogenic Escherichia coli (23),
Burkholderia pseudomallei (24), Vibrio cholerae (25), Shigella
flexneri (26), and Salmonella enterica serovar typhimurium
(27). DsbA inhibitors are potential anti-virulence drugs (28).
Here we characterize DsbA from A. baumannii (AbDsbA)6
and show that it has an unusually basic surface, with redox and
catalytic properties that qualify it as a bona fide dithiol oxidase.
We also report an unexpected interaction between AbDsbA
and E. coli EF-Tu (EcEF-Tu); the complex can be co-purified
from the cytoplasm of the E. coli expression system. This ser-
endipitous discovery allowed the crystal structure determina-
tion of the AbDsbA!EcEF-Tu complex at 2.15 Å resolution and
identification of specific intermolecular interactions.
Although the highly conserved EF-Tu is generally considered
to be a cytoplasmic protein, extracellular localization has been
reported in bacterial pathogens including A. baumannii (29),
P. aeruginosa (30, 31), and Mycobacterium tuberculosis (32).
Moreover, EF-Tu has been found to bind human fibronectin,
platelet-activating factor receptor, plasminogen, and factor H
for adhesion, tissue infiltration, and complement system inac-
tivation. Intracellularly, EF-Tu has functions additional to its
central role in protein translation. For example, inBacillus sub-
tilis EF-Tu plays a role in cell shape by interacting with actin-
like proteins (33). Bacteriophages Q! and T4 both recruit
EF-Tu to perform essential functions (34, 35). We investigated
the interaction by generating peptides derived from EF-Tu and
showed that these bind tightly toAbDsbA, providing a platform
for the future design of peptidomimetic inhibitors targeting
AbDsbA.
EXPERIMENTAL PROCEDURES
Protein Expression and Purification—A codon-optimized
synthetic gene coding for A. baumannii (AYE strain) DsbA
(amino acids 27–205; Uniprot: B0V5X3) lacking the predicted
periplasmic leader sequence (amino acids 1–22) was cloned
into the pMCSG7 (36) plasmid to enable expression in the bac-
terial cytoplasm. This expression construct was alsomutated to
the A. baumannii (SDF strain) DsbA using the QuikChange"
(Agilent) procedure. These two natural DsbA variants differ by
a single amino acid at the CXXC catalytic motif (CPHC in AYE
strain and CPLC in SDF strain).
AbDsbA proteins were expressed in BL21(DE3) cells using
autoinduction (37). Cell pellets were resuspended in 50 mM
Tris, pH 8.0, 100 mM NaCl and lysed in a Cell Disruptor (TS-
Series, Constant Systems LTD.). Cell debris was removed by
centrifugation. The supernatant was loaded onto Talon resin
(Clontech), packed in a disposable gravity column, and equili-
brated with 50 mM Tris, pH 8.0, 100 mM NaCl. Unbound pro-
teins were removed with washing buffer (50 mM Tris, pH 8.0,
100 mM NaCl, 10% glucose, and 10% sucrose). Elution was
achieved using wash buffer containing 300mM imidazole. SDS-
PAGE analysis of eluent fractions revealed that AbDsbA co-
eluted with a second protein, identified as E. coli EF-Tu using
mass spectrometry analysis (see below). The His6 affinity tag
was removed by tobacco etch virus protease, leaving three vec-
tor-borne residues (Ser-Asn-Ala) at theN terminus ofAbDsbA.
The AbDsbA!EF-Tu complex was further purified using a
Superdex S200 gel-filtration column (GEHealthcare). For puri-
fication of AbDsbA free from EF-Tu, the above procedure was
modified to a batch purification step with Talon resin and
repeated high salt wash (50 mM Tris, pH 8.0, 1.0 M NaCl).
EcDsbA and E. coli membrane extracts containing overex-
pressed E. coliDsbB (EcDsbB) were prepared as described pre-
viously (38) and resuspended in phosphate-buffered saline con-
taining 10% glycerol.
Protein Identification by Mass Spectrometry—Coomassie-
stained bands corresponding to AbDsbA (21 kDa) and a !40-
kDa endogenous E. coli protein were cut from SDS-PAGE and
subjected to in-gel tryptic digestion as described previously
(39). The extracted peptides were applied to the MALDI target
plate with "-cyano-4-hydroxycinnamic acid matrix. MS spec-
tra were recorded in positive reflector mode at a laser energy of
3200 using a 4700 Proteomics Analyzer MALDI TOF-TOF
(Applied Biosystems, CA). AllMS/MS data from the TOF-TOF
were acquired using the default positive ion, 1-kV collision
energy, at a laser energy of 4400. Thirteen dominant species
from the MALDI-MS data for the E. coli protein were queried
against the SwissProt E. coli database with a tolerance of 0.2 Da
using the MASCOT Peptide Mass Fingerprint server (Matrix
Science). The top hit from the search indicated that the
unknown protein was EF-Tu. In addition, MALDI TOF-TOF
data were used to identify a 2117.2 m/z species as the peptide
AIDKPFLLPIEDVFSISGR, an EF-Tu tryptic peptide. The band
corresponding to 21 kDa was confirmed as AbDsbA by com-
parison of the MALDI-MS species detected in its tryptic digest
with those expected to arise from the tryptic digestion of
AbDsbA.
Crystallization and Structure Determination—AbDsbA!EF-Tu
complex crystals were grown at 20 °C by setting drops with 250
nl of protein solution (10 mg/ml in 25 mM HEPES, pH 7.4, and
100 mMNaCl) and 250 nl of precipitant solution (200–300 mM
KCl and 4.5–6% PEG 3350) using a Mosquito robot (TTP
Labtech) at the University of Queensland Remote Operation
Crystallization and X-ray (ROCX) diffraction facility. Crystals
were cryoprotected (in 250mMKCl, 30mMHEPES, pH7.4, 15%
PEG3350, and 25% glycerol) and flash-frozen in liquid nitrogen.
Diffraction data from the cryo-cooled crystal were collected at
the Australian Synchrotron MX2 beamline with an ADSC
Quantum 315r detector controlled by BLU-ICE (40). Reflec-
tions were indexed and integrated in XDS (41), analyzed in
6 The abbreviations used are: AbDsbA, A. baumannii DsbA; EcDsbB; E. coli
DsbB; Bis-Tris, 2-[bis(2-hydroxyethyl)amino]-2-(hydroxymethyl)propane-
1,3-diol; ITC, isothermal titration calorimetry; EF-Tu, elongation factor Tu;
EcEF-Tu, E. coli EF-Tu; AbEF-Tu, A. baumannii EF-Tu.
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Pointless (42), and scaled in SCALA (42) from the CCP4 suite
(43).
Cell content analysis indicated one copy of AbDsbA!EF-Tu
complex in the crystallographic asymmetric unit. Molecular
replacement using E. coli EF-Tu (PDB ID 1EFC), truncated into
its three individual domains, yielded a solution in PHASER (44).
The initial electron densitymap after Phenix refinement guided
the location ofAbDsbAand allowed tracing 33%of theAbDsbA
sequence (59 of 178 residues). Iterativemanual rebuilding, den-
sity modification, and refinement in PHENIX (45) and COOT
(46) permitted tracing the entire AbDsbA sequence. Density
corresponding to bound diphosphate nucleoside (GDP) and
Mg2!wasmodeled in the guanosine binding domain of EF-Tu.
The first seven residues of EF-Tu and the last residue of
AbDsbA were not modeled due to a lack of electron density in
these regions. The final R-factor/R-free was 17.2%/21.5%. Data
processing and refinement statistics are provided in Table 1.
The coordinates and structure factors have been deposited to
the Protein Data Bank and assigned the identifier 4P3Y.
Molecular Modeling—Molecular figures were prepared
using PyMOL Molecular Graphics System, Version 1.6
Schro¨dinger, LLC. Electrostatic surface potential calculations
were carried out in APBS (47). Interaction analysis of the inter-
face residues and the buried surface areawere determinedusing
PISA (48). Molecular modeling and rotamer analysis were per-
formed using Coot model building tools (46), and geometry
idealization was carried out in Phenix.pdbtools (45). Mem-
brane protein topology was analyzed in TOPSCON (49).
EcDsbA Complementation—A chimera gene encoding for a
mature AbDsbA with an E. coli DsbA signal peptide or a wild-
type EcDsbA was cloned under an arabinose-inducible pro-
moter in the pBAD33 plasmid (50). DsbA null E. coli cells
(JCB817; Ref. 51) harboring the EcDsbA/pBAD33 or AbDsbA/
pBAD33 plasmid were spotted onto a soft M63 minimal agar
plate containing 40 mg/ml concentrations of each amino acid
(except L-cysteine) and 0.1% arabinose. Cell swarming was ana-
lyzed after incubating the plates for 4–5 h at 30 °C. The exper-
iment was repeated two times, and the agar plates were
photographed.
Determination of Standard Redox Potential—Oxidized
AbDsbA (2 !M) in degassed 100 mM phosphate buffer, pH 7.0,
containing 1mM EDTA and 1mM oxidized glutathione (GSSG)
was incubated with a range of reduced glutathione (GSH) con-
centrations (0.01 !M–1 mM) for 24 h at 25 °C. AbDsbA was
precipitated with 10% trichloroacetic acid, and the pellet was
washedwith 100% ice-cold acetone. Free thiols in AbDsbawere
labeled with 4 mM 4-acetamido-4"-maleimidylstilbene-2–2"-
disulfonate in 50 mM Tris, pH 7.0, and 1% SDS. Reduced and
oxidized forms of AbDsbA were separated on a NuPAGE 12%
Bis-Tris gel (Invitrogen) and stained with Coomassie. Intensi-
ties of the reduced proteinwere analyzed using ImageJ (Version
1.44) (52). The fraction of the reduced protein was plotted
against the ratio of [GSH]2/[GSSG], and the equilibrium con-
stantKeqwas calculated using a binding equation,Z# ([GSH]2/
[GSSH])/(Keq ! ([GSH]2/[GSSH])), where Z is the fraction of
reduced protein at equilibrium. The redox potential was calcu-
lated using the Nernst equation: E0" # EGSH/GSSG0" $ (RT/nF)ln
Keq, where EGSH/GSSG0" is the standard potential of $240 mV
(53), R is the universal gas constant 8.314 JK$1mol$1, T is the
absolute temperature in K, n is the number of electrons trans-
ferred, F is the Faraday constant 9.648% 104 Cmol$1, andKeq is
the equilibrium constant. The redox equilibria measurements
were repeated two times, and the resulting mean values are
plotted including S.D. for each measurement.
Disulfide Reductase Assay—Insulin turbidity as a result of
disulfide bond reduction was monitored using a spectropho-
tometer at 650 nm for 60 min (54). The reaction mixture con-
tained 131!M insulin, 10!MAbDsbA or EcDsbA or EcDsbC in
100mMphosphate buffer, pH 7.0, containing 0.33mMDTTand
2 mM EDTA. The mean values obtained for each data point
from three repeats are plotted, and the standard deviations are
displayed as error bars.
Cysteine Thiol Oxidation Assay—Labeled synthetic peptide
substrate (CQQGFDGTQNSCK) with a europium DOTA
(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) at
the N terminus and a methylcoumarin at the C-terminal lysine
side chain was prepared as previously described (55). The assay
was performed in a 50-!l reaction volume in the presence of 2
mM oxidized glutathione or 1.6 !M membrane-solubilized
E. coli DsbB (EcDsbB) in a 384-well plate (PerkinElmer Life
Sciences OptiPlate). The reaction mixture contained 50 mM
MES, pH 5.5, 50 mM NaCl, 2 mM EDTA, and 80 or 120 nM
AbDsbAorAbDsbA!EF-Tu complex. Disulfide bond formation
of the peptide (7!M), which was added at the end to initiate the
reaction, was followed using time-resolved fluorescence with
excitation at 340 nmand emission at 615 nm,with a delay of 150
TABLE 1
Data collection and refinement statistics
Statistics for the highest resolution shell are shown in parentheses. The 100th Mol-
probity (85) percentile is the best among the structures of comparable resolution.
The percentile (bracket) and the number of structures included in the comparison
(N) are given in parentheses within bracket. The two Ramachandran outliers, resi-
dues Asp-142 and Arg-333, were also observed in the previous EF-Tu structure
(PDB ID 1EFC).
Data collection
Wavelength (Å) 0.9537
Resolution range (Å) 74.32–2.15
Higher resolution shell (Å) 2.27-2.15
Space group P 21 21 21
Unit cell
a, b, c (Å) 74.3, 78.2, 122.8
", #, $ (°) 90, 90, 90
Total reflections 140,846
Unique reflections 39,200 (5,568)
Multiplicity 3.6 (3.6)
Completeness (%) 99.4 (98.2)
Mean I/ %(I) 13.7 (2.5)
R-merge 0.065 (0.596)
R-pim 0.040 (0.366)
Refinement statistics
R-work (%) 17.2 (24.0)
R-free (%) 21.5 (28.0)
No. of non-H atoms
Protein 4,454
Ligands 35
Water 245
Protein residues 567
Root mean square bond lengths (Å) 0.008
Root mean square bond angles (°) 1.12
Ramachandran
Favored (%) 97.0
Outliers (%) 0.3
Average B-factor (Å2) 46.3
Wilson B-factor (Å2) 36.1
Molprobity
Clashscore (percentile) 2.0 [100th (483)]
Score (percentile) 1.16 [100th (10,544)]
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!s and reading time of 100!s in a Synergy H1multimode plate
reader (Biotek) as described before (56). The reaction in the
absence of enzyme served as the control. The mean values
obtained from three repeat experiments were plotted, and the
S.E. are shown for each data point unless otherwise indicated.
Isothermal Titration Calorimetry (ITC)—Synthetic peptides
were purchased from Genicbio Ltd. Peptides were dissolved in
25 mM HEPES, pH 7.4, 100 mM NaCl (ITC buffer) to obtain 4
mM stock solutions, which were flash-frozen and stored at
!80 °C. The isothermal titration experiments were performed
using either a MicrocalTm ITC200 or an autoITC200 (GE
Healthcare). The syringewas loadedwith titrant peptide at con-
centrations of 2 or 4 mM (DsbB P2 peptide) or 200 !M (EF-Tu
switch I peptide). The sample cell was loaded with oxidized
AbDsbA with concentrations of 100 !M (for titrations with
DsbB P2 peptide) or oxidized/reduced/mixed AbDsbA of 10
!M (for titrations with EF-Tu switch I peptide) in ITC buffer.
To assess whether EF-Tu switch I peptide competes for the
DsbB P2 peptide binding site, 100 !M oxidized AbDsbA was
incubated with 125 !M EF-Tu switch I peptide for 60 min in
ITC buffer before titration with DsbB P2 peptide at 2 mM con-
centration as described above. Titrations were executed at
25 °C using 19 titrations of 2!l each separated by 180 s and at a
constant stirring speed of 1000 rpm. A pre-injection of 0.5 !l
was performed to limit slow diffusion of titrant into the cell
before the titration, and the corresponding data point was
removed from subsequent analysis. Thermodynamic parame-
ters were obtained from non-linear curve fitting with the
MicroCalTMOrigin software (Version 7.0552) using a 1:1 bind-
ing model. Each titration experiment was repeated twice, and
the resulting mean and standard deviations are tabulated.
RESULTS
AbDsbA Exhibits the Typical Characteristics of a Dithiol
Oxidase—A. baumannii exhibits extensive genetic variation
even among closely related strains due to gene transfer, mobi-
lization of insertion sequences, recombination, gene loss, and
mutation (57). Nevertheless, DsbA is highly conserved with
sequence identities of "99% among 122 A. baumannii strains
analyzed using BLAST against the Uniprot AcinetobacterKnowl-
edgebase. One prominent variation in AbDsbA sequences is
located in the active site CXXC motif of an avirulent (SDF)
strain. Specifically, the active site motif 34CPHC37 in virulent
AYE strain (AbDsbAH36) is substituted for 34CPLC37 in the SDF
strain (AbDsbAL36). Because variations in the active site motif
can directly influence redox potential and disulfide-bond form-
ing activity of DsbA enzymes (58, 59), we measured the redox
potentials of both AbDsbA natural variants (Fig. 1, A and B).
We found that the redox potential of AbDsbAH36 is more oxi-
dizing (!101" 1.4 mV) than that of AbDsbAL36 redox poten-
tial (!134 mV" 1.2 mV), comparable to the reported value of
!94mV forP. aeruginosaDsbA (PaDsbA) (60). Conversely, the
redox potential of AbDsbAL36 was more similar to the Entero-
bacteriaceae DsbAs (!116 to!129 mV) (61).
Recombinant expression of a DsbA can rescue themotility of
DsbA null E. coli cells because DsbAs typically have a broad
protein substrate specificity (62, 63). However, we found that
FIGURE 1.Oxidoreductase properties of AbDsbA.A and B, Redox equilibriawith glutathione at pH 7.0 and 25 °C for AbDsbAH36 andAbDsbAL36, respectively.
AbDsbAwas equilibratedwith redox buffer containing various ratios of glutathione to glutathione disulfide. The fraction of reducedDsbAwas fit to a one-site
binding equation using a non-linear regression method to obtain the equilibrium constant Keq as described under “Experimental Procedures.” C, in vivo
disulfide oxidase activity. The ability of DsbA to recognize EcDsbB and EcDsbA substrates was assessed in vivo using non-motile dsbA null E. coli (72). A
representative agar plate shows that expression of AbDsbA (right panel) weakly restores motility of dsbA null E. coli compared with the control EcDsbA (left
panel). The motility zone, indicated by the white bar, was imaged 7 h after inoculating with#2$ 106 cells. In vitro dithiol oxidase activity in the presence of
EcDsbB (D) or oxidized glutathione (E) is shown. Fluorescence increase as a consequence of disulfide bond formation in peptide substrate is monitored. F,
disulfide reductase activity. Enzyme catalyzed or DTT-mediated disulfide reduction causes insulin precipitation, whichwasmonitored spectrophotometrically
at 650nm.Ameanof two (panels A andB) or three (panelsD–F)measurements for eachdatapoint are shown. Error bars indicate theS.D. (A,B, and F) or S.E. (D–E).
Filled circle; AbDsbAH33; empty circle, AbDsbAL33; diamond, EcDsbA; star, EcDsbC; cross, control in the absence of DsbA/DsbC.
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AbDsbA only weakly restores the motility of E. coli DsbA-null
cells in the cell-swarming assay (Fig. 1C).
To assess whether AbDsbA has in vitro disulfide bond-
forming activity, we used a time-resolved fluorescence assay
using a substrate peptide labeled with a europium chelate and a
coumarin donor (see “Experimental Procedures.”). In the pres-
ence of EcDsbB as a source of DsbA oxidant, we found that
AbDsbA enzymes were only marginally active compared with
EcDsbA (Fig. 1D). However, using oxidized glutathione as the
DsbA oxidant (Fig. 1E), we found that AbDsbAL36 and EcDsbA
dithiol oxidase had comparable activity and that AbDsbAH36
was more active again, under the same conditions. These
results suggest that AbDsbA is an oxidase, but it does not inter-
act with EcDsbB.
We then assessed for the ability of AbDsbA to catalyze disul-
fide reduction using insulin as the general substrate in the pres-
ence of dithiothreitol as a mild reducing agent (51). In this
experiment AbDsbAL36 reduced the intermolecular disulfide
bonds of insulinmore rapidly than AbDsbAH36 butmuchmore
slowly than the dedicated disulfide isomerase EcDsbC (Fig. 1F).
The results of these experiments demonstrated that both
variants of AbDsbA are bona fide dithiol oxidases. The data also
indicated that the interaction surface for DsbBmay be different
from that of EcDsbA. The lack of AbDsbA interaction with
EcDsbB was somewhat surprising given that PaDsbA, which
shares 44% sequence identity to AbDsbA, does interact with
EcDsbB (60). However, AbDsbA has a calculated pI of 9.5 com-
pared with 5.8 for PaDsbA, and this may contribute to differing
interaction propensities.
AbDsbA Directly Interacts with EF-Tu—Recombinant His-
tagged AbDsbA (AbDsbAH36, hereafter referred to as AbDsbA,
for simplicity) expressed in the cytoplasm of E. coli and purified
by His-affinity chromatography consistently co-purified with a
40-kDa contaminant thatwe identified as an endogenousE. coli
protein (Fig. 2A). Binding of the E. coli protein by His-immobi-
lized AbDsbA was unchanged up to 1.1 M NaCl or 0.5% v/v
Triton X-100. Even after metal affinity purification, AbDsbA
and the E. coli protein co-eluted as a major fraction in size
exclusion chromatography (Fig. 2B). Analysis of samples in
SDS-PAGE run under non-reducing conditions indicated that
the interaction between AbDsbA and EF-Tu was not thiol-me-
diated (Fig. 2A). Using in-gel digestion and mass spectrometric
analysis, we identified the co-eluant as the E. coli elongation
factor Tu (EF-Tu). Notably, the dithiol oxidase activity of the
AbDsbA!EF-Tu 1:1 complex was reduced by !2/3 compared
with the activity of AbDsbA alone (Fig. 2C).
Structure of the AbDsbA!EF-Tu!GDPComplex—To elucidate
the structural basis for the recognition of EF-TubyAbDsbA,we
determined the structure of AbDsbA!EF-Tu complex. Before
crystallization the protein complex was purified by size exclu-
sion chromatography. The crystal structure of the complex was
phased by molecular replacement using the coordinates of
E. coli EF-Tu (PDB ID 1EFC) as the search model (Fig. 3A) and
refined to 2.15 Å resolution.
The crystal structure revealed a 1:1 complex and showed that
EF-Tu is captured in its guanosine diphosphate (GDP)-bound
state (Fig. 3, A and E). EF-Tu!GDP folds into three distinct
domains: the N-terminal guanine nucleotide binding catalytic
domain (Domain 1, also known as the G domain) connected
to 7-stranded and 6-stranded !-barrel domains (Domains 2
and 3). The global architecture of EF-Tu!GDP in complex
with AbDsbA is similar to that of the previously reported
EF-Tu!GDP structure except for a minor movement of
Domains 2 and 3 and a major local conformational rear-
rangement in the catalytic Domain 1 (Fig. 3, B–C).
Previous structural studies showed that the EF-Tu catalytic
domain can undergo nucleotide-dependent rearrangements
primarily involving two flexible regions, known as switch I (res-
idues 51–65) and switch II (residues 84–100). In the GTP-
FIGURE 2. EF-Tu forms a stable non-covalent interactionwith AbDsbA. A,
His-tagged AbDsbA is co-purified with an endogenous !40-kDa E. coli pro-
tein. Elution fraction pretreated with DTT (") or without (#) pretreatment
was analyzed by SDS-PAGE and stained with Coomassie Blue. B, a major pro-
portion of AbDsbA co-elutes with EF-Tu in size-exclusion chromatography.
FPLC chromatogram shows the analysis of elution fractions from His affinity
purification on superdex200 10/300 GL column.mAU, milliabsorbance units.
C, in vitro dithiol oxidase activity of AbDsbA!EF-Tu complex in the presence of
oxidized glutathione. Fluorescence measurement of the dithiol activity of
AbDsbA or AbDsbA!EcEF-Tu 1:1 complex (120 nM) was performed as
described under “Experimental Procedures.” Error bars indicate the S.E. of 10
repeats.
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bound form, switch I forms an !-helix (PDB ID 1OB2), which
rearranges in the GDP-bound form to a "-hairpin (PDB ID
1EFC; Ref. 64) or a disordered segment (PDB ID 1EFU; Ref. 65).
The switch II helix alters both its orientation and length
between these two nucleotide binding states. In contrast, in the
present complex, switch I binds to AbDsbA in an extended
conformation (Fig. 3, B and D), whereas the switch II confor-
mation and the GDP binding mode are as described previously
for EF-Tu!GDP (PDB ID 1EFC; Ref. 64).
In this complex with EF-Tu, AbDsbA adopts the canonical
DsbA fold comprising a non-contiguous thioredoxin foldwith a
helical domain insertion (Fig. 4A). The AbDsbA structure is
similar to that of PaDsbA with a root mean square deviation of
1.28 Å for 164 C! atoms. The structure encompasses a five-
stranded mixed "-sheet surrounded by 7 helices (H1-H7) with
the crucial CXXC motif located at the N terminus of helix H1.
Structural comparison of AbDsbA and PaDsbA shows that the
catalytic residues formed by the CXXC (34CPHC37) motif and
the adjacent essential cis-Pro motif (Val150–Pro151) are identi-
cal (Fig. 4B). In AbDsbA, the distance between sulfur atoms of
the first and the second of the two active site cysteinesmeasures
3.6 Å, which falls within the range observed in other reduced
DsbA structures (3.3–3.8 Å). The interatomic distances of key
atoms of the active site residues of AbDsbA are similar to those
of PaDsbA, suggesting that EF-Tu binding does not induce
changes at the AbDsbA active site. Catalytic residues of DsbA
enzymes are surrounded by three surface loops (Fig. 4A): the
"3-H2 connecting loop (L1), the H6-"4 connecting loop (L2,
the well characterized cis-Pro loop), and the "5-H7 connecting
loop (L3). In E. coli DsbA these three loops create a catalytic
surface targeted by substrate and partner proteins (63, 66, 67).
In the present structure, however, the switch I-mediated EF-Tu
interaction does not engage the catalytic surface but instead
interacts with the solvent-exposed non-catalytic surface of
AbDsbA (see below).
The Positively Charged Non-catalytic Surface of AbDsbA
Engages EF-Tu—We previously identified two DsbA classes
based on the topological arrangements of strand "1: class I
DsbA (3–2-4–5-1) and class II DsbA (1–3-2–4-5) (61).
AbDsbA falls into the class I topology, with "1 forming hydro-
gen bonds to"5, creating a"-sheet topology of 3–2-4–5-1. The
structural consequence of the class I DsbA topology (Fig. 4C) is
the formation of a large groove between the thioredoxin and
helical domains on the non-catalytic surface. This groove is
truncated in the class II DsbAs in which "1 interacts with "3.
The surface shape and electrostatic features of the non-cat-
alytic surface groove are variable among class I DsbAmembers
(Fig. 4, D–G). In AbDsbA, the non-catalytic surface groove has
a distinct positive electrostatic potential, and it is this region
that is engaged by the EF-Tu switch I segment (Fig. 4G).
FIGURE 3. Switch I region of EF-Tu binds to AbDsbA. A, crystal structure reveals AbDsbA!EF-Tu forms 1:1 complex. EF-Tu is comprised of three domains with
GDP (orange sphere) andMg2! (gray sphere) binding to its guanosine bindingDomain 1. AbDsbA is shown inmediumblue. B, EF-Tu undergoes conformational
changes in associationwithAbDsbA. Structural superpositionofGDP-bound states of EF-Tu (blue) in complexwithAbDsbAandpreviously reported EF-Tu (red,
PDB ID 1EFC) is shown. EF-Tu alignment relative toDomain 1 showsmovements in Domains 2 and 3. Conformations of switch I and switch II regions are shown
in different color shades (Switch I: yellow, AbDsbA!EF-Tu; green, EF-Tu; Switch II: black, AbDsbA!EF-Tu; white, EF-Tu). C, minimal conformational change within
EF-Tu domain 2 and 3. Shown is the comparison of domain 2–3 of EF-Tu in the complex structure (blue) with previous EF-Tu structure (red). 2mFo" DFcmaps
are displayed at 1.0 # contour around switch I segment (cyan) (D) and GDP!Mg2! (E).
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Analysis of the interactions between the two proteins
shows that the EF-Tu switch I segment (residues 47–56) adopts
an extended conformation, occupying the groove between
H1-to-!3 and H3 on the non-catalytic surface of AbDsbA (Fig.
5A). The C terminus of switch I (residues 51–56) forms exten-
sive hydrogen bonds and electrostatic interactions with four
basic residues (Arg-56, Arg-59, Arg-84, Lys-85) and a polar res-
idue (Gln-45) of AbDsbA (Fig. 5B). Asp-51 at the center of the
EF-Tu switch I segment makes contact with five AbDsbA resi-
dues in the groove. In addition, EF-Tu residues Phe-47, Gln-49,
Ala-53, and Pro-54 form van der Waals contact with Leu-48,
Ile-51, His-88, Leu-89, Pro-90, and His-93 of AbDsbA. These
polar and hydrophobic interactions bury 40% (683 Å2) of the
solvent-accessible surface area of the EF-Tu switch I segment
(residues 47–56).
On the basis of this structurally characterized interaction, we
designed an 11-residue peptide derived from the E. coli EF-Tu
switch I sequence and assessed its binding to AbDsbA using
ITC. The binding study showed that the switch I peptide seg-
ment (46AFDQIDAPEE56) binds to AbDsbA with an affinity
range of 74–162 nM (Table 2). Binding of the switch I peptide is
unaffected by the redox status of AbDsbA. In contrast, we did
not detect binding of this same switch I peptide to EcDsbA
under the same conditions.
We also investigated whether EF-Tu from A. baumannii
(AbEF-Tu)might interact withAbDsbA. Sequence comparison
of switch I of E. coli EF-Tu with that of AbEF-Tu showed that
the two sequences are similar but not identical (Table 2). Posi-
tions 1 and 3 of EcEF-Tu switch I are not conserved in AbEF-
Tu, but neither of these residues interacts with AbDsbA in the
FIGURE 4.AbDsbA and other DsbA I enzymes have a large groove on the non-catalytic surface. A, structural overlay of AbDsbA (blue/violet) and PaDsbA
(gold/green). DsbA contains a TRX-domain (bottom) and a helical domain (top) with the domains identified by different colors. Secondary structural elements
are annotated, and the catalytic cysteines are shownasgreen spheres. B, structural superposition of catalytic sites of AbDsbAandPaDsbA.C, AbDsbA shares the
same!-sheet topology (3–2-4–5-1) as theDsbA I enzymes (61). The switch I peptide segment of EF-Tu binds to the non-catalytic surface groove created at the
interdomain space of AbDsbA. D–G, the non-catalytic groove on the DsbA I enzymes has a charged surface. Electrostatic surface potentials of B. pseudomallei
DsbA (D), EcDsbA (E), PaDsbA (F), andAbDsbA (G) are contouredbetween!6.0 (red) and"6.0 (blue) kT/e. The shapeof thenon-catalytic surfacegroove (located
on the surface opposite to the catalytic site) and the electrostatic potential was not conserved among DsbA I enzymes. The switch I peptide segment of EF-Tu
binds to the positively charged non-catalytic surface groove of AbDsbA.NeisseriameningitidisDsbA3 (PDB ID 3DVX) is the only other structurally characterized
DsbA that has a positive potential in this region.
Peptide Interaction Sites of a Class I DsbA Enzyme
JULY 18, 2014•VOLUME 289•NUMBER 29 JOURNAL OF BIOLOGICAL CHEMISTRY 19875
 at Univ of Queensland (CAUL) on July 24, 2014
http://www.jbc.org/
Downloaded from 
APPENDIX A 
 
 199  
crystal structure (Fig. 5).However, Asn at position 7 of EcEF-Tu
does interact with Gln-45 of AbDsbA, and this residue is
replaced by Ser in AbEF-Tu. Side-chain modeling suggested
that substitution of Asn for Ser at position 7 should maintain
the hydrogen bond interaction with Gln-45 of AbDsbA. As
expected, the switch I peptide of AbEF-Tu did bind toAbDsbA,
although with a 3-fold reduced affinity of !500 nM compared
with the EcEF-Tu peptide (Table 2). Removal of the 3 residues
at the N terminus of the AbEF-Tu switch I peptide reduced
binding by a further !3.5-fold, suggesting that the interaction
of Phe/Tyr at position 2withHis93 ofAbDsbA is very favorable.
AbDsbA Binds a Peptide Derived from AbDsbB—Dithiol oxi-
dase activity of AbDsbA relies on interaction with the redox
cycling enzyme DsbB (Fig. 1, D–E). Structural studies of
EcDsbA!EcDsbB complex revealed that a transient interaction
between the cysteine-containing second periplasmic loop (P2)
of the 4-helix bundle protein EcDsbB and the surface surround-
ing the catalytic cysteine of EcDsbA is responsible formaintain-
ing EcDsbA in a functionally active oxidized state. The interac-
tion of EcDsbAwith EcDsbB is mediated in part by three loops,
L1, L2, and L3, that define the catalytic surface. In AbDsbA, the
L1 loop comprises five residues and is conformationally similar
to that of P. aeruginosa DsbA (Fig. 4A), whereas the L3 loop is
much shorter in AbDsbA, formed from just 3 residues (Gln162–
Gly163–Glu164). As a consequence, AbDsbA has small discon-
tinuous pockets (!50 Å3) on the catalytic surface between the
cis-Pro loop (L2) and L3 as opposed to a large continuous
groove found in this region in EcDsbA.
The A. baumannii genome encodes for a protein homolo-
gous to EcDsbB (25% sequence identity, Uniprot: B0V9V0).
The high secondary structural similarity of the predicted trans-
membrane helical regions suggested that the putative AbDsbB
retains the same four-helix topology as EcDsbB with two loops
pointing into the periplasm.
FIGURE 5. Analysis of the interaction between EF-Tu and AbDsbA. A, location of the bound EF-Tu switch I region on the non-catalytic surface of AbDsbA.
Both the EF-Tu switch I residues (Phe-47–Glu-56) and the ADsbA residues (on H1, H3, "3, and the connecting loop between H1 and "3) contributing to the
interaction are shown as sticks. B, details of EF-Tu switch I interaction with AbDsbA. The C terminus of EF-Tu switch I (green, Asp-51–Glu-56) forms the key
hydrophilic and electrostatic interactions with AbDsbA. EF-Tu residues are labeled in blue; AbDsbA residues are labeled in black (hydrophobic interaction) or
red (polar interaction). Interactions of the cis-Pro loop of E. coliDsbAwith the P2 loop of E. coliDsbB (C) and similar interactions observed at the AbDsbA cis-Pro
loop with a symmetry-relatedmolecule of EF-Tu (domain 2) in the crystal structure (D) are shown. Potential hydrogen-bond interactions are shown as dashed
lines. Cysteine thiols are shown as green spheres.
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In the structure of the EcDsbA!EcDsbB complex, Cys-104
from the EcDsbB P2 loop segment (98PSPFATCDFM107) forms
a mixed disulfide bond with catalytic residue Cys-30 of
EcDsbA, and other residues form hydrophobic interactions
and three hydrogen bonds with the cis-Pro loop (Fig. 5C).
The corresponding P2 loop of AbDsbB comprises residues
95PDQVPSCGPG104.
Analyzing the crystallographic packing interface of the
AbDsbA!EcEF-Tu complex showed that residues 262RKLLD266
of a neighboring EF-Tu domain 2 interact with the catalytic
surface of AbDsbA, placing the EF-Tu Leu-264! side chain very
close to the catalytic cysteine of AbDsbA (3.8 Å from Cys-34
S!). Hydrogen bond interactions are formed between EF-Tu
Leu-264! and Asp-266! and the AbDsbA cis-Pro loop in a man-
ner similar to that observed between the EcDsbA cis-Pro loop
and the P2 loop of the EcDsbA!DsbB crystal structure (Fig. 5D).
Modeling theAbDsbB P2 loop segment onto the observed crys-
tal structure conformation of EF-TuRKLLD residues suggested
that 7–8 AbDsbB residues could bind to the catalytic surface of
AbDsbA. On the basis of this molecular model, we designed a
heptapeptide (PSCGPGL) from the AbDsbB P2 sequence and
showed that it bound to AbDsbA with a KD of 7.9 "M (Table 2).
Similar to a previous study (56), binding of the AbDsbB peptide
is cysteine-dependent in that substitution of Cys for Leu in
the peptide eliminated binding. Importantly, binding of the
AbDsbB P2 peptide to AbDsbA is independent of EF-Tu pep-
tide binding, supporting the notion that EF-Tu and AbDsbB
bind to AbDsbA at distinct sites (Table 2).
DISCUSSION
Multidrug resistant A. baumannii is emerging as an agent of
serious nosocomial and community-acquired infection (68).
The current economic loss of preventable hospital-acquired
infections ($5.7–6.7 billion) is now comparable to the costs of
stroke ($6.7 billion), diabetes mellitus ($4.5 billion), and
chronic obstructive lung disease ($4.2 billion) in the United
States (69). Anti-virulence therapy is an attractive strategy to
combat rapidly spreading infections caused by multidrug-re-
sistant A. baumannii (28, 70, 71).
Studies from animal models suggested that the absence of
DsbA or DsbB attenuates infection and pathogenesis of Gram-
negative bacteria (23, 24, 73). Because DsbA/B is not essential
for bacterial survival (51) but is required for virulence (17),
DsbA/B is a target for the development of novel anti-virulence
agents against Gram-negative bacteria (17). For example, bio-
film formation is essential for colonization and infection by
A. baumannii (13, 74, 75). Interference with this process by
inhibiting DsbA could impair the ability of bacteria to establish
infection.
Our characterization of AbDsbA showed that it is a member
of the DsbA Ib sub-class, which also includes DsbAs fromNeis-
seria and Pseudomonas (61). Using ITC, we demonstrated that
an AbDsbB-derived peptide binds to AbDsbA via its catalytic
cysteine, supporting the idea that DsbA and DsbB form a func-
tional redox pair in A. baumannii. The absence of an interac-
tion between AbDsbA and EcDsbB suggests that the truncated
catalytic surface of AbDsbAmay engage AbDsbB by a different
binding mode to that described for EcDsbB and EcDsbA.
We also reported the detailed interaction between AbDsbA
and EF-Tu. EF-Tu is highly conserved (85% sequence identity
between AbEF-Tu and EcEF-Tu) and is best known for its cat-
alytic role in the elongation cycle of bacterial protein synthesis.
However, EF-Tu also acts as a response protein in abiotic and
biotic stresses (76, 77), and it has roles in biofilm development
(78) and immunospecific immunity (79). EF-Tu is generally
considered to be a cytoplasmic protein, but there is evidence for
localization on the surface and outermembrane vesicles of bac-
teria (29, 80, 81). It is also a relatively ubiquitous interactor with
other proteins (actin like MreB (33) and fibronectin (32)). The
association between AbDsbA and EF-Tu provides new avenues
for understanding the interaction of EF-Tuwith other proteins;
for example, the Switch I region may interact tightly with cyto-
plasmic proteins that exhibit similarly strong positive surface
TABLE 2
Thermodynamic parameters for peptides derived from EF-Tu or AbDsbB binding to AbDsbA or EeDsbA
KD is apparent dissociation constant, "H is enthalpy change, T is absolute temperature (K), "S is entropy change, N is apparent stoichiometry, and n.b. is no detectable
binding.#T"S is calculated from the free energy equation ("G$"H# T"S$#RT ln KD). The averaged values from two ITC experiments are tabulated with standard
deviation. A. baumannii EF-Tu-derived peptides are differentiated from EcEF-Tu peptides by grey shading. The redox status of AbDsbA used in the titration experiment
is identified by: ox, oxidized; red, reduced; mix, mixed.
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charge. The switch I region is also the binding site for other
proteins including ribosome (82). The PDB entry 4IW3 (yet to
be published) shows the EF-Tu switch I region interacts with
Pseudomonas putida prolyl-4-hydroxylase, although in a some-
what different conformation. Overall, these data suggest that
the switch I region of EF-Tu is a flexible protein interaction
loop.
It is tempting to speculate a physiological/pathological role
for the association between AbDsbA and EF-Tu that might
involve regulation of cell growth in response to nutrient depri-
vation or oxidative stress in the host environment or chaperon-
ing of EF-Tu by AbDsbA. Both AbDsbA and EF-Tu are impor-
tant proteins in their own right, and both have been identified
as antibacterial targets. Although we showed that AbEF-Tu-
derived peptides do bind to AbDsbA, we have no direct evi-
dence for an AbDsbA!AbEF-Tu interaction in A. baumannii.
Consequently, we cannot rule out the possibility that the inter-
action between EcEF-Tu and AbDsbA is simply an artifact.
Nevertheless, the detailed interactions derived from the
AbDsbA!EF-Tu structure provides a potential new approach
for AbDsbA inhibitor development. TheDsbA catalytic surface
is widely accepted as the major target surface for substrate/
partner protein interactions (63, 66, 67). This interaction is
essential for formation of intermediate mixed disulfides with
substrate proteins. However, the non-catalytic surfacemay also
contribute to the folding of substrates or to the interactionwith
as-yet unidentified regulatory proteins.
Members of class I DsbAs all have a large charged non-cata-
lytic surface groove (Fig. 4, D–G). In EcDsbA the equivalent
acidic surface was identified several decades ago as a potential
interaction site (83). The variable molecular landscape and
nature of this surface among DsbAs may reflect the extraordi-
nary variability of substrates (61, 84). The high resolution struc-
ture of the AbDsbA!EcEF-Tu complex supports the idea that
the pronounced non-catalytic surface groove of class I DsbA
enzymes serves as an additional protein interaction site.
Whether or not this is the case remains to be elucidated. Nev-
ertheless, the reduced activity of AbDsbA in the presence of
bound EcEF-Tu suggests compounds designed to target this
non-catalytic site would inhibit AbDsbA enzyme activity.
In summary, we have characterized AbDsbA and identified
two peptides that bind to non-overlapping AbDsbA surfaces.
These distinct peptides provide the starting point for peptide-
based inhibitors targeting AbDsbA activity.
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Structural and Functional Characterization of ScsC,
a Periplasmic Thioredoxin-Like Protein
from Salmonella enterica Serovar Typhimurium
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Abstract
Aims: The prototypical protein disulfide bond (Dsb) formation and protein refolding pathways in the bacterial
periplasm involving Dsb proteins have been most comprehensively defined in Escherichia coli. However,
genomic analysis has revealed several distinct Dsb-like systems in bacteria, including the pathogen Salmonella
enterica serovar Typhimurium. This includes the scsABCD locus, which encodes a system that has been shown
via genetic analysis to confer copper tolerance, but whose biochemical properties at the protein level are not
defined. The aim of this study was to provide functional insights into the soluble ScsC protein through struc-
tural, biochemical, and genetic analyses. Results: Here we describe the structural and biochemical character-
ization of ScsC, the soluble DsbA-like component of this system. Our crystal structure of ScsC reveals a similar
overall fold to DsbA, although the topology of b-sheets and a-helices in the thioredoxin domains differ. The
midpoint reduction potential of the CXXC active site in ScsC was determined to be - 132mV versus normal
hydrogen electrode. The reactive site cysteine has a low pKa, typical of the nucleophilic cysteines found in DsbA-
like proteins. Deletion of scsC from S. Typhimurium elicits sensitivity to copper (II) ions, suggesting a potential
involvement for ScsC in disulfide folding under conditions of copper stress. Innovation and Conclusion: ScsC is
a novel disulfide oxidoreductase involved in protection against copper ion toxicity. Antioxid. Redox Signal. 19,
1494–1506.
Introduction
Thioredoxin (TRX)
2-like proteins are central to the redox
biology of the cell. These proteins catalyze the thiol–
disulfide exchange reactions that are essential for the mainte-
nance of the correct thiol redox state of proteins. Such systems
are of particular importance in the periplasm of pathogenic
bacteria, where disulfide bond (Dsb) formation is essential for
motility, type III secretion systems, and for folding a variety of
toxins and secreted enzymes (24, 52).
The formation of Dsb in the periplasm of most
c-Proteobacteria is facilitated by two processes: (i) oxi-
dative disulfide folding, and (ii) disulfide isomerization.
The most extensively studied example of oxidative dis-
ulfide folding is that of the DsbAB system of Escherichia
coli K-12, where periplasmic thiols are oxidized by the
soluble protein DsbA, and the electrons are shuttled to
the electron transport chain by the membrane-bound
DsbB (4). Misfolded disulfides are then corrected by the
soluble disulfide isomerase DsbC, driven by reducing
1School of Biosciences, University of Kent, Canterbury, United Kingdom.
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power from the integral membrane protein DsbD [re-
viewed in (14)]. However, a wide diversity of oxidizing
machineries exists among bacteria (15), exemplified by
the existence of three functionally distinct DsbA proteins
in Neisseria meningitidis (52).
In addition to the oxidative DsbAB system, S. Typhimur-
ium also encodes an alternative DsbLI redox pair similar to
that of Uropathogenic E. coli (UPEC) strain CFT073 (57), as
well as a plasmid-encoded DsbA-like protein called SrgA (6).
S. Typhimurium DsbA (StDsbA) is required for disulfide
folding of the P-ring flagellar protein FlgI (58), DsbL is likely
to be involved in the assembly of arylsulfate sulfotransferase
(AssT) (18), and SrgA is necessary for the assembly of the
major structural subunit of the plasmid-encoded fimbriae,
PefA (6). In addition to these TRX-like proteins, the scs (sup-
pressor of copper sensitivity) locus of S. Typhimurium en-
codes four proteins with TRX-like CXXC motifs (19). The
expression of all four genes, denoted scsA-D, was shown to
restore tolerance to copper in copper-sensitive mutants of
E. coli, hence the scs nomenclature (19). The ScsA protein was
predicted to be a copper-binding integral membrane complex,
while the ScsB protein was reported to exhibit homology to
several proteins, including the membrane-spanning disulfide
interchange protein DsbD. The ScsC protein was predicted to
be an outer membrane protein involved in disulfide folding,
although work presented herein indicates that ScsC is a sol-
uble periplasmic protein. ScsD was predicted to be a peri-
plasmically located, membrane-anchored, TRX-like protein
with similarities to TlpA of Bradyrhizobium japonicum or
Neisseria gonorrhoeae (1). A recent study in Caulobacter cres-
centus has demonstrated that CcScsB maintains ScsC protein
of C. crescentus (CcScsC) in a reduced form; it therefore ap-
pears that these proteins interact in a similar way to the
DsbC/DsbD system. Reduced CcScsC was then shown to
facilitate disulfide folding of periplasmic RNase I (of C. cres-
centus) and RcsF (an outer membrane protein of E. coliK12) via
an isomerization mechanism (9). CcScsB was also shown to
directly reduce TlpA (TRX-like-protein A), which subse-
quently reduces the peroxiredoxins PprX and PrxL (9). The
CGYC active site motif of CcScsC is identical to that of
EcDsbC (Table 1) and like this E. coli isomerase, CcScsC also
forms a homodimer in solution. However, dimerization in
CsScsC appears to bemediated by a long alpha helix, whereas
the dimerization interface in EcDsbC is formed by b-strand
interactions.
The current work describes the structural and biochemical
characterization of the soluble, periplasmically located,
S. Typhimurium ScsC (StScsC) protein, and provides evi-
dence that the scs cluster has a role in protection against the
toxic effects of redox-active copper (II) ions.
Results
Three-dimensional architecture of ScsC:
ScsC is a soluble TRX-like protein
StScsC was crystallized in the monoclinic space group P21,
the crystals diffracted to 2.04 A˚ and contained four molecules
in the asymmetric unit. The structurewas solved bymolecular
replacement using the TRX-like protein from Silicibacter po-
meroyi (PDB: 3GYK) as a model. After subsequent building
and refinement, the structure of StScsC corresponding to
residues 9–186 of the processed peptide (178 residues) was
refined to a final Rfactor of 19.9 (Rfree = 25.3) (Supplementary
Innovation
Many bacterial pathogens overcome the biocidal ac-
tion of copper during infection. The scsABCD locus of
Salmonella encodes four proteins with thioredoxin-like
motifs that restore tolerance to copper in copper-sensitive
mutants of Escherichia coli. Here we have determined the
structural and biochemical properties of the soluble,
periplasmically located ScsC protein. We also demon-
strate that ScsC contributes to the survival of Salmonella
during conditions of copper stress. Our findings have
implications on the mechanism by which Salmonella cir-
cumvents the toxic effects of redox-active copper (II) ions.
Scs proteins are encoded by several pathogens, suggest-
ing this system may constitute a broad protective
mechanism.
Table 1. Redox Midpoints and pKa Values of Selected Thioredoxin-Like Proteins
Protein Motif Redox midpoint Eo¢ (mV) [Reference] pKa of active cysteine [Reference]
Escherichia coli thioredoxin 1 CGPC - 284 (20) 7.1 (20)
E. coli thioredoxin 2 CGPC - 221 (20) 5.1 (20)
E. coli glutaredoxin 1 CPYC - 233 (3) N/A
E. coli glutaredoxin 3 CPYC - 198 (3) < 5.5 (44)
Salmonella Typhimurium SrgA CPPC - 154 (25) 4.7 (25)
S. Typhimurium ScsC CPYC - 132 [This work] 3.4 [This work]
E. coli DsbG CPYC - 129 (59)
- 126 (5)
3.5 (48)
S. Typhimurium DsbA CPHC - 126 (25) 3.3 (25)
Homo sapiens protein disulfide isomerase CGHCa - 110 (22) 4.5 (35)
E. coli DsbA CPHC - 124 (3)
- 125 [This work]
3.5 (43)
S. Typhimurium DsbL CPFC - 97 (25) 3.8 (25)
E. coli DsbC CGYC - 130 (63) 4.3 (55)
Bacillus subtilis BdbD CPSC - 75 (11) < 4.5 (11)
aHuman protein disulfide isomerase has two CGHC motifs.
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Table S1; Supplementary Data are available online at
www.liebertpub.com/ars). Pairwise comparison of the four
symmetrically independent monomers showed no significant
differences between molecules in the asymmetric unit; all
following structural comparisons were performed with
monomer A.
The architecture of StScsC comprises all structural hall-
marks that characterize canonical thiol oxidases like StDsbA
[PDB: 3L9S (25)]; it consists of a TRX domain (residues 38–75
form the bab motif and residues 141 to 189 form the con-
necting helix and the bba motif) and a long helical insertion
(residues 75–140) (Fig. 1A, B). Despite the overall structural
similarity, superposition of these two proteins is poor with an
r.m.s.d. value of 3.3 A˚ for 128 of the 189 Ca aligned. This poor
match is primarily due to the different topology of StScsC,
where the core b-strands (b2–b5) are structurally equivalent to
those of StDsbA, but the strand b1 is hydrogen bonded to the
opposite edge of the central b-sheet in the TRX domain (Figs.
1B & 2A). Another notable discrepancy between StScsC and
StDsbA resides in the helical domain inserted in the TRX fold.
In StDsbA, this region consists of a three helical bundle (a2–
a4), plus an additional helix (a5) and an extension of the
connecting helix a6, while in StScsC, a deletion in this section
results in the loss of the a5 helix, which is substituted by a
comparatively short loop (Fig. 1A, B). Additionally, super-
position of StScsC with StDsbA (Fig. 2A) highlights a shorter
loop linking b5 to a7 and a shorter a7 helix (by 1.5 turns) in
StScsC compared to StDsbA. Moreover, unlike StDsbA, the
StScsC b5 strand and b5-a7 loop map near the active site, a
position that is stabilized by hydrogen bonds between Ile166
(O and NH) and Thr159 (NH and O) and Gly168 (NH) and cis-
Pro157 (Supplementary Fig. S1). The latter modifications in
StScsC alter the size and shape of the groove adjacent to the
active site, which in prototypical DsbAs is defined as the
hydrophobic peptide-binding groove, which binds to the re-
dox partner DsbB (31). Other minor differences between
StScsC and StDsbA include a less pronounced kink in a1 of
StScsC, and longer loops linking a2, a3, and a4 in StDsbA.
The Dali search (29) identified 3GYK, BdbD (PDB code
3GHA), and DsbG (PDB code 1V58) as the closest structural
homologues to StScsC. 3GYK and StScsC exhibit high struc-
tural similarity (r.m.s.d. value of 1.5 A˚ over 165 Ca aligned);
this protein is a DsbA-like homologue from Silicibacter po-
meroyi although no functional characterization or publication
FIG. 1. Secondary structural elements of ScsC protein of Salmonella Typhimurium (StScsC) and structural homologues.
(A) Structure-based sequence alignment of StScsC, BdbD from Bacillus subtilis (BsBsbD), DsbG from Escherichia coli (EcDsbG),
and DsbA from S. Typhimurium (StDsbA). Cleavage site is depicted by a gray triangle, and conserved active site residues are
highlighted in yellow and green. (B) Three-dimensional structures of StScsC (PDB: 4GXZ), BsBsbD [PDB: 3GHA (11)], the
thioredoxin (TRX) domain of EcDsbG [PDB: 1V58 (23)], and StDsbA [PDB: 3L9S (25)]. The TRX-fold and N-terminus are
shown in tan and black, respectively. Secondary structural features are labeled with the active site sulfur atoms shown as
yellow spheres.
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is available. Structural superposition of StScsC with Bacillus
subtilis DsbA protein BsBdbD (11) (r.m.s.d. value of 2.0 A˚ for
148 Ca aligned) highlights features of StScsC that deviate from
this close structural homologue. For example, although
BsBdbD and StScsC share a similar topology (b1 interacts with
b3 instead of b5), the a5 helix is present in the helical domain
of BsBdbD (Fig. 1B, 2B). Rotation of these structures by 90o
also shows a longer loop connecting BsBdbD a3 and a4, which
protrudes into the catalytic site (Fig. 2B). StScsC also shows
structural similarity with DsbG, a disulfide isomerase from
E. coli (23), which has also been shown to control cysteine
sulfenylation in the oxidizing periplasm (13). EcDsbG is a
homodimer, where each monomer incorporates a dimeriza-
tion domain and a TRX domain linked by a connecting helix.
StScsC superimposes unexpectedlywell with the TRXdomain
of EcDsbG (2.3 A˚ for 134 Ca aligned, Fig. 2C). Furthermore,
the lack of a5 in StScsC appears to emulate the shorter inser-
tion present in this reductase, which only contains two helices
and a long loop embedded in the TRX fold (23).
Analysis of surface electrostatics of StScsC
The electrostatic surface of StScsC partially resembles
that of the thiol oxidase StDsbA, displaying a hydrophobic
peptide-binding groove running along the protein surface
and a hydrophobic patch, both adjacent to the CPYC catalytic
motif (Fig. 3A). However, compared with StDsbA (Fig. 3B),
the hydrophobic groove in StScsC is truncated. Moreover,
next to the hydrophobic patch, StScsC displays a positively
charged ridge above the exposed cysteine, comprising Lys52
on a1, Lys78 on the loop between b3 and a2 and Arg111 in the
a3-a4 loop that overhangs the entrance to the active site cys-
teines (Fig. 3A). This cluster of positive residues surrounding
the catalytic site is likely to stabilize the thiolate form of the
nucleophilic cysteine Cys48. Interestingly, EcDsbG also has a
positively charged ridge above the active site, with Lys139 on
the loop between b3 and a2 directly above the exposed cys-
teine, although not as close as the Lys78 of StScsC. Lys168 (loop
between a3 and a6) and Lys113 (a1) provide the additional
positive charge to the right of Lys139 of EcDsbG (Fig. 3C).
Although BsBdbD is the closest structural homologue for
StScsC, these two proteins are not closely related (24% se-
quence identity), which results in discrepancies in their sur-
face properties. Overall, BsBdbD displays a more acidic
surface, primarily in areas surrounding the catalytic CPSC
motif (Fig. 3A–D). The long loop between a3 and a4 is lined
with negatively charged residues thatmap on top of the active
site (11) (Fig. 3D). Despite their different surface properties,
both StScsC and BdBdbD have acidic patches in the groove
between the TRX and the helical domain, which map at the
opposite side of their active sites, (Fig. 3, right panels). This
acidic patch is conserved in other DsbA homologues although
its exact role remains unclear (40).
The StScsC redox active site
The catalytic active site of StScsC resembles that of the
disulfide isomerase EcDsbG rather than the oxidase StDsbA,
FIG. 2. Superpositions of StScsC and structural homologues. a-carbon trace stereo views of StScsC (black) superposed
with (A) StDsbA (cyan), (B) BsBdbD (blue), and (C) the TRX domain of EcDsbG (orange). a5 indicates the position of the fifth
alpha helix in the inserted helical domain of DsbA-like proteins StDsbA and BsBdbD. Structures in the left panel are in the
same orientation as those in Fig 1B, and in the right panel, all three structures are rotated clockwise 90! around the vertical
axis, highlighting the extended loop between a3 and a4 in BsBdbD (indicated with blue asterisk).
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it consists of a 48CPYC51 motif located at the N-terminus of
helix a1 and a cis-Pro loop (156Thr-157cisPro) in the a6-b4
connecting loop (Fig. 4A). StScsC was crystallized in its re-
duced form, as cleavage of the His-tag with tobacco etch virus
(TEV) protease before crystallization involved incubation
with 1mM dithiothreitol (DTT). As shown in Figure 4B, the
StScsC cysteine sulfur atoms are separated by a distance of 3.2
A˚, which clearly indicates that these residues remained in
their free thiol/thiolate forms upon crystallization. Several
interactions may stabilize the reduced form of this protein; the
nucleophilic N-terminal Cys48 Sc is within hydrogen bond
distance of themain chain nitrogen of the second cysteine (3.5 A˚)
and the side chain hydroxyl of Thr156 (3.5 A˚). Furthermore,
the protruding lysine residue (Lys78) forms a positively
charged lip that overhangs the access route to the Cys48
residue. The close proximity between Lys78 and Cys48 could
promote stabilization of the Cys48 thiolate, following a con-
formational rearrangement in this region; the Cd atom of
Lys78 is 3.9 A˚ away from the Ca atom of Cys48, but the Nf of
Lys78 is 6.6 A˚ from the Sc of Cys48, so a conformational re-
arrangement would be required for this interaction to pro-
vide a significant stabilizing effect (Fig. 4A). The catalytic
sites of BsBdbD and EcDsbG also reveal hydrogen bonds
between the Sc of the first cysteine and two acceptor groups:
the second cysteine mainchain NH and the hydroxyl group
of the Thr preceding the cis-Pro (Fig. 4C). The residues cor-
responding to StScsC Lys78 in BsBdbD and EcDsbG are
His103 and Lys139, respectively. In BsBdbD, the Nd2 of His103
is 4.8 A˚ away from the Sc of Cys69, although a histidine
residue is less likely to be cationic at physiological pH
compared to a lysine residue, and is therefore less able to
stabilize a cysteine thiolate. In EcDsbG, Lys139 generates a
basic patch near the active site, which may also contribute to
stabilizing the thiolate form of the cysteine (Fig. 4C).
Biochemical characterization of StScsC
The biochemical properties of StScsC were characterized to
gain further insights into its potential function. The oxidiz-
ing/reducing power of StScsC was quantified by measuring
the equilibrium constant (Keq) for the disulfide exchange re-
action with glutathione via monitoring changes in NMR
spectra (Fig. 5A). The measured constants for StScsC and
DsbA protein of E. coli (EcDsbA) were 21.7 – 2.6 · 10 - 5 M and
12.9 – 2.1 · 10 - 5 M, respectively. These Keq values convert into
intrinsic redox potential values of - 132mV and - 125mV,
respectively (Table 1). The redox midpoint of our EcDsbA-
positive control is in close agreement with previously mea-
sured values for this protein (3). In addition, control spectra
were recorded for the fully oxidized protein (using 5mM
oxidized glutathione [GSSG]) and for the fully reduced pro-
tein (using 5mMDTT), providing confidence for the choice of
peaks used to monitor the redox transition.
The first of the two cysteines in the CXXCmotif of TRX-like
proteins is a solvent-exposed, reactive nucleophilic cysteine.
This reactivity is partly due to a lower pKa (*3.5–5) compared
with most cysteines (*8.5) (43). The pKa of StScsC was
measured as 3.4 (Fig. 5B), an unusually low value for a CXXC
motif with such reducing power. Indeed, this is comparable to
that of the oxidizing exposed thiol of EcDsbA [pKa= 3.5 (43),
Table 1].
Given the redox potential exhibited by StScsC is similar to
that of disulfide isomerases (Table 1) and its low pKa, which is
also common in highly oxidizing proteins, we investigated the
in vitro oxidoreductase activity using the classic insulin re-
duction assay: most TRX-like oxidoreductases, including
DsbC and DsbA, catalyze DTT-induced insulin reduction.
StScsC catalyzed the reduction of insulin more slowly than
EcDsbA, and showed an activity*71% of the maximal rate of
EcDsbA (Fig. 5C). To further understand the function of
StScsC, we also investigated its ability to catalyze Dsb
FIG. 3. Electrostatic surfaces of StScsC and structural
homologues. Positive (blue), negative (red), and hydropho-
bic (white) surfaces (saturation at 20 kT/e) of (A) ScsC from
S. Typhimurium, (B) DsbA from S. Typhimurium, (C) the
TRX domain of DsbG form E. coli, and (D) BdbD from
B. subtilis. Surface is omitted from the exposed active site
cysteine residues to reveal the S atoms (shown as yellow
spheres). Structures in the left panel are in the same orienta-
tion as those in Fig 1B.
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isomerization using the scrambled RNaseA (scRNaseA) re-
folding assay (27). Under our conditions, StScsC did not show
any activity in this assay (Supplementary Fig. S2). In addition,
to experimentally verify that StScsC is able to perform dis-
ulfide reduction in the native host, the in vivo redox status was
measured using the thiol modification reagent 4-acetamino-4-
acetamido-4¢-maleimidylstilbene-2,2¢-disulfonic acid (AMS)
(Fig. 5D). Alkylation assays clearly indicate that StScsC is
predominantly in the reduced state in the periplasm of
S. Typhimurium.
Loss of StScsC elicits copper sensitivity
in S. Typhimurium
To examine the role of StScsC in S. Typhimurium, we
constructed a scsC mutant in SL1344 (referred to as
SL1344scsC). Loss of StScsC expression in SL1344scsC was
confirmed by Western blot analysis with a StScsC-specific
antibody (data not shown).Wild-type SL1344 and SL1344scsC
were assessed for copper sensitivity using disk diffusion as-
says. In these assays, SL1344scsC displayed enhanced sensi-
tivity to copper, as evidenced by the larger zones of growth
inhibition observed in the presence of copper (Fig. 6A). Re-
introduction of the scs genes on plasmid pScs restored the
wild-type phenotype, confirming a role for StScsC in resis-
tance to copper. To confirm this role for StScsC in S. Typhi-
murium and to more accurately assess the concentration of
copper that inhibited growth of SL1344scsC, wild-type SL1344
and SL1344scsC strains were assessed for copper sensitivity
by spotting a series of 10-fold dilutions of overnight cultures
onto agar plates containing a range of different copper con-
centrations. In these assays, wild-type SL1344 and SL1344scsC
displayed significantly different sensitivity to 2.8mM copper
(Fig. 6B). Reintroduction of the scs genes on plasmid pScs
restored the wild-type phenotype, confirming a role for
StScsC in resistance to copper.
Discussion
The formation of Dsb is an essential process for the correct
folding of many periplasmic and secreted proteins. Bacteria
exhibit a diverse array of disulfide folding machineries (15),
particularly the Gram-negative bacteria, which encode a va-
riety of systems that have evolved to catalyze the oxidative
folding of virulence proteins required for infection (18, 38). A
striking example of this is S. Typhimurium, which in addition
to the oxidative DsbAB system also encodes an alternative
DsbLI disulfide oxidation system similar to that of UPEC
strain CFT073 (18, 57), as well as a plasmid-encoded DsbA-
like protein called SrgA (6). In addition to these TRX-like
proteins, the scs (suppressor of copper sensitivity) locus of
S. Typhimurium encodes four proteins with TRX-like CXXC
FIG. 4. Active site regions of StScsC and structural homologues. (A) Active sites of StScsC showing the catalytic Cys-Pro-
Tyr-Cys motif, the adjacent cisPro loop (Thr156-cisPro157) and the sidechain of Lys78, which protrudes into the solvent to form
a positively charged lip over the active site. The 2Fo-Fc map is also shown contoured at 1.3 r. (B) Close-up view of the StScsC
active site, refined in the reduced form (2Fo-Fc maps contoured at 1.3 r). (C) Active site regions of StScsC, BsBdbD, EcDsbG,
and StDsbA showing the hydrogen bond interactions stabilizing the side chain of the nucleophilic cysteine in each active site.
Hydrogen bonds are depicted by dashed lines.
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motifs (19), including the soluble periplasmic ScsC protein
(sequence prediction programs predict that this protein has a
signal sequence and lacks membrane anchors). Scs proteins
are encoded by a diverse range of bacteria, including the
highly invasive UPEC strain UTI89 (7).
To date, little is known about the specific function of the Scs
additional redox pathway in bacteria. A recent work on the
C. crecentus Scs system showed that the membrane protein
CcScsB and the soluble CcScsC form a redox pair similar to the
DsbC/DsbD system. CcScsB mediates the reduction of di-
meric CsScsC which, in turn, catalyzes the folding of proteins
containingmultiple cysteines via an isomerizationmechanism
(9). StScsC and CcScsC exhibit 24% sequence identity (Sup-
plementary Fig. S3). Notable sequence differences between
these two proteins include a different catalytic motif (CPYC
vs. CGYC), the absence in StScsC of the long CcScsC N-
terminal extension (which appears to mediate dimerization),
and a deletion in CcScsC thirty residues upstream of the
conserved cis-Proline present in these TRX-like proteins. To
gain a better understanding of the Scs machinery in
S. Typhimurium, we pursued a comprehensive structural and
biochemical characterization of StScsC.
FIG. 5. Biochemical characterization of StScsC. (A) Redox equilibria of EcDsbA and StScsC with glutathione. The fraction
of oxidized and reduced EcDsbA and StScsC was determined using NMR spectroscopy and these data were used to calculate
Keq and redox potential (E
o¢) as previously described (42). Keq(StScsC) = 21.7 – 2.6 · 10 - 5 M, Eo¢(StScsC) = - 132mV, Keq(Ds-
bA) = 12.9 – 2.1 · 10 - 5 M, Eo¢(DsbA) = - 125mV. (B) Determination of the pKa of the nucleophilic cysteine in StScsC. The pH
dependence of the thiolate-specific absorbance signal (S = (A240/A280) reduced/(A240/A280) oxidized) was fitted according
to the Henderson–Hasselbalch equation (the oxidized proteins were used as a reference). pKa (StScsC) = 3.38 – 0.03. (C)
Catalyzed reduction of insulin. Reduction of insulin (131lM) was measured in a 0.1 M phosphate buffer, pH 7.0, 2mM
EDTA. The assay was performed in the absence or presence of 10lM StScsC and 10 lM EcDsbA was used as a positive
control. At time zero, DTT was added to each reaction to a final concentration of 0.35mM, and the catalyzed reduction of
insulin was measured as an increase in absorbance at 650 nm. The maximal rates have been fitted using linear regression. (D)
Determination of the in vivo redox state of StScsC. (i) The fully reduced (R) and fully oxidized (O) purified StScsC is shown in
lanes 1 and 2, respectively. (ii) Samples prepared from SL1344. Samples were incubated with 4-acetamino-4-acetamido-4¢-
maleimidylstilbene-2,2¢-disulfonic acid (AMS) or left untreated as indicated. The shift in the migration of StScsC following
treatment with AMS demonstrates it exists in a reduced form in vivo. (iii) Samples prepared from SL1344scsC pScs. Samples
were incubated with AMS or left untreated as indicated. The use of a plasmid containing the scsC gene resulted in increased
expression of StScsC. As observed in the wild-type strain, shift in the migration of StScsC following treatment with AMS
demonstrates it exists in a reduced form in vivo. Lane M on panels A, B, and C correspond to the 30 and 20 kDa bands of the
ladder Novex Sharp protein standard (Life Technologies).
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Structural characterization of StScsC revealed a canonical
TRX domain with an inserted helical domain, characteristic of
disulfide oxidoreductases like StDsbA or EcDsbA (25, 40).
Despite this, StScsC has structural properties intermediate
between DsbA-like thiol oxidases and disulfide isomerases.
Indeed, a Dali search identified a DsbA homologue (BsBdbD)
and an isomerase (EcDsbG) as close structural homologues
for StScsC. Structural comparisons with those homologues
revealed interesting peculiarities of StScsC. For example, a
striking difference between StScsC and archetypal DsbA-like
proteins is that the antiparallel b-strands in the TRX domain
differ with respect to their topological arrangement: the b1
strand forms a b-sheet with b3 rather than b5 (Fig. 1). While
this topology is uncommon in DsbA-like proteins, [only ob-
served in few cases, including Wolbachia pipientis DsbA1
(WpDsbA1 (37)] and BsBdbD), this arrangement is present in
the TRX domain of disulfide isomerases like EcDsbG and
EcDsbC (23, 41). Moreover, a deletion in the helical domain of
StScsC, which is not conserved in its homologue CcScsC (Fig.
S2), results in StScsC lacking a5, one of the four usual alpha
helices present in DsbA-like proteins like StDsbA or BsBdbD.
Thus, the StScsC helical domain is somewhat reminiscent of
the isomerase EcDsbG, which has a helical insertion contain-
ing two helices and a long loop substituting a4 and a5.
StScsC retains some surface features of the canonical
StDsbA or EcDsbA, including a hydrophobic patch, shown to
be important for substrate binding (40, 46), and a compara-
tively small hydrophobic groove under the active site, which
in EcDsbA interacts with the partner protein EcDsbB and is
key for reoxidation (31). The groove truncation in StScsC may
compromise its ability to interact with StDsbB, maintaining
StScsC separate from the S. Typhimurium StDsbA/StDsbB
oxidative pathway. Furthermore, unlike archetypal DsbAs,
the surface of StScsC also incorporates positively charged
residues that generate basic protrusions flanking the 48CPYC51
active site (Fig. 3A). The latter surface properties resemble the
lysines found adjacent to the also conserved 109CPYC112 active
site of EcDsbG (Fig. 3C) and may contribute to stabilizing the
thiolate form of the nucleophilic N-terminal cysteine.
StScsC differs from EcDsbG in that this protein is mono-
meric. Disulfide isomerases, EcDsbC and EcDsbG, contain
extended N-terminal domains that allow dimerization, which
is essential for their isomerase activity (50, 51). StScsC has an
N-terminal helix that projects into the solvent (Fig. 1B, black,
initial eight residues were not modeled due to weak electron
density). This N-terminal helical domain is shorter than the
one predicted in the C. crescentus homologue CcScsC (Sup-
plementary Fig. S3) which is proposed to promote dimeriza-
tion (9). Thus, unlike CcScsC or EcDsbG, StScsC purifies as a
monomer. Furthermore, a protein interfaces, surfaces, and
assemblies analysis (62) of StScsC crystal packing revealed no
indication of dimer formation.
The structural analysis of ScsC revealed significant simi-
larities to the TRX family proteins catalyzing both oxidation
and isomerization/reduction. The redox properties of StScsC
are similar to those of the archetypal disulfide-oxidizingDsbA
and disulfide-reducing DsbG (Table 1). Furthermore, the pKa
of the exposed nucleophilic cysteine of StScsC is 3.4 (Fig. 5B), a
low value that is a common characteristic of Dsb-like proteins
like DsbA and DsbG (Table 1). This low pKa may arise from
the sulfur atom of Cys48 being hydrogen bonded to the
backbone amide group of Cys51 and the hydroxyl of Thr156 in
the cis-Pro loop as well as being flanked by a cluster of posi-
tively charged residues (Figs. 3 and 4) all of which contribute
to the stabilization of Cys48 in the thiolate form. The low pKa
value of the nucleophilic cysteine for StScsC would favor a
reduced disulfide, which is consistent with the relatively ox-
idizing redox midpoint of - 132mV (this disulfide is rela-
tively easy to reduce). In the case of EcDsbA, a linear
relationship between the pKa of the exposed CXXC cysteine
and redox midpoint of the active site thiol pair has been
demonstrated, lower pKa values pairing up with higher, more
oxidizing, redox midpoints (36). Hence, with a low pKa and a
low redox midpoint, StScsC exhibits typical characteristics of a
Dsb disulfide oxidoreductase. A common activity for TRX-like
oxidoreductases is the reduction of insulin; StScsC and EcDsbA
reduce insulin at a similar rate (Fig. 5C). Although some
structural properties of StScsC are characteristic of E. coli dis-
ulfide isomerases, EcDsbC and EcDsbG, these features do not
confer such activity to the protein. By contrast, its dimeric or-
thologue CcScsC catalyzes isomerization of Dsb in substrate
RNase I (9). Our presentwork shows that StScsC ismonomeric,
and this probably limits the ability of the protein to reshuffle
non-native disulfide linkages. Indeed, previous work has
shown that modification of dimeric EcDsbC into a monomeric
molecule dramatically reduces its disulfide isomerase activity
(33). This suggests that theremay be functional diversitywithin
members of the ScsC family of proteins.
Copper (II) is known to drive the oxidation of thiols (53) and
since StScsC is required for protection against copper stress,
this suggests that StScsC is part of a system in S. Typhimurium
that is dedicated to protecting periplasmic proteins against the
formation of non-native Dsb induced by this transition metal.
Themechanistic role that StScsC plays is still unclear; however,
our results indicate that StScsC exists in the reduced state in
FIG. 6. ScsC is required for S. Typhimurium copper re-
sistance in vitro. (A) Disk diffusion assays of wild-type S.
Typhimurium SL1344, SL1344scsC and SL1344scsC com-
plemented with plasmid pScs. Sterile filter disks were placed
on bacterial lawns and treated with 5ll CuSO4 (1 M). The
data presented are representative of five independent re-
peats. (B) Copper sensitivity and complementation of S.
Typhimurium SL1344 scsC mutant was tested by spotting a
series of 10-fold dilutions of cultures of the same density onto
Tris agar plates containing increasing amounts of copper.
Pictures were taken after a 24-h incubation at 37!C in the
presence (right panel) or absence (left panel) of 2.8mM CuSO4.
To see this illustration in color, the reader is referred to the
web version of this article at www.liebertpub.com/ars
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resting cells, which may indicate that this protein is a disulfide
reducing protein. The reason why S. Typhimurium would
possess a system dedicated to protection against copper-
catalyzedDsb formation is not entirely clear, but it is noted that
copper ions have recently been shown to play an antimicrobial
role in the innate immune response and there is evidence that
this ion is trafficked to the phagosome inmacrophages (28, 60).
In macrophage infection studies, we did not observe any dif-
ference in the bacterial load when we compared wild-type
S. Typhimurium with the scsC mutant (Achard & McEwan,
unpublished), but it should be noted that copper tolerance in
S. Typhimurium is complex and no single locus may be
essential for survival in the macrophage.
Materials and Methods
Production of purified proteins
Native ScScsC was expressed using a method similar to the
one descried previously for other S. Typhimurium DsbA-like
proteins (32). Briefly, the coding DNA sequence for ScScsC
lacking the signal peptide (residues 19–189), was cloned into a
pET21a-based LIC vector (for cloning primers, see Supple-
mentary Table S1). The recombinant protein containing an
N-terminal hexa-histidine tag was expressed using auto-
induction (54), and then purified by Ni2 + -affinity chroma-
tography and gel filtration chromatography (in 50mM
HEPES pH 7.0, 150mM NaCl). Upon removal of the tagged
signal peptide by cleavage with TEV protease (in a gel filtra-
tion buffer supplementedwith 1mMDTT), uncleaved protein
was removed using cobalt affinity (Talon resin) chromatog-
raphy. Histidine-tagged E. coli DsbA (EcDsbA) was purified
as previously described (48).
Crystallization and diffraction data collection
Purified StScsC (in 50mM HEPES pH 7.0, 150mM NaCl)
was stored in aliquots frozen at - 80!C until needed. StScsC
was concentrated using a 3K Amicon centrifugal concentrator
up to 26mg$ml - 1. High-throughput crystallization experi-
ments were performed with a Mosquito robot using com-
mercial screening kits. Initial condition screening was
performed in the hanging-drop format in 96-well plates,
StScsC was at 26mg$ml- 1 and the commercial screens JCSG
(Molecular Dimensions), Index (Hampton), and PegRx1/
PegRx2 (Hampton) were used. Drops were set using the
Mosquito" robot (TTP LabTech Ltd.) by mixing 100 nL of
protein with 100 nL of well condition. The plates were incu-
bated at 20!C and monitored and scored using the Rock-
Imager and Rockmaker system (Formulatrix, Inc.). Crystals
were observed in three PegRx conditions (PegRx1 #33, 0.1M
Tris pH 8.0, 28% w/v PEG 4000; PegRx2 #28, 18% v/v
2-Propanol, 0.1M sodium citrate tribasic dihydrate pH 5.5,
20% w/v PEG 4000; PegRx2 #29, 6% v/v Tacsimate pH 6.0,
0.1M 2-(N-morpholino)ethanesulfonic acid monohydrate pH
6.0, 25% w/v PEG 4000). Optimization using random and
grid screening strategies produced crystals that diffracted to
2.04 A˚. These crystals were grown in 96-well plates in gradient
screens of 18%–27% (w/v) PEG 4000 and 0.1M Tris buffer pH
8.2–9.2. A further round of optimization designed to grow
larger crystals free of precipitate was performed in 24-well
plates using 18%–27% (w/v) PEG 4000 with 0.1M Tris buffer
pH 8.2 with protein at 9mg$ml- 1 using microseeding. The
hanging drops were prepared by adding 1ll of protein
(9mg$ml - 1) to 1ll of well condition and were microseeded
within 30min of setup with a seed stock prepared from small
crystals grown in the same condition. Diffraction data were
collected on a crystal (*300 · 50· 50lm) grown by this
method (Supplementary Fig. S4) with a well condition of 22%
(w/v) PEG 4000 in 0.1 M Tris buffer pH 8.2. The crystal was
cryoprotected by the well solution supplemented with 25%
ethylene glycol and flash cooled in the cryostream. Data were
collected using a Rigaku FR-E Superbright X-ray generator
with Osmic HiRes2 optics and a Rigaku R-Axis IV + + Image
Plate detector. CrystalClear 2.0 was used to record the dif-
fraction and indexing and scaling was performed using
HKL2000 (45).
Structure determination
The crystal structure of StScsC was solved by molecular
replacement using BALBES (39) with a final search model
based on the crystal structure of a TRX-like oxidoreductase
from Silicibacter pomeroyi (PDB: 3GYK): Model building and
refinement were carried out iteratively using COOT (16) and
Phenix (2). Structure validation was performed using Mol-
probity (8). Supplementary Table S1 provides the statistics for
the X-ray data collection and final refined model. Super-
position of molecules and generation of molecular figures
(including electrostatic potential) were carried out using the
CCP4 Molecular Graphics program (47).
Bioinformatic analyses
Pairwise sequence alignments and calculation of sequence
identities were performed using Biolign (21). Structural
alignments were performed using MUSTANG (34), and the
secondary structure was assigned using PDBsum.
Determination of the equilibrium constants
with glutathione
The redox equilibrium of StScsC with glutathione was de-
termined alongside that of EcDsbA as a positive control, using
a recently developed NMR approach (56) (using his-tagged
proteins). To determine the reduction potentials, different
ratios of [reduced glutathione (GSH)]/[GSSG] were used,
where [GSH] + [GSSG] equalled 5mM. All NMR data were
obtained at 298 K using a 14.1 T (600MHz 1H) Bruker Avance
III NMR spectrometer equipped with a QCI-F cryoprobe. All
NMR samples were 330 lL within a Shigemi NMR tube and
contained 100 lM protein in a 20mM sodium phosphate
buffer at pH 6.5 containing 50mM sodium chloride and 5%
(v/v) deuterium oxide. All buffers had nitrogen bubbled
through to ensure the removal of any oxygen. We found that
bubbling for 30–60min was sufficient to remove all effects of
dissolved oxygen and the redox equilibrium was complete in
all sampleswithin 5min of equilibration of buffers. All 15N-1H
HSQC spectra were acquired with 2048 points in the direct F2
dimension (1H) and 256 points in the F1 dimension (15N).
NMR data processing was completed using NMRpipe. NMR
backbone assignments have previously been completed for
EcDsbA (10) and were used to confirm analysis. Two control
spectra were recorded for each protein (Supplementary Fig.
S5), the fully oxidized protein (using 5mM GSSG) and the
fully reduced protein (using 5mM DTT). To determine the
1502 SHEPHERD ET AL.
APPENDIX B 
 
 214  
reduction potential of each protein, the fraction reduced was
calculated for four and six resonances for StScsC and EcDsbA,
respectively. The equilibrium constant Keq and redox mid-
point potential were determined from standard thermody-
namic equations (42). A redoxmidpoint potential of - 240mV
was used for the glutathione couple (49).
Determination of pKa values
The pKa of the nucleophilic cysteine in StScsC was deter-
mined by monitoring the specific absorbance of the thiolate
anion at 240 nm (43). Measurements were carried out at room
temperature in a buffer system consisting of 10mM K2HPO4,
10mM boric acid, 10mM sodium succinate, 1mM EDTA, and
200mM KCl, pH 7.5. Oxidized and reduced protein samples
(final concentration of 20 lM) were prepared by incubating
the proteins with 20mM GSSG or 10mM DTT, respectively.
Upon removal of the oxidizing and reducing agents using a
PD10 column (GE Healthcare), the absorbance of the samples
at 240 and 280 nm was recorded as the pH of the protein
solution was lowered to 2.5 by the stepwise addition of ali-
quots of 0.2 M HCl. The pH dependence of the thiolate-
specific absorbance signal (S= (A240/A280)reduced/(A240/
A280)oxidized) was fitted according to the Henderson–Hassel-
balch equation as previously described (42). The oxidation
state of StScsC samples was assessed using the DTNB assay
with an extinction coefficient of e412 = 13.8mM
- 1 cm - 1 (17).
Insulin reduction and refolding of scRNaseA assays
The disulfide oxidoreductase activity of StScsC and
EcDsbA was determined by measuring the ability to catalyze
insulin reduction in the presence of DTT as described previ-
ously (37). The in vitro isomerase activity of StScsC, EcDsbC,
and EcDsbA was assessed using the refolding of scRNaseA
assay essentially as described by Hillson et al. (27).
Bacterial strains, plasmids, and culture conditions
S. Typhimurium SL1344 strains (wild-type and deletion
mutants) and E. coli strains (BL21[DE3] and DH5a) were rou-
tinely cultured at 37!C on the solid or in liquid Luria Bertani
(LB) medium supplemented with the appropriate antibiotics;
kanamycin (Km, 50lg$ml- 1), ampicillin (Ap, 100lg$ml- 1 or
chloramphenicol (Cm, 30lg$ml- 1). Culture media were sup-
plemented with 1mM isopropyl b-D-thiogalactopyranoside
(IPTG) to induce expression of StScsABCD from plasmid pScs.
Plasmid pScs was generated by PCR amplification of the
scsABCD operon (primers scsA-DF, scsA-DR) from the chro-
mosome of SL1344 and subsequent cloning into EcoRI-XhoI
digested pWSK29 (61). Expression of cloned genes was con-
trolled by the inducible lac promoter. All primers used in this
section are shown in Supplementary Table S2.
Construction of S. Typhimurium SL1344 mutants
To delete the scsC gene, a three-step PCR procedure was
employed to generate an amplification product containing the
Km cassette frompKD4 (12) flanked on both sides by*500 bp
of DNA sequence homologous to the target gene to be mod-
ified. The following sets of primers were used for scsC:
scsCP1F, scsCP2R, scsCP5F, and scsCP6R (Supplementary
Table S2). These primers were used in combination with the
Km cassette amplification primers KanP3 and KanP4 (Sup-
plementary Table S2). The final three-step PCR product for
each target gene was gel-purified and cloned into pT7Blue
(Merck) according to the manufacturer’s instructions, to
generate a donor plasmid. SL1344 deletion mutants were
constructed using the gene gorging method as previously
described (26). Briefly, SL1344 cells were electrotransformed
with a donor plasmid [pT7Blue::scsC::kan, and a mutagenesis
plasmid (pACBSR, (26)]. Cells containing both plasmids
were cultured for 9 h in the LB broth supplemented with
25lg$ml- 1 Cm and 0.2% (w/v) L-arabinose to induce the
l-Red and I-SceI genes on pACBSR. Induction of these genes
leads to linearization of the donor plasmid and a double re-
combination event with the regions flanking scsC, resulting in
disruption of the respective gene. Clones sensitive to Ap and
Cm (but resistant to Km) were selected and deletion of scsC
was confirmed by PCR and subsequent DNA sequencing.
Copper sensitivity assays
Copper sensitivity was assessed via growth on solid media.
For disk diffusion assays, strains were grown at 37!C to
mid-exponential phase, adjusted to the same cell density and
plated using the agar overlay technique on LB supplemented
with 1.5% agar. Sterile filter disks soaked with 5lL of 1 M
CuSO4 were placed on the center of each plate and the zones
of inhibition were measured after an overnight incubation at
37!C. The data presented are representative of three inde-
pendent experiments. For colony spot assays, serial 10-fold
dilutions of cultures of the same density were prepared and
5ll of each dilution was spotted on the Tris agar medium
supplemented with 1.4–3.6mM CuSO4 (at 0.2mM incre-
ments) or left untreated. Pictures were taken after 24 h of in-
cubation at 37!C. The data presented are representative of
three independent experiments comparing growth in the
presence or absence of 2.8mM CuSO4.
Determination of the in vivo redox state of StScsC
The periplasmic protein fraction of SL1344 and SL1344scsC
pScs was prepared by cold osmotic shock. Bacteria grown
overnight at 37!C were washed in an ice-cold buffer con-
taining 20% surcrose, 200mM Tris HCl, pH8, and cells were
harvested by centrifugation and resuspended in ice-cold
10mM Tris HCl, pH8. After centrifugation, the supernatant
was retained for analysis. The redox state of ScsC was mea-
sured by thiol alkylation using AMS and analysis of the mo-
lecular mass of proteins following sodium dodecyl sulfate
polyacrylamide gel electrophoresis and Western blotting as
previously described (30). ScsC proteinswere detected using a
StScsC-specific antibody (1:100) and an anti-rabbit IgG
coupled with alkaline phosphatase (1:10000; Sigma) as the
secondary antibody. Blots were stained with 5-bromo-4-
chloro-3-indolyl-phosphate/nitro blue tetrazolium.
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Abbreviations Used
AMS¼ 4-acetamino-4-acetamido-4¢-maleimidylstilbene-
2,2¢-disulfonic acid
Ap¼ ampicillin
BCIP/NBT¼ 5-bromo-4-chloro-3-indolyl-phosphate/nitro
blue tetrazolium
BsBdbD¼BdbD protein of B. subtilis
CcScsC¼ ScsC protein of C. crescentus
Cm¼ chloramphenicol
Dsb¼disulfide bond
DTT¼dithiothreitol
EcDsbA¼DsbA protein of E. coli
GSH¼ reduced glutathione
GSSG¼ oxidized glutathione
IPTG¼ isopropyl b-D-thiogalactopyranoside
Km¼ kanamycin
MES¼ 2-(N-morpholino)ethanesulfonic acid
PISA¼protein interfaces, surfaces, and assemblies
SDS PAGE¼ sodium dodecyl sulfate polyacrylamide
gel electrophoresis
StDsbA¼DsbA protein of S. Typhimurium
StScsC¼ ScsC protein of S. Typhimurium
TRX¼ thioredoxin
UPEC¼uropathogenic E. coli
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Supplementary Data
SUPPLEMENTARY FIG. S1. Hydrogen bond stabiliza-
tion of the b5–a7 loop of ScsC protein of S. Typhimurium
(StScsC). Hydrogen bonds between Ile166 (O and NH) and
Thr159 (NH and O) and Gly168 (NH) and cis-Pro157 are shown
as dashed lines.
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SUPPLEMENTARY FIG. S2. In vitro refolding of
scrambled RNaseA (scRNaseA). scRNaseA (40mM) was
incubated in a 0.1M sodium phosphate buffer, pH 7.0, 1mM
EDTA, 10mM dithiothreitol (DTT) in the presence of 10mM
EcDsbC (-), 10mM EcDsbA (:), or 10mM StScsC (!).
RNaseA activity was measured by monitoring cCMP hy-
drolysis spectrophotometrically at 296 nm. As positive and
negative controls, we performed two additional reactions
with folded RNaseA and scRNaseA, respectively, and
without any additional enzyme. The former was normalized
to 100% RNaseA activity and the latter was subtracted from
all measurements. After 300min, EcDsbC, EcDsbA, and
StScsC catalyzed the recovery of 90%, 40%, and 20% of the
oxidized scRNaseA, respectively.
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SUPPLEMENTARY FIG. S3. Pairwise sequence comparison of ScsC from S. Typhimurium (StScsC) and C. crescentus
(CcScsC). Sequences lack targeting peptides. Blosum matrix was used, where sequence ends are permitted to slide over one
another. Sequence identities (black shading) and similarities (gray shading) were 24% and 40%, respectively. The conserved
cis-proline residues are denoted by an asterisk. The ScsC sequence used for C. crescentus was CC_1879 from strain CB15.
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SUPPLEMENTARY FIG. S4. Crystallization of ScsC from
S. Typhimurium. Crystallization buffer: 22% (w/v) PEG
4000 in 0.1 M Tris buffer pH 8.2.
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SUPPLEMENTARY FIG. S5. 15N-1H HSQC spectra of fully oxidized and fully reduced StScsC. The spectra in blue on
both panels are the fully reduced sample (treated with 5mM DTT). Spectra in red and black are taken from the reduced
glutathione/oxidized glutathione titration, and are fully oxidized and fully reduced, respectively. The peaks selected to
calculate the reduction potential overlay with the fully reduced DTT sample.
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Supplementary Table S1. X-ray Data Collection
and Refinement Statistics for StScsC
Data collection ScsC
Wavelength (A˚) 1.5419
Resolution range (A˚) 48.7 - 1.98 (2.05 - 1.98)
Space group P21
Unit cell dimensions (A˚) a = 53.1, b = 91.0, c= 83.3
a= c = 90, b= 102.23
Observed reflections 790723
Unique reflections 106172
Rmerge
a* 0.06 (0.48)
Completeness (%)* 100 (100)
< I >/r(I) > * 13.0 (2.4)
Redundancyc 7.5 (7.3)
Refinement
Resolution (A˚) 48.7 - 2.04
Completeness for range (%) 99.8
Rfactor
b (%)* 19.9 (43.7)
Rfree
c (%)* 25.3 (47.9)
Number of non-H protein atoms 5503
Number of waters 411
Wilson B 35.41
Average B factor (A˚2)–All atoms 45.32
Average B factor (A˚2)–Water 46.28
Average B factor (A˚2)–Nonsolvent 45.25
R.m.s.d. from ideal geometry
Bonds (A˚) 0.008
Angles (o) 1.003
Molprobity analysis
Residues in most favored/
additionally allowed regions (%)
98.7/1.3
Residues with bad angles (%) 0
Poor rotamers (%) 2
Clashscore (percentile) 11.55 (76th)
Molprobity score (percentile) 1.81 (87th)
*Values in parentheses refer to the highest resolution shell.
aRmerge=+ jI- < I> j/+ < I> , where I is the intensity of individual
reflections.
bRfac=+h jFo- Fcj/+hjFoj, where Fo and Fc are the observed and
calculated structure-factor amplitudes for each reflection ‘‘h.’’
cRfree was calculated with 5% of the diffraction data selected
randomly and excluded from refinement.
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Supplementary Table S2. Primers Used for the Amplification of the scsC Gene, the scsABCD Operon,
and the Construction of the S. Typhimurium SL1344scsC Mutant
Primer name Sequence (5¢ - 3¢)
scsA-DF TTTGAATTCATAGCTCGCGTTAAACAGTGAGGGCGCAATGGCG
scsA-DR TTTCTCGAGTCAGAACGTTTTTGCCCACCATAGCCGAAGC
scsCP1F GGCCGGGATCCTAGGGATAACAGGGTAATATGTCCTGCGCAGGATCCTCGGTCT
scsCP2R GAAGCAGCTCCAGCCTACACACGAAAACAGCGCCAGCAGTAAAACA
scsCP5F GAACTAAGGAGGATATTCATATGGGATACGCTGGAAGCGGTGGTGAAA
scsCP6R CGCGCGGATCCTAGGGATAACAGGGTAATTCCAGCCGCTGGTGGTGAACACAAC
KanP3 GTGTAGGCTGGAGCTGCTTC
KanP4 CATATGAATATCCTCCTTAG
StScsC, ScsC protein of S. Typhimurium.
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The bacterial disulfide machinery is an attractive molecular
target for developing new antibacterials because it is required
for the production of multiple virulence factors. The arche-
typal disulfide oxidase proteins in Escherichia coli (Ec) are
DsbA and DsbB, which together form a functional unit: DsbA
introduces disulfides into folding proteins and DsbB re-
oxidizes DsbA to maintain it in the active form. In
Mycobacterium tuberculosis (Mtb), no DsbB homologue is
encoded but a functionally similar but structurally divergent
protein, MtbVKOR, has been identified. Here, the Mtb
protein Rv2969c is investigated and it is shown that it is the
DsbA-like partner protein of MtbVKOR. It is found that it
has the characteristic redox features of a DsbA-like protein: a
highly acidic catalytic cysteine, a highly oxidizing potential and
a destabilizing active-site disulfide bond. Rv2969c also has
peptide-oxidizing activity and recognizes peptide segments
derived from the periplasmic loops of MtbVKOR. Unlike the
archetypal EcDsbA enzyme, Rv2969c has little or no activity
in disulfide-reducing and disulfide-isomerase assays. The
crystal structure of Rv2969c reveals a canonical DsbA fold
comprising a thioredoxin domain with an embedded helical
domain. However, Rv2969c diverges considerably from other
DsbAs, including having an additional C-terminal helix (H8)
that may restrain the mobility of the catalytic helix H1. The
enzyme is also characterized by a very shallow hydrophobic
binding surface and a negative electrostatic surface potential
surrounding the catalytic cysteine. The structure of Rv2969c
was also used to model the structure of a paralogous DsbA-
like domain of the Ser/Thr protein kinase PknE. Together,
these results show that Rv2969c is a DsbA-like protein with
unique properties and a limited substrate-binding specificity.
Received 23 April 2013
Accepted 28 June 2013
PDB Reference: Rv2969c,
4k6x
1. Introduction
The devastating disease tuberculosis (TB) caused by the
bacterium Mycobacterium tuberculosis (Mtb) is responsible
for approximately two million deaths annually. The loss of
effectiveness of the only available TB vaccine, Bacillus
Calmette–Gue´rin (BCG), for people of economically
productive age (15–59 years) has created an enormous drain
on the world economy (World Health Organization, 2011). A
major hurdle to eradicating TB is the requirement for multi-
antibiotic therapy administered over a period of six to nine
months (Connolly et al., 2007). Multidrug-resistant (MDR)
and extensively drug-resistant (XDR) Mtb strains have
evolved for which therapeutic options are limited to toxic and
expensive second-line and third-line reserved drugs (Phillips,
2013). Aside from MDR and XDR strains, Mtb has evolved
mechanisms to succeed as an intracellular pathogen by
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cobalt resin (Clontech) and the His6 tag was removed by TEV
protease leaving three vector-derived residues (Ser-Asn-Ala)
at the N-terminus. For crystallization experiments, the protein
was incubated with 100 mM oxidized glutathione to generate
the oxidized enzyme, prior to final purification on a Superdex
75 gel-filtration column (GE Healthcare). Site-directed
mutagenesis was performed using the QuikChange method
and the mutation was confirmed by DNA sequencing. A
noncatalytic double cysteine mutant MtbDsbAm (Cys140Ala,
Cys192Ala) and an active-site single cysteine mutant
MtbDsbA (Cys92Ala) were expressed and purified in the
same way as for wild-type MtbDsbA.
2.2. Crystallization and diffraction data collection
MtbDsbA crystals were grown by the hanging-drop vapour-
diffusion method at 293 K; drops were set up using a Mosquito
crystallization robot (TTP Labtech) and were incubated and
imaged in a RockImager 1000 (Formulatrix). 250 nl MtbDsbA
solution concentrated to 55 mg ml!1 in 25 mMHEPES pH 7.4,
100 mM NaCl was mixed with 250 nl reservoir solution
consisting of 2.4M sodium malonate pH 5.5, 3.7% 1,4-
dioxane, 0.08% polyvinylpyrrolidone. Crystals grew as long
thin rods ("30 # 500 mm) in 3–4 weeks and were flash-cooled
in liquid nitrogen after brief rinsing in 3.4M sodium malonate
pH 5.5. Diffraction data were collected on the MX2 beamline
at the Australian Synchrotron at a wavelength of 0.9537 A˚ and
were recorded using an ADSC Quantum 315r detector
controlled by Blu-Ice (McPhillips et al., 2002). Data were
integrated in XDS (Kabsch, 2010), space-group possibilities
were analyzed using POINTLESS (Evans, 2006) and data
were scaled in SCALA from the CCP4 suite (Winn et al.,
2011).
2.3. Structure determination and refinement
Molecular-replacement (MR) searches for MtbDsbA with
Phaser (McCoy et al., 2007) using intact DsbA templates (less
than 21% sequence identity) were unsuccessful. Regions
contributing to DsbA structural divergence were identified by
superposition of DsbA structures currently available in the
PDB and the structurally divergent regions were trimmed to
generate a collection of DsbA ‘Poly Ser’ MR templates
(nonglycine and non-alanine residues that were not conserved
were changed to serine) for MR trials in Phaser. A Poly Ser
conserved structural core search model derived from
Staphylococcus aureus DsbA (SaDsbA) (PDB entry 3bci;
Heras et al., 2008) gave an MR solution (TFZ = 8.0) with two
copies in the asymmetric unit. This trimmed MR search model
provided 39% coverage with 48% identity to the MtbDsbA
sequence (Supplementary Fig. S11). Iterative manual building,
density modification and refinement in PHENIX (Adams et
al., 2010) and Coot (Emsley & Cowtan, 2004) allowed tracing
of almost the entire MtbDsbA sequence. Final refinement
cycles involving TLS were carried out in phenix.refine.
Electron density was absent for the three vector-derived
residues and the N-terminal 11 residues of the MtbDsbA
construct in both molecules in the asymmetric unit. At the
interface of the two MtbDsbA molecules in the asymmetric
unit, two additional regions of electron density were observed
in the difference Fourier map contoured at 3.0!. These were
interpreted as 1,4-dioxane and HEPES, both of which were
present in the crystallization condition. A summary of the
data-processing and refinement statistics is presented in Table
1. The stereochemical quality of the final model was assessed
using AutoDep Input Tool (Yang et al., 2004), MolProbity
(Chen et al., 2010) and SFCHECK (Vaguine et al., 1999). The
coordinates and structure factors have been deposited in the
Protein Data Bank (PDB entry 4k6x).
2.4. Isothermal titration calorimetry (ITC)
Experiments were carried out on a Microcal Auto-iTC200
(GE Healthcare). Peptides with N-terminal acetylation and
C-terminal amidation were chemically synthesized manually
by classic solid-phase peptide synthesis using rink amide
MBHA resin (ChemImpex International, loading
0.65 mmol g!1) and Fmoc-protected amino acids (ChemImpex
International). Peptides were purified by reversed-phase
HPLC (C18, Phenomenex) and characterized by retention
times, electrospray mass spectrometry and 1H NMR spectro-
scopy. Each ITC titration involved an initial 0.5 ml injection
(not included in the subsequent analysis) followed by 19
injections of 2 ml of 2–4 mM peptide into cells containing
100 mMMtbDsbA in 25 mM HEPES pH 7.4, 100 mM NaCl at
research papers
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Table 1
Summary of data-collection and refinement statistics.
Values in parentheses are for the highest resolution shell.
Space group I4122
Unit-cell parameters (A˚) a = 92.05, b = 92.05, c = 232.76
Data-collection wavelength (A˚) 0.9537
Resolution range (A˚) 85.6–1.97 (2.08–1.97)
No. of observations 286100 (39641)
No. of unique reflections 35185 (5080)
Mean I/!(I) 14.9 (3.3)
Rmerge 0.096 (0.66)
Rp.i.m. 0.036 (0.246)
Multiplicity 8.1 (7.8)
Wilson B factor (A˚2) 26.1
Model and refinement statistics
Resolution range (A˚) 59.3–1.97
No. of unique reflections 35175
Completeness 98.4
Rwork (%) 14.5 (20.3)
Rfree† (%) 19.2 (28.4)
No. of non-H atoms
Protein 2996
Ligand 17
Water 415
R.m.s.d., bond lengths (A˚) 0.011
R.m.s.d., bond angles (%) 1.27
Ramachandran favoured/allowed (%) 97.5/99.5
Average B factor (A˚2)
Protein 23.7
Ligand 24.6
Water 34.6
† Rfree is calculated as for Rwork but for 5% of the total reflections chosen at random and
omitted from refinement.
1 Supplementary material has been deposited in the IUCr electronic archive
(Reference: TZ5033). Services for accessing this material are described at the
back of the journal.
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298 K. Thermodynamic parameters were obtained from
nonlinear curve fitting using a single-site binding mode in
Origin 7.0 (SR4 v7.0552 beta, Microcal).
2.5. Thermal stability measurement
Temperature-induced unfolding of MtbDsbA was recorded
by far-UV circular dichroism (CD), with the temperature
increasing from 298 to 368 K at a rate of 1 K min!1 using a
Jasco J-810 spectropolarimeter. The normalized CD signal for
oxidized (219 nm) and reduced (220.5 nm) MtbDsbA in
100 mM phosphate buffer, 1 mM ethylenediaminetetraacetic
acid (EDTA) pH 7.0 was fitted to a two-state unfolding model
as described previously (Kurz et al., 2009). The redox status of
the oxidized and reduced protein preparation with oxidized
glutathione and DTT (dithiothreitol), respectively, was veri-
fied with Ellman’s reagent.
2.6. Insulin-reduction assay
The catalytic ability of MtbDsbA to reduce insulin in the
presence of DTTwas monitored by the increase in absorbance
at 650 nm over 80 min as described previously (Heras et al.,
2008). Briefly, the reaction mixture contained 131 mM insulin
and 10 mM of oxidized MtbDsbA or EcDsbA in 100 mM
phosphate buffer pH 7.0, 2 mM EDTA. The reaction was
initiated by adding DTT to a final concentration of 0.35 mM.
The noncatalyzed aggregation of insulin by DTT was moni-
tored in a control reaction without enzyme.
2.7. Isomerization of scrambled RNaseA
In vitro disulfide isomerase activity of MtbDsbA, EcDsbC
and EcDsbA was monitored using a scrambled RNaseA
refolding assay (Hillson et al., 1984). Scrambled RNaseA was
produced as previously described (Heras et al., 2008).
Isomerization of scrambled RNaseA (40 mM) was conducted
in 100 mM sodium phosphate buffer containing 1 mM EDTA
pH 7.0, 10 mM DTT and 10 mM DsbA or DsbC at 298 K
(750 ml). At various time intervals, 50 ml of refolded RNase
sample was taken to monitor the hydrolysis activity of cytidine
30,50-cyclic monophosphate (3 mM) using a BioTek H1 plate
reader at 296 nm. Native RNaseA and scrambled RNaseA in
the absence of DsbA or DsbC served as positive and negative
controls, respectively.
2.8. Ubiquinone-reduction assay
DsbB-catalyzed oxidation of DsbA can be monitored by
following the decrease in ubiquinone absorbance at 275 nm
(Bader et al., 2000). The reaction mixture (70 ml) contained
30 mM reduced MtbDsbA or EcDsbA, 30 mM ubiquinone-1
(UQ1) in 50 mM Tris pH 7.0, 100 mM NaCl and 0.01%
n-dodecyl !-d-maltoside. The decrease in absorbance was
recorded for 3 min at 303 K after addition of 57 nM EcDsbB
using a Varian Cary 50 UV–visible spectrophotometer.
2.9. Determination of redox potential
Oxidized MtbDsbAm (2 mM) was incubated in 200 ml
degassed buffer consisting of 100 mM phosphate buffer, 1 mM
EDTA pH 7.0, 1 mM oxidized glutathione (GSSG) for 1 h at
room temperature. The protein was then incubated in buffers
with a range of reduced glutathione (GSH) concentrations
(0.01 mM–1 mM) for 24 h at 298 K (10 ml per reaction
containing 2 mM protein concentration). After incubation, the
reactions were stopped with 10% trichloroacetic acid and the
precipitated protein pellets were collected by centrifugation at
14 000 rev min!1 for 10 min at 277 K. The pellets were washed
with 100% ice-cold acetone and dissolved in buffer consisting
of 50 mM Tris pH 7.0, 1% SDS, 4 mM 4-acetamido-40-male-
imidylstilbene-2,20-disulfonate (AMS) to label the free thiols.
Separation of reduced and oxidized forms was performed on a
NuPAGE 12% bis-tris gel (1.0 mm thick, 12 well; Invitrogen,
Australia). The gel was stained with Coomassie, scanned
(Perfection V700 Scanner, Epson) and intensities of the
reduced protein were analyzed using ImageJ v.1.42q
(Schneider et al., 2012). The fraction of the reduced protein
was plotted against the ratio [GSH]2/[GSSG] and the equili-
brium constant Keq was calculated using the binding equation
Y = ([GSH]2/[GSSH])/{Keq + ([GSH]
2/[GSSH])}, where Y is
the fraction of reduced protein at equilibrium. The redox
potential was calculated using the Nernst equation E0
0
=
E0
0
GSH/GSSG ! (RT/nF)lnKeq, where E00GSH/GSSG is the standard
potential of !240 mV (Gilbert, 1995), R is the universal gas
constant 8.314 J K!1 mol!1, T is the absolute temperature in
K, n is the number of electrons transferred, F is the Faraday
constant 9.648 " 104 C mol!1 and Keq is the equilibrium
constant.
2.10. Determination of pKa
The pH-dependent UV absorbance of the nucleophilic
cysteine thiol was followed at 240 nm (Nelson & Creighton,
1994). Measurements of oxidized or reduced MtbDsbAm
(lacking the second disulfide) of 24 or 16 mM in a total volume
of 200 ml buffer comprising 10 mM dipotassium phosphate,
10 mM monopotassium phosphate, 10 mM sodium citrate,
10 mM Tris, 1 mM EDTA, 200 mM KCl were performed at pH
values ranging from 2.2 to 7.5 using Greiner 96-well UV-Star
microplates. The redox status of the protein preparation was
verified with Ellman’s reagent. The absorbance at 240 and
280 nm was recorded on a BioTek Synergy H1 microplate
reader and corrected for blank absorbance. The pH-depen-
dent thiolate-specific absorbance signal [(A240/A280)reduced/
(A240/A280)oxidized] was fitted to the Henderson–Hasselbach
equation as described previously (Kurz et al., 2009).
2.11. Complementation assay
Complementation of EcDsbA by MtbDsbAwas monitored
in a cell-swarming assay as described previously (Kurz et al.,
2009). A chimeric gene encoding an EcDsbA signal peptide
fused to the mature form of MtbDsbA was cloned into the
arabinose-inducible pBAD33 vector (Guzman et al., 1995). A
nonmotile E. coli dsbA! mutant (JCB817) strain transformed
research papers
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with this chimera construct was stabbed into a minimal agar
(M63) plate supplemented with 40 mg ml!1 of each amino
acid and 1 mg ml!1 arabinose. The swarming of E. coli cells
was analyzed after incubating the plate for 4–6 h at 303 K.
JCB817 cells transformed with pBAD33::EcDsbA were used
as a positive control. A nonmotile dsbA!/dsbB! double-
mutant strain (JCB818) served as a negative control. Plates
without arabinose were used to monitor background
complementation.
2.12. Peptide-oxidation assay
A synthetic peptide substrate CQQGFDGTQNSCK with a
europium DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-
tetraacetic acid europium) chelate at the N-terminus and a
methylcoumarin amide at the "-amino group of the lysine was
obtained from Anaspec, USA (for further details of the
peptide, see Vivian et al., 2009). Disulfide-bond formation of
the peptide was fluorometrically followed using time-resolved
fluorescence with excitation at 340 nm and emission at 615 nm,
a delay of 150 ms and a reading time of 100 ms in a Synergy H1
multimode plate reader (BioTek, USA). The assay was
performed in a 384-well white plate (PerkinElmer OptiPlate)
containing EcDsbA or MtbDsbA and 2 mM GSSG in 50 mM
MES, 50 mM NaCl, 2 mM EDTA at pH 5.5. The reaction was
initiated by the addition of substrate peptide at 4–8 mM in a
total volume of 50 ml. The reaction was performed in triplicate
and repeated at various concentrations of EcDsbA or
MtbDsbA. The reaction in the absence of enzyme was used as
a control.
3. Results
3.1. Putative Mtb DsbA-like proteins
To identify potential Mtb DsbA-like oxidases, we searched
the genome of the virulent strain Mtb H37Rv by using
keyword and BLASTP searches. 15 Trx-related gene products
were identified (Table 2) and nine of these were eliminated as
potential DsbA-like proteins as they are likely to be located in
the cytoplasm (on the basis of literature reports, the absence
of sorting signal/transmembrane region and sequence-to-
structure relationships). Of the remaining six predicted to be
extracytoplasmic Trx-related proteins, only the sequences of
hypothetical Rv2969c and the DsbA-like domain of PknE
(Rv1743) remotely resembled DsbA homologues. The
sequence identity of the nearest structurally characterized
neighbour, Bacillus subtilis DsbA (BsDsbA), is less than 19%
(by sequence-based alignment) to these two Mtb DsbA
paralogues. Rv2969c and Rv1743 share "50% sequence
similarity (31% identity) and both contain four conserved
cysteine residues. The sequence positions of two of the four
cysteines are similar to that of the characteristic redox-active
CXXC motif of the Trx fold, whereas the other two cysteines
are consistent with the structural (noncatalytic) cysteines
found in Wolbachia pipientis !-DsbA1 (Wp!-DsbA1; Kurz et
al., 2009).
The presence of a predicted sorting signal or trans
membrane helix in Rv2969c (currently annotated as
uncharacterized) indicates it is either secreted into, or
membrane-anchored with the catalytic domain facing, the
recently characterized mycobacterial periplasm (Patarroyo et
research papers
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Table 2
Survey of Trx-related proteins in M. tuberculosis strain H37Rv.
Summary of the 15 Trx-related proteins found using keyword and BLASTP searches. Only Rv2969c and Rv1743 could be considered similar to DsbA-like proteins.
Structural similarities to Trx-related proteins were identified using BLASTP and Fold and Function Assignment (FFAS; http://ffas.burnham.org/) searches against
PDB codes or % identity to reported structure (PDB code in parentheses) are given. The functional annotation, presence and location of signal peptide/
membrane-spanning region and operon are derived information from Target TB annotation (http://genome.tbdb.org/). The presence of signal sequence and
transmembrane region were also confirmed using SignalP3.0 and transmembrane prediction using hidden Markov models (TMHMM). DsbA-like (Rv2969c) is
predicted to have an N-terminal transmembrane (TM) helix or signal peptide (SP).
Protein Length Functional annotation Signal peptide Structural representative Operon
PknE-DsbA (Rv1743) 566 Ser/Thr kinase Integral
membrane
2h34 (kinase; Gay et al., 2006),
31% (DsbA-like)
Ser-Thr protein kinase, fused
DsbA-like
DsbA-like (Rv2969c) 255 Conserved, unknown TM or SP Present work Pyruvate carboxylase-like, VKOR,
Dsb-like
DsbE (Rv2878c) 173 Unknown Yes 1lu4 (Goulding et al., 2004) Rv2877c, DsbE
DsbF (Rv1677) 182 Unknown Yes 3ios (Chim et al., 2010) Rv1676, DsbF
ResA-like (Rv3673c) 227 Unknown Yes 30% (DsbE/F) Rv3673c, endonuclease III
Trx-related (Rv0526) 216 Unknown Yes 47% (3lwa; Midwest Center for
Structural Genomics, unpublished work)
HemeL, Rv0525, Rv0526, ccdA,
Rv0528, ccsA
TrxC (Rv3914) 116 Disulfide exchange No 3o6t (Hall et al., 2011) TrxB2, TrxC
TrxB2 (Rv3913) 335 Disulfide reductase No 2a87 (Akif et al., 2005) TrxB2, TrxC
TrxB1 (Rv1471) 123 Disulfide exchange No 36% (3hhv; Ruggiero et al., 2009) TrxA, TrxB1
TrxA (Rv1470) 124 Disulfide exchange No 32% (3hhv; Ruggiero et al., 2009) TrxA, TrxB1
Trx-like (Rv0816c) 140 Disulfide exchange ?? 28% (3ilu; Ptak et al., 2009) Rv0816c, Rv0817c
Trx-like (Rv2183c) 131 Conserved, unknown ?? 14% (3raz; New York SGX Research Center
for Structural Genomics, unpublished work)
Rv2183c, Rv2184c
Trx-fusion protein (Rv1324) 304 Disulfide exchange No 24% (3qdn; Center for Structural Genomics
of Infectious Diseases, unpublished work)
Rv1324
Trx-related (Rv2286c) 230 Conserved, unknown No 20% (3fz5; Midwest Center for Structural
Genomics, unpublished work)
Rv2286c
Trx-related (Rv2466c) 207 Unknown No 14% (3fz5; Midwest Center for Structural
Genomics, unpublished work)
Rv2466c
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al., 2008; Sani et al., 2010) and may therefore represent a
potential candidate for a DsbA-like protein. Hereafter, we
refer to it as MtbDsbA. Its paralogue PknE is a single-pass
transmembrane Ser/Thr protein kinase that comprises an
extracytoplasmic DsbA-like domain and a cytoplasmic kinase
domain (Gay et al., 2006). PknE has been shown to regulate
cellular events in response to host-mediated apoptotic stimuli
such as nitric oxide (Jayakumar et al., 2008). As such, PknE
appears to promote the survival of Mtb in the latent state by
suppressing host apoptosis (Kumar & Narayanan, 2012).
3.2. MtbDsbA is highly oxidizing
Typically, DsbA enzymes have a highly acidic catalytic
cysteine and a highly oxidizing redox potential that enable its
participation in thiol–disulfide exchange reactions. To study
the redox characteristics of MtbDsbA, we created a double
noncatalytic cysteine mutant MtbDsbAm (Cys140Ala,
Cys192Ala). Similar to Wp!-DsbA1, this mutation did not
affect the solubility and integrity of MtbDsbA. Using a pH-
titration experiment (Fig. 1a), we found that the measured pKa
of the catalytic cysteine Cys89 is 4.2! 0.2, which falls between
the previously reported values for EcDsbA (pKa = 3.3) and
Vibrio cholerae DsbA (VcDsbA, pKa = 5.1). The redox
potentials of DsbA proteins also vary among characterized
DsbAs; the most reducing and oxidizing DsbAs reported to
date are Wp!-DsbA1 ("163 mV) and neisserial NmDsbA3
("80 mV), respectively. We measured the standard redox
potential by equilibration of MtbDsbAm with glutathione at
298 K and pH 7.0 (Fig. 1b). We found that the oxidizing power
of MtbDsbA ("99 mV) is comparable to that of Pseudomonas
aeruginosa DsbA (PdDsbA) ("94 mV; Shouldice et al., 2010),
somewhat more oxidizing than EcDsbA ("122 mM;
Wunderlich & Glockshuber, 1993) and a little less oxidizing
than BsDsbA ("80 mM; Crow et al., 2009).
Another characteristic feature common to DsbA enzymes is
that the catalytic cysteine disulfide bond reduces the stability
of the protein (Heras et al., 2008). A thermal unfolding
experiment comparing the stability of the redox forms showed
that the oxidized (disulfide) form of MtbDsbA is less stable
than its reduced form by 13 K (Fig. 1c), which is in agreement
with the findings for other DsbA enzymes.
Taken together, these results show that the putative DsbA
protein encoded byM. tuberculosis has the redox hallmarks of
a DsbA disulfide oxidoreductase.
3.3. MtbDsbA is a disulfide oxidase
An in vivo complementation experiment has been devel-
oped to demonstrate that the expression of a DsbA enzyme
can rescue the motility of E. coli cells deficient in EcDsbA
(Kurz et al., 2009; Paxman et al., 2009). However, MtbDsbA
does not restore the motility of E. coli DsbA null cells as
shown by the results of the cell-swarming assay (Fig. 2a). To
establish whether this might be a consequence of a lack of
interaction between MtbDsbA and EcDsbB (the essential
redox partner of EcDsbA), we monitored the ability of
EcDsbB to oxidize MtbDsbA in an EcDsbB-catalyzed
ubiquinone reduction assay (Fig. 2b). This experiment showed
as expected that EcDsbB can oxidize EcDsbA, but it failed to
redox couple with MtbDsbA. This could explain why
MtbDsbA does not complement EcDsbA in the motility assay,
but we cannot rule out the possibility that MtbDsbA is in-
active because it also does not recognize the P-ring protein
(FlgI) substrate of EcDsbA in the assay (Dailey & Berg,
1993).
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Figure 1
Characterization of the redox properties of MtbDsbA. (a) pKa determination of the nucleophilic cysteine of MtbDsbA. This is a representative plot of
three independent measurements of the pH-dependent thiolate-specific absorbance of the catalytic cysteine. The pKa was obtained from the nonlinear fit
to the Henderson–Hasselbach equation. (b) Determination of the redox equilibria of MtbDsbAwith glutathione at pH 7.0 and 298 K. The plot shows the
averaged fraction (three replicates) of reduced MtbDsbA at various ratios of reduced:oxidized glutathione. The resulting equilibrium constantKeq (17.37
! 0.1 mM) from the nonlinear curve fit for a one-site binding equation was used to calculate the redox potential of MtbDsbA relative to the glutathione
(GSH/GSSG) standard potential of "240 mV (Gilbert, 1995). (c) Relative thermal stability of oxidized (grey) and reduced (black) MtbDsbA at pH 7.0.
The normalized average far-UV CD signal from three measurements was fitted to a two-state unfolding model as described previously (Kurz et al., 2009).
The resulting melting temperature (Tm) of MtbDsbA shows that its reduced form (351.7 ! 0.1 K) is more stable than its oxidized form (338.6 ! 0.1 K).
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We then set out to determine the redox-activity profile of
MtbDsbA in standard disulfide oxidase, reductase and
isomerase assays.
The disulfide oxidase activity of MtbDsbAwas investigated
using an in vitro peptide-oxidation assay with a fluorescently
labelled peptide substrate (CQQGFDGTQNSCK), using
GSSG as the electron donor to regenerate the oxidized DsbA
(Fig. 3a). MtbDsbA catalyzed peptide oxidation well above
the background rate [in the absence of enzyme or in the
presence of the catalytic cysteine mutant MtbDsbA
(Cys92Ala)]. However, EcDsbA-mediated peptide oxidation
was found to be faster than MtbDsbA as it required five times
more MtbDsbA to match the catalytic rate of EcDsbA. This
suggests the possibility that MtbDsbA and EcDsbA recognize
the substrate peptide with differing affinities or kinetics.
The reductase activity of MtbDsbA was assessed spectro-
photometrically by analyzing the ability of the enzyme to
reduce the interchain disulfides of insulin (measured as an
increase in turbidity through precipitation of the insulin B
chain; Fig. 3c). In contrast to EcDsbA, MtbDsbA did not show
any disulfide reductase activity against insulin, supporting the
possibility that the two enzymes have different substrate-
binding surfaces.
Finally, we tested the ability of MtbDsbA to isomerize, or
shuffle, the incorrect disulfides of scrambled RNaseA to form
the correctly folded RNaseA. Under the conditions of the
assay, MtbDsbA was able to generate just 10% of the activity
of fully folded RNaseA after 5 h (Fig. 3c). By comparison,
EcDsbA and EcDsbC (a disulfide isomerase enzyme)
produced !60 and !90%, respectively, of the activity of
correctly folded RNase over the same time period. These
observations are consistent with the view that MtbDsbA has
the characteristic redox properties of a disulfide oxidase but
differs functionally in other redox assays compared with the
prototypical EcDsbA oxidase.
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Figure 3
Disulfide oxidoreductase activities. (a) Disulfide oxidase activity. Representative fluorescence curves of peptide cysteine oxidation by MtbDsbA and
EcDsbA in the presence of glutathione as the electron donor. Enzyme-catalyzed peptide oxidation is significantly faster than the glutathione-mediated
reaction. Peptide oxidation in the buffer control or by the catalytically inactive MtbDsbA (Cys89Ala) or EcDsbA (Cys33Ala) was insignificant over the
duration of the assay (not shown for clarity). (b) Insulin disulfide-reduction assay. The precipitation of insulin by MtbDsbA or EcDsbA or DTT (trace
overlaps that of EcDsbA) was monitored as described in x2. (c) Scrambled RNase disulfide isomerization assay. Disulfide isomerization activity of
MtbDsbA, EcDsbA and EcDsbC was monitored using scrambled RNase as the substrate.
Figure 2
Ability of MtbDsbA to recognize EcDsbB. (a) Restoration of E. coli
motility. Constructs expressing MtbDsbA or EcDsbA (control) were
transformed into E. coli DsbA null (JCB817) and DsbA/DsbB double
null (JCB818) mutant cells. FlgI function is impaired in the absence of
EcDsbA or EcDsbB owing to the absence of disulfide-bonding activity
(Dailey & Berg, 1993). The ability to recognize EcDsbB and EcDsbA
substrates in vivo by MtbDsbA was evaluated by restoration of E. coli
motility in the agar, as seen in the induced EcDsbA control. Shown is the
summary of three replicates of induced (containing arabinose) and
uninduced bacterial swarming plates (not containing arabinose, as a
negative control). See Supplementary Fig. S2 for bacterial plate images.
(b) Ubiquinone reduction of EcDsbB–UQ1 by MtbDsbA. The data
presented here are the normalized mean absorbance of UQ1 from three
independent measurements. EcDsbB was added to the EcDsbA/UQ1
mixture to initiate the reaction.
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3.4. The crystal structure of MtbDsbA reveals unique features
To explore the atomic details of MtbDsbA, we determined
its structure at 2.0 A˚ resolution. The structure was solved by
MR searches using trimmed ‘Poly Ser’ templates derived from
remote DsbA homologues (see x2 and Supplementary Fig.
S1). Two independent MtbDsbA molecules were well resolved
in the asymmetric unit (residues 57–255; 199 residues for each
monomer) and were refined to Rwork and Rfree values of 14.5
and 19.2%, respectively (Table 1). TheMtbDsbA structure has
a canonical DsbA-like architecture comprising a Trx domain
with a helical domain inserted into the middle of the Trx
domain (Fig. 4a). The two MtbDsbA molecules in the asym-
metric unit are very similar (r.m.s. deviation of 0.26 A˚ for all
C! atoms). However, the structure of MtbDsbA differs
significantly from the prototypical EcDsbA with an r.m.s.
deviation of 3.7 A˚ for 149 C! atoms (PDB entry 1fvk chain A;
3.7 A˚ for 148 C! atoms for 1fvk chain B; Guddat et al., 1997).
Notable differences from EcDsbA include the folding
topology of the central "-sheet, an additional helix H8 at the
C-terminus and a much shorter connecting loop between "5
and H7 (Fig. 4a) that forms part
of the binding interface between
EcDsbA and its redox partner
EcDsbB. As in all thioredoxin-
like proteins, the catalytic CXXC
motif is located at the N-terminus
of helix H1 in MtbDsbA.
A structural comparison of
MtbDsbA against all structures in
the PDB using DALI (Holm et
al., 2008) revealed similarities to
other DsbA structures, albeit
with relatively large r.m.s. devia-
tions (2.1–4.0 A˚ for 148–168 C!
atoms) and weak sequence
conservation (Supplementary
Fig. S3). The closest structural
similarity occurs with DsbAs
from Gram-positive organisms:
BsDsbA (r.m.s. deviation 2.6 A˚
for 168 C! atoms; 21% identity)
and SaDsbA (r.m.s. deviation
2.1 A˚ for 154 C! atoms; 21%
identity). The central four strands
of the core "-sheet have the same
topology (3–2–4–5) in the Trx
domains of this group of DsbAs.
However, a topological differ-
ence is noted in the arrangement
of strand "1 (Figs. 4 and 5a):
in MtbDsbA, BsDsbA and
WpDsbA1 "1 forms hydrogen
bonds to "5 (3–2–4–5–1), whereas
in the majority of DsbA struc-
tures "1 forms hydrogen bonds to
"3 on the opposite edge of the "-
sheet (1–3–2–4–5).
A unique feature of MtbDsbA
compared with all other structu-
rally characterized DsbAs is the
C-terminal extension that forms
an additional helix, H8, that
packs against helices H1 and H7
(Figs. 4b and 5a). Crystallo-
graphic B factors plotted onto
these helices suggest the possibi-
lity that the H8 helix may reduce
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Figure 4
Structural comparison of MtbDsbA. (a) The crystal structure of MtbDsbA (left) is compared with the
prototypical EcDsbA (right; PDB entry 1fvk; Guddat et al., 1998). Catalytic/noncatalytic cysteine residues
are shown as light grey spheres. The noncatalytic structural disulfide of MtbDsbA is absent in EcDsbA.
Helix H8 appears to be unique to MtbDsbA. The orientation of helix H5 dramatically varies in these two
proteins. Gly204 breaks the hydrogen-bonding pattern in the middle of helix H6 of MtbDsbA (helix H6 is
kinked in MtbDsbA compared with EcDsbA). MtbDsbA appears to be much smaller in size than EcDsbA
in this orientation. However, the molecular surface areas of MtbDsbA (8208 A˚2) and EcDsbA (8670 A˚2)
are comparable. The intramolecular interaction of helix H1 with the C-terminal region of (b) MtbDsbA, (c)
EcDsbA (PDB entry 1fvk; Guddat et al., 1998) and (d) VcDsbA (PDB entry 1bed; Hu et al., 1997) is also
shown. For (b), (c) and (d) the backbone colour is set to the temperature factor from the PDB. The side
chains of interfacing residues identified by PISA (Protein Interfaces, Surfaces and Assemblies; Krissinel &
Henrick, 2007) analysis are shown as sticks. Catalytic and noncatalytic cysteines are shown as grey spheres.
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Figure 5
Structural elements of DsbAs and the catalytic site of MtbDsbA. (a) Structure-based sequence alignment of DsbAs. Structurally equivalent positions
(upper case), variable regions (lower case) and insertions (dashes) are shown. PknE DsbA sequence alignment is based on MtbDsbA and BsDsbA (see
Supplementary Fig. S6 for the PknE hypothetical model). Secondary-structure assignments for MtbDsbA (top green), EcDsbA (bottom blue) and
topological variations originating at strand !1 in MtbDsbA and EcDsbA (orange) are presented. The catalytic motif and cis-Pro motif are highlighted in
cyan and the equivalent EcDsbA residues involved in partner/substrate interaction are highlighted in orange. A negatively charged residue (Glu165) in
the vicinity of the catalytic cysteine, a residue blocking the hydrophobic groove (Trp226) and a noncatalytic structural disulfide bond are marked with red
arrows (see text for details). (b) The structure of the catalytic face of MtbDsbA. Residues forming the putative binding surface and negatively charged
residues neighbouring the catalytic cysteine are shown. The inset displays the 2mFo" DFc electron-density map around the catalytic motif, the cis-Pro
loop and ordered active-site water molecules (1.0" contour level).
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the mobility of the catalytic helix H1 in comparison to
EcDsbA and VcDsbA (Figs. 4b–4d). We then analyzed the
interface between helix H1 and the C-terminal H8 region
(Table 3). Compared with other structurally characterized
DsbAs, the presence of helix H8 in MtbDsbA buries a greater
proportion of helix H1 (buried surface area of 592 versus 401–
260 A˚2). The H8 helix interaction may restrict the conforma-
tional flexibility of helices H1 and H7. Similarly, the second
disulfide bond (Cys140–Cys192) of MtbDsbA that links
helices H2 and H5 may also restrict flexibility of the four-helix
bundle (Figs. 4 and 5a). The functional effects of these
conformational restrictions are unclear but might explain at
least in part the differences that we observe in the functional
assays for MtbDsbA and EcDsbA.
The highly conserved structural regions in these DsbAs are
the catalytic motif and cis-proline (cis-Pro) loop, both of which
are known to be critical for activity in other DsbA enzymes
(Kadokura et al., 2004). However, the catalytic motif (Cys89-
Pro90-Ala91-Cys92) in MtbDsbA differs from other structu-
rally characterized DsbAs, which are generally Cys-Pro-His/
Tyr/Ser-Cys. The catalytic cysteines Cys89 and Cys92 display
alternative side-chain conformations corresponding to
oxidized and reduced states (estimated approximately 50 and
65% for reduced states on the basis of crystallographic occu-
pancy), despite the fact that
oxidized protein was used for
crystal growth (Fig. 5b). The
active-site disulfides of DsbA
proteins are susceptible to radia-
tion damage in the crystal
(Guddat et al., 1998) and the
broken disulfide bond in
MtbDsbA is therefore likely to be
a result of the synchrotron
radiation used to measure the
diffraction data. In its reduced
form in the crystal, Cys89 of
MtbDsbA is likely to exist as the
thiolate (pKa 4.2, pH in the
crystal drop 5.5). Ordered active-
site water molecules are present
in the crystal structure at posi-
tions consistent with formation of
stabilizing hydrogen bonds to the
Cys89 thiolate and to Thr214, a
residue preceding the cis-Pro
loop. This hydrogen-bonding
network differs from that in
EcDsbA, which has a Val at the
equivalent position to Thr214, but
is similar to that in SaDsbA,
which also has a Thr prior to the
cis-Pro residue (Heras et al.,
2008).
3.5. The surface surrounding the
active site of MtbDsbA differs
from that of EcDsbA
The conformation and amino-
acid composition of the loop
connecting the Trx domain and
the helical domain (!3–H2, L1),
an inter-helix loop (H3–H4, L2),
the cis-Pro loop (H6–!4, L3) and
the connecting loop !5–H7 (L4)
create the surface features
surrounding the catalytic cysteine
(Cys89) of MtbDsbA (Fig. 5).
research papers
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Figure 6
Comparison of surface properties. (a) Hydrophobicity surface presentations for MtbDsbA and EcDsbA.
Surface colourings are mapped to the Kyte–Doolittle hydrophobicity scale from purple (most hydrophilic)
to white to tan (most hydrophobic). The MtbDsbA structure is shown (left) with the modelled VKOR
peptide (VPSCNV) and crystallographically identified artificial ligand 1,4-dioxane (see text and
Supplementary Fig. S4 for details). The EcDsbA–EcDsbB complex structure is shown on the right
(PDB entry 3e9j; Malojcic´ et al., 2008). For clarity only the periplasmic loop segment ‘PFATCDF’ of
EcDsbB is shown. Electrostatic surface comparisons of (b) MtbDsbA, (c) the hypothetical model of PknE
DsbA and (d) EcDsbA. Electrostatic surface potential is contoured between "6 (red) and +6 (blue) kT/e.
The homology model of PknE (template based on MtbDsbA and BsDsbA) was prepared inMODELLER
(Eswar et al., 2006) and atomic clashes were minimized in Chiron (Ramachandran et al., 2011).
APPENDIX C 
 
 235  
Crystal structures of EcDsbA in complex with protein part-
ners have shown that the hydrophobic patch created by loops
L1 and L3, the active-site motif and the hydrophobic groove
formed by loop L4 and helix H1 contribute to interactions
with partner proteins (Paxman et al., 2009; Inaba et al., 2006).
The length and amino-acid identity of these loops are gener-
ally not conserved among DsbAs (Fig. 5a). The relatively long
L4 loop in EcDsbA creates a large hydrophobic groove
compared with the short loop found in MtbDsbA, SaDsbA
and BsDsbA (Fig. 6). In MtbDsbA, the side chain of Trp226
(L4 loop) sits in a shallow groove formed by Ile94, Phe95,
Gly98, Phe99, Ser227, Thr228 and Pro229 (Fig. 5b). The
hydrophobic nature of the surrounding catalytic residues is
largely preserved in MtbDsbA (Fig. 6). Unexpectedly, a
ligand, 1,4-dioxane from the crystallization solution, was
bound in this shallow groove, forming contacts with Ile94,
Gly98, Phe99 and Pro229 (Supplementary Fig. S4). MtbDsbA
also has two negatively charged residues near the catalytic
Cys89, similar to those observed in SaDsbA (Glu165 and
Glu225, see Fig. 5b). The SaDsbA glutamate equivalent to
Glu165 has been shown to influence the pKa of the catalytic
cysteine (Heras et al., 2008).
3.6. MtbDsbA binds a peptide derived from VKOR
Although the binding surface of MtbDsbA does not have
the distinct binding groove of EcDsbA that interacts with a
periplasmic loop of its membrane partner EcDsbB, we inves-
tigated whether a fragment of a periplasmic loop from the
putative binding partner MtbVKOR would interact with
MtbDsbA. We used ITC to assess the binding of MtbDsbA to
several peptides derived from MtbVKOR (see Supplementary
Fig. S5 for the quality of the ITC data). Topological prediction
indicated that MtbVKOR is comprised of five transmembrane
helices connected by two periplasmic loops. Cys57 from the
first periplasmic loop has been shown to form a mixed disul-
fide bond with EcDsbA (Wang et al., 2011), although a direct
interaction of MtbVKOR with any mycobacterial protein has
not been reported. We found that the MtbVKOR 11-residue
peptide segment surrounding Cys57 (51PIYVPSCNVNP61)
binds to MtbDsbA with an apparent Kd of 3.8 mM (Table 4).
Trimming from either end of this peptide showed that a
minimal hexapeptide (54VPSCNV59) binds to MtbDsbA with
Kd,app = 6.7 mM. Further, modelling of the 54VPSCNV59
peptide onto MtbDsbA suggested that Tyr53 of the VKOR
sequence might bind to the site occupied by 1,4-dioxane in the
crystal structure (Fig. 6a). Indeed, this heptapeptide
53YVPSCNV59 showed improved binding (Kd,app =2.9 mM) to
MtbDsbA. Binding of this VKOR peptide to MtbDsbA is
cysteine-dependent, as substitution of Cys with Ala or Leu or
mutation of the MtbDsbA catalytic Cys89 to Ala abolished
binding under the conditions tested.
3.7. Comparison with the predicted mycobacterial DsbA-like
domain of PknE
Aside from MtbDsbA, the H37Rv strain encodes five other
putative extracytoplasmic Trx-related proteins: DsbE
(Rv2878c), DsbF (Rv1677), Rv3673c, Rv0526 and the trans-
membrane protein kinase PknE (Rv1743). PknE is a clear
structural homologue of MtbDsbA and also contains a kinase
domain. Curiously, sequence searches suggest that PknE
orthologues are restricted to pathogenic mycobacteria and
PknE appears to be the only Mtb protein kinase fused to a
DsbA homologous domain. The PknE predicted DsbA
domain (residues 377–566) is linked to the intracellular
protein kinase domain (residues 1–289) through a single-pass
transmembrane helix (residues 337–359). Sequence compar-
ison and secondary-structure prediction are consistent with
the notion that PknE DsbA shares the same overall fold as
that of MtbDsbA. We generated a homology model for PknE
DsbA based on the MtbDsbA structure to compare the
sequence variation in the context of the three-dimensional
structure (Supplementary Fig. S6). Predicted differences from
MtbDsbA in the PknE DsbA domain include the absence of
helix H8 and a short helix H7 at the C-terminus. There are also
sequence variations in loops L1, L3 and L4 (Fig. 5a). Predicted
similarities in PknE DsbA include conservation of the Thr-cis-
research papers
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Table 3
Analysis of the interface between helix H1 and the C-terminal region of DsbA structures.
The buried surface area (BSA) in helix H1 (column 3) was determined using PISA analysis (Krissinel & Henrick, 2007). DsbAs, their PDB codes (column 1, in
parentheses) and the residue ranges in helix H1 (column 2, in parentheses) and the C-terminal region (column 4, in parentheses) included in the PISA analysis are
listed. The percentage of surface area buried in helix H1 relative to its total accessible surface area ("2000 A˚2) is given in column 3 (in parentheses). For MtbDsbA
and EcDsbA, BSA and the values reported for the percentage of surface area buried are an average of two MtbDsbA chains (molecule 1 and molecule 2 in the
asymmetric unit) and nine EcDsbA chains [PDB entries 1dsb (two chains; Martin et al., 1993), 1fvk (two chains; Guddat et al., 1997), 1a2m (two chains; Guddat et
al., 1998), 1a2l (two chains; Guddat et al., 1998) and 1a2j (one chain; Guddat et al., 1998)].
Protein (PDB code)
No. of interfacing
residues in helix H1 Helix H1 BSA (A˚2)
No. of interfacing residues
in C-terminal region
MtbDsbA 13 (89–109) 592 # 4 (29.6) 18 (226–255)
EcDsbA 9 (30–50) 401 # 42 (18.9) 10 (168–188)
BsDsbA (3eu3; Crow et al., 2009) 8 (69–91) 355 (15.9) 8 (205–222)
SaDsbA (3bci; Heras et al., 2008) 9 (26–46) 370 (15.8) 7 (167–178)
PaDsbA (3h93; Shouldice et al., 2010) 7 (37–55) 282 (14.3) 9 (166–192)
VcDsbA (1bed; Hu et al., 1997) 8 (30–48) 261 (13.7) 6 (164–181)
WpDsbA (3f4r; Kurz et al., 2009) 9 (51–71) 363 (16.5) 9 (196–218)
NmDsbA1 (3a3t; Vivian et al., 2009) 7 (57–74) 290 (15.5) 7 (189–212)
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Pro motif, a glutamate equivalent of Glu225 and a tyrosine
equivalent of Trp226. The calculated electrostatic potential
surfaces are negative in the region surrounding the catalytic
site in both proteins (Figs. 6c and 6d). However, the CPPC
catalytic motif in PknE DsbA differs from that of CPAC of
MtbDsbA. These differences may contribute to a difference in
redox characteristics. In EcDsbA, mutation of CPHC to CPPC
dramatically increased its reducing potential (!122 mV to
!220 mV; Bessette et al., 2001). The native CPPC active site in
a DsbA homologue from Salmonella enterica (SeSrgA) has
also been linked to a more strongly reducing potential
(!154 mV). Indeed, the insulin reductase activity of SeSrgA
was shown to be similar to that of the disulfide isomerase
EcDsbC (Heras et al., 2010).
4. Discussion
Novel drug targets are desperately needed to combat tuber-
culosis. Mycobacterial proteins exported across the cyto-
plasmic membrane play important roles in Mtb adhesion,
invasion, virulence, pathogenesis and survival inside host cells.
Drugs targeting export systems in Gram-negative bacteria
have been tested for their ability to block delivery of effector
proteins required for virulence (Moir et al., 2011). Likewise,
there are intensive efforts to develop antituberculosis drugs
that target the major mycobacterial protein-export systems:
the Sec pathway, the Tat pathway and the ESX pathways
(Feltcher et al., 2010; McCann et al., 2011).
Another approach is to target the disulfide pathways that
mediate disulfide-bond formation and correct folding of
exported proteins in Mtb (Chim et al., 2010, 2011; Goulding et
al., 2004). In bacteria, disulfide-bond formation in newly
exported proteins is commonly mediated through mechanisms
that rely on electron transfer between redox proteins. The
best-studied protein redox pair, DsbA/DsbB, is found in most
aerobic !-, "- and #-proteobacteria. However, in myco-
bacteria and other actinobacteria, cyanobacteria and $- and "-
proteobacteria, it has been proposed that DsbA/VKOR forms
a functional redox pair to catalyze disulfide-bond formation
(Dutton et al., 2008; Li et al., 2010; Wang et al., 2011). The
currently accepted mechanism is that the cysteine-containing
periplasmic loop of transmembrane protein DsbB or VKOR is
transiently drawn into the binding groove of DsbA (Fig. 6) to
drive the flow of electrons (Inaba & Ito, 2008). Oxidized DsbA
then exchanges its catalytic disulfide bond with newly
exported proteins by transiently interacting with them through
its catalytic cysteine and binding surface (Inaba & Ito, 2008;
Inaba et al., 2006; Kadokura et al., 2003). Thus, compounds
targeting the protein–protein interaction surface responsible
for interaction between DsbA and its substrate proteins or
between DsbA and DsbB/VKOR may inhibit virulence-factor
maturation in pathogens.
The data we present here show that Rv2969c has disulfide
oxidase activity, a highly acidic active-site cysteine, a desta-
bilizing active-site disulfide and a highly oxidizing potential.
Structurally, MtbDsbA has a canonical DsbA architecture
with a CXXC active-site motif. We therefore conclude that
Mtb Rv2969c is an authentic DsbA enzyme. Our data also
show that MtbDsbA is able to interact tightly with a seven-
residue peptide corresponding to the periplasmic loop of
MtbVKOR and these data support the notion that MtbDsbA
and MtbVKOR are a functional redox pair that could catalyze
disulfide-bond formation in newly translocated substrates.
Helix H8 at the C-terminus of MtbDsbA and its interaction
with active-site helix H1 are unique to MtbDsbA among
structurally characterized DsbAs. This feature appears to be
absent in the DsbA-like domain of PknE. Substrate binding
and mobility of DsbAs has been linked to the catalytic activity
of DsbA (Horne et al., 2007). In this context, restraint of helix
H1 by helix H8 in MtbDsbA may contribute to the catalytic
activity of MtbDsbA. Moreover, the relatively negative
surface potential surrounding the catalytic site of MtbDsbA
compared with EcDsbA suggests that these two enzymes have
very different substrate-binding specificities. This is supported
by our assay data showing the relative activities of these two
enzymes in assays for reductase (MtbDsbA no activity),
oxidase (MtbDsbA slower activity) and isomerase (MtbDsbA
marginal activity) activity. EcDsbA is known to be a promis-
cuous enzyme that interacts with many substrates. Our struc-
tural and functional data suggest that MtbDsbA may have a
more limited number of specific substrates.
Previous work has shown that the anticoagulant warfarin
that inhibits human VKOR can also inhibit MtbVKOR and it
interferes with the growth of Mtb in cell studies (Dutton et al.,
2010). Inhibiting MtbVKOR is an appealing strategy for
treating Mtb, but will require the design of selective inhibitors
that target MtbVKOR and not its human counterpart. Our
results suggest that MtbDsbA may represent an alternative
target for inhibiting disulfide oxidation in Mtb and for
preventing the production of virulence factors.
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Australian Synchrotron for data-collection facilities. We also
acknowledge use of the University of Queensland Remote
Operation Crystallization and X-ray (UQROCX) Diffraction
Facility and the assistance of Mr Karl Byriel and Dr Gordon
King. This work was supported by an Australian Laureate
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Table 4
Thermodynamic parameters for VKOR-derived peptides binding to
MtbDsbA.
Kd,app, apparent dissociation constant; !H, enthalpy change; T!S, tempera-
ture (K)# entropy change;N is the apparent stoichiometry. T!S is calculated
from the free energy equation (!H ! T!S = !RTlnKd,app). Values reported
are the mean and standard deviation of the curve fits from two ITC runs in
each case. Representative ITC profiles are provided in Supplementary Fig. S5.
n.b., no binding detected. 1 cal = 4.184 J.
N
Kd,app
(mM)
!H
(kcal mol!1)
!T!S
(kcal mol!1)
PIYVPSCNVNP 1.0 3.8 $ 0.2 !10.9 $ 0.0 3.5
VPSCNVNP 1.0 5.9 $ 2.6 !7.1 $ 4.0 2.5
VPSCNV 1.0 6.7 $ 0.0 !6.8 $ 0.2 !0.1
VPSLNV n.b.
YVPSCNV 1.1 2.9 $ 0.3 !7.0 $ 0.4 !0.5
YVPSANV n.b.
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Supplementary Figure S1  
Molecular replacement phasing of MtbDsbA with a ‘twilight zone’ template. (A) Amino acid 
sequence alignment. SaDsbA (3bci) shares 18% sequence identity and 83% coverage to MtbDsbA. 
However, successful MR solution could only be obtained using a trimmed  “Poly-Ser”  template  
derived from SaDsbA that shares 48% sequence identity and just 39% coverage to MtbDsbA. 
Identical residues are shown in red. See Figure S3 for structure-based sequence identities and RMSDs 
of MtbDsbA to other DsbAs. (B) Structural overlays of MtbDsbA (blue), SaDsbA  (green)  and  “poly-
Ser”  template  (brown). 
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Supplementary Figure S2  
EcDsbA in vivo complementation assay. EcDsbA or MtbDsbA was cloned into a EcDsBA signal 
sequence under an arabinose inducible promotor. As shown, MtDsbA does not complement EcDsbA 
in dsbA null JCB817 cells. As expected, EcDsbA rescues the motility of JCB817 cells, but not 
DsbA/DsbB double null JCB818 cells, in an arabinose dependent manner. See text for details. 
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Supplementary Figure S3  
Assessment of structural homologs for MtbDsbA by DALI. The top structural homologs with 
significant  sequence  coverage  are  listed.  “Z-scores”  above  6  are  considered significant. Columns are: 
PDB  code,  “Z-score”,  RMS  deviation  on  Cα  for  the  given  number  of  aligned  residues  (align), the total 
number of residues in the protein are shown under aa. %id is the % identity of the aligned residues. 
Gram-positive organisms are highlighted in green. 
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Supplementary Figure S4 
Crystallographic identification of the binding of an artificial ligand 1,4-dioxane in MtbDsbA. 1,4-
dioxane (DIO) from the crystallization solution was bound in a shallow sub-pocket contributed by the 
catalytic helix H1 and loop L4. Residues surrounding 1,4-dioxane are shown. A simulated annealing 
omit difference map for 1,4-dioxane is shown contoured  at  3.0  σ.   
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Supplementary Figure S5  
Representative isothermal titration calorimetry profiles for VKOR-derived peptide binding to 
MtbDsbA. The data were generated using 2  μl  injections  of  peptides  at a concentration of 2-4 mM 
titrated  into  a  cell  containing  100  μM  MtbDsbA. 
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Supplementary Figure S6 
Structural comparison of MtbDsbA crystal structure and modelled structure of PknE DsbA domain. 
Homology model of PknE (template MtbDsbA and BsDsbA) was prepared in Modeller (Eswar et al., 
2006) and atomic clashes were minimized in Chiron (Ramachandran et al., 2011). Spheres show the 
position of cysteines forming the catalytic and non-catalytic disulfides. The non-catalytic disulfides 
are marked with an asterisk.  
 
 
